

2021

Prescription Drug Guide

Humana Medicare Employer Plan Formulary

List of covered drugs

PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT THE DRUGS WE COVER IN THIS PLAN.

2

This formulary was updated on 09/18/2020. For more recent information or other questions, please contact Humana Medicare Employer Plan at the number on the back of your membership card or, for TTY users, 711, Monday through Friday, from 8 a.m. - 9 p.m. Eastern Time. The automated phone system may answer your call on Saturdays, Sundays, and some public holidays. Please leave your name and telephone number, and we'll call you back by the end of the next business day, or visit **Humana.com**.

Humana[®]

Welcome to Humana Medicare Employer Plan!

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to "we," "us", or "our," it means Humana. When it refers to "plan" or "our plan," it means the Humana Medicare Employer Plan. This document includes a list of the drugs (formulary) for our plan which is current as of January 1, 2021. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1 of each year, and from time to time during the year.

What is the Humana Medicare Employer formulary?

A formulary is the entire list of covered drugs or medicines selected by the Humana Medicare Employer Plan. The terms formulary and Drug List may be used interchangeably throughout communications regarding changes to your pharmacy benefits. The Humana Medicare Employer Plan worked with a team of doctors and pharmacists to make a formulary that represents the prescription drugs we think you need for a quality treatment program. The Humana Medicare Employer Plan will generally cover the drugs listed in the formulary as long as the drug is medically necessary, the prescription is filled at a Humana Medicare Employer Plan network pharmacy, and other plan rules are followed. For more information on how to fill your medicines, please review your Evidence of Coverage.

If you're thinking about enrolling in a Humana Medicare Employer Plan and need help or information, call the Group Medicare Customer Care number listed in your enrollment materials. If you're a current member, call the number listed in your Annual Notice of Change (ANOC) or Evidence of Coverage (EOC), or call the number on the back of your Humana member identification card Monday through Friday, from 8 a.m. - 9 p.m. Eastern Time. The automated phone system may answer your call on Saturdays, Sundays, and some public holidays. Please leave your name and telephone number, and we'll call you back by the end of the next business day.

Can the formulary change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the Drug List during the year, move them to different cost sharing tiers, or add new restrictions. We must follow Medicare rules in making these changes.

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **New generic drugs.** We may immediately remove a brand name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand name drug on our Drug List, but immediately move it to a different cost sharing tier or add new restrictions. If you are currently taking that brand name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
 - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled "How do I request an exception to the Formulary?"
- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug's manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to market to replace a brand name drug currently on the formulary or add new restrictions to the brand name drug or move it to a different cost sharing tier or both. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, or add prior authorization, quantity limits and/or step therapy restrictions on a drug or move a drug to a higher cost sharing tier, we must

notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 30-day supply of the drug.

We'll notify members who are affected by the following changes to the formulary:

- When a drug is removed from the formulary
- When prior authorization, quantity limits, or step-therapy restrictions are added to a drug or made more restrictive
- When a drug is moved to a higher cost sharing tier

If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled "How do I request an exception to the Formulary?"

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2021 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2021 coverage year except as described above. This means these drugs will remain available at the same cost sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs.

What if you're affected by a Drug List change?

We'll notify you by mail at least 30 days before one of these changes happens or we will provide a 30-day refill of the affected medicine with notice of the change.

The enclosed formulary is current as of January 1, 2021. We'll update the printed formularies each month and they'll be available on [Humana.com/medicaredruglist](https://www.humana.com/medicaredruglist).

To get updated information about the drugs that Humana covers, please visit [Humana.com/medicaredruglist](https://www.humana.com/medicaredruglist). The Drug List Search tool lets you search for your drug by name or drug type.

How do I use the formulary?

There are two ways to find your drug in the formulary:

Medical condition

The formulary starts on page 10. We've put the drugs into groups depending on the type of medical conditions that they're used to treat. For example, drugs that treat a heart condition are listed under the category "Cardiovascular Agents." If you know what medical condition your drug is used for, look for the category name in the list that begins on page 10. Then look under the category name for your drug. The formulary also lists the Tier and Utilization Management Requirements for each drug (see page 5 for more information on Utilization Management Requirements).

Alphabetical listing

If you're not sure about your drug's group, you should look for your drug in the Index that begins on page 177. The Index is an alphabetical list of all of the drugs included in this document. Both brand-name drugs and generic drugs are listed. Look in the Index to search for your drug. Next to each drug, you'll see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of the drug in the first column of the list.

Prescription drugs are grouped into one of four tiers.

The Humana Medicare Employer Plan covers both brand-name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand-name drug. Generally, generic drugs cost less than brand-name drugs.

- **Tier 1 - Generic or Preferred Generic:** Generic or brand drugs that are available at the lowest cost share for the plan
- **Tier 2 - Preferred Brand:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 1 Generic or Preferred Generic, and at a lower cost to you than Tier 3 Non-Preferred Drug
- **Tier 3 - Non-Preferred Drug:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 2 Preferred Brand drug
- **Tier 4 - Specialty Tier:** Some injectables and other high-cost drugs

How much will I pay for covered drugs?

The Humana Medicare Employer Plan pays part of the costs for your covered drugs and you pay part of the costs, too.

The amount of money you pay depends on:

- Which tier your drug is on
- Whether you fill your prescription at a network pharmacy
- Your current drug payment stage - please read your Evidence of Coverage (EOC) for more information

If you qualified for extra help with your drug costs, your costs may be different from those described above. Please refer to your Evidence of Coverage (EOC) or call Group Medicare Customer Care to find out what your costs are.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These are called Utilization Management Requirements. These requirements and limits may include:

- **Prior Authorization (PA):** The Humana Medicare Employer Plan requires you to get prior authorization for certain drugs to be covered under your plan. This means that you'll need to get approval from the Humana Medicare Employer Plan before you fill your prescriptions. If you don't get approval, the Humana Medicare Employer Plan may not cover the drug.
- **Quantity Limits (QL):** For some drugs, the Humana Medicare Employer Plan limits the amount of the drug that is covered. The Humana Medicare Employer Plan might limit how many refills you can get or how much of a drug you can get each time you fill your prescription. For example, if it's normally considered safe to take only one pill per day for a certain drug, we may limit coverage for your prescription to no more than one pill per day. Some drugs are limited to a 30-day supply regardless of tier placement.
- **Step Therapy (ST):** In some cases, the Humana Medicare Employer Plan requires that you first try certain drugs to treat your medical condition before coverage is available for another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, the Humana Medicare Employer Plan may not cover Drug B unless you try Drug A first. If Drug A does not work for you, the Humana Medicare Employer Plan will then cover Drug B.
- **Part B versus Part D (B vs D):** Some drugs may be covered under Medicare Part B or Part D depending upon the circumstances. Information may need to be submitted to the Humana Medicare Employer Plan that describes the use and the place where you receive and take the drug so a determination can be made.

For drugs that need prior authorization or step therapy, or drugs that fall outside of quantity limits, your health care provider can fax information about your condition and need for those drugs to the Humana Medicare Employer Plan at **1-877-486-2621**. Representatives are available Monday - Friday, 8 a.m. - 8 p.m.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 10.

You can also visit [Humana.com/medicaredruglist](https://www.humana.com/medicaredruglist) to get more information about the restrictions applied to specific covered drugs.

You can ask the Humana Medicare Employer Plan to make an exception to these restrictions or limits. See the section "**How do I request an exception to the formulary?**" on page 6 for information about how to request an exception.

What if my drug isn't on the formulary?

If your drug isn't included in this list of covered drugs, visit [Humana.com/medicaredruglist](https://www.humana.com/medicaredruglist) to see if your plan covers your drug. You can also call Group Medicare Customer Care and ask if your drug is covered.

If the Humana Medicare Employer Plan doesn't cover your drug, you have two options:

- You can ask Group Medicare Customer Care for a list of similar drugs that the Humana Medicare Employer Plan covers. Show the list to your doctor and ask him or her to prescribe a similar drug that is covered by the Humana Medicare Employer Plan.
- You can ask the Humana Medicare Employer Plan to make an exception and cover your drug. See below for information about how to request an exception.

Talk to your health care provider to decide if you should switch to another drug that is covered or if you should request a formulary exception so that it can be considered for coverage.

How do I request an exception to the formulary?

You can ask the Humana Medicare Employer Plan to make an exception to the coverage rules. There are several types of exceptions that you can ask to be made.

- **Formulary exception:** You can request that your drug be covered if it's not on the formulary. If approved, this drug will be covered at a pre-determined cost sharing level, and you would not be able to ask us to provide the drug at a lower cost sharing level.
- **Utilization restriction exception:** You can request coverage restrictions or limits not be applied to your drug. For example, if your drug has a quantity limit, you can ask for the limit not to be applied and to cover more doses of the drug.
- **Tier exception:** You can request a higher level of coverage for your drug. For example, if your drug is usually considered a non-preferred drug, you can request it to be covered as a preferred drug instead. This would lower how much money you must pay for your drug. Please remember a higher level of coverage cannot be requested for the drug if approval was granted to cover a drug that was not on the formulary.

Generally, the Humana Medicare Employer Plan will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost sharing drug, or other restrictions wouldn't be as effective in treating your health condition and/or would cause adverse medical effects.

You should contact us to ask for an initial coverage decision for a formulary, tier, or utilization restriction exception.

When you ask for an exception, you should submit a statement from your health care provider that supports your request. This is called a supporting statement.

Generally, we must make the decision within 72 hours of receiving your health care provider's supporting statement. You can request a fast, or expedited, exception if you or your health care provider thinks your health would seriously suffer if you wait as long as 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get your health care provider's supporting statement.

Will my plan cover my drugs if they are not on the formulary?

You may take drugs that your plan doesn't cover. Or, you may talk to your provider about taking a different drug that your plan covers, but that drug might have a Utilization Management Requirement, such as a Prior Authorization or Step Therapy, that keeps you from getting the drug right away. In certain cases, we may cover as much as a 30-day supply of your drug during the first 90 days you're a member of the plan.

Here is what we'll do for each of your current Part D drugs that aren't on the formulary, or if you have limited ability to get your drugs:

- We'll temporarily cover a 30-day supply of your drug unless you have a prescription written for fewer days (in which case we will allow multiple fills to provide up to a total of 30 days of a drug) when you go to a pharmacy.
- There will be no coverage for the drugs after your first 30-day supply, even if you've been a member of the plan for less than 90 days, unless a formulary exception has been approved.

If you're a resident of a long-term care facility and you take Part D drugs that aren't on the formulary, we'll cover a 31-day supply unless you have a prescription written for fewer days (in which case we will allow multiple fills to provide up to a total of 31 days of a drug) during the first 90 days you're a member of our plan. We'll cover a 31-day emergency supply of your drug unless you have a prescription for fewer days (in which we will allow multiple fills to provide up to a total of 31 days of a drug) while you request a formulary exception if:

- You need a drug that's not on the formulary *or*
- You have limited ability to get your drugs *and*
- You're past the first 90 days of membership in the plan

Throughout the plan year, your treatment setting (the place where you receive and take your medicine) may change. These changes include:

- Members who are discharged from a hospital or skilled-nursing facility to a home setting
- Members who are admitted to a hospital or skilled-nursing facility from a home setting
- Members who transfer from one skilled-nursing facility to another and use a different pharmacy
- Members who end their skilled-nursing facility Medicare Part A stay (where payments include all pharmacy charges) and who now need to use their Part D plan benefit
- Members who give up Hospice Status and go back to standard Medicare Part A and B coverage
- Members discharged from chronic psychiatric hospitals with highly individualized drug regimens

For these changes in treatment settings, the Humana Medicare Employer Plan will cover as much as a 31-day temporary supply of a Part D-covered drug when you fill your prescription at a pharmacy. If you change treatment settings multiple times within the same month, you may have to request an exception or prior authorization and receive approval for continued coverage of your drug. The Humana Medicare Employer Plan will review requests for continuation of therapy on a case-by-case basis understanding when you're on a stabilized drug regimen that, if changed, is known to have risks.

Transition extension

The Humana Medicare Employer Plan will consider on a case-by-case basis an extension of the transition period if your exception request or appeal hasn't been processed by the end of your initial transition period. We'll continue to provide necessary drugs to you if your transition period is extended.

A Transition Policy is available on Humana's Medicare website, **Humana.com**, in the same area where the Prescription Drug Guides are displayed.

Humana Pharmacy® makes it easy to manage your prescriptions with mail delivery solutions

You may be able to fill your medicines through Humana Pharmacy – Humana's mail-delivery pharmacy. You can have your maintenance medicines, specialty medicines, or supplies mailed to a place that's most convenient for you. You should get your new prescription by mail in 7 – 10 days after Humana Pharmacy has received your prescription and all the necessary information. Refills should arrive within 5 – 7 days. To get started or learn more, visit hprxweb.com. You can also call Humana Pharmacy at 1-855-899-3134 (TTY: 711) Monday – Friday, 8 a.m. to 11 p.m., and Saturday, 8 a.m. to 6:30 p.m., Eastern time.

Other pharmacies are available in our network.

For More Information

For more detailed information about your Humana Medicare Employer Plan prescription drug coverage, please read your Evidence of Coverage (EOC) and other plan materials.

If you have questions about Humana, please visit our website at **[Humana.com/medicaredruglist](https://www.humana.com/medicaredruglist)**. The Drug List Search tool lets you search for your drug by name or drug type.

If you have general questions about Medicare prescription drug coverage, please call Medicare at **1-800-MEDICARE (1-800-633-4227)** 24 hours a day, seven days a week. TTY users should call **1-877-486-2048**. You can also visit **www.medicare.gov**.

Humana Medicare Employer Plan Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by the Humana Medicare Employer Plan. If you have trouble finding your drug in the list, turn to the Index that begins on page 177.

How to read your formulary

The first column of the chart lists categories of medical conditions in alphabetical order. The drug names are then listed in alphabetical order within each category. Brand-name drugs are CAPITALIZED and generic drugs are listed in lower-case italics. Next to the drug name you may see an indicator to tell you about additional coverage information for that drug. You might see the following indicators:

DL - Dispensing Limit; Drugs that may be limited to a 30 day supply, regardless of tier placement.

MO - Drugs that are typically available through mail-order. Please contact your mail-order pharmacy to make sure your drug is available.

LA - The health plan has authorized certain pharmacies to dispense this medicine, as it requires extra handling, doctor coordination or patient education. Please call the number on the back of your ID card for additional information.

The second column lists the tier of the drug. See page 5 for more details on the drug tiers in your plan.

The third column shows the Utilization Management Requirements for the drug. The Humana Medicare Employer Plan may have special requirements for covering that drug. If the column is blank, then there are no utilization requirements for that drug. The supply for each drug is based on benefits and whether your health care provider prescribes a supply for 30, 60, or 90 days. The amount of any quantity limits will also be in this column (Example: "QL - 30 for 30 days" means you can only get 30 doses every 30 days). See page 5 for more information about these requirements.

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
Analgesics		
ABSTRAL 100 MCG, 200 MCG, 300 MCG, 400 MCG, 600 MCG, 800 MCG TAB SUBLINGUAL DL	4	PA,QL (128 per 30 days)
acetamin-caf-dihydrocodein 325 DL	1	QL (300 per 30 days)
acetamn-caf-dihydrcodein 320.5 DL	1	QL (300 per 30 days)
acetamin-codein 300-30 mg/12.5; acetaminop-codeine 120-12 mg/5 DL	1	QL (2700 per 30 days)
acetaminophen-cod #2 tablet DL	1	QL (390 per 30 days)
acetaminophen-cod #3 tablet DL	1	QL (360 per 30 days)
acetaminophen-cod #4 tablet DL	1	QL (180 per 30 days)
ACTIQ 1,200 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG LOZENGE ON A HANDLE DL	4	PA,QL (120 per 30 days)
ALLZITAL 25 MG-325 MG TABLET DL	4	QL (360 per 30 days)
ANAPROX DS 550 MG TABLET MO	3	
ARTHROTEC 50 MG-200 MCG TABLET,FILM-COATED MO	3	PA
ARTHROTEC 75 75 MG-200 MCG TABLET,FILM-COATED MO	3	PA
ARYMO ER 15 MG, 30 MG, 60 MG TABLET,CRUSH RESISTANT, EXTENDED RELEASE DL	4	ST,QL (90 per 30 days)
ascomp with codeine 30 mg-50 mg-325 mg-40 mg capsule DL	1	QL (360 per 30 days)
BELBUCA 150 MCG, 300 MCG, 450 MCG, 600 MCG, 75 MCG, 750 MCG, 900 MCG BUCCAL FILM DL	3	QL (60 per 30 days)
bupap 50 mg-300 mg tablet MO	1	QL (180 per 30 days)
BUPRENEX 0.3 MG/ML INJECTION SOLUTION DL	4	QL (240 per 30 days)
buprenorphine 10 mcg/hr patch; buprenorphine 15 mcg/hr patch; buprenorphine 20 mcg/hr patch; buprenorphine 5 mcg/hr patch; buprenorphine 7.5 mcg/hr patch DL	1	QL (4 per 28 days)
buprenorphine 0.3 mg/ml crpjct DL	1	QL (240 per 30 days)
butalbital compound with codeine 30 mg-50 mg-325 mg-40 mg capsule DL	1	QL (360 per 30 days)
butalb-acetaminoph-caff-codein DL	1	QL (180 per 30 days)
butalb-caff-acetaminoph-codein DL	1	QL (360 per 30 days)
butalbital-acetaminophn 25-325 DL	4	QL (360 per 30 days)
butalbital-acetaminophn 50-300 DL	4	QL (180 per 30 days)
butalbital-acetaminophn 50-300; butalbital-acetaminophn 50-325 MO	1	QL (180 per 30 days)
butalb-acetamin-caff 50-300-40; butalb-acetamin-caff 50-325-40 MO	1	QL (180 per 30 days)
butalb-acetamin-caff 50-325-40 MO	1	QL (180 per 30 days)
butalb-aspirin-caffe 50-325-40 MO	1	QL (180 per 30 days)
butalbital-asa-caffeine cap MO	1	QL (180 per 30 days)
butorphanol 1 mg/ml vial DL	1	QL (960 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>butorphanol 10 mg/ml spray</i> DL	1	QL (5 per 28 days)
<i>butorphanol 2 mg/ml vial</i> DL	1	QL (480 per 30 days)
BUTRANS 10 MCG/HOUR, 15 MCG/HOUR, 20 MCG/HOUR, 5 MCG/HOUR, 7.5 MCG/HOUR TRANSDERMAL PATCH DL	3	PA,QL (4 per 28 days)
CALDOLOR 800 MG/200 ML (4 MG/ML) INTRAVENOUS PIGGYBACK MO	3	B vs D
CALDOLOR 800 MG/8 ML (100 MG/ML) INTRAVENOUS SOLUTION MO	3	B vs D
CAMBIA 50 MG ORAL POWDER PACKET DL	4	ST,QL (9 per 30 days)
CELEBREX 100 MG, 200 MG, 400 MG, 50 MG CAPSULE MO	3	PA,QL (60 per 30 days)
<i>celecoxib 100 mg, 200 mg, 400 mg, 50 mg capsule</i> MO	1	QL (60 per 30 days)
<i>codeine sulfate 15 mg, 30 mg tablet</i> DL	1	QL (360 per 30 days)
<i>codeine sulfate 60 mg tablet</i> DL	1	QL (180 per 30 days)
<i>asa-butalb-caff-cod #3 capsule</i> DL	1	QL (360 per 30 days)
CONZIP 100 MG, 200 MG, 300 MG CAPSULE, EXTENDED RELEASE; CONZIP 100 MG, 200 MG, 300 MG CAPSULE, EXTENDED RELEASE DL	3	ST,QL (30 per 30 days)
DAYPRO 600 MG TABLET MO	3	
DEMEROL 100 MG TABLET DL	3	QL (360 per 30 days)
DEMEROL 100 MG/ML INJECTION SOLUTION DL	3	B vs D,QL (360 per 30 days)
DEMEROL 50 MG/ML INJECTION SOLUTION DL	3	B vs D,QL (720 per 30 days)
DEMEROL (PF) 100 MG/2 ML, 100 MG/ML INJECTION SOLUTION; DEMEROL 100 MG/2 ML, 100 MG/ML AMPUL DL	3	B vs D,QL (360 per 30 days)
DEMEROL (PF) 100 MG/ML INJECTION SYRINGE DL	3	B vs D,QL (360 per 30 days)
DEMEROL (PF) 25 MG/ML INJECTION SYRINGE DL	3	B vs D,QL (1440 per 30 days)
DEMEROL (PF) 50 MG/ML INJECTION SYRINGE DL	3	B vs D,QL (720 per 30 days)
DEMEROL (PF) 75 MG/ML INJECTION SYRINGE DL	3	B vs D,QL (480 per 30 days)
DEMEROL 25 MG/0.5 ML, 50 MG/ML, 75 MG/1.5 ML AMPUL DL	3	B vs D,QL (720 per 30 days)
<i>diclofenac epolamine 1.3% ptch</i> MO	1	PA,QL (60 per 30 days)
<i>diclofenac pot 50 mg tablet</i> MO	1	
<i>diclofenac 1.5% topical soln</i> MO	1	PA,QL (300 per 30 days)
<i>diclofenac sod ec 25 mg, 50 mg, 75 mg tab</i> MO	1	
<i>diclofenac sod er 100 mg tab</i> MO	1	
<i>diclofenac sodium 1% gel</i> MO	1	
<i>diclofenac-misoprost 50-0.2 tb; diclofenac-misoprost 75-0.2 tb</i> MO	1	
<i>diflunisal 500 mg tablet</i> MO	1	
DILAUDID 1 MG/ML ORAL LIQUID DL	3	PA,QL (2400 per 30 days)
DILAUDID 2 MG, 4 MG TABLET DL	4	PA,QL (360 per 30 days)
DILAUDID 8 MG TABLET DL	4	PA,QL (240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DOLOPHINE 10 MG TABLET DL	3	QL (240 per 30 days)
DOLOPHINE 5 MG TABLET DL	3	QL (480 per 30 days)
DUEXIS 800 MG-26.6 MG TABLET DL	4	PA,QL (90 per 30 days)
DURAGESIC 100 MCG/HR, 12 MCG/HR, 25 MCG/HR, 50 MCG/HR, 75 MCG/HR TRANSDERMAL PATCH DL	4	PA,QL (20 per 30 days)
DURAMORPH (PF) 0.5 MG/ML INJECTION SOLUTION DL	3	B vs D,QL (7200 per 30 days)
DURAMORPH (PF) 1 MG/ML INJECTION SOLUTION DL	3	B vs D,QL (3600 per 30 days)
<i>divorah 325 mg-30 mg-16 mg tablet</i> DL	1	QL (300 per 30 days)
EC-NAPROSYN 375 MG, 500 MG TABLET,DELAYED RELEASE MO	3	PA
<i>ec-naproxen 375 mg tablet,delayed release</i> MO	3	PA
<i>ec-naproxen 500 mg tablet,delayed release</i> MO	1	
EMBEDA ER 100-4 MG, 20-0.8 MG, 30-1.2 MG, 50-2 MG, 60-2.4 MG, 80-3.2 MG CAPSULE DL	3	ST,QL (60 per 30 days)
<i>endocet 10 mg-325 mg tablet; endocet 2.5 mg-325 mg tablet; endocet 5 mg-325 mg tablet; endocet 7.5 mg-325 mg tablet</i> DL	1	QL (360 per 30 days)
ESGIC 50 MG-325 MG-40 MG CAPSULE MO	1	QL (180 per 30 days)
ESGIC 50 MG-325 MG-40 MG TABLET MO	1	QL (180 per 30 days)
<i>etodolac 200 mg, 300 mg capsule</i> MO	1	
<i>etodolac 400 mg, 500 mg tablet</i> MO	1	
<i>etodolac er 400 mg, 500 mg, 600 mg tablet</i> MO	1	
EXALGO ER 12 MG TABLET DL	4	ST,QL (180 per 30 days)
EXALGO ER 16 MG TABLET DL	4	ST,QL (120 per 30 days)
EXALGO ER 32 MG TABLET DL	4	ST,QL (60 per 30 days)
EXALGO ER 8 MG TABLET DL	4	ST,QL (240 per 30 days)
FELDENE 10 MG, 20 MG CAPSULE MO	3	
<i>fenoprofen 200 mg, 400 mg capsule</i> MO	1	
<i>fenoprofen 600 mg tablet</i> MO	1	
<i>fentanyl 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75 mcg/hr, 87.5 mcg/hour patch; fentanyl 37.5 mcg/hr patch; fentanyl 62.5 mcg/hr patch; fentanyl 87.5 mcg/hr patch</i> DL	1	QL (20 per 30 days)
<i>fentanyl cit 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg buccal tb</i> DL	4	PA,QL (120 per 30 days)
<i>fentanyl cit otfc 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg; fentanyl citrate otfc 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg</i> DL	4	PA,QL (120 per 30 days)
<i>fentanyl 100 mcg/2 ml ampul</i> DL	1	B vs D,QL (720 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
FENTORA 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG BUCCAL TABLET, EFFERVESCENT DL	4	PA,QL (120 per 30 days)
<i>fioricet 50 mg-300 mg-40 mg capsule</i> MO	1	QL (180 per 30 days)
FIORICET WITH CODEINE 50 MG-300 MG-40 MG-30 MG CAPSULE DL	4	QL (180 per 30 days)
FIORINAL 50 MG-325 MG-40 MG CAPSULE MO	3	QL (180 per 30 days)
FIORINAL-CODEINE #3 30 MG-50 MG-325 MG-40 MG CAPSULE DL	3	QL (360 per 30 days)
FLECTOR 1.3 % TRANSDERMAL 12 HOUR PATCH MO	3	PA,QL (60 per 30 days)
<i>flurbiprofen 100 mg, 50 mg tablet</i> MO	1	
<i>hydrocodone er 10 mg, 15 mg, 20 mg, 30 mg, 40 mg capsule</i> DL	1	ST,QL (90 per 30 days)
<i>hydrocodone er 50 mg capsule</i> DL	1	ST,QL (120 per 30 days)
<i>hydrocodone-acetamin 10-300 mg, 5-300 mg, 7.5-300 mg;</i> <i>hydrocodone-acetamin 7.5-300</i> DL	1	QL (390 per 30 days)
<i>hydrocodone-acetamin 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg;</i> <i>hydrocodone-acetamin 2.5-325; hydrocodone-acetamin 7.5-325</i> DL	1	QL (360 per 30 days)
<i>hydrocodone-acetamin 10-325/15</i> DL	1	QL (2700 per 30 days)
<i>hydrocodone-acetamin 7.5-325/15</i> DL	1	QL (5520 per 30 days)
<i>hydrocodone-ibuprofen 10-200; hydrocodone-ibuprofen 10-200 mg, 5-200 mg,</i> <i>7.5-200 mg; hydrocodone-ibuprofen 7.5-200</i> DL	1	QL (150 per 30 days)
<i>hydromorphone 0.5 mg/0.5 ml, 1 mg/ml; hydromorphone 0.5 mg/0.5 ml, 1</i> <i>mg/ml carpuct</i> DL	1	B vs D,QL (720 per 30 days)
<i>hydromorphone 1 mg/ml solution</i> DL	1	QL (2400 per 30 days)
<i>hydromorphone 2 mg, 4 mg tablet</i> DL	1	QL (360 per 30 days)
<i>hydromorphone 2 mg/ml carpuct</i> DL	1	QL (360 per 30 days)
<i>hydromorphone 2 mg/ml vial</i> DL	1	B vs D,QL (360 per 30 days)
<i>hydromorphone 4 mg/ml carpuct</i> DL	1	B vs D,QL (180 per 30 days)
<i>hydromorphone 8 mg tablet</i> DL	1	QL (240 per 30 days)
<i>hydromorphone hcl 1 mg/ml amp</i> DL	1	B vs D,QL (720 per 30 days)
<i>hydromorphone hcl 4 mg/ml amp</i> DL	1	B vs D,QL (180 per 30 days)
<i>hydromorphone hcl er 12 mg tab</i> DL	1	ST,QL (180 per 30 days)
<i>hydromorphone hcl er 16 mg tab</i> DL	1	ST,QL (120 per 30 days)
<i>hydromorphone hcl er 32 mg tab</i> DL	1	ST,QL (60 per 30 days)
<i>hydromorphone hcl er 8 mg tab</i> DL	1	ST,QL (240 per 30 days)
<i>hydromorphone 1 mg/ml vial</i> DL	1	B vs D,QL (720 per 30 days)
<i>hydromorphone 4 mg/ml vial</i> DL	1	B vs D,QL (180 per 30 days)
<i>hydromorphone 500 mg/50 ml vl</i> DL	1	QL (144 per 30 days)
HYSINGLA ER 100 MG, 120 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG TABLET, CRUSH RESISTANT, EXTENDED RELEASE DL	3	ST,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ibu 400 mg, 600 mg, 800 mg tablet</i> MO	1	
IBUDONE 10 MG-200 MG TABLET DL	1	QL (150 per 30 days)
<i>ibudone 5-200 mg tablet</i> DL	1	QL (150 per 30 days)
<i>ibuprofen 100 mg/5 ml susp</i> MO	1	
<i>ibuprofen 400 mg, 600 mg, 800 mg tablet</i> MO	1	
<i>oxycodone-ibuprofen 5-400 tab</i> DL	1	QL (240 per 30 days)
INDOCIN 25 MG/5 ML ORAL SUSPENSION DL	4	
INDOCIN 50 MG RECTAL SUPPOSITORY DL	4	
<i>indomethacin 25 mg, 50 mg, 75 mg capsule; indomethacin er 25 mg, 50 mg, 75 mg capsule</i> MO	1	
<i>indomethacin 1 mg vial</i> MO	1	
INFUMORPH P/F 10 MG/ML INJECTION SOLUTION DL	3	B vs D,QL (360 per 30 days)
INFUMORPH P/F 25 MG/ML INJECTION SOLUTION DL	3	B vs D,QL (150 per 30 days)
KADIAN 10 MG, 100 MG, 20 MG, 200 MG, 30 MG, 40 MG, 50 MG, 60 MG, 80 MG CAPSULE,EXTENDED RELEASE DL	4	ST,QL (60 per 30 days)
<i>ketoprofen 25 mg, 50 mg, 75 mg capsule</i> MO	1	
<i>ketoprofen er 200 mg capsule</i> MO	1	
<i>ketorolac 10 mg tablet</i> MO	1	QL (20 per 30 days)
<i>ketorolac 15 mg/ml, 30 mg/ml, 30 mg/ml (1 ml), 60 mg/2 ml vial; ketorolac 30 mg/ml vial; ketorolac 300 mg/10 ml vial</i> MO	1	
<i>ketorolac 15 mg/ml, 30 mg/ml, 60 mg/2 ml carpject</i> MO	1	
<i>ketorolac 15 mg/ml, 30 mg/ml, 60 mg/2 ml isecure syr; ketorolac 15 mg/ml, 30 mg/ml, 60 mg/2 ml syringe</i> MO	1	
<i>ketorolac 15.75 mg nasal spray</i> DL	4	PA,QL (5 per 30 days)
LAZANDA 100 MCG/SPRAY, 300 MCG/SPRAY, 400 MCG/SPRAY NASAL SPRAY DL	4	PA,QL (30 per 30 days)
<i>levorphanol 2 mg tablet</i> DL	4	QL (240 per 30 days)
<i>levorphanol 3 mg tablet</i> DL	4	QL (150 per 30 days)
LICART 1.3 % TRANSDERMAL 24 HOUR PATCH DL	4	PA,QL (30 per 30 days)
LODINE 400 MG TABLET MO	3	PA
<i>lorcet (hydrocodone) 5 mg-325 mg tablet</i> DL	1	QL (360 per 30 days)
<i>lorcet hd 10 mg-325 mg tablet</i> DL	1	QL (360 per 30 days)
<i>lorcet plus 7.5-325 mg tablet</i> DL	1	QL (360 per 30 days)
<i>lortab elixir 10 mg-300 mg/15 ml oral solution</i> DL	1	QL (6000 per 30 days)
<i>meclofenamate 100 mg, 50 mg capsule</i> MO	1	
<i>mefenamic acid 250 mg capsule</i> MO	1	
<i>meloxicam 15 mg tablet</i> MO	1	QL (30 per 30 days)
<i>meloxicam 7.5 mg tablet</i> MO	1	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
meperidine 10 mg/ml cartrdge ^{DL}	1	B vs D,QL (3600 per 30 days)
meperidine 100 mg tablet ^{DL}	1	QL (360 per 30 days)
meperidine 50 mg tablet ^{DL}	1	QL (480 per 30 days)
meperidine 50 mg/5 ml solution ^{DL}	1	QL (720 per 30 days)
meperidine 100 mg/ml vial ^{DL}	1	B vs D,QL (360 per 30 days)
meperidine 25 mg/ml vial ^{DL}	1	B vs D,QL (1440 per 30 days)
meperidine 50 mg/ml vial ^{DL}	1	B vs D,QL (720 per 30 days)
methadone 10 mg/5 ml solution ^{DL}	1	QL (1800 per 30 days)
methadone 10 mg/ml oral conc ^{DL}	1	QL (360 per 30 days)
methadone 5 mg/5 ml solution ^{DL}	1	QL (3600 per 30 days)
methadone hcl 10 mg tablet ^{DL}	1	QL (240 per 30 days)
methadone hcl 10 mg/ml vial ^{DL}	1	QL (360 per 30 days)
methadone hcl 5 mg tablet ^{DL}	1	QL (480 per 30 days)
methadone intensol 10 mg/ml oral concentrate ^{DL}	1	QL (360 per 30 days)
METHADOSE 10 MG/ML ORAL CONCENTRATE ^{DL}	3	QL (360 per 30 days)
mitigo (pf) 10 mg/ml injection solution ^{DL}	4	B vs D,QL (360 per 30 days)
mitigo (pf) 25 mg/ml injection solution ^{DL}	4	B vs D,QL (150 per 30 days)
MOBIC 15 MG TABLET ^{MO}	3	PA,QL (30 per 30 days)
MOBIC 7.5 MG TABLET ^{MO}	3	PA,QL (60 per 30 days)
MORPHABOND ER 100 MG TABLET ^{DL}	3	ST,QL (180 per 30 days)
MORPHABOND ER 15 MG, 30 MG TABLET ^{DL}	3	ST,QL (90 per 30 days)
MORPHABOND ER 60 MG TABLET ^{DL}	3	ST,QL (60 per 30 days)
morphine 10 mg/ml carpject ^{DL}	1	B vs D,QL (360 per 30 days)
morphine 2 mg/ml carpject ^{DL}	1	B vs D,QL (1800 per 30 days)
morphine 4 mg/ml carpject ^{DL}	1	B vs D,QL (900 per 30 days)
morphine 5 mg/ml syringe ^{DL}	1	B vs D
morphine 8 mg/ml isecure syrng ^{DL}	1	B vs D,QL (450 per 30 days)
morphine sulf 10 mg/5 ml soln ^{DL}	1	QL (2700 per 30 days)
morphine sulf 20 mg/5 ml soln ^{DL}	1	QL (1350 per 30 days)
morphine sulf er 100 mg tablet ^{DL}	1	QL (180 per 30 days)
morphine sulf er 15 mg, 30 mg, 60 mg tablet ^{DL}	1	QL (120 per 30 days)
morphine sulf er 200 mg tablet ^{DL}	1	QL (90 per 30 days)
morphine sulfate 10 mg/ml vial ^{DL}	1	B vs D,QL (360 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>morphine sulfate 2 mg/ml vial</i> DL	1	B vs D,QL (1800 per 30 days)
<i>morphine sulfate 4 mg/ml vial</i> DL	1	B vs D,QL (900 per 30 days)
<i>morphine sulfate 5 mg/ml vial</i> DL	1	B vs D,QL (720 per 30 days)
<i>morphine sulfate 8 mg/ml vial</i> DL	1	B vs D,QL (450 per 30 days)
<i>morphine sulfate er 10 mg, 100 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg cap</i> DL	1	ST,QL (60 per 30 days)
<i>morphine sulfate er 120 mg, 60 mg, 75 mg, 90 mg cap</i> DL	1	ST,QL (60 per 30 days)
<i>morphine sulfate er 30 mg, 45 mg cap</i> DL	1	ST,QL (30 per 30 days)
<i>morphine sulfate ir 15 mg, 30 mg tab</i> DL	1	QL (180 per 30 days)
<i>morphine 10 mg/10 ml vial; morphine sulfate 1 mg/ml vial</i> DL	1	B vs D,QL (3600 per 30 days)
<i>morphine 5 mg/10 ml vial</i> DL	1	B vs D,QL (7200 per 30 days)
<i>morphine 5 mg/ml vial</i> DL	1	B vs D,QL (720 per 30 days)
<i>morphine sulf 100 mg/5 ml conc</i> DL	1	QL (540 per 30 days)
MS CONTIN 100 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (180 per 30 days)
MS CONTIN 15 MG, 30 MG, 60 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (120 per 30 days)
MS CONTIN 200 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (90 per 30 days)
<i>nabumetone 500 mg, 750 mg tablet</i> MO	1	
<i>nalbuphine 100 mg/10 ml vial</i> DL	1	QL (240 per 30 days)
<i>nalbuphine 200 mg/10 ml vial</i> DL	1	QL (120 per 30 days)
NALFON 400 MG CAPSULE MO	3	
NALFON 600 MG TABLET MO	1	
<i>nalocet 2.5 mg-300 mg tablet</i> DL	4	PA,QL (360 per 30 days)
NAPRELAN CR 375 MG TAB,EXTENDED RELEASE 24 HR MPHASE DL	4	ST,QL (120 per 30 days)
NAPRELAN CR 500 MG TAB,EXTENDED RELEASE 24 HR MPHASE DL	4	ST,QL (90 per 30 days)
NAPRELAN CR 750 MG TAB,EXTENDED RELEASE 24 HR MPHASE DL	4	ST,QL (60 per 30 days)
NAPROSYN 500 MG TABLET MO	3	PA
<i>naproxen 125 mg/5 ml suspen</i> MO	1	
<i>naproxen 250 mg, 375 mg, 500 mg tablet; naproxen dr 250 mg, 375 mg, 500 mg tablet</i> MO	1	
<i>naproxen sod cr 375 mg tablet</i> MO	1	ST,QL (120 per 30 days)
<i>naproxen sod cr 500 mg tablet</i> MO	1	ST,QL (90 per 30 days)
<i>naproxen sodium 275 mg, 550 mg tab</i> MO	1	
<i>naproxen-esomepraz dr 375-20mg; naproxen-esomepraz dr 500-20mg</i> DL	4	PA,QL (60 per 30 days)
NORCO 10 MG-325 MG TABLET; NORCO 5 MG-325 MG TABLET; NORCO 7.5 MG-325 MG TABLET DL	1	PA,QL (360 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NUCYNTA 100 MG, 50 MG, 75 MG TABLET DL	3	ST,QL (180 per 30 days)
NUCYNTA ER 100 MG, 150 MG, 200 MG, 250 MG, 50 MG TABLET,EXTENDED RELEASE DL	4	ST,QL (60 per 30 days)
OPANA 10 MG, 5 MG TABLET DL	4	PA,QL (360 per 30 days)
oxaprozin 600 mg tablet MO	1	
OXAYDO 5 MG, 7.5 MG TABLET,ORAL ONLY (NOT FEEDING TUBES); OXAYDO 5 MG, 7.5 MG TABLET,ORAL ONLY (NOT FOR FEEDING TUBES) DL	4	PA,QL (360 per 30 days)
oxycodone hcl 10 mg, 15 mg, 20 mg, 30 mg, 5 mg tablet DL	1	QL (360 per 30 days)
oxycodone hcl 100 mg/5 ml conc DL	1	QL (270 per 30 days)
oxycodone hcl 5 mg capsule DL	1	QL (360 per 30 days)
oxycodone hcl 5 mg/5 ml soln DL	1	QL (5400 per 30 days)
oxycodone hcl er 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg tablet DL	3	PA,QL (90 per 30 days)
oxycodone hcl er 80 mg tablet DL	3	PA,QL (120 per 30 days)
oxycodon-acetaminophen 2.5-300 DL	4	PA,QL (360 per 30 days)
oxycodon-acetaminophen 2.5-325; oxycodon-acetaminophen 7.5-325; oxycodone-acetaminophen 10-325; oxycodone-acetaminophen 5-325 DL	1	QL (360 per 30 days)
oxycodone-aspirin 4.8355-325 DL	1	QL (360 per 30 days)
OXYCONTIN 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG TABLET,CRUSH RESISTANT,EXTENDED RELEASE DL	3	PA,QL (90 per 30 days)
OXYCONTIN 80 MG TABLET,CRUSH RESISTANT,EXTENDED RELEASE DL	3	PA,QL (120 per 30 days)
oxymorphone hcl 10 mg, 5 mg tablet DL	1	QL (360 per 30 days)
oxymorphone hcl er 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg tab; oxymorphone hcl er 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg tablet DL	1	ST,QL (60 per 30 days)
PENNSAID 2 % TOPICAL SOLUTION IN PACKET DL	4	PA
PENNSAID 20 MG/GRAM/ACTUATION (2 %) TOPICAL SOLN IN METERED-DOSE PUMP DL	4	PA,QL (224 per 28 days)
pentazocine-naloxone tablet DL	1	QL (360 per 30 days)
PERCOCET 10 MG-325 MG TABLET; PERCOCET 5 MG-325 MG TABLET; PERCOCET 7.5 MG-325 MG TABLET DL	4	PA,QL (360 per 30 days)
PERCOCET 2.5 MG-325 MG TABLET DL	1	PA,QL (360 per 30 days)
phrenilin forte 50-300-40 mg MO	1	QL (180 per 30 days)
piroxicam 10 mg, 20 mg capsule MO	1	
primlev 10 mg-300 mg tablet; primlev 5 mg-300 mg tablet; primlev 7.5 mg-300 mg tablet DL	4	QL (390 per 30 days)
profeno 600 mg tablet MO	1	
prolate 10 mg-300 mg tablet; prolate 5 mg-300 mg tablet; prolate 7.5 mg-300 mg tablet DL	4	QL (390 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
QMIIZ ODT 15 MG, 7.5 MG TABLET MO	3	ST,QL (30 per 30 days)
RELAFEN 500 MG, 750 MG TABLET DL	4	ST
RELAFEN DS 1,000 MG TABLET DL	4	ST,QL (60 per 30 days)
ROXICODONE 15 MG, 30 MG, 5 MG TABLET DL	3	PA,QL (360 per 30 days)
ROXYBOND 15 MG, 30 MG TABLET DL	4	PA,QL (180 per 30 days)
ROXYBOND 5 MG TABLET DL	4	PA,QL (360 per 30 days)
SPRIX 15.75 MG/SPRAY NASAL SPRAY DL	4	PA,QL (5 per 30 days)
SUBSYS 1,200 MCG (600 MCG/SPRAY X 2), 1,600 MCG (800 MCG/SPRAY X 2), 100 MCG/SPRAY, 200 MCG/SPRAY, 400 MCG/SPRAY, 600 MCG/SPRAY, 800 MCG/SPRAY SUBLINGUAL SPRAY; SUBSYS 1,200 MCG (600 MCG/SPRAY X2) SUBLINGUAL SPRAY; SUBSYS 1,600 MCG (800 MCG/SPRAY X2) SUBLINGUAL SPRAY DL	4	PA,QL (120 per 30 days)
<i>sulindac 150 mg, 200 mg tablet</i> MO	1	
TALWIN 30 MG/ML VIAL DL	3	QL (360 per 30 days)
<i>tencon 50 mg-325 mg tablet</i> MO	1	QL (180 per 30 days)
TIVORBEX 20 MG, 40 MG CAPSULE DL	4	ST,QL (90 per 30 days)
<i>tolmetin sodium 200 mg, 600 mg tab</i> MO	1	
<i>tolmetin sodium 400 mg cap</i> MO	1	
<i>tramadol er 100 mg, 200 mg, 300 mg tablet; tramadol hcl er 100 mg, 200 mg, 300 mg tablet</i> DL	1	QL (30 per 30 days)
<i>tramadol hcl 100 mg tablet</i> DL	1	QL (120 per 30 days)
<i>tramadol hcl 50 mg tablet</i> DL	1	QL (240 per 30 days)
<i>tramadol hcl er 100 mg, 150 mg, 200 mg, 300 mg capsule</i> DL	1	ST,QL (30 per 30 days)
<i>tramadol-acetaminophn 37.5-325</i> DL	1	QL (240 per 30 days)
TREZIX 320.5 MG-30 MG-16 MG CAPSULE DL	1	QL (300 per 30 days)
TYLENOL WITH CODEINE #3 TABLET DL	1	PA,QL (360 per 30 days)
TYLENOL WITH CODEINE #4 TABLET DL	1	PA,QL (180 per 30 days)
ULTRACET 37.5 MG-325 MG TABLET DL	3	QL (240 per 30 days)
ULTRAM 50 MG TABLET DL	3	QL (240 per 30 days)
<i>vanatol lq 50 mg-325 mg-40 mg/15 ml oral solution</i> DL	4	QL (450 per 30 days)
<i>vanatol s 50 mg-325 mg-40 mg/15 ml oral solution</i> DL	4	QL (450 per 30 days)
<i>vicodin 5-300 mg tablet</i> DL	1	QL (390 per 30 days)
<i>vicodin hp 10 mg-300 mg tablet</i> DL	1	QL (390 per 30 days)
VIMOVO 375 MG-20 MG TABLET,IMMEDIATE AND DELAY RELEASE; VIMOVO 500 MG-20 MG TABLET,IMMEDIATE AND DELAY RELEASE DL	4	PA,QL (60 per 30 days)
VIVLODEX 10 MG, 5 MG CAPSULE DL	4	PA,QL (30 per 30 days)
VOLTAREN 1 % TOPICAL GEL MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VOLTAREN-XR 100 MG TABLET,EXTENDED RELEASE MO	3	PA
vtol lq 50 mg-325 mg-40 mg/15 ml oral solution DL	4	QL (450 per 30 days)
XTAMPZA ER 13.5 MG, 18 MG, 27 MG, 36 MG, 9 MG CAPSULE SPRINKLE DL	2	QL (60 per 30 days)
ZEBUTAL 50 MG-325 MG-40 MG CAPSULE MO	1	QL (180 per 30 days)
ZIPSOR 25 MG CAPSULE DL	4	QL (120 per 30 days)
ZOHYDRO ER 10 MG, 15 MG, 20 MG, 30 MG, 40 MG CAPSULE, ORAL ONLY,EXTENDED RELEASE DL	3	ST,QL (90 per 30 days)
ZOHYDRO ER 50 MG CAPSULE, ORAL ONLY,EXTENDED RELEASE DL	3	ST,QL (120 per 30 days)
ZORVOLEX 18 MG, 35 MG CAPSULE DL	4	ST,QL (90 per 30 days)
Anesthetics		
bupivacaine 0.25% vial; bupivacaine 0.5% vial MO	1	
bupivacaine 0.25% vial; bupivacaine 0.5% (5 mg/ml) amp; bupivacaine 0.75% vial MO	1	
bupivacain 0.75%-dextros 8.25% MO	1	
bupivacaine 0.25%-epi 1:200000; bupivacaine 0.5%-epi 1:200,000 MO	1	
bupivacaine 0.25%-epi 1:200000; bupivacaine 0.5%-epi 1:200,000 MO	1	
bupivacaine 0.5%-epi 1:200,000 MO	1	
CARBOCAINE 1 % (10 MG/ML), 2 % INJECTION SOLUTION MO	3	
CARBOCAINE (PF) 10 MG/ML (1 %), 15 MG/ML (1.5 %), 20 MG/ML (2 %) INJECTION SOLUTION MO	3	
CARBOCAINE WITH NEO-COBEFRIN 2 %-1:20,000 INJECTION CARTRIDGE MO	1	
chloroprocaine 2% vial; chloroprocaine 3% vial MO	1	
CLOROTEKAL 10 MG/ML (1 %) INTRATHECAL SOLUTION MO	3	
glydo 2 % mucosal jelly in applicator MO	1	
lidocaine 5% ointment MO	1	PA
lidocaine 5% patch MO	1	PA,QL (90 per 30 days)
lidocaine 5% in d7.5w ampul MO	1	
lidocaine hcl 0.5% vial; lidocaine hcl 1% 50 mg/5 ml vl; lidocaine hcl 1.5% ampul; lidocaine hcl 2% 100 mg/5 ml; lidocaine hcl 4% ampul MO	1	
lidocaine hcl 0.5% vial; lidocaine hcl 1% vial; lidocaine hcl 2% vial; lidocaine hcl 4% solution MO	1	
lidocaine hcl 2% jelly MO	1	
lidocaine hcl 2% jelly uro-jet MO	1	
lidocaine viscous 2 % mucosal solution MO	1	
lidocaine 0.5%-epi 1:200,000; lidocaine 2%-epi 1:100,000 MO	1	
lidocaine 2%-epi 1:100,000; lidocaine 2%-epi 1:50,000 cart MO	1	
lidocaine-prilocaine cream MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LIDODERM 5 % TOPICAL PATCH DL	4	PA,QL (90 per 30 days)
MARCAINE 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML) INJECTION SOLUTION MO	3	
MARCAINE (PF) 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML), 0.75 % (7.5 MG/ML) INJECTION SOLUTION MO	3	
MARCAINE SPINAL (PF) 0.75 % (7.5 MG/ML) INJECTION SOLUTION MO	3	
MARCAINE-EPINEPHRINE 0.25 %-1:200,000, 0.5 %-1:200,000 INJECTION SOLUTION MO	3	
<i>marcaine-epinephrine 0.5 %-1:200,000 injection cartridge</i> MO	1	
MARCAINE-EPINEPHRINE (PF) 0.25 %-1:200,000, 0.5 %-1:200,000 INJECTION SOLUTION MO	3	
<i>mepivacaine hcl 3% cartridge</i> MO	1	
NAROPIN (PF) 10 MG/ML (1 %), 2 MG/ML (0.2 %), 5 MG/ML (0.5 %), 7.5 MG/ML (0.75 %) INJECTION SOLUTION MO	3	
NESACAINE 10 MG/ML (1 %), 20 MG/ML (2 %) INJECTION SOLUTION MO	3	
NESACAINE-MPF 20 MG/ML (2 %), 30 MG/ML (3 %) INJECTION SOLUTION MO	3	
PLIAGLIS 7 %-7 % TOPICAL CREAM MO	3	
<i>polocaine 1 % (10 mg/ml), 2 % injection solution</i> MO	1	
<i>polocaine-mpf 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %) injection solution</i> MO	1	
<i>ropivacaine 0.2% 200 mg/100 ml; ropivacaine 0.5% 100 mg/20 ml; ropivacaine 0.75% 150 mg/20 ml; ropivacaine 1% 200 mg/20 ml v1</i> MO	1	
SENSORCAINE 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML) INJECTION SOLUTION MO	1	
<i>sensorcaine-epinephrine 0.25 %-1:200,000, 0.5 %-1:200,000 injection solution</i> MO	1	
SENSORCAINE-MPF 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML) INJECTION SOLUTION MO	1	
<i>sensorcaine-mpf 0.75 % (7.5 mg/ml) injection solution</i> MO	1	
<i>sensorcaine-mpf spinal 0.75 % (7.5 mg/ml) injection solution</i> MO	1	
<i>sensorcaine-mpf/epinephrine 0.25 %-1:200,000 injection solution</i> MO	1	
SENSORCAINE-MPF/EPINEPHRINE 0.5 %-1:200,000, 0.75 %-1:200,000 INJECTION SOLUTION MO	1	
SYNERA 70 MG-70 MG PATCH DL	4	PA
<i>vivacaine 0.5 %-1:200,000 injection cartridge</i> MO	1	
ZTLIDO 1.8 % TOPICAL PATCH MO	3	PA,QL (90 per 30 days)
ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS		
<i>acamprosate calc dr 333 mg tab</i> MO	1	
ANTABUSE 250 MG, 500 MG TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BUNAVAIL 2.1 MG-0.3 MG BUCCAL FILM; BUNAVAIL 4.2 MG-0.7 MG BUCCAL FILM; BUNAVAIL 6.3 MG-1 MG BUCCAL FILM MO	3	PA,QL (60 per 30 days)
<i>buprenorphine 2 mg, 8 mg tablet sl</i> MO	1	QL (90 per 30 days)
<i>bupreno-nalox 2-0.5 mg, 4-1 mg, 8-2 mg sl film; buprenorp-nalox 2-0.5 mg, 4-1 mg, 8-2 mg sl film</i> MO	1	QL (90 per 30 days)
<i>buprenor-nalox 12-3 mg sl film</i> MO	1	QL (60 per 30 days)
<i>buprenorphin-naloxon 2-0.5 mg, 8-2 mg sl; buprenorphn-naloxn 2-0.5 mg, 8-2 mg sl</i> MO	3	PA,QL (90 per 30 days)
<i>bupropion hcl sr 150 mg tablet</i> MO	1	QL (90 per 30 days)
CHANTIX 0.5 MG, 1 MG TABLET MO	3	QL (56 per 28 days)
CHANTIX CONTINUING MONTH BOX 1 MG TABLET MO	3	QL (56 per 28 days)
CHANTIX STARTING MONTH BOX 0.5 MG (11)-1 MG (42) TABLETS IN DOSE PACK MO	3	QL (56 per 28 days)
<i>disulfiram 250 mg, 500 mg tablet</i> MO	1	
EVZIO 2 MG AUTO-INJECTOR DL	4	PA,QL (0.8 per 30 days)
LUCEMYRA 0.18 MG TABLET DL	4	PA,QL (224 per 365 days)
<i>naloxone 0.4 mg/ml vial</i> MO	1	
<i>naloxone 0.4 mg/ml, 1 mg/ml carpject; naloxone 2 mg/2 ml syringe</i> MO	1	
<i>naloxone 2 mg auto-injector</i> MO	3	QL (0.8 per 30 days)
<i>naltrexone 50 mg tablet</i> MO	1	
NARCAN 4 MG/ACTUATION NASAL SPRAY MO	2	QL (2 per 30 days)
NICOTROL 10 MG INHALATION CARTRIDGE MO	3	
NICOTROL NS 10 MG/ML NASAL SPRAY MO	3	
SUBOXONE 12 MG-3 MG SUBLINGUAL FILM MO	3	PA,QL (60 per 30 days)
SUBOXONE 2 MG-0.5 MG SUBLINGUAL FILM; SUBOXONE 4 MG-1 MG SUBLINGUAL FILM; SUBOXONE 8 MG-2 MG SUBLINGUAL FILM MO	3	PA,QL (90 per 30 days)
VIVITROL 380 MG INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE DL	4	QL (1 per 28 days)
ZUBSOLV 0.7 MG-0.18 MG SUBLINGUAL TABLET; ZUBSOLV 1.4 MG-0.36 MG SUBLINGUAL TABLET; ZUBSOLV 2.9 MG-0.71 MG SUBLINGUAL TABLET; ZUBSOLV 5.7 MG-1.4 MG SUBLINGUAL TABLET MO	1	QL (90 per 30 days)
ZUBSOLV 11.4 MG-2.9 MG SUBLINGUAL TABLET MO	1	QL (30 per 30 days)
ZUBSOLV 8.6 MG-2.1 MG SUBLINGUAL TABLET MO	1	QL (60 per 30 days)
ZYBAN SR 150 MG TABLET MO	3	QL (90 per 30 days)
ANTIBACTERIALS		
<i>acetic acid 2% ear solution</i> MO	1	
ACTICLATE 150 MG TABLET DL	4	ST,QL (30 per 30 days)
ACTICLATE 75 MG TABLET DL	4	ST,QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
amikacin sulf 1 gram/4 ml vial; amikacin sulf 1,000 mg/4 ml, 500 mg/2 ml vial MO	1	
amoxicillin 125 mg, 250 mg tab chew MO	1	
amoxicillin 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml susp MO	1	
amoxicillin 250 mg, 500 mg capsule MO	1	
amoxicillin 500 mg, 875 mg tablet MO	1	
amox-clav 200-28.5 mg, 400-57 mg tab chew MO	1	
amox-clav 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml sus; amox-clav 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml susp MO	1	
amox-clav 250-125 mg, 500-125 mg, 875-125 mg tablet MO	1	
amox-clav er 1,000-62.5 mg tab MO	1	
ampicillin 250 mg, 500 mg capsule MO	1	
ampicillin 1 gm add-vantage vl; ampicillin 1 gm vial; ampicillin 1 gram, 10 gram, 125 mg, 2 gram, 250 mg, 500 mg vial; ampicillin 10 gm vial; ampicillin 2 gm add-vantage vl; ampicillin 2 gm vial MO	1	
ampicillin-sulb 1.5 g add vial; ampicillin-sulbactam 1.5 gm vl; ampicillin-sulbactam 15 gm vl; ampicillin-sulbactam 3 gm vial MO	1	
ARIKAYCE 590 MG/8.4 ML SUSPENSION FOR INHALATION VIA NEBULIZATION DL	4	PA,QL (235.2 per 28 days)
AUGMENTIN 125 MG-31.25 MG/5 ML ORAL SUSPENSION; AUGMENTIN 250 MG-62.5 MG/5 ML ORAL SUSPENSION DL	4	
AUGMENTIN 500 MG-125 MG TABLET; AUGMENTIN 875 MG-125 MG TABLET MO	3	PA
AUGMENTIN ES-600 600 MG-42.9 MG/5 ML ORAL SUSPENSION MO	3	
AUGMENTIN XR 1,000 MG-62.5 MG TABLET,EXTENDED RELEASE MO	3	
AVC 15% CREAM MO	3	
AVELOX 400 MG TABLET MO	3	PA
AVELOX 400 MG/250 ML IN SODIUM CHLORIDE(ISO-OSM) INTRAVENOUS PIGGYBACK MO	3	PA
avidoxy 100 mg tablet MO	1	ST
AVYCAZ 2.5 GRAM INTRAVENOUS SOLUTION DL	4	B vs D
AZACTAM 1 GRAM, 2 GRAM SOLUTION FOR INJECTION MO	3	PA
AZACTAM-ISO-OSMOT 1 GM/50 ML; AZACTAM-ISO-OSMOT 2 GM/50 ML MO	3	
azithromycin 1 gm pwd packet MO	1	
azithromycin 100 mg/5 ml, 200 mg/5 ml susp MO	1	
azithromycin 250 mg, 500 mg, 600 mg tablet MO	1	
azithromycin i.v. 500 mg vial MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
aztreonam 1 gm vial MO	1	
aztreonam 2 gm vial DL	4	
baciim 50,000 unit vial MO	1	
bacitracin 50,000 unit vial MO	1	
BACTRIM 400 MG-80 MG TABLET MO	3	
BACTRIM DS 800 MG-160 MG TABLET MO	3	
BAXDELA 300 MG INTRAVENOUS SOLUTION DL	4	QL (28 per 14 days)
BAXDELA 450 MG TABLET DL	4	QL (28 per 14 days)
BETHKIS 300 MG/4 ML SOLUTION FOR NEBULIZATION DL	4	PA
BICILLIN C-R 1,200,000 UNIT/2 ML INTRAMUSCULAR SYRINGE; BICILLIN C-R 900,000 UNIT-300K UNIT/2 ML INTRAMUSCULAR SYRINGE MO	3	
BICILLIN L-A 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML INTRAMUSCULAR SYRINGE MO	3	
cefaclor 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml susp; cefaclor 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml suspen MO	1	
cefaclor 250 mg, 500 mg capsule MO	1	
cefaclor er 500 mg tablet MO	1	
cefadroxil 1 gm tablet MO	1	
cefadroxil 250 mg/5 ml, 500 mg/5 ml susp MO	1	
cefadroxil 500 mg capsule MO	1	
cefazolin 1 gm add-van vial; cefazolin 1 gm vial; cefazolin 1 gram, 10 gram, 500 mg vial; cefazolin 10 gm vial MO	1	
cefazolin 1 g/50 ml-dextrose; cefazolin 2 g/100 ml-dextrose; cefazolin 2 g/50 ml-dextrose MO	1	
cefdinir 125 mg/5 ml, 250 mg/5 ml susp MO	1	
cefdinir 300 mg capsule MO	1	
cefepime hcl 1 gm vial; cefepime hcl 1 gram, 2 gram vial MO	1	
cefepime-dextrose 1 gm/50 ml; cefepime-dextrose 2 gm/50 ml MO	1	
cefepime 1 gm injection; cefepime 2 gm injection MO	3	
cefixime 100 mg/5 ml, 200 mg/5 ml susp MO	1	
cefixime 400 mg capsule MO	1	
CEFOTAN 1 GRAM, 2 GRAM SOLUTION FOR INJECTION MO	3	
cefotaxime sodium 1 gm vial MO	1	
cefotetan 1 gm vial; cefotetan 10 gm vial; cefotetan 2 gm vial MO	1	
cefotetan-dextr 1 g duplex bag; cefotetan-dextr 2 g duplex bag MO	1	
cefoxitin 1 gm vial; cefoxitin 10 gm vial; cefoxitin 2 gm vial MO	1	
cefoxitin 1 gm piggyback bag; cefoxitin 2 gm piggyback bag MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
cefpodoxime 100 mg, 200 mg tablet ^{MO}	1	
cefpodoxime 100 mg/5 ml, 50 mg/5 ml susp ^{MO}	1	
cefprozil 125 mg/5 ml, 250 mg/5 ml susp ^{MO}	1	
cefprozil 250 mg, 500 mg tablet ^{MO}	1	
ceftazidime 1 gm vial; ceftazidime 2 gm vial; ceftazidime 6 gm vial ^{MO}	1	
ceftazidime 1 gm piggyback; ceftazidime 2 gm piggyback ^{MO}	1	
ceftriaxone 1 gm add-vant vial; ceftriaxone 1 gm vial; ceftriaxone 1 gram, 10 gram, 100 gram, 2 gram, 250 mg, 500 mg bulk bag; ceftriaxone 1 gram, 10 gram, 100 gram, 2 gram, 250 mg, 500 mg vial; ceftriaxone 10 gm vial; ceftriaxone 2 gm add vial; ceftriaxone 2 gm vial ^{MO}	1	
ceftriaxone 1 gm-d5w bag; ceftriaxone 2 gm-d5w bag ^{MO}	1	
cefuroxime axetil 250 mg, 500 mg tab ^{MO}	1	
cefuroxime sod 1.5 gm vial; cefuroxime sod 1.5 gram, 7.5 gram, 750 mg vial; cefuroxime sod 7.5 gm vial ^{MO}	1	
cephalexin 125 mg/5 ml, 250 mg/5 ml susp ^{MO}	1	
cephalexin 250 mg, 500 mg tablet ^{MO}	1	
cephalexin 250 mg, 500 mg, 750 mg capsule ^{MO}	1	
chloramphen na succ 1 gm vl ^{MO}	1	
CIPRO 250 MG, 500 MG TABLET ^{MO}	3	
CIPRO 250 MG/5 ML, 500 MG/5 ML ORAL SUSPENSION ^{MO}	3	
ciprofloxacin 250 mg/5 ml, 500 mg/5 ml susp ^{MO}	1	
ciprofloxacin er 1,000 mg, 500 mg tab; ciprofloxacin er 1,000 mg, 500 mg tablet ^{MO}	1	
ciprofloxacin hcl 100 mg, 250 mg, 500 mg, 750 mg tab ^{MO}	1	
ciprofloxacin 200 mg/100ml-d5w; ciprofloxacin 400 mg/200ml-d5w ^{MO}	1	
CLAFORAN 1 GRAM, 10 GRAM, 2 GRAM INTRAVENOUS SOLUTION; CLAFORAN 1 GRAM, 10 GRAM, 2 GRAM SOLUTION FOR INJECTION ^{MO}	3	
clarithromycin 125 mg/5 ml, 250 mg/5 ml sus ^{MO}	1	
clarithromycin 250 mg, 500 mg tablet ^{MO}	1	
clarithromycin er 500 mg tab ^{MO}	1	
CLEOCIN 100 MG VAGINAL SUPPOSITORY ^{MO}	3	
CLEOCIN 150 MG/ML, 600 MG/4 ML, 900 MG/6 ML INJECTION SOLUTION; CLEOCIN PHOS 600 MG/4ML ADDVAN; CLEOCIN PHOS 900 MG/6ML ADDVAN ^{MO}	1	
CLEOCIN 2 % VAGINAL CREAM ^{MO}	3	PA
cleocin phos 300 mg/2ml addvan ^{MO}	1	
CLEOCIN HCL 150 MG, 300 MG, 75 MG CAPSULE ^{MO}	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CLEOCIN 300 MG-D5W-GALAXY; CLEOCIN 600 MG-D5W-GALAXY; CLEOCIN 900 MG-D5W-GALAXY MO	3	
CLEOCIN PEDIATRIC 75 MG/5 ML ORAL SOLUTION MO	1	
<i>clindamycin hcl 150 mg, 300 mg, 75 mg capsule</i> MO	1	
<i>clindamycin 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml-ns</i> MO	1	B vs D
<i>clindamycin-d5w 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml</i> MO	1	
<i>clindamycin 75 mg/5 ml soln</i> MO	1	
<i>clindamycin pediatric 75 mg/5 ml oral solution</i> MO	1	
<i>clindamycin 150 mg/ml, 300 mg/2 ml, 600 mg/4 ml, 900 mg/6 ml addvan;</i> <i>clindamycin ph 600 mg/4 ml vl</i> MO	1	
<i>clindamycin 2% vaginal cream</i> MO	1	
CLINDESSE 2 % VAGINAL CREAM,EXTENDED RELEASE MO	3	
<i>colistimethate 150 mg vial</i> MO	1	
COLY-MYCIN M PARENTERAL 150 MG SOLUTION FOR INJECTION DL	4	
<i>coremino 135 mg, 45 mg, 90 mg tablet,extended release</i> MO	1	ST,QL (30 per 30 days)
CUBICIN 500 MG INTRAVENOUS SOLUTION DL	4	
CUBICIN RF 500 MG INTRAVENOUS SOLUTION DL	4	
DALVANCE 500 MG INTRAVENOUS SOLUTION DL	4	QL (4 per 28 days)
<i>daptomycin 350 mg, 500 mg vial</i> DL	4	
<i>demeclocycline 150 mg tablet</i> MO	1	QL (240 per 30 days)
<i>demeclocycline 300 mg tablet</i> MO	1	QL (120 per 30 days)
<i>dicloxacillin 250 mg, 500 mg capsule</i> MO	1	
DIFICID 200 MG TABLET DL	4	
<i>doripenem 250 mg, 500 mg vial</i> MO	1	
DORYX 200 MG TABLET,DELAYED RELEASE MO	3	ST,QL (30 per 30 days)
DORYX 50 MG TABLET,DELAYED RELEASE MO	3	ST,QL (60 per 30 days)
DORYX 80 MG TABLET,DELAYED RELEASE DL	4	ST,QL (60 per 30 days)
DORYX MPC 120 MG TABLET, DELAYED RELEASE MO	3	ST,QL (60 per 30 days)
<i>doxy-100 100 mg intravenous solution</i> MO	1	
<i>doxycycline 50 mg tablet</i> MO	1	ST,QL (180 per 30 days)
<i>doxycycline hyc dr 100 mg tab</i> MO	1	ST,QL (90 per 30 days)
<i>doxycycline hyc dr 150 mg, 200 mg tab; doxycycline hyclate 150 mg, 200 mg tab</i> MO	1	ST,QL (30 per 30 days)
<i>doxycycline hyc dr 150 mg, 50 mg, 75 mg tab; doxycycline hyclate 150 mg, 50 mg, 75 mg tab</i> MO	1	ST,QL (60 per 30 days)
<i>doxycycline hyc dr 80 mg tab</i> DL	4	ST,QL (60 per 30 days)
<i>doxycycline hyclate 100 mg vl</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
doxycycline hyclate 100 mg, 20 mg tab MO	1	
doxycycline hyclate 100 mg, 50 mg cap MO	1	
doxycycline 25 mg/5 ml susp MO	1	
doxycycline ir-dr 40 mg cap MO	1	ST,QL (30 per 30 days)
doxycycline mono 100 mg, 150 mg, 50 mg, 75 mg tablet MO	1	
doxycycline mono 100 mg, 50 mg cap MO	1	
doxycycline mono 150 mg cap MO	1	QL (30 per 30 days)
doxycycline mono 75 mg capsule MO	1	QL (60 per 30 days)
E.E.S. 400 MG TABLET MO	1	
E.E.S. GRANULES 200 MG/5 ML ORAL SUSPENSION MO	3	
ertapenem 1 gram vial DL	4	
ERY-TAB 250 MG, 333 MG, 500 MG TABLET,DELAYED RELEASE MO	1	
ERYPED 200 200 MG/5 ML ORAL SUSPENSION MO	3	
ERYPED 400 MG/5 ML ORAL SUSPENSION DL	4	
ERYTHROCIN 500 MG INTRAVENOUS SOLUTION MO	1	
ERYTHROCIN (AS STEARATE) 250 MG TABLET MO	1	
erythromycin 250 mg, 333 mg, 500 mg filmtab; erythromycin dr 250 mg, 333 mg, 500 mg tablet MO	1	
erythromycin dr 250 mg cap MO	1	
erythromycin 200 mg/5 ml, 400 mg/5 ml susp MO	1	
erythromycin es 400 mg tab MO	1	
FETROJA 1 GRAM INTRAVENOUS SOLUTION DL	4	B vs D,QL (84 per 14 days)
FIRVANQ 25 MG/ML, 50 MG/ML ORAL SOLUTION MO	3	
FLAGYL 250 MG, 500 MG TABLET MO	3	
FLAGYL 375 MG CAPSULE MO	3	QL (320 per 30 days)
FORTAZ 1 GRAM, 2 GRAM, 500 MG SOLUTION FOR INJECTION MO	3	
FURADANTIN 25 MG/5 ML ORAL SUSPENSION MO	3	
gentamicin 0.1% cream MO	1	
gentamicin 0.1% ointment MO	1	
gentamicin 20 mg/2 ml, 40 mg/ml vial; gentamicin 80 mg/2 ml vial MO	1	
gentamicin 70 mg/ns 50 ml pb; gentamicin 90 mg/ns 100 ml pb; iso gentamicin 100 mg/100 ml, 100 mg/50 ml, 120 mg/100 ml, 60 mg/50 ml, 70 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml, 90 mg/100 ml; isoton gentamicin 100 mg/100 ml, 100 mg/50 ml, 120 mg/100 ml, 60 mg/50 ml, 70 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml, 90 mg/100 ml MO	1	
gentamicin ped 20 mg/2 ml vial MO	1	
gentamicin 10 mg/ml vial MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HIPREX 1 GRAM TABLET MO	3	PA
<i>imipenem-cilastatin 250 mg, 500 mg vial</i> MO	1	
INVANZ 1 GRAM SOLUTION FOR INJECTION DL	4	
KEFLEX 250 MG, 500 MG, 750 MG CAPSULE MO	3	
KITABIS PAK 300 MG/5 ML SOLUTION FOR NEBULIZATION DL	4	PA
KLARON 10 % LOTION (SUSPENSION) MO	3	QL (118 per 30 days)
LEVAQUIN 500 MG, 750 MG TABLET MO	3	
<i>levofloxacin 25 mg/ml solution; levofloxacin 500 mg/20 ml vial</i> MO	1	
<i>levofloxacin 250 mg, 500 mg, 750 mg tablet</i> MO	1	
<i>levofloxacin 250 mg/50 ml, 500 mg/100 ml, 750 mg/150 ml-d5w</i> MO	1	
LINCOCIN 300 MG/ML INJECTION SOLUTION MO	3	
<i>lincomycin hcl 600 mg/2 ml vial</i> MO	1	
<i>linezolid 100 mg/5 ml susp</i> DL	4	QL (1800 per 30 days)
<i>linezolid 600 mg tablet</i> MO	1	QL (60 per 30 days)
<i>linezolid 600 mg/300 ml-d5w</i> MO	1	
<i>linezolid 600mg/300ml-0.9%nacl</i> MO	1	
MACROBID 100 MG CAPSULE MO	3	
MACRODANTIN 100 MG, 25 MG, 50 MG CAPSULE MO	3	
MAXIPIME 1 GM ADD-VANTAGE VL; MAXIPIME 2 GM ADD-VANTAGE VL MO	3	
MAXIPIME 1 GRAM, 2 GRAM VIAL MO	3	PA
<i>meropenem iv 1 gm vial; meropenem iv 1 gram, 500 mg vial</i> MO	1	
<i>meropenem-0.9% nacl 1 gram/50; meropenem-0.9% nacl 500 mg/50</i> MO	1	
MERREM 1 GRAM, 500 MG INTRAVENOUS SOLUTION MO	3	
<i>methenamine hipp 1 gm tablet</i> MO	1	
METRO I.V. 500 MG/100 ML INTRAVENOUS PIGGYBACK MO	3	
METROCREAM 0.75 % TOPICAL MO	3	PA
METROGEL 1 % TOPICAL; METROGEL TOPICAL 1% PUMP MO	3	ST
METROGEL VAGINAL 0.75 % MO	3	
METROLOTION 0.75 % TOPICAL MO	3	PA
<i>metronidazole 0.75% cream</i> MO	1	
<i>metronidazole 0.75% lotion</i> MO	1	
<i>metronidazole 250 mg, 500 mg tablet</i> MO	1	
<i>metronidazole 375 mg capsule</i> MO	1	QL (320 per 30 days)
<i>metronidazole top 1% gel pump; metronidazole topical 0.75% gl;</i> <i>metronidazole topical 1% gel; metronidazole vaginal 0.75% gl</i> MO	1	
<i>metronidazole 500 mg/100 ml</i> MO	1	
MINOCIN 100 MG INTRAVENOUS SOLUTION MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MINOCIN 50 MG PELLETTIZED CAP MO	3	PA
<i>minocycline 100 mg, 50 mg, 75 mg capsule</i> MO	1	
<i>minocycline er 105 mg, 115 mg, 135 mg, 45 mg, 55 mg, 65 mg, 80 mg, 90 mg tablet</i> MO	1	ST,QL (30 per 30 days)
<i>minocycline hcl 100 mg, 50 mg, 75 mg tablet</i> MO	1	
MINOLIRA ER 105 MG, 135 MG TABLET, EXTENDED RELEASE MO	3	ST,QL (30 per 30 days)
<i>mondoxyme nl 100 mg, 50 mg capsule</i> MO	1	ST
<i>mondoxyme nl 75 mg capsule</i> MO	1	ST,QL (60 per 30 days)
MONODOX 100 MG, 50 MG CAPSULE MO	3	ST
MONODOX 75 MG CAPSULE MO	3	ST,QL (60 per 30 days)
MONUROL 3 GRAM ORAL PACKET MO	3	
<i>morgidox 100 mg, 50 mg capsule</i> MO	1	ST
<i>moxifloxacin hcl 400 mg tablet</i> MO	1	
<i>moxifloxacin 400 mg/250 ml bag</i> MO	1	
<i>moxifloxacin 400 mg/250 ml bag</i> MO	1	
<i>nafcillin 1 gm add-van vial; nafcillin 1 gm vial; nafcillin 10 gm bulk vial; nafcillin 2 gm add-vant vial; nafcillin 2 gm vial</i> MO	1	
<i>nafcillin 1 gm/ 50 ml inj; nafcillin 2 gm/ 100 ml inj</i> DL	4	
<i>neomycin 500 mg tablet</i> MO	1	
<i>nitrofurantoin 25 mg/5 ml susp</i> DL	4	
<i>nitrofurantoin mcr 100 mg, 25 mg, 50 mg cap</i> MO	1	
<i>nitrofurantoin mono-mcr 100 mg</i> MO	1	
NORITATE 1 % TOPICAL CREAM DL	4	ST,QL (60 per 30 days)
NUVESSA 1.3 % VAGINAL GEL MO	3	
NUZYRA 100 MG INTRAVENOUS SOLUTION DL	4	B vs D
NUZYRA 150 MG TABLET DL	4	QL (30 per 14 days)
NUZYRA 150 MG-7 DAY WITH LOAD DL	4	QL (30 per 14 days)
NUZYRA 150 MG TABLET-7 DAY DL	4	QL (30 per 14 days)
<i>ofloxacin 300 mg, 400 mg tablet</i> MO	1	
<i>okebo 75 mg capsule</i> MO	1	ST,QL (60 per 30 days)
ORACEA 40 MG CAPSULE, IMMEDIATE - DELAY RELEASE DL	4	ST,QL (30 per 30 days)
ORBACTIV 400 MG INTRAVENOUS SOLUTION DL	4	QL (3 per 28 days)
<i>oxacillin 1 gm add-vantage vl; oxacillin 1 gm vial; oxacillin 2 gm add-vantage vl; oxacillin 2 gm vial</i> MO	1	
<i>oxacillin 10 gm vial</i> DL	4	
<i>oxacillin 1 gm/ 50 ml inj; oxacillin 2 gm/ 50 ml inj</i> MO	3	
<i>paromomycin 250 mg capsule</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
pen g k 1 million unit/50 ml, 2 million unit/50 ml, 3 million unit/50 ml MO	3	
penicillin gk 20 million unit, 5 million unit MO	1	
pen g 1.2 million unit/2 ml MO	1	
penicillin g 600,000 unit/1 ml DL	4	
penicillin g na 5 million unit DL	4	
penicillin vk 125 mg/5 ml, 250 mg/5 ml soln MO	1	
penicillin vk 250 mg, 500 mg tablet MO	1	
pfizerpen-g 20 million unit, 5 million unit solution for injection DL	4	
piperacil-tazobact 13.5 gm vL; piperacil-tazobact 13.5 gram, 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram; piperacil-tazobact 2.25 gm vL; piperacil-tazobact 3.375 gm vL; piperacil-tazobact 4.5 gm vial MO	1	
polymyxin b sulfatate vial MO	1	
PRIMAXIN 500 MG INTRAVENOUS SOLUTION MO	3	
PRIMSOL 50 MG/5 ML ORAL SOLUTION MO	3	
RECARBRIO 1.25 GRAM INTRAVENOUS SOLUTION DL	4	
rosadan 0.75 % topical cream MO	1	ST
rosadan 0.75 % topical gel MO	1	ST
SEYSARA 100 MG, 150 MG, 60 MG TABLET DL	4	ST,QL (30 per 30 days)
SIVEXTRO 200 MG INTRAVENOUS SOLUTION DL	4	QL (6 per 28 days)
SIVEXTRO 200 MG TABLET DL	4	QL (6 per 28 days)
SOLODYN 105 MG, 115 MG, 55 MG, 65 MG, 80 MG TABLET,EXTENDED RELEASE DL	4	ST,QL (30 per 30 days)
SOLOSEC 2 GRAM ORAL DR GRANULES IN PACKET MO	3	PA
soloxide dr 150 mg tablet MO	1	ST,QL (60 per 30 days)
streptomycin sulf 1 gm vial DL	4	
sulfacetamide 10% eye ointment MO	1	
sulfacetamide sod 10% top susp MO	1	QL (118 per 30 days)
sulfadiazine 500 mg tablet MO	1	
sulfamethoxazole-tmp ds tablet; sulfamethoxazole-tmp ss tablet MO	1	
sulfamethoxazole-tmp iv vial MO	1	
sulfamethoxazole-tmp susp MO	1	
SULFATRIM 200 MG-40 MG/5 ML ORAL SUSPENSION MO	3	
SUPRAX 100 MG, 200 MG CHEWABLE TABLET MO	1	
SUPRAX 100 MG/5 ML, 200 MG/5 ML ORAL SUSPENSION MO	1	
SUPRAX 400 MG CAPSULE MO	3	
SUPRAX 500 MG/5 ML ORAL SUSPENSION MO	3	
SYNERCID 500 MG INTRAVENOUS SOLUTION DL	4	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TARGADOX 50 MG TABLET MO	1	ST,QL (180 per 30 days)
tazicef 1 gram, 2 gram, 6 gram intravenous solution; tazicef 1 gram, 2 gram, 6 gram solution for injection MO	1	
TEFLARO 400 MG, 600 MG INTRAVENOUS SOLUTION DL	4	
tetracycline 250 mg, 500 mg capsule MO	1	
tigecycline 50 mg vial DL	4	
TINDAMAX 500 MG TABLET MO	3	
tinidazole 250 mg, 500 mg tablet MO	1	
TOBI 300 MG/5 ML SOLUTION FOR NEBULIZATION DL	4	PA
tobramycin 300 mg/5 ml ampule DL	4	PA
tobramycin 1.2 gm vial DL	4	
tobramycin 10 mg/ml, 40 mg/ml vial MO	1	
tobramycin pak 300 mg/5 ml DL	4	PA
trimethoprim 100 mg tablet MO	1	
TYGACIL 50 MG INTRAVENOUS SOLUTION DL	4	
UNASYN 1.5 GRAM, 15 GRAM, 3 GRAM SOLUTION FOR INJECTION MO	3	
VABOMERE 2 GRAM INTRAVENOUS SOLUTION DL	4	QL (84 per 14 days)
VANCOGIN 125 MG CAPSULE DL	4	PA,QL (120 per 30 days)
VANCOGIN 250 MG CAPSULE DL	4	PA,QL (240 per 30 days)
vancomycin 1 gm vial; vancomycin 1,000 mg, 1.25 gram, 1.5 gram, 10 gram, 250 mg, 5 gram, 50 mg/ml, 500 mg, 750 mg vial; vancomycin 250 mg/5 ml soln; vancomycin hcl 1,000 mg, 1.25 gram, 1.5 gram, 10 gram, 250 mg, 5 gram, 50 mg/ml, 500 mg, 750 mg vial; vancomycin hcl 10 gm vial; vancomycin hcl 5 gm vial MO	1	
vancomycin hcl 125 mg capsule MO	1	PA,QL (120 per 30 days)
vancomycin hcl 250 mg capsule DL	4	PA,QL (240 per 30 days)
vanco 1 gram/200 ml, 500 mg/100 ml, 750 mg/150 ml-0.9% nacl; vancomycin 1 g/200ml-0.9% nacl MO	3	
vancomycin 1 gram/200 ml, 750 mg/150 ml bag; vancomycin hcl 1g/200 ml bag MO	3	
vancomycin 1 gram/200 ml, 1.25 gram/250 ml, 1.5 gram/300 ml, 1.75 gram/350 ml, 2 gram/400 ml, 500 mg/100 ml, 750 mg/150 ml bag; vancomycin 1.25 gm/250 ml bag; vancomycin 1.75 gm/350 ml bag MO	3	
VANDAZOLE 0.75 % VAGINAL GEL MO	3	
VIBATIV 750 MG INTRAVENOUS SOLUTION DL	4	
VIBRAMYCIN 100 MG CAPSULE MO	3	
VIBRAMYCIN 25 MG/5 ML ORAL SUSPENSION MO	3	ST
VIBRAMYCIN 50 MG/5 ML ORAL SYRUP MO	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
XENLETA 150 MG/15 ML INTRAVENOUS SOLUTION DL	4	B vs D,QL (210 per 7 days)
XENLETA 600 MG TABLET DL	4	QL (10 per 5 days)
XERAVA 50 MG INTRAVENOUS SOLUTION DL	4	B vs D
XIMINO 135 MG, 45 MG, 90 MG CAPSULE, EXTENDED RELEASE MO	3	ST,QL (30 per 30 days)
ZEMDRI 50 MG/ML INTRAVENOUS SOLUTION DL	4	
ZERBAXA 1.5 GRAM INTRAVENOUS SOLUTION DL	4	
ZITHROMAX 1 GRAM ORAL PACKET MO	3	
ZITHROMAX 100 MG/5 ML, 200 MG/5 ML ORAL SUSPENSION MO	3	
ZITHROMAX 250 MG, 500 MG, 600 MG TABLET MO	3	
ZITHROMAX 500 MG INTRAVENOUS SOLUTION MO	3	
ZITHROMAX TRI-PAK 500 MG TABLET MO	3	
ZITHROMAX Z-PAK 250 MG TABLET MO	3	
ZOSYN 2.25 GRAM, 3.375 GRAM, 4.5 GRAM, 40.5 GRAM BULK VIAL; ZOSYN 2.25 GRAM, 3.375 GRAM, 4.5 GRAM, 40.5 GRAM VIAL MO	3	
ZOSYN 2.25 GRAM/50 ML, 3.375 GRAM/50 ML, 4.5 GRAM/100 ML IN DEXTROSE (ISO-OSMOTIC) INTRAVENOUS PIGGYBACK MO	3	
ZYVOX 100 MG/5 ML ORAL SUSPENSION DL	4	PA,QL (1800 per 30 days)
ZYVOX 200 MG/100 ML, 600 MG/300 ML INTRAVENOUS PIGGYBACK MO	3	
ZYVOX 600 MG TABLET DL	4	PA,QL (60 per 30 days)
ANTICONVULSANTS		
APTIOM 200 MG, 400 MG TABLET DL	4	PA,QL (30 per 30 days)
APTIOM 600 MG, 800 MG TABLET DL	4	PA,QL (60 per 30 days)
BANZEL 200 MG TABLET DL	4	PA,QL (480 per 30 days)
BANZEL 40 MG/ML ORAL SUSPENSION DL	4	PA,QL (2760 per 30 days)
BANZEL 400 MG TABLET DL	4	PA,QL (240 per 30 days)
BRIVIACT 10 MG, 100 MG, 25 MG, 50 MG, 75 MG TABLET DL	4	PA,QL (60 per 30 days)
BRIVIACT 10 MG/ML ORAL SOLUTION DL	4	PA,QL (600 per 30 days)
BRIVIACT 50 MG/5 ML INTRAVENOUS SOLUTION DL	4	PA
carbamazepine 100 mg tab chew MO	1	
carbamazepine 100 mg/5 ml susp MO	1	
carbamazepine 200 mg tablet MO	1	
carbamazepine er 100 mg, 200 mg tablet MO	1	QL (120 per 30 days)
carbamazepine er 100 mg, 200 mg, 300 mg cap MO	1	
carbamazepine er 400 mg tablet MO	1	QL (225 per 30 days)
CARBATROL 100 MG, 200 MG, 300 MG CAPSULE, EXTENDED RELEASE MO	3	
CELONTIN 300 MG CAPSULE MO	3	
CEREBYX 100 MG PE/2 ML, 500 MG PE/10 ML INJECTION SOLUTION MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>clobazam 10 mg, 20 mg tablet</i> DL	1	PA
<i>clobazam 2.5 mg/ml suspension</i> DL	1	PA
DEPAACON 500 MG VIAL MO	3	
DEPAKENE 250 MG CAPSULE MO	3	
DEPAKENE 250 MG/5 ML SOLUTION MO	3	
DEPAKOTE 125 MG, 250 MG, 500 MG TABLET, DELAYED RELEASE MO	3	
DEPAKOTE ER 250 MG, 500 MG TABLET, EXTENDED RELEASE MO	3	
DEPAKOTE SPRINKLES 125 MG CAPSULE, DELAYED RELEASE MO	3	
DIASTAT 2.5 MG RECTAL KIT DL	3	PA
DIASTAT ACUDIAL 12.5 MG-15 MG-17.5 MG-20 MG RECTAL KIT DL	3	
DIASTAT ACUDIAL 5 MG-7.5 MG-10 MG RECTAL KIT DL	3	PA
<i>diazepam 10 mg rectal gel syst; diazepam 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg rectal gel sys; diazepam 20 mg rectal gel syst</i> DL	1	
DILANTIN 30 MG CAPSULE MO	1	
DILANTIN EXTENDED 100 MG CAPSULE MO	1	
DILANTIN INFATABS 50 MG CHEWABLE TABLET MO	1	
DILANTIN-125 125 MG/5 ML ORAL SUSPENSION MO	3	
<i>divalproex dr 125 mg cap sprnk</i> MO	1	
<i>divalproex sod dr 125 mg, 250 mg, 500 mg tab</i> MO	1	
<i>divalproex sod er 250 mg, 500 mg tab</i> MO	1	
EPIDIOLEX 100 MG/ML ORAL SOLUTION DL	4	PA
<i>epitol 200 mg tablet</i> MO	1	
EQUETRO 100 MG, 200 MG, 300 MG CAPSULE, EXTENDED RELEASE MO	3	PA
<i>ethosuximide 250 mg capsule</i> MO	1	
<i>ethosuximide 250 mg/5 ml soln</i> MO	1	
<i>felbamate 400 mg, 600 mg tablet</i> MO	1	
<i>felbamate 600 mg/5 ml susp</i> DL	4	
FELBATOL 400 MG, 600 MG TABLET DL	4	
FELBATOL 600 MG/5 ML ORAL SUSPENSION DL	4	
FINTEPLA 2.2 MG/ML ORAL SOLUTION DL	4	PA, QL (360 per 30 days)
<i>fosphenytoin 100 mg pe/2 ml, 500 mg pe/10 ml; fosphenytoin 100 mg pe/2 ml, 500 mg pe/10 ml v1</i> MO	1	
FYCOMPA 0.5 MG/ML ORAL SUSPENSION DL	4	PA, QL (680 per 28 days)
FYCOMPA 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET DL	4	PA, QL (30 per 30 days)
<i>gabapentin 100 mg, 300 mg, 400 mg capsule</i> MO	1	QL (270 per 30 days)
<i>gabapentin 250 mg/5 ml soln; gabapentin 250 mg/5 ml, 250 mg/5 ml (5 ml), 300 mg/6 ml (6 ml) soln; gabapentin 300 mg/6 ml soln</i> MO	1	QL (2250 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>gabapentin 600 mg, 800 mg tablet</i> MO	1	QL (180 per 30 days)
GABITRIL 12 MG, 16 MG, 2 MG, 4 MG TABLET DL	4	
KEPPRA 1,000 MG, 500 MG, 750 MG TABLET DL	4	
KEPPRA 100 MG/ML, 500 MG/5 ML INTRAVENOUS SOLUTION; KEPPRA 100 MG/ML, 500 MG/5 ML ORAL SOLUTION DL	4	
KEPPRA 250 MG TABLET DL	4	QL (60 per 30 days)
KEPPRA XR 500 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (180 per 30 days)
KEPPRA XR 750 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (120 per 30 days)
LAMICTAL 100 MG, 150 MG, 200 MG, 25 MG TABLET DL	4	
LAMICTAL 25 MG, 5 MG CHEWABLE DISPERSIBLE TABLET DL	4	
LAMICTAL ODT 100 MG, 200 MG, 25 MG, 50 MG DISINTEGRATING TABLET DL	4	
LAMICTAL ODT STARTER (BLUE) 25 MG (21)-50 MG (7) TABLET,DISINTEGRATING DL	4	
LAMICTAL ODT STARTER (GREEN) 50 MG (42)-100 MG (14) TABLET,DISINTEGRAT DL	4	
LAMICTAL ODT STARTER(ORANGE) 25 MG(14)-50 MG(14)-100 MG(7) TAB,DISINT DL	4	
LAMICTAL STARTER (BLUE) KIT 25 MG (35) TABLETS IN A DOSE PACK DL	4	
LAMICTAL STARTER (GREEN) KIT 25 MG (84)-100 MG (14) TABLETS, DOSE PACK DL	4	
LAMICTAL STARTER (ORANGE) KIT 25 MG (42)-100 MG (7) TABLETS, DOSE PACK DL	4	
LAMICTAL XR 100 MG, 200 MG, 25 MG, 250 MG, 300 MG, 50 MG TABLET,EXTENDED RELEASE DL	4	
LAMICTAL XR STARTER (BLUE) 25 MG (21)-50 MG (7) TABLET,EXTEND RELEASE MO	3	
LAMICTAL XR STARTER (GREEN) 50 MG(14)-100 MG(14)-200 MG(7) TAB,EXT.REL MO	3	
LAMICTAL XR STARTER (ORANGE) 25 MG(14)-50 MG(14)-100 MG(7) TAB,EXT.REL MO	3	
<i>lamotrigine 100 mg, 150 mg, 200 mg, 25 mg, 25 mg (21) -50 mg (7), 25 mg (35), 25 mg (42) -100 mg (7), 25 mg (84) -100 mg (14), 25 mg(14)-50 mg (14)-100 mg (7), 50 mg, 50 mg (42) -100 mg (14) tablet; lamotrigine odt 100 mg, 150 mg, 200 mg, 25 mg, 25 mg (21) -50 mg (7), 25 mg (35), 25 mg (42) -100 mg (7), 25 mg (84) -100 mg (14), 25 mg(14)-50 mg (14)-100 mg (7), 50 mg, 50 mg (42) -100 mg (14) tablet; lamotrigine odt kit (blue); lamotrigine odt kit (green); lamotrigine odt kit (orange); lamotrigine tab start kit-blue; lamotrigine tab start kt-green; lamotrigine tab start kt-orang</i> MO	1	
<i>lamotrigine 25 mg, 5 mg disper tab; lamotrigine 25 mg, 5 mg disper tablet</i> MO	1	
<i>lamotrigine er 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg tablet</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
levetiracetam 1,000 mg, 500 mg, 750 mg tablet MO	1	
levetiracetam 100 mg/ml, 500 mg/5 ml soln; levetiracetam 100 mg/ml, 500 mg/5 ml vial MO	1	
levetiracetam 250 mg tablet MO	1	QL (60 per 30 days)
levetiracetam 500 mg/5 ml soln MO	1	QL (900 per 30 days)
levetiracetam er 500 mg tablet MO	1	QL (180 per 30 days)
levetiracetam er 750 mg tablet MO	1	QL (120 per 30 days)
levetiracetam-nacl 1,000mg/100; levetiracetam-nacl 1,500mg/100; levetiracetam-nacl 500 mg/100 MO	1	
MYSOLINE 250 MG, 50 MG TABLET DL	4	PA
NAYZILAM 5 MG/SPRAY (0.1 ML) NASAL SPRAY DL	3	QL (10 per 30 days)
NEMBUTAL SODIUM 50 MG/ML INJECTION SOLUTION MO	1	
NEURONTIN 100 MG, 300 MG, 400 MG CAPSULE DL	4	PA,QL (270 per 30 days)
NEURONTIN 250 MG/5 ML ORAL SOLUTION MO	3	PA,QL (2250 per 30 days)
NEURONTIN 600 MG, 800 MG TABLET DL	4	PA,QL (180 per 30 days)
ONFI 10 MG, 20 MG TABLET DL	4	PA
ONFI 2.5 MG/ML ORAL SUSPENSION DL	4	PA
oxcarbazepine 150 mg, 300 mg tablet MO	1	QL (60 per 30 days)
oxcarbazepine 300 mg/5 ml susp MO	1	
oxcarbazepine 600 mg tablet MO	1	
OXTELLAR XR 150 MG, 300 MG, 600 MG TABLET,EXTENDED RELEASE DL	4	ST
PEGANONE 250 MG TABLET MO	3	
pentobarbital 2,500 mg/50 ml MO	1	
phenobarbital 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg tablet MO	1	QL (90 per 30 days)
phenobarbital 15 mg, 60 mg tablet MO	1	QL (120 per 30 days)
phenobarbital 20 mg/5 ml elix MO	1	QL (1500 per 30 days)
phenobarbital 30 mg tablet MO	1	QL (300 per 30 days)
phenobarbital 130 mg/ml, 65 mg/ml vial DL	4	
PHENYTEK 200 MG, 300 MG CAPSULE MO	1	
phenytoin 100 mg/4 ml, 125 mg/5 ml susp MO	1	
phenytoin 50 mg tablet chew MO	1	
phenytoin 50 mg/ml syringe MO	1	
phenytoin 50 mg/ml vial MO	1	
phenytoin sod ext 100 mg, 200 mg, 300 mg cap MO	1	
primidone 250 mg, 50 mg tablet MO	1	
QUDEXY XR 100 MG, 50 MG CAPSULE SPRINKLE,EXTENDED RELEASE DL	4	PA,QL (30 per 30 days)
QUDEXY XR 150 MG, 200 MG CAPSULE SPRINKLE,EXTENDED RELEASE DL	4	PA,QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
QUDEXY XR 25 MG CAPSULE SPRINKLE,EXTENDED RELEASE DL	4	PA,QL (90 per 30 days)
roweepra 1,000 mg, 500 mg, 750 mg tablet MO	1	
roweepra xr 500 mg tablet,extended release MO	1	QL (180 per 30 days)
roweepra xr 750 mg tablet,extended release MO	1	QL (120 per 30 days)
SABRIL 500 MG ORAL POWDER PACKET DL	4	PA,QL (180 per 30 days)
SABRIL 500 MG TABLET DL	4	PA,QL (180 per 30 days)
SECONAL SODIUM 100 MG CAPSULE DL	4	QL (90 per 30 days)
SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION MO	3	ST,QL (90 per 30 days)
SPRITAM 250 MG TABLET FOR ORAL SUSPENSION MO	3	ST,QL (360 per 30 days)
SPRITAM 500 MG TABLET FOR ORAL SUSPENSION MO	3	ST,QL (180 per 30 days)
SPRITAM 750 MG TABLET FOR ORAL SUSPENSION MO	3	ST,QL (120 per 30 days)
subvenite 100 mg, 150 mg, 200 mg, 25 mg tablet MO	1	
subvenite starter (blue) kit 25 mg (35) tablets in a dose pack MO	1	
subvenite starter (green) kit 25 mg (84)-100 mg (14) tablet, dose pack MO	1	
subvenite starter (orange) kit 25 mg (42)-100 mg (7) tablet, dose pack MO	1	
SYMPAZAN 10 MG, 20 MG, 5 MG ORAL FILM DL	4	PA,QL (60 per 30 days)
TEGRETOL 100 MG/5 ML ORAL SUSPENSION MO	3	
TEGRETOL 200 MG TABLET MO	3	
TEGRETOL XR 100 MG, 200 MG TABLET,EXTENDED RELEASE MO	3	QL (120 per 30 days)
TEGRETOL XR 400 MG TABLET,EXTENDED RELEASE MO	3	QL (225 per 30 days)
tiagabine hcl 12 mg, 16 mg, 2 mg, 4 mg tablet MO	1	
TOPAMAX 100 MG, 200 MG, 50 MG TABLET DL	4	QL (120 per 30 days)
TOPAMAX 15 MG, 25 MG SPRINKLE CAPSULE DL	4	
TOPAMAX 25 MG TABLET DL	4	QL (90 per 30 days)
topiramate 100 mg, 200 mg, 50 mg tablet MO	1	QL (120 per 30 days)
topiramate 15 mg, 25 mg sprinkle cap MO	1	
topiramate 25 mg tablet MO	1	QL (90 per 30 days)
topiramate er 100 mg, 50 mg capsule MO	3	PA,QL (30 per 30 days)
topiramate er 150 mg, 200 mg capsule MO	3	PA,QL (60 per 30 days)
topiramate er 25 mg capsule MO	3	PA,QL (90 per 30 days)
TRILEPTAL 150 MG, 300 MG TABLET DL	4	PA,QL (60 per 30 days)
TRILEPTAL 300 MG/5 ML (60 MG/ML) ORAL SUSPENSION DL	4	PA
TRILEPTAL 600 MG TABLET DL	4	PA
TROKENDI XR 100 MG, 50 MG CAPSULE, EXTENDED RELEASE DL	4	PA,QL (30 per 30 days)
TROKENDI XR 200 MG CAPSULE, EXTENDED RELEASE DL	4	PA,QL (60 per 30 days)
TROKENDI XR 25 MG CAPSULE,EXTENDED RELEASE DL	4	PA,QL (90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
valproate sod 500 mg/5 ml vl MO	1	
valproic acid 250 mg capsule MO	1	
valproic acid 250 mg/5 ml soln; valproic acid 250 mg/5 ml, 250 mg/5 ml (5 ml), 500 mg/10 ml (10 ml) soln; valproic acid 500 mg/10 ml sol MO	1	
VALTOCO 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML) NASAL SPRAY; VALTOCO 15 MG/2 SPRAY(7.5MG/0.1ML X2) NASAL SPRAY DL	4	QL (10 per 30 days)
vigabatrin 500 mg powder packt DL	4	PA,QL (180 per 30 days)
vigabatrin 500 mg tablet DL	4	PA,QL (180 per 30 days)
vigadrone 500 mg oral powder packet DL	4	PA,QL (180 per 30 days)
VIMPAT 10 MG/ML ORAL SOLUTION MO	3	QL (1395 per 30 days)
VIMPAT 100 MG, 150 MG, 200 MG, 50 MG TABLET MO	3	QL (60 per 30 days)
VIMPAT 200 MG/20 ML INTRAVENOUS SOLUTION MO	3	
XCOPRI 100 MG, 50 MG TABLET DL	4	PA,QL (30 per 30 days)
XCOPRI 150 MG, 200 MG TABLET DL	4	PA,QL (60 per 30 days)
XCOPRI MAINTENANCE PACK 250 MG/DAY (200 MG X 1 AND 50 MG X 1) TABLETS; XCOPRI MAINTENANCE PACK 350 MG/DAY (200 MG X 1 AND 150 MG X 1) TABLETS DL	4	PA,QL (56 per 28 days)
XCOPRI TITRATION PACK 12.5 MG (14)-25 MG (14) TABLETS IN A DOSE PACK MO	3	PA,QL (28 per 28 days)
XCOPRI TITRATION PACK 150 MG (14)-200 MG (14) TABLETS IN A DOSE PACK; XCOPRI TITRATION PACK 50 MG (14)-100 MG (14) TABLETS IN A DOSE PACK DL	4	PA,QL (28 per 28 days)
ZARONTIN 250 MG CAPSULE MO	3	
ZARONTIN 250 MG/5 ML ORAL SOLUTION MO	1	
ZONEGRAN 100 MG, 25 MG CAPSULE DL	4	PA
zonisamide 100 mg, 25 mg, 50 mg capsule MO	1	
Antidementia Agents		
ARICEPT 10 MG TABLET MO	3	PA,QL (60 per 30 days)
ARICEPT 23 MG, 5 MG TABLET MO	3	PA,QL (30 per 30 days)
donepezil hcl 10 mg tablet MO	1	QL (60 per 30 days)
donepezil hcl 10 mg, 23 mg, 5 mg tablet; donepezil hcl odt 10 mg, 23 mg, 5 mg tablet MO	1	QL (30 per 30 days)
ergoloid mesylates 1 mg tab DL	4	
EXELON PATCH 13.3 MG/24 HOUR, 4.6 MG/24 HR, 9.5 MG/24 HR TRANSDERMAL MO	3	PA,QL (30 per 30 days)
galantamine 4 mg/ml oral soln MO	1	QL (200 per 30 days)
galantamine er 16 mg, 24 mg, 8 mg capsule MO	1	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
galantamine hbr 12 mg, 4 mg, 8 mg tablet MO	1	QL (60 per 30 days)
memantine 5-10 mg titration pk MO	1	PA,QL (98 per 30 days)
memantine hcl 10 mg, 5 mg tablet MO	1	PA,QL (60 per 30 days)
memantine hcl 2 mg/ml solution MO	1	PA,QL (360 per 30 days)
memantine hcl er 14 mg, 21 mg, 28 mg, 7 mg capsule MO	1	PA,QL (30 per 30 days)
NAMENDA 10 MG, 5 MG TABLET MO	3	PA,QL (60 per 30 days)
NAMENDA TITRATION PAK 5 MG-10 MG TABLETS IN A DOSE PACK MO	3	PA,QL (98 per 30 days)
NAMENDA XR 14 MG, 21 MG, 28 MG, 7 MG CAPSULE SPRINKLE,EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
NAMENDA XR 7 MG-14 MG-21 MG-28 MG CAPSULE,SPRINKLE,EXT REL, DOSE PACK MO	3	PA,QL (28 per 28 days)
NAMZARIC 14 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE; NAMZARIC 21 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE; NAMZARIC 28 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE; NAMZARIC 7 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE MO	2	QL (30 per 30 days)
NAMZARIC 7/14/21/28 MG-10 MG CAPSULE,SPRINKLE,EXTEND RELEASE,DOSE PACK MO	2	QL (28 per 28 days)
RAZADYNE 12 MG, 4 MG, 8 MG TABLET MO	3	PA,QL (60 per 30 days)
RAZADYNE ER 16 MG, 24 MG, 8 MG CAPSULE,EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
rivastigmine 13.3 mg/24hr ptch; rivastigmine 4.6 mg/24hr patch; rivastigmine 9.5 mg/24hr patch MO	1	QL (30 per 30 days)
rivastigmine 1.5 mg, 3 mg capsule MO	1	QL (90 per 30 days)
rivastigmine 4.5 mg, 6 mg capsule MO	1	QL (60 per 30 days)
Antidepressants		
amitriptyline hcl 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg tab MO	1	
chlordiazepo-amitriptyl 5-12.5; chlordiazepox-amitriptyl 10-25 DL	1	
amoxapine 100 mg, 150 mg, 25 mg, 50 mg tablet MO	1	
ANAFRANIL 25 MG, 50 MG, 75 MG CAPSULE DL	4	
APLENZIN 174 MG, 348 MG, 522 MG TABLET,EXTENDED RELEASE DL	4	ST,QL (30 per 30 days)
BRISDELLE 7.5 MG CAPSULE MO	3	QL (30 per 30 days)
bupropion hcl 100 mg, 75 mg tablet MO	1	QL (180 per 30 days)
bupropion hcl sr 100 mg tablet MO	1	QL (120 per 30 days)
bupropion hcl sr 150 mg tablet MO	1	QL (90 per 30 days)
bupropion hcl sr 200 mg tablet MO	1	QL (60 per 30 days)
bupropion hcl xl 150 mg tablet MO	1	QL (90 per 30 days)
bupropion hcl xl 300 mg tablet MO	1	QL (60 per 30 days)
bupropion hcl xl 450 mg tablet MO	1	ST,QL (30 per 30 days)
CELEXA 10 MG, 40 MG TABLET MO	3	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CELEXA 20 MG TABLET MO	3	PA,QL (60 per 30 days)
citalopram hbr 10 mg, 40 mg tablet MO	1	QL (30 per 30 days)
citalopram hbr 10 mg/5 ml soln MO	1	
citalopram hbr 20 mg tablet MO	1	QL (60 per 30 days)
clomipramine 25 mg, 50 mg, 75 mg capsule MO	1	
CYMBALTA 20 MG, 30 MG, 60 MG CAPSULE,DELAYED RELEASE MO	3	QL (60 per 30 days)
desipramine 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg tablet MO	1	
desvenlafaxine er 100 mg, 50 mg tab; desvenlafaxine er 100 mg, 50 mg tablet MO	3	ST,QL (30 per 30 days)
desvenlafaxine succnt er 100 mg, 25 mg, 50 mg; desvenlafaxine succnt er 100mg MO	1	QL (30 per 30 days)
DRIZALMA SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG CAPSULE,DELAYED RELEASE MO	3	PA,QL (60 per 30 days)
duloxetine hcl dr 20 mg, 30 mg, 40 mg, 60 mg cap MO	1	QL (60 per 30 days)
EFFEXOR XR 150 MG CAPSULE,EXTENDED RELEASE DL	4	PA,QL (60 per 30 days)
EFFEXOR XR 37.5 MG CAPSULE,EXTENDED RELEASE DL	4	PA,QL (30 per 30 days)
EFFEXOR XR 75 MG CAPSULE,EXTENDED RELEASE DL	4	PA,QL (90 per 30 days)
EMSAM 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH DL	4	QL (30 per 30 days)
escitalopram 10 mg tablet MO	1	QL (45 per 30 days)
escitalopram 20 mg, 5 mg tablet MO	1	QL (30 per 30 days)
escitalopram oxalate 5 mg/5 ml MO	1	QL (600 per 30 days)
FETZIMA 120 MG, 20 MG, 40 MG, 80 MG CAPSULE,EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK MO	3	PA,QL (28 per 28 days)
fluoxetine 20 mg/5 ml solution MO	1	
fluoxetine dr 90 mg capsule MO	1	QL (4 per 28 days)
fluoxetine hcl 10 mg tablet MO	1	QL (240 per 30 days)
fluoxetine hcl 10 mg, 40 mg capsule MO	1	QL (60 per 30 days)
fluoxetine hcl 20 mg capsule MO	1	QL (120 per 30 days)
fluoxetine hcl 20 mg tablet MO	1	QL (120 per 30 days)
fluoxetine hcl 60 mg tablet MO	1	QL (30 per 30 days)
fluvoxamine er 100 mg, 150 mg capsule MO	1	QL (60 per 30 days)
fluvoxamine maleate 100 mg, 25 mg, 50 mg tab MO	1	QL (90 per 30 days)
FORFIVO XL 450 MG TABLET,EXTENDED RELEASE MO	3	ST,QL (30 per 30 days)
imipramine hcl 10 mg, 25 mg, 50 mg tablet MO	1	
imipramine pamoate 100 mg, 125 mg, 150 mg, 75 mg cap MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
KHEDEZLA ER 100 MG, 50 MG TABLET MO	3	ST,QL (30 per 30 days)
LEXAPRO 10 MG TABLET MO	3	PA,QL (45 per 30 days)
LEXAPRO 20 MG, 5 MG TABLET MO	3	PA,QL (30 per 30 days)
<i>maprotiline 25 mg, 50 mg, 75 mg tablet</i> MO	1	
MARPLAN 10 MG TABLET MO	3	
<i>mirtazapine 15 mg, 30 mg, 45 mg odt</i> MO	1	QL (30 per 30 days)
<i>mirtazapine 15 mg, 30 mg, 45 mg, 7.5 mg tablet</i> MO	1	
NARDIL 15 MG TABLET MO	3	
<i>nefazodone hcl 100 mg, 150 mg, 200 mg, 250 mg, 50 mg tablet</i> MO	1	
NORPRAMIN 10 MG, 25 MG TABLET MO	3	
<i>nortriptyline 10 mg/5 ml soln</i> MO	1	
<i>nortriptyline hcl 10 mg, 25 mg, 50 mg, 75 mg cap</i> MO	1	
<i>olanzapine-fluoxetine 12-25 mg, 12-50 mg, 3-25 mg, 6-25 mg, 6-50 mg</i> MO	1	QL (30 per 30 days)
PAMELOR 10 MG, 25 MG, 50 MG, 75 MG CAPSULE DL	4	
PARNATE 10 MG TABLET DL	4	
<i>paroxetine er 12.5 mg, 37.5 mg tablet</i> MO	1	QL (60 per 30 days)
<i>paroxetine er 25 mg tablet</i> MO	1	QL (90 per 30 days)
<i>paroxetine hcl 10 mg, 20 mg tablet</i> MO	1	QL (30 per 30 days)
<i>paroxetine hcl 30 mg, 40 mg tablet</i> MO	1	QL (60 per 30 days)
<i>paroxetine mesylate 7.5 mg cap</i> MO	1	QL (30 per 30 days)
PAXIL 10 MG, 20 MG TABLET MO	3	QL (30 per 30 days)
PAXIL 10 MG/5 ML ORAL SUSPENSION MO	3	
PAXIL 30 MG, 40 MG TABLET MO	3	QL (60 per 30 days)
PAXIL CR 12.5 MG, 37.5 MG TABLET,EXTENDED RELEASE MO	3	QL (60 per 30 days)
PAXIL CR 25 MG TABLET,EXTENDED RELEASE MO	3	QL (90 per 30 days)
<i>perphen-amitrip 2 mg-10 mg tab; perphen-amitrip 2 mg-25 mg tab; perphen-amitrip 4 mg-10 mg tab; perphen-amitrip 4 mg-25 mg tab; perphen-amitrip 4 mg-50 mg tab</i> MO	1	
PEXEVA 10 MG, 20 MG TABLET MO	3	QL (30 per 30 days)
PEXEVA 30 MG, 40 MG TABLET MO	3	QL (60 per 30 days)
<i>phenelzine sulfate 15 mg tab</i> MO	1	
PRISTIQ 100 MG, 25 MG, 50 MG TABLET,EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
<i>protriptyline hcl 10 mg, 5 mg tablet</i> MO	1	
PROZAC 10 MG, 40 MG CAPSULE DL	4	PA,QL (60 per 30 days)
PROZAC 20 MG CAPSULE DL	4	PA,QL (120 per 30 days)
REMERON 15 MG, 30 MG TABLET MO	3	
REMERON SOLTAB 15 MG, 30 MG, 45 MG DISINTEGRATING TABLET MO	3	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SARAFEM 10 MG TABLET MO	3	QL (240 per 30 days)
SARAFEM 20 MG TABLET MO	3	QL (120 per 30 days)
sertraline 20 mg/ml oral conc MO	1	
sertraline hcl 100 mg tablet MO	1	QL (60 per 30 days)
sertraline hcl 25 mg, 50 mg tablet MO	1	QL (90 per 30 days)
SURMONTIL 100 MG, 25 MG, 50 MG CAPSULE MO	3	
SYMBYAX 12 MG-50 MG CAPSULE; SYMBYAX 12-25 MG, 12-50 MG, 3-25 MG, 6-25 MG, 6-50 MG CAPSULE; SYMBYAX 3 MG-25 MG CAPSULE; SYMBYAX 6 MG-25 MG CAPSULE; SYMBYAX 6 MG-50 MG CAPSULE MO	3	PA,QL (30 per 30 days)
TOFRANIL 10 MG, 25 MG, 50 MG TABLET DL	4	
tranylcypromine sulf 10 mg tab MO	1	
trazodone 100 mg, 150 mg, 300 mg, 50 mg tablet MO	1	
trimipramine maleate 100 mg, 25 mg, 50 mg cap; trimipramine maleate 100 mg, 25 mg, 50 mg cp MO	1	
TRINTELLIX 10 MG, 20 MG, 5 MG TABLET MO	3	ST,QL (30 per 30 days)
venlafaxine hcl 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg tablet MO	1	
venlafaxine hcl er 150 mg cap MO	1	QL (60 per 30 days)
venlafaxine hcl er 150 mg, 225 mg, 37.5 mg tab MO	1	QL (30 per 30 days)
venlafaxine hcl er 37.5 mg cap MO	1	QL (30 per 30 days)
venlafaxine hcl er 75 mg cap MO	1	QL (90 per 30 days)
venlafaxine hcl er 75 mg tab MO	1	QL (60 per 30 days)
VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK; VIIBRYD 10 MG, 10 MG (7)- 20 MG (23), 20 MG, 40 MG TABLET MO	3	PA,QL (30 per 30 days)
WELLBUTRIN SR 100 MG TABLET, 12 HR SUSTAINED-RELEASE MO	3	PA,QL (120 per 30 days)
WELLBUTRIN SR 150 MG TABLET, 12 HR SUSTAINED-RELEASE MO	3	PA,QL (90 per 30 days)
WELLBUTRIN SR 200 MG TABLET, 12 HR SUSTAINED-RELEASE MO	3	PA,QL (60 per 30 days)
WELLBUTRIN XL 150 MG 24 HR TABLET, EXTENDED RELEASE DL	4	PA,QL (90 per 30 days)
WELLBUTRIN XL 300 MG 24 HR TABLET, EXTENDED RELEASE DL	4	PA,QL (60 per 30 days)
ZOLOFT 100 MG TABLET MO	3	PA,QL (60 per 30 days)
ZOLOFT 20 MG/ML ORAL CONCENTRATE MO	3	PA
ZOLOFT 25 MG, 50 MG TABLET MO	3	PA,QL (90 per 30 days)
ZULRESSO 5 MG/ML INTRAVENOUS SOLUTION DL	4	PA,QL (100 per 365 days)
Antiemetics		
AKYNZEO (FOSNETUPITANT) 235 MG-0.25 MG INTRAVENOUS POWDER FOR SOLUTION DL	4	PA,QL (4 per 28 days)
AKYNZEO (FOSNETUPITANT) 235 MG-0.25 MG/20 ML INTRAVENOUS SOLUTION DL	4	PA,QL (80 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AKYNZEO (NETUPITANT) 300 MG-0.5 MG CAPSULE DL	4	PA,QL (4 per 28 days)
ANZEMET 100 MG, 50 MG TABLET MO	3	B vs D,QL (4 per 28 days)
<i>aprepitant 125 mg, 40 mg capsule</i> MO	1	B vs D,QL (2 per 28 days)
<i>aprepitant 125-80-80 mg pack</i> MO	1	B vs D,QL (6 per 28 days)
<i>aprepitant 80 mg capsule</i> MO	1	B vs D,QL (4 per 28 days)
BONJESTA 20 MG-20 MG TABLET,IMMEDIATE AND DELAY RELEASE MO	3	QL (60 per 30 days)
CESAMET 1 MG CAPSULE DL	4	PA,QL (180 per 30 days)
COMPAZINE 10 MG, 5 MG TABLET MO	3	B vs D
COMPAZINE 25 MG RECTAL SUPPOSITORY MO	1	
<i>compro 25 mg rectal suppository</i> MO	1	
DICLEGIS 10 MG-10 MG TABLET,DELAYED RELEASE MO	3	QL (120 per 30 days)
<i>dimenhydrinate 50 mg/ml vial</i> MO	1	
<i>doxylamine-pyridoxine 10-10 mg</i> MO	1	QL (120 per 30 days)
<i>dronabinol 10 mg, 2.5 mg, 5 mg capsule</i> MO	1	B vs D,QL (120 per 30 days)
EMEND 125 MG (1)-80 MG (2) CAPSULES IN A DOSE PACK MO	3	PA,QL (6 per 28 days)
EMEND 125 MG (25 MG/ML FINAL CONC.) ORAL SUSPENSION MO	3	B vs D,QL (3 per 28 days)
EMEND 125 MG, 40 MG CAPSULE MO	3	PA,QL (2 per 28 days)
EMEND 80 MG CAPSULE MO	3	PA,QL (4 per 28 days)
EMEND (FOSAPREPITANT) 150 MG INTRAVENOUS SOLUTION MO	3	PA
<i>fosaprepitant 150 mg vial</i> MO	1	PA
<i>granisetron hcl 0.1 mg/ml vial; granisetron hcl 1 mg/ml vial</i> MO	1	
<i>granisetron hcl 1 mg tablet</i> MO	1	B vs D,QL (28 per 28 days)
<i>granisetron hcl 1 mg/ml vial; granisetron hcl 4 mg/4 ml vial</i> MO	1	
MARINOL 10 MG, 2.5 MG, 5 MG CAPSULE DL	4	PA,QL (120 per 30 days)
<i>meclizine 12.5 mg, 25 mg tablet</i> MO	1	
<i>metoclopramide 10 mg, 5 mg tablet</i> MO	1	
<i>metoclopramide 10 mg/2 ml syr</i> MO	1	
<i>metoclopramide 10 mg/2 ml vial; metoclopramide 5 mg/5 ml, 5 mg/ml soln</i> MO	1	
<i>metoclopramide hcl 10 mg odt</i> MO	1	QL (180 per 30 days)
<i>metoclopramide hcl 5 mg odt</i> MO	1	QL (360 per 30 days)
<i>ondansetron odt 4 mg, 8 mg tablet</i> MO	1	B vs D,QL (90 per 30 days)
<i>ondansetron 4 mg/5 ml solution</i> MO	1	B vs D,QL (450 per 30 days)
<i>ondansetron 40 mg/20 ml vial</i> MO	1	
<i>ondansetron hcl 24 mg tablet</i> MO	1	B vs D,QL (30 per 30 days)
<i>ondansetron hcl 4 mg, 8 mg tablet</i> MO	1	B vs D,QL (90 per 30 days)
<i>ondansetron hcl 4 mg/2 ml syr</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ondansetron hcl 4 mg/2 ml vial MO	1	
phenadoz 12.5 mg, 25 mg suppository MO	1	
PHENERGAN 25 MG/ML, 50 MG/ML INJECTION SOLUTION MO	1	
prochlorperazine 25 mg supp MO	1	
prochlorperazine 10 mg/2 ml vl MO	1	
prochlorperazine 10 mg, 5 mg tab; prochlorperazine 10 mg, 5 mg tablet MO	1	B vs D
promethazine 12.5 mg, 25 mg, 50 mg suppos; promethazine 12.5 mg, 25 mg, 50 mg suppository MO	1	
promethazine 12.5 mg, 25 mg, 50 mg tablet MO	1	
promethazine 25 mg/ml, 50 mg/ml vial MO	1	
promethazine 6.25 mg/5 ml syrj MO	1	
promethegan 12.5 mg, 25 mg, 50 mg rectal suppository MO	1	
REGLAN 10 MG, 5 MG TABLET MO	3	
SANCUSO 3.1 MG/24 HOUR TRANSDERMAL PATCH MO	3	QL (4 per 30 days)
scopolamine 1 mg/3 day patch MO	1	QL (10 per 30 days)
SYNDROS 5 MG/ML ORAL SOLUTION DL	4	PA
TIGAN 100 MG/ML INTRAMUSCULAR SOLUTION MO	3	
TIGAN 300 MG CAPSULE MO	3	B vs D
TRANSDERM-SCOP 1.5 MG TRANSDERMAL PATCH (1 MG OVER 3 DAYS) MO	3	QL (10 per 30 days)
trimethobenzamide 300 mg cap MO	1	B vs D
VARUBI 166.5 MG/92.5 ML INTRAVENOUS EMULSION MO	3	PA,QL (185 per 28 days)
ZOFRAN 4 MG, 8 MG TABLET DL	4	PA,QL (90 per 30 days)
ZOFRAN 4 MG/5 ML ORAL SOLN MO	3	PA,QL (450 per 30 days)
ZOFRAN ODT 4 MG, 8 MG TABLET MO	3	PA,QL (90 per 30 days)
ZUPLENZ 4 MG, 8 MG ORAL SOLUBLE FILM DL	4	B vs D,QL (90 per 30 days)
Antifungals		
ABELCET 5 MG/ML INTRAVENOUS SUSPENSION DL	4	B vs D
AMBISOME 50 MG INTRAVENOUS SUSPENSION DL	4	B vs D
amphotericin b 50 mg vial MO	1	B vs D
ANCOBON 250 MG, 500 MG CAPSULE DL	4	
CANCIDAS 50 MG, 70 MG INTRAVENOUS SOLUTION DL	4	PA
caspofungin acetate 50 mg, 70 mg vial DL	4	
ciclodan 8 % topical solution MO	1	QL (13.2 per 30 days)
ciclopirox 0.77% cream MO	1	QL (90 per 30 days)
ciclopirox 0.77% gel MO	1	QL (100 per 30 days)
ciclopirox 0.77% topical susp MO	1	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ciclopirox 1% shampoo</i> MO	1	QL (120 per 30 days)
<i>ciclopirox 8% solution</i> MO	1	QL (13.2 per 30 days)
<i>clotrimazole 1% solution</i> MO	1	
<i>clotrimazole 1% topical cream</i> MO	1	
<i>clotrimazole 10 mg troche</i> MO	1	
<i>clotrimazole-betamethasone crm</i> MO	1	QL (180 per 30 days)
<i>clotrimazole-betamethasone lot</i> MO	1	QL (90 per 28 days)
CRESEMBA 186 MG CAPSULE DL	4	PA,QL (180 per 30 days)
CRESEMBA 372 MG INTRAVENOUS SOLUTION DL	4	PA
DIFLUCAN 10 MG/ML, 40 MG/ML ORAL SUSPENSION DL	4	PA
DIFLUCAN 100 MG, 150 MG, 200 MG, 50 MG TABLET MO	3	PA
<i>econazole nitrate 1% cream</i> MO	1	PA,QL (85 per 30 days)
ERAXIS(WATER DILUENT) 100 MG INTRAVENOUS SOLUTION DL	4	
ERAXIS(WATER DILUENT) 50 MG INTRAVENOUS SOLUTION MO	3	
ERTACZO 2 % TOPICAL CREAM DL	4	QL (60 per 30 days)
EXELDERM 1 % TOPICAL CREAM MO	3	
EXELDERM 1 % TOPICAL SOLUTION MO	3	QL (60 per 30 days)
EXTINA 2 % TOPICAL FOAM MO	3	QL (100 per 30 days)
<i>fluconazole 10 mg/ml, 40 mg/ml susp</i> MO	1	
<i>fluconazole 100 mg, 150 mg, 200 mg, 50 mg tablet</i> MO	1	
<i>fluconazole-dext 200 mg/100 ml</i> MO	1	
<i>fluconazole-nacl 100 mg/50 ml, 200 mg/100 ml, 400 mg/200 ml</i> MO	1	
<i>flucytosine 250 mg, 500 mg capsule</i> DL	4	
<i>griseofulvin 125 mg/5 ml susp</i> MO	1	
<i>griseofulvin micro 500 mg tab</i> MO	1	
<i>griseofulvin ultra 125 mg, 250 mg tab</i> MO	1	
<i>gynazole-1 2 % vaginal cream</i> MO	1	
<i>itraconazole 10 mg/ml solution</i> MO	1	QL (150 per 30 days)
<i>itraconazole 100 mg capsule</i> MO	1	QL (120 per 30 days)
JUBLIA 10 % TOPICAL SOLUTION WITH APPLICATOR DL	4	PA,QL (4 per 28 days)
KERYDIN 5 % TOPICAL SOLUTION WITH APPLICATOR DL	4	QL (10 per 30 days)
<i>ketoconazole 2% cream</i> MO	1	QL (60 per 30 days)
<i>ketoconazole 2% foam</i> MO	1	QL (100 per 30 days)
<i>ketoconazole 2% shampoo</i> MO	1	QL (120 per 30 days)
<i>ketoconazole 200 mg tablet</i> MO	1	PA
<i>ketodan 2 % topical foam</i> MO	1	QL (100 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LOPROX 1 % SHAMPOO MO	3	PA,QL (120 per 30 days)
LOPROX (AS OLAMINE) 0.77 % TOPICAL CREAM MO	3	PA,QL (90 per 30 days)
LOPROX (AS OLAMINE) 0.77 % TOPICAL SUSPENSION MO	3	PA,QL (60 per 30 days)
LOTRISONE CREAM MO	3	PA,QL (180 per 30 days)
<i>luliconazole 1% cream</i> MO	1	ST,QL (60 per 28 days)
LUZU 1 % TOPICAL CREAM MO	3	ST,QL (60 per 28 days)
MENTAX 1 % TOPICAL CREAM MO	3	QL (30 per 30 days)
<i>micafungin 100 mg, 50 mg vial</i> DL	4	
<i>miconazole-zinc-petro 0.25-15%</i> MO	1	
<i>miconazole-3 200 mg vaginal suppository</i> MO	1	
MYCAMINE 100 MG, 50 MG INTRAVENOUS SOLUTION DL	4	
<i>naftifine hcl 1% cream</i> MO	1	ST,QL (90 per 30 days)
<i>naftifine hcl 1% gel</i> MO	1	ST,QL (90 per 30 days)
<i>naftifine hcl 2% cream</i> MO	1	ST,QL (120 per 30 days)
NAFTIN 1 % TOPICAL GEL MO	3	ST,QL (90 per 30 days)
NAFTIN 2 % TOPICAL CREAM MO	3	ST,QL (120 per 30 days)
NAFTIN 2 % TOPICAL GEL MO	3	ST,QL (120 per 30 days)
NIZORAL 2 % SHAMPOO MO	3	QL (120 per 30 days)
NOXAFIL 100 MG TABLET,DELAYED RELEASE DL	4	PA
NOXAFIL 200 MG/5 ML (40 MG/ML) ORAL SUSPENSION DL	4	PA,QL (840 per 28 days)
NOXAFIL 300 MG/16.7 ML INTRAVENOUS SOLUTION DL	4	PA
<i>nyamyc 100,000 unit/gram topical powder</i> MO	1	PA
<i>nystatin 100,000 unit/gm cream</i> MO	1	
<i>nystatin 100,000 unit/gm oint</i> MO	1	
<i>nystatin 100,000 unit/gm powd</i> MO	1	PA
<i>nystatin 100,000 unit/ml susp</i> MO	1	
<i>nystatin 500,000 unit oral tab</i> MO	1	
<i>nystatin-triamcinolone cream</i> MO	1	
<i>nystatin-triamcinolone ointm</i> MO	1	
<i>nystop 100,000 unit/gram topical powder</i> MO	1	PA
ONMEL 200 MG TABLET DL	4	QL (28 per 28 days)
ORAVIG 50 MG BUCCAL TABLET DL	4	QL (14 per 30 days)
<i>oxiconazole nitrate 1% cream</i> DL	4	PA
OXISTAT 1 % LOTION DL	4	PA
OXISTAT 1 % TOPICAL CREAM DL	4	
PENLAC 8% SOLUTION MO	3	QL (13.2 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>posaconazole 200 mg/5 ml susp</i> ^{DL}	4	PA,QL (840 per 28 days)
<i>posaconazole dr 100 mg tablet</i> ^{DL}	4	PA
SPORANOX 10 MG/ML ORAL SOLUTION ^{DL}	4	QL (150 per 30 days)
SPORANOX 100 MG CAPSULE ^{DL}	4	PA,QL (120 per 30 days)
SPORANOX PULSEPAK 100 MG CAPSULE ^{MO}	3	PA,QL (120 per 30 days)
<i>terbinafine hcl 250 mg tablet</i> ^{MO}	1	
<i>terconazole 0.4% cream; terconazole 0.8% cream</i> ^{MO}	1	
<i>terconazole 80 mg suppository</i> ^{MO}	1	
TOLSURA 65 MG ORAL SOLID DISPERSION CAPSULE ^{DL}	4	PA,QL (120 per 30 days)
VFEND 200 MG, 50 MG TABLET ^{DL}	4	PA,QL (120 per 30 days)
VFEND 200 MG/5 ML (40 MG/ML) ORAL SUSPENSION ^{DL}	4	PA,QL (400 per 30 days)
VFEND IV 200 MG INTRAVENOUS SOLUTION ^{DL}	4	B vs D
<i>voriconazole 200 mg vial</i> ^{DL}	4	PA
<i>voriconazole 200 mg, 50 mg tablet</i> ^{MO}	1	PA,QL (120 per 30 days)
<i>voriconazole 40 mg/ml susp</i> ^{DL}	4	PA,QL (400 per 30 days)
VUSION 0.25 %-15 %-81.35 % TOPICAL OINTMENT ^{MO}	3	
XOLEGEL 2 % TOPICAL ^{DL}	4	
Antigout Agents		
<i>allopurinol 100 mg, 300 mg tablet</i> ^{MO}	1	
<i>allopurinol sodium 500 mg vial</i> ^{MO}	1	
ALOPRIM 500 MG INTRAVENOUS SOLUTION ^{MO}	3	
DUZALLO 200 MG-200 MG TABLET; DUZALLO 200 MG-300 MG TABLET ^{MO}	3	PA,QL (30 per 30 days)
<i>febuxostat 40 mg, 80 mg tablet</i> ^{MO}	1	ST,QL (30 per 30 days)
GLOPERBA 0.6 MG/5 ML ORAL SOLUTION ^{MO}	3	PA,QL (300 per 30 days)
MITIGARE 0.6 MG CAPSULE ^{MO}	2	
<i>probenecid 500 mg tablet</i> ^{MO}	1	
<i>probenecid-colchicine tablet</i> ^{MO}	1	
ULORIC 40 MG, 80 MG TABLET ^{MO}	3	ST,QL (30 per 30 days)
ZURAMPIC 200 MG TABLET ^{MO}	3	PA,QL (30 per 30 days)
ZYLOPRIM 100 MG, 300 MG TABLET ^{MO}	3	
ANTIMIGRAINE AGENTS		
AIMOVIG AUTOINJECTOR 140 MG/ML SUBCUTANEOUS AUTO-INJECTOR ^{MO}	3	PA,QL (1 per 30 days)
AIMOVIG AUTOINJECTOR 70 MG/ML SUBCUTANEOUS AUTO-INJECTOR ^{MO}	3	PA,QL (2 per 30 days)
AIMOVIG 140 MG DOSE-2 AUTOINJ ^{MO}	3	PA,QL (2 per 30 days)
AJOVY 225 MG/1.5 ML SUBCUTANEOUS AUTO-INJECTOR ^{MO}	3	PA,QL (1.5 per 30 days)
AJOVY SYRINGE 225 MG/1.5 ML SUBCUTANEOUS ^{MO}	3	PA,QL (1.5 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>almotriptan malate 12.5 mg, 6.25 mg tab</i> MO	1	ST,QL (9 per 30 days)
AMERGE 1 MG, 2.5 MG TABLET MO	3	PA,QL (9 per 30 days)
CAFERGOT 1 MG-100 MG TABLET MO	1	QL (40 per 30 days)
D.H.E.45 1 MG/ML INJECTION SOLUTION DL	4	
<i>dihydroergotamine 1 mg/ml amp</i> DL	4	
<i>dihydroergotamine 4 mg/ml spry</i> DL	4	QL (8 per 30 days)
<i>eletriptan hbr 20 mg, 40 mg tablet</i> MO	1	ST,QL (9 per 30 days)
EMGALITY PEN 120 MG/ML SUBCUTANEOUS PEN INJECTOR MO	3	PA,QL (2 per 30 days)
EMGALITY 120 MG/ML SUBCUTANEOUS SYRINGE MO	3	PA,QL (2 per 30 days)
EMGALITY 300 MG/3 ML (100 MG/ML X 3) SUBCUTANEOUS SYRINGE MO	3	PA,QL (3 per 30 days)
ERGOMAR 2 MG SUBLINGUAL TABLET DL	4	QL (20 per 28 days)
<i>ergotamine-caffeine 1-100mg tb</i> MO	1	QL (40 per 30 days)
FROVA 2.5 MG TABLET DL	4	ST,QL (12 per 30 days)
<i>frovatriptan succ 2.5 mg tab</i> MO	1	ST,QL (12 per 30 days)
IMITREX 100 MG, 25 MG, 50 MG TABLET DL	4	PA,QL (9 per 30 days)
IMITREX 20 MG/ACTUATION, 5 MG/ACTUATION NASAL SPRAY DL	4	PA,QL (12 per 30 days)
IMITREX 6 MG/0.5 ML SUBCUTANEOUS SOLUTION DL	4	PA,QL (6 per 30 days)
IMITREX STATDOSE PEN 4 MG/0.5 ML, 6 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR MO	3	PA,QL (6 per 30 days)
IMITREX STATDOSE REFILL 4 MG/0.5 ML, 6 MG/0.5 ML SUBCUTANEOUS CARTRIDGE DL	4	PA,QL (6 per 30 days)
MAXALT 10 MG TABLET MO	3	PA,QL (12 per 30 days)
MAXALT MLT 10 MG, 5 MG TABLET; MAXALT-MLT 10 MG, 5 MG DISINTEGRATING TABLET MO	3	PA,QL (12 per 30 days)
<i>migergot 2 mg-100 mg rectal suppository</i> DL	4	QL (20 per 28 days)
MIGRANAL 0.5 MG/PUMP ACT. (4 MG/ML) NASAL SPRAY DL	4	QL (8 per 30 days)
<i>naratriptan hcl 1 mg, 2.5 mg tablet</i> MO	1	QL (9 per 30 days)
ONZETRA XSAIL 11 MG POWDER FOR NASAL INHALATION DL	4	ST,QL (16 per 30 days)
RELPAZ 20 MG, 40 MG TABLET MO	3	ST,QL (9 per 30 days)
REYVOW 100 MG TABLET MO	3	PA,QL (8 per 30 days)
REYVOW 50 MG TABLET MO	3	PA,QL (4 per 30 days)
<i>rizatriptan 10 mg, 5 mg odt; rizatriptan 10 mg, 5 mg tablet</i> MO	1	QL (12 per 30 days)
<i>sumatriptan 20 mg nasal spray; sumatriptan 5 mg nasal spray</i> MO	1	QL (12 per 30 days)
<i>sumatriptan 4 mg/0.5 ml, 6 mg/0.5 ml cart</i> MO	3	QL (6 per 30 days)
<i>sumatriptan 4 mg/0.5 ml, 6 mg/0.5 ml inject</i> MO	1	QL (6 per 30 days)
<i>sumatriptan 6 mg/0.5 ml syrng</i> MO	1	QL (6 per 30 days)
<i>sumatriptan 6 mg/0.5 ml vial</i> MO	1	QL (6 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
sumatriptan succ 100 mg, 25 mg, 50 mg tablet MO	1	QL (9 per 30 days)
sumatriptan-naproxen 85-500 mg MO	1	ST,QL (18 per 30 days)
SUMAVEL DOSEPRO 6 MG/0.5 ML MO	3	ST,QL (6 per 30 days)
TOSYMRA 10 MG/ACTUATION NASAL SPRAY MO	3	ST,QL (12 per 30 days)
TREXIMET 10-60 MG, 85-500 MG TABLET; TREXIMET 85 MG-500 MG TABLET DL	4	ST,QL (18 per 30 days)
VYEPTI 100 MG/ML INTRAVENOUS SOLUTION MO	3	PA,QL (1 per 90 days)
ZEMBRACE SYMTOUCH 3 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR DL	4	ST,QL (6 per 30 days)
zolmitriptan 2.5 mg, 5 mg odt; zolmitriptan 2.5 mg, 5 mg tablet MO	1	ST,QL (9 per 30 days)
ZOMIG 2.5 MG, 5 MG NASAL SPRAY DL	4	ST,QL (12 per 30 days)
ZOMIG 2.5 MG, 5 MG TABLET DL	4	ST,QL (9 per 30 days)
ZOMIG ZMT 2.5 MG, 5 MG DISINTEGRATING TABLET DL	4	ST,QL (9 per 30 days)
Antimyasthenic Agents		
guanidine hcl 125 mg tablet MO	1	
MESTINON 60 MG TABLET DL	4	PA
MESTINON 60 MG/5 ML ORAL SYRUP DL	4	
MESTINON TIMESPAN 180 MG TABLET,EXTENDED RELEASE DL	4	PA
pyridostigmine 60 mg/5 ml soln DL	4	
pyridostigmine br 30 mg, 60 mg tablet MO	1	
pyridostigmine er 180 mg tab MO	1	
REGONOL 5 MG/ML INJECTION SOLUTION MO	3	
Antimycobacterials		
CAPASTAT 1 GRAM SOLUTION FOR INJECTION MO	3	
cycloserine 250 mg capsule DL	4	
dapsone 100 mg, 25 mg tablet MO	1	
ethambutol hcl 100 mg, 400 mg tablet MO	1	
isoniazid 100 mg, 300 mg tablet MO	1	
isoniazid 100 mg/ml, 50 mg/5 ml solution; isoniazid 100 mg/ml, 50 mg/5 ml vial MO	1	
MYAMBUTOL 400 MG TABLET MO	3	
MYCOBUTIN 150 MG CAPSULE MO	3	
PASER 4 GRAM GRANULES DELAYED-RELEASE PACKET MO	1	
PRETOMANID 200 MG TABLET MO	3	PA,QL (30 per 30 days)
PRIFTIN 150 MG TABLET MO	3	
pyrazinamide 500 mg tablet MO	1	
rifabutin 150 mg capsule MO	1	
RIFADIN 150 MG, 300 MG CAPSULE MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RIFADIN 600 MG INTRAVENOUS SOLUTION MO	3	
RIFAMATE 300 MG-150 MG CAPSULE MO	1	
<i>rifampin 150 mg, 300 mg capsule</i> MO	1	
<i>rifampin iv 600 mg vial</i> DL	4	
RIFATER 50 MG-120 MG-300 MG TABLET MO	3	
SIRTURO 100 MG TABLET DL	4	PA,QL (68 per 28 days)
SIRTURO 20 MG TABLET DL	4	PA,QL (340 per 28 days)
TRECTOR 250 MG TABLET MO	3	
Antineoplastics		
<i>abiraterone acetate 250 mg tab</i> DL	4	PA,QL (120 per 30 days)
ABRAXANE 100 MG INTRAVENOUS SUSPENSION DL	4	PA
ADCETRIS 50 MG INTRAVENOUS SOLUTION DL	4	PA
<i>adriamycin 10 mg, 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml intravenous solution</i> MO	1	B vs D
ADRIAMYCIN 50 MG INTRAVENOUS SOLUTION MO	1	B vs D
<i>adrucil 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml intravenous solution; adrucil 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml vial</i> MO	1	B vs D
AFINITOR 10 MG, 2.5 MG, 5 MG, 7.5 MG TABLET DL	4	PA,QL (30 per 30 days)
AFINITOR DISPERZ 2 MG, 3 MG, 5 MG TABLET FOR ORAL SUSPENSION DL	4	PA
ALECENSA 150 MG CAPSULE DL	4	PA,QL (240 per 30 days)
ALIMTA 100 MG, 500 MG INTRAVENOUS SOLUTION DL	4	PA
ALIQOPA 60 MG INTRAVENOUS SOLUTION DL	4	PA,QL (3 per 28 days)
ALKERAN 2 MG TABLET MO	3	B vs D
ALKERAN (AS HCL) 50 MG INTRAVENOUS SOLUTION MO	3	B vs D
ALUNBRIG 180 MG, 90 MG, 90 MG (7)- 180 MG (23) TABLET; ALUNBRIG 90 MG (7)-180 MG (23) TABLETS IN A DOSE PACK DL	4	PA,QL (30 per 30 days)
ALUNBRIG 30 MG TABLET DL	4	PA,QL (180 per 30 days)
<i>amifostine 500 mg vial</i> DL	4	B vs D
<i>anastrozole 1 mg tablet</i> MO	1	QL (30 per 30 days)
ARIMIDEX 1 MG TABLET DL	4	PA,QL (30 per 30 days)
AROMASIN 25 MG TABLET DL	4	PA,QL (60 per 30 days)
ARRANON 250 MG/50 ML INTRAVENOUS SOLUTION DL	4	
<i>arsenic trioxide 10 mg/10ml vl; arsenic trioxide 12 mg/6 ml vl</i> DL	4	PA
ARZERRA 1,000 MG/50 ML, 100 MG/5 ML INTRAVENOUS SOLUTION DL	4	PA,QL (400 per 28 days)
ASPARLAS 750 UNIT/ML INTRAVENOUS SOLUTION DL	4	PA
AVASTIN 25 MG/ML INTRAVENOUS SOLUTION DL	4	PA
AYVAKIT 100 MG, 200 MG, 300 MG TABLET DL	4	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>azacitidine 100 mg vial</i> DL	4	PA
BALVERSA 3 MG TABLET DL	4	PA,QL (90 per 30 days)
BALVERSA 4 MG TABLET DL	4	PA,QL (60 per 30 days)
BALVERSA 5 MG TABLET DL	4	PA,QL (30 per 30 days)
BAVENCIO 20 MG/ML INTRAVENOUS SOLUTION DL	4	PA
BELEODAQ 500 MG INTRAVENOUS SOLUTION DL	4	PA
BENDEKA 25 MG/ML INTRAVENOUS SOLUTION DL	4	PA
BESPONSA 0.9 MG(0.25 MG/ML INITIAL CONCENTRATION) INTRAVENOUS SOLUTION DL	4	PA
<i>bexarotene 75 mg capsule</i> DL	4	PA,QL (300 per 30 days)
<i>bicalutamide 50 mg tablet</i> MO	1	QL (30 per 30 days)
BICNU 100 MG INTRAVENOUS SOLUTION MO	3	B vs D
BLENREP 100 MG INTRAVENOUS SOLUTION DL	4	PA
<i>bleomycin sulfate 15 unit, 30 unit vial</i> MO	1	B vs D
<i>bortezomib 3.5 mg vial</i> DL	4	PA
BOSULIF 100 MG TABLET DL	4	PA,QL (120 per 30 days)
BOSULIF 400 MG, 500 MG TABLET DL	4	PA,QL (30 per 30 days)
BRAFTOVI 50 MG CAPSULE DL	4	PA,QL (120 per 30 days)
BRAFTOVI 75 MG CAPSULE DL	4	PA,QL (180 per 30 days)
BRUKINSA 80 MG CAPSULE DL	4	PA,QL (120 per 30 days)
<i>busulfan 60 mg/10 ml vial</i> MO	1	B vs D
BUSULFEX 60 MG/10 ML INTRAVENOUS SOLUTION MO	3	B vs D
CABOMETYX 20 MG, 40 MG, 60 MG TABLET DL	4	PA,QL (30 per 30 days)
CALQUENCE 100 MG CAPSULE DL	4	PA,QL (60 per 30 days)
CAMPTOSAR 100 MG/5 ML, 300 MG/15 ML, 40 MG/2 ML INTRAVENOUS SOLUTION DL	4	B vs D
CAPRELSA 100 MG TABLET DL	4	PA,QL (60 per 30 days)
CAPRELSA 300 MG TABLET DL	4	PA,QL (30 per 30 days)
<i>carboplatin 50 mg/5 ml vial</i> MO	1	B vs D
<i>carmustine 100 mg vial</i> MO	1	B vs D
CASODEX 50 MG TABLET DL	4	QL (30 per 30 days)
<i>cisplatin 100 mg/100 ml vial</i> MO	1	B vs D
<i>cladribine 10 mg/10 ml vial</i> DL	4	B vs D
<i>clofarabine 20 mg/20 ml vial</i> DL	4	B vs D
CLOLAR 20 MG/20 ML INTRAVENOUS SOLUTION DL	4	B vs D
COMETRIQ 100 MG/DAY (80 MG X 1-20 MG X 1) CAPSULES DL	4	PA,QL (56 per 28 days)
COMETRIQ 140 MG/DAY (80 MG X 1-20 MG X 3) CAPSULES DL	4	PA,QL (112 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
COMETRIQ 60 MG/DAY (20 MG X 3/DAY) CAPSULES DL	4	PA,QL (84 per 28 days)
COPIKTRA 15 MG, 25 MG CAPSULE DL	4	PA,QL (56 per 28 days)
COSMEGEN 0.5 MG INTRAVENOUS SOLUTION DL	4	B vs D
COTELLIC 20 MG TABLET DL	4	PA,QL (63 per 28 days)
cyclophosphamide 1 gm vial; cyclophosphamide 1 gram, 2 gram, 500 mg vial; cyclophosphamide 2 gm vial MO	1	B vs D
CYCLOPHOSPHAMIDE 1 GM/5 ML VL MO	1	B vs D
cyclophosphamide 25 mg, 50 mg capsule MO	1	B vs D
CYRAMZA 10 MG/ML INTRAVENOUS SOLUTION DL	4	PA
cytarabine 20 mg/ml vial MO	1	B vs D
cytarabine 100 mg/5 ml (20 mg/ml), 2 gram/20 ml (100 mg/ml), 20 mg/ml vial; cytarabine 100 mg/5 ml vial; cytarabine 2 g/20 ml vial MO	1	B vs D
dacarbazine 100 mg, 200 mg vial MO	1	B vs D
DACOGEN 50 MG INTRAVENOUS SOLUTION DL	4	PA
dactinomycin 0.5 mg vial DL	4	B vs D
DARZALEX 20 MG/ML INTRAVENOUS SOLUTION DL	4	PA
DARZALEX FASPRO 1,800 MG-30,000 UNIT/15 ML SUBCUTANEOUS SOLUTION DL	4	PA
daunorubicin 20 mg/4 ml vial MO	1	B vs D
DAURISMO 100 MG TABLET DL	4	PA,QL (30 per 30 days)
DAURISMO 25 MG TABLET DL	4	PA,QL (60 per 30 days)
decitabine 50 mg vial DL	4	PA
dexrazoxane 250 mg, 500 mg vial MO	1	B vs D
DOCEFREZ 20 MG INTRAVENOUS SOLUTION MO	3	B vs D
DOCEFREZ 80 MG INTRAVENOUS SOLUTION DL	4	B vs D
docetaxel 160 mg/16 ml vial; docetaxel 160 mg/8 ml vial; docetaxel 20 mg/2 ml vial; docetaxel 20 mg/ml vial; docetaxel 200 mg/10 ml vial; docetaxel 80 mg/4 ml vial; docetaxel 80 mg/8 ml vial MO	1	B vs D
DOXIL 2 MG/ML INTRAVENOUS SUSPENSION DL	4	B vs D
doxorubicin 10 mg, 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg, 50 mg/25 ml vial; doxorubicin 150 mg/75 ml vial MO	1	B vs D
doxorubicin liposome 20mg/10ml DL	4	PA
ELITEK 1.5 MG, 7.5 MG INTRAVENOUS SOLUTION DL	4	PA
ELLENC 200 MG/100 ML, 50 MG/25 ML INTRAVENOUS SOLUTION DL	4	B vs D
ELZONRIS 1,000 MCG/ML INTRAVENOUS SOLUTION DL	4	PA,QL (10 per 21 days)
EMCYT 140 MG CAPSULE DL	4	
EMPLICITI 300 MG, 400 MG INTRAVENOUS SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ENHERTU 100 MG INTRAVENOUS SOLUTION DL	4	PA
<i>epirubicin 200 mg/100 ml, 50 mg/25 ml vial</i> MO	1	B vs D
<i>epirubicin hcl 50 mg vial</i> MO	3	B vs D
ERBITUX 100 MG/50 ML, 200 MG/100 ML INTRAVENOUS SOLUTION DL	4	PA
ERIVEDGE 150 MG CAPSULE DL	4	PA,QL (28 per 28 days)
ERLEADA 60 MG TABLET DL	4	PA,QL (120 per 30 days)
<i>erlotinib hcl 100 mg, 150 mg tablet</i> DL	4	PA,QL (30 per 30 days)
<i>erlotinib hcl 25 mg tablet</i> DL	4	PA,QL (90 per 30 days)
ERWINAZE 10,000 UNIT SOLUTION FOR INJECTION DL	4	PA
ETHYOL 500 MG INTRAVENOUS SOLUTION DL	4	B vs D
ETOPOPHOS 100 MG INTRAVENOUS SOLUTION MO	3	B vs D
<i>etoposide 100 mg/5 ml vial</i> MO	1	B vs D
EVOMELA 50 MG INTRAVENOUS SOLUTION DL	4	PA
<i>exemestane 25 mg tablet</i> MO	1	QL (60 per 30 days)
FARESTON 60 MG TABLET DL	4	QL (30 per 30 days)
FARYDAK 10 MG, 15 MG, 20 MG CAPSULE DL	4	PA,QL (6 per 21 days)
FASLODEX 250 MG/5 ML INTRAMUSCULAR SYRINGE DL	4	PA,QL (30 per 30 days)
FEMARA 2.5 MG TABLET MO	3	PA,QL (30 per 30 days)
<i>floxuridine 500 mg vial</i> MO	1	B vs D
<i>fludarabine 50 mg, 50 mg/2 ml vial</i> MO	1	B vs D
<i>fluorouracil 1 gram/20 ml, 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml vial; fluorouracil 1,000 mg/20 ml vl; fluorouracil 2,500 mg/50 ml vl; fluorouracil 5,000 mg/100 ml</i> MO	1	B vs D
<i>flutamide 125 mg capsule</i> MO	1	
FOLOTYN 20 MG/ML (1 ML), 40 MG/2 ML (20 MG/ML) INTRAVENOUS SOLUTION DL	4	PA
<i>fulvestrant 250 mg/5 ml syring</i> DL	4	PA,QL (30 per 30 days)
FUSILEV 50 MG INTRAVENOUS SOLUTION DL	4	PA
GAZYVA 1,000 MG/40 ML INTRAVENOUS SOLUTION DL	4	PA,QL (120 per 28 days)
<i>gemcitabine 1 gram/26.3 ml vl; gemcitabine 2 gram/52.6 ml vl; gemcitabine 200 mg/5.26 ml vl; gemcitabine hcl 1 gram, 1 gram/26.3 ml (38 mg/ml), 2 gram, 2 gram/52.6 ml (38 mg/ml), 200 mg, 200 mg/5.26 ml (38 mg/ml) vial</i> MO	1	B vs D
GEMZAR 1 GRAM, 200 MG VIAL DL	4	PA
GILOTRIF 20 MG, 30 MG, 40 MG TABLET DL	4	PA,QL (30 per 30 days)
GLEEVEC 100 MG TABLET DL	4	PA,QL (90 per 30 days)
GLEEVEC 400 MG TABLET DL	4	PA,QL (60 per 30 days)
HALAVEN 1 MG/2 ML (0.5 MG/ML) INTRAVENOUS SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HERCEPTIN 150 MG, 440 MG INTRAVENOUS SOLUTION; HERCEPTIN 150 MG, 440 MG VIAL DL	4	PA
HERCEPTIN HYLECTA 600 MG-10,000 UNIT/5 ML SUBCUTANEOUS SOLUTION DL	4	PA,QL (5 per 21 days)
HERZUMA 150 MG, 420 MG INTRAVENOUS SOLUTION DL	4	PA
HEXALEN 50 MG CAPSULE DL	4	
HYCAMTIN 4 MG INTRAVENOUS SOLUTION DL	4	B vs D
HYDREA 500 MG CAPSULE MO	3	
<i>hydroxyurea 500 mg capsule</i> MO	1	
IBRANCE 100 MG, 125 MG, 75 MG CAPSULE DL	4	PA,QL (21 per 28 days)
IBRANCE 100 MG, 125 MG, 75 MG TABLET DL	4	PA,QL (21 per 28 days)
ICLUSIG 15 MG TABLET DL	4	PA,QL (60 per 30 days)
ICLUSIG 45 MG TABLET DL	4	PA,QL (30 per 30 days)
IDAMYCIN PFS 1 MG/ML INTRAVENOUS SOLUTION DL	4	B vs D
<i>idarubicin hcl 20 mg/20 ml vial</i> DL	4	B vs D
IDHIFA 100 MG, 50 MG TABLET DL	4	PA,QL (30 per 30 days)
IFEX 1 GRAM, 3 GRAM INTRAVENOUS SOLUTION MO	3	B vs D
<i>ifosfamide 1 gm vial; ifosfamide 1 gm/20 ml vial; ifosfamide 3 gm vial; ifosfamide 3 gm/60 ml vial</i> MO	1	B vs D
<i>imatinib mesylate 100 mg tab</i> DL	4	PA,QL (90 per 30 days)
<i>imatinib mesylate 400 mg tab</i> DL	4	PA,QL (60 per 30 days)
IMBRUVICA 140 MG CAPSULE DL	4	PA,QL (90 per 30 days)
IMBRUVICA 420 MG, 560 MG TABLET DL	4	PA,QL (28 per 28 days)
IMBRUVICA 70 MG CAPSULE DL	4	PA,QL (28 per 28 days)
IMFINZI 50 MG/ML INTRAVENOUS SOLUTION DL	4	PA
IMLYGIC 10EXP6 (1 MILLION) PFU/ML SUSPENSION FOR INJECTION DL	4	PA,QL (4 per 365 days)
IMLYGIC 10EXP8 (100 MILLION) PFU/ML SUSPENSION FOR INJECTION DL	4	PA,QL (8 per 28 days)
INFUGEM 1,200 MG/120 ML (10 MG/ML), 1,300 MG/130 ML (10 MG/ML), 1,400 MG/140 ML (10 MG/ML), 1,500 MG/150 ML (10 MG/ML), 1,600 MG/160 ML (10 MG/ML), 1,700 MG/170 ML (10 MG/ML), 1,800 MG/180 ML (10 MG/ML), 1,900 MG/190 ML (10 MG/ML), 2,000 MG/200 ML (10 MG/ML), 2,200 MG/220 ML (10 MG/ML) INTRAVENOUS PIGGYBACK DL	4	B vs D
INLYTA 1 MG TABLET DL	4	PA,QL (180 per 30 days)
INLYTA 5 MG TABLET DL	4	PA,QL (60 per 30 days)
INQOVI 35 MG-100 MG TABLET DL	4	PA,QL (5 per 28 days)
INREBIC 100 MG CAPSULE DL	4	PA,QL (120 per 30 days)
IRESSA 250 MG TABLET DL	4	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>irinotecan hcl 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml, 500 mg/25 ml vial; irinotecan hcl 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml, 500 mg/25 ml vial</i> ^{MO}	1	B vs D
ISTODAX 10 MG/2 ML INTRAVENOUS SOLUTION ^{DL}	4	PA
IXEMPRA 15 MG, 45 MG INTRAVENOUS SOLUTION ^{DL}	4	PA
JAKAFI 10 MG, 15 MG, 20 MG, 25 MG, 5 MG TABLET ^{DL}	4	PA,QL (60 per 30 days)
JEVTANA 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION ^{DL}	4	PA
KADCYLA 100 MG, 160 MG INTRAVENOUS SOLUTION ^{DL}	4	PA
KANJINTI 150 MG, 420 MG INTRAVENOUS SOLUTION ^{DL}	4	PA
KEYTRUDA 25 MG/ML INTRAVENOUS SOLUTION ^{DL}	4	PA
KHAPZORY 175 MG, 300 MG INTRAVENOUS SOLUTION ^{DL}	4	PA
KISQALI 200 MG/DAY (200 MG X 1) TABLET ^{DL}	4	PA,QL (21 per 28 days)
KISQALI 400 MG/DAY (200 MG X 2) TABLET ^{DL}	4	PA,QL (42 per 28 days)
KISQALI 600 MG/DAY (200 MG X 3) TABLET ^{DL}	4	PA,QL (63 per 28 days)
KISQALI FEMARA CO-PACK 200 MG/DAY(200 MG X 1)-2.5 MG TABLET ^{DL}	4	PA,QL (49 per 28 days)
KISQALI FEMARA CO-PACK 400 MG/DAY(200 MG X 2)-2.5 MG TABLET ^{DL}	4	PA,QL (70 per 28 days)
KISQALI FEMARA CO-PACK 600 MG/DAY(200 MG X 3)-2.5 MG TABLET ^{DL}	4	PA,QL (91 per 28 days)
KOSELUGO 10 MG CAPSULE ^{DL}	4	PA,QL (240 per 30 days)
KOSELUGO 25 MG CAPSULE ^{DL}	4	PA,QL (120 per 30 days)
KYPROLIS 10 MG INTRAVENOUS SOLUTION ^{DL}	4	PA,QL (6 per 28 days)
KYPROLIS 30 MG INTRAVENOUS SOLUTION ^{DL}	4	PA,QL (3 per 28 days)
KYPROLIS 60 MG INTRAVENOUS SOLUTION ^{DL}	4	PA,QL (12 per 28 days)
LARTRUVO 500 MG/50 ML VIAL ^{DL}	4	PA
LENVIMA 10 MG/DAY (10 MG X 1), 4 MG CAPSULE ^{DL}	4	PA,QL (30 per 30 days)
LENVIMA 12 MG/DAY (4 MG X 3), 18 MG/DAY (10 MG X 1-4 MG X2), 24 MG/DAY(10 MG X 2-4 MG X 1) CAPSULE; LENVIMA 18 MG/DAY (10 MG X 1 AND 4 MG X 2) CAPSULE; LENVIMA 24 MG PER DAY (10 MG X 2 AND 4 MG X 1) CAPSULE ^{DL}	4	PA,QL (90 per 30 days)
LENVIMA 14 MG/DAY(10 MG X 1-4 MG X 1), 20 MG/DAY (10 MG X 2), 8 MG/DAY (4 MG X 2) CAPSULE ^{DL}	4	PA,QL (60 per 30 days)
<i>letrozole 2.5 mg tablet</i> ^{MO}	1	QL (30 per 30 days)
<i>leucovorin cal 500 mg/50 ml vial; leucovorin calcium 10 mg/ml, 100 mg, 200 mg, 350 mg, 50 mg, 500 mg vial; leucovorin calcium 10 mg/ml, 100 mg, 200 mg, 350 mg, 50 mg, 500 mg vial</i> ^{MO}	1	B vs D
<i>leucovorin calcium 10 mg, 15 mg, 25 mg, 5 mg tab</i> ^{MO}	1	
LEUKERAN 2 MG TABLET ^{MO}	3	
<i>levoleucovorin 10 mg/ml, 175 mg, 50 mg vial; levoleucovorin 175 mg/17.5 ml</i> ^{DL}	4	PA
LEVULAN 20 % TOPICAL SOLUTION ^{MO}	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LIBTAYO 50 MG/ML INTRAVENOUS SOLUTION DL	4	PA,QL (7 per 21 days)
<i>lipodox 2 mg/ml vial</i> DL	4	PA
<i>lipodox 50 2 mg/ml vial</i> DL	4	PA
LONSURF 15 MG-6.14 MG TABLET DL	4	PA,QL (100 per 30 days)
LONSURF 20 MG-8.19 MG TABLET DL	4	PA,QL (80 per 30 days)
LORBRENA 100 MG TABLET DL	4	PA,QL (30 per 30 days)
LORBRENA 25 MG TABLET DL	4	PA,QL (90 per 30 days)
LUMOXITI 1 MG INTRAVENOUS SOLUTION DL	4	PA
LYNPARZA 100 MG, 150 MG TABLET DL	4	PA,QL (120 per 30 days)
MARQIBO 5 MG/31 ML (0.16 MG/ML) (FINAL CONC.) INTRAVENOUS KIT DL	4	PA
MATULANE 50 MG CAPSULE DL	4	
MEKINIST 0.5 MG TABLET DL	4	PA,QL (120 per 30 days)
MEKINIST 2 MG TABLET DL	4	PA,QL (30 per 30 days)
MEKTOVI 15 MG TABLET DL	4	PA,QL (180 per 30 days)
<i>melphalan 2 mg tablet</i> MO	1	B vs D
<i>melphalan hcl 50 mg vial</i> MO	1	B vs D
<i>mercaptopurine 50 mg tablet</i> MO	1	
<i>mesna 1 gram/10 ml vial</i> MO	1	B vs D
MESNEX 100 MG/ML INTRAVENOUS SOLUTION DL	4	B vs D
MESNEX 400 MG TABLET DL	4	
<i>mitomycin 20 mg, 40 mg, 5 mg vial</i> DL	4	B vs D
<i>mitoxantrone 30 mg/15 ml vial</i> MO	1	B vs D
MUSTARGEN 10 MG VIAL MO	3	B vs D
MUTAMYCIN 20 MG, 40 MG, 5 MG INTRAVENOUS SOLUTION DL	4	B vs D
MVASI 25 MG/ML INTRAVENOUS SOLUTION DL	4	PA
MYLOTARG 4.5 MG (1 MG/ML INITIAL CONCENTRATION) INTRAVENOUS SOLUTION DL	4	PA
NAVELBINE 10 MG/ML, 50 MG/5 ML INTRAVENOUS SOLUTION MO	3	B vs D
NERLYNX 40 MG TABLET DL	4	PA,QL (180 per 30 days)
NEXAVAR 200 MG TABLET DL	4	PA,QL (120 per 30 days)
NILANDRON 150 MG TABLET DL	4	PA,QL (60 per 30 days)
<i>nilutamide 150 mg tablet</i> DL	4	QL (60 per 30 days)
NINLARO 2.3 MG, 3 MG, 4 MG CAPSULE DL	4	PA,QL (3 per 28 days)
NIPENT 10 MG INTRAVENOUS SOLUTION DL	4	B vs D
NUBEQA 300 MG TABLET DL	4	PA,QL (120 per 30 days)
ODOMZO 200 MG CAPSULE DL	4	PA,QL (30 per 30 days)
OGIVRI 150 MG, 420 MG INTRAVENOUS SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ONCASPAR 750 UNIT/ML INJECTION SOLUTION DL	4	PA
ONIVYDE 4.3 MG/ML INTRAVENOUS DISPERSION DL	4	PA
ONTRUZANT 150 MG, 420 MG INTRAVENOUS SOLUTION DL	4	PA
ONUREG 200 MG, 300 MG TABLET DL	4	PA,QL (14 per 28 days)
OPDIVO 100 MG/10 ML INTRAVENOUS SOLUTION DL	4	PA,QL (40 per 28 days)
OPDIVO 240 MG/24 ML INTRAVENOUS SOLUTION DL	4	PA,QL (48 per 28 days)
OPDIVO 40 MG/4 ML INTRAVENOUS SOLUTION DL	4	PA,QL (16 per 28 days)
oxaliplatin 100 mg, 100 mg/20 ml, 50 mg, 50 mg/10 ml (5 mg/ml) vial; oxaliplatin 50 mg/10 ml vial MO	1	B vs D
paclitaxel 100 mg/16.7 ml vial MO	1	B vs D
PADCEV 20 MG INTRAVENOUS SOLUTION DL	4	PA,QL (21 per 28 days)
PADCEV 30 MG INTRAVENOUS SOLUTION DL	4	PA,QL (15 per 28 days)
PANRETIN 0.1 % TOPICAL GEL DL	4	
paraplatin 10 mg/ml intravenous solution MO	1	B vs D
PEMAZYRE 13.5 MG, 4.5 MG, 9 MG TABLET DL	4	PA,QL (14 per 21 days)
PERJETA 420 MG/14 ML (30 MG/ML) INTRAVENOUS SOLUTION DL	4	PA
PHESGO 1,200 MG-600 MG-30,000 UNIT/15 ML SUBCUTANEOUS SOLUTION DL	4	PA,QL (15 per 21 days)
PHESGO 600 MG-600 MG-20,000 UNIT/10 ML SUBCUTANEOUS SOLUTION DL	4	PA,QL (10 per 21 days)
PIQRAY 200 MG/DAY (200 MG X 1) TABLET DL	4	PA,QL (28 per 28 days)
PIQRAY 250 MG/DAY (200 MG X 1-50 MG X 1) TABLET; PIQRAY 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) TABLET DL	4	PA,QL (56 per 28 days)
POLIVY 140 MG INTRAVENOUS SOLUTION DL	4	PA,QL (2 per 21 days)
POMALYST 1 MG, 2 MG, 3 MG, 4 MG CAPSULE DL	4	PA,QL (21 per 28 days)
PORTRAZZA 800 MG/50 ML (16 MG/ML) INTRAVENOUS SOLUTION DL	4	PA,QL (100 per 21 days)
POTELIGEO 4 MG/ML INTRAVENOUS SOLUTION DL	4	PA
PROLEUKIN 22 MILLION UNIT INTRAVENOUS SOLUTION DL	4	
PURIXAN 20 MG/ML ORAL SUSPENSION DL	4	QL (300 per 30 days)
QINLOCK 50 MG TABLET DL	4	PA,QL (90 per 30 days)
RETEVMO 40 MG CAPSULE DL	4	PA,QL (180 per 30 days)
RETEVMO 80 MG CAPSULE DL	4	PA,QL (120 per 30 days)
REVLIMID 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG CAPSULE DL	4	PA,QL (28 per 28 days)
RITUXAN 10 MG/ML CONCENTRATE, INTRAVENOUS DL	4	PA
RITUXAN HYCELA 1,400 MG/11.7 ML (120 MG/ML) SUBCUTANEOUS SOLUTION DL	4	PA,QL (46.8 per 28 days)
RITUXAN HYCELA 1,600 MG/13.4 ML (120 MG/ML) SUBCUTANEOUS SOLUTION DL	4	PA,QL (13.4 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>romidepsin 10 mg kit</i> DL	4	PA
ROMIDEPSIN 27.5 MG/5.5 ML VIAL DL	4	PA
ROZLYTREK 100 MG, 200 MG CAPSULE DL	4	PA,QL (90 per 30 days)
RUBRACA 200 MG, 250 MG, 300 MG TABLET DL	4	PA,QL (120 per 30 days)
RUXIENCE 10 MG/ML CONCENTRATE,INTRAVENOUS DL	4	PA
RYDAPT 25 MG CAPSULE DL	4	PA,QL (224 per 28 days)
SARCLISA 20 MG/ML INTRAVENOUS SOLUTION DL	4	PA,QL (16 per 28 days)
SOLTAMOX 20 MG/10 ML ORAL SOLUTION DL	4	
SPRYCEL 100 MG, 50 MG, 70 MG, 80 MG TABLET DL	4	PA,QL (60 per 30 days)
SPRYCEL 140 MG TABLET DL	4	PA,QL (30 per 30 days)
SPRYCEL 20 MG TABLET DL	4	PA,QL (90 per 30 days)
STIVARGA 40 MG TABLET DL	4	PA,QL (84 per 28 days)
SUTENT 12.5 MG, 25 MG, 37.5 MG, 50 MG CAPSULE DL	4	PA,QL (28 per 28 days)
SYNRIBO 3.5 MG SUBCUTANEOUS SOLUTION DL	4	PA,QL (28 per 28 days)
TABLOID 40 MG TABLET MO	3	
TABRECTA 150 MG, 200 MG TABLET DL	4	PA,QL (112 per 28 days)
TAFINLAR 50 MG CAPSULE DL	4	PA,QL (180 per 30 days)
TAFINLAR 75 MG CAPSULE DL	4	PA,QL (120 per 30 days)
TAGRISSE 40 MG, 80 MG TABLET DL	4	PA,QL (30 per 30 days)
TALZENNA 0.25 MG CAPSULE DL	4	PA,QL (90 per 30 days)
TALZENNA 1 MG CAPSULE DL	4	PA,QL (30 per 30 days)
<i>tamoxifen 10 mg, 20 mg tablet</i> MO	1	
TARCEVA 100 MG, 150 MG TABLET DL	4	PA,QL (30 per 30 days)
TARCEVA 25 MG TABLET DL	4	PA,QL (90 per 30 days)
TARGRETIN 1 % TOPICAL GEL DL	4	PA
TARGRETIN 75 MG CAPSULE DL	4	PA,QL (300 per 30 days)
TASIGNA 150 MG, 200 MG, 50 MG CAPSULE DL	4	PA,QL (120 per 30 days)
TAXOTERE 20 MG/ML (1 ML), 80 MG/4 ML (20 MG/ML) INTRAVENOUS SOLUTION DL	4	B vs D
TAZVERIK 200 MG TABLET DL	4	PA,QL (240 per 30 days)
TECENTRIQ 1,200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION DL	4	PA,QL (20 per 21 days)
TECENTRIQ 840 MG/14 ML (60 MG/ML) INTRAVENOUS SOLUTION DL	4	PA,QL (28 per 28 days)
TEMODAR 100 MG INTRAVENOUS SOLUTION DL	4	PA,QL (27 per 30 days)
<i>temsirolimus 25 mg vial</i> DL	4	PA,QL (8 per 28 days)
<i>teniposide 50 mg/5 ml ampule</i> MO	1	B vs D
THALOMID 100 MG, 200 MG, 50 MG CAPSULE DL	4	PA,QL (30 per 30 days)
THALOMID 150 MG CAPSULE DL	4	PA,QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
thiotepa 100 mg vial DL	4	B vs D
thiotepa 15 mg vial MO	1	B vs D
TIBSOVO 250 MG TABLET DL	4	PA,QL (60 per 30 days)
toposar 20 mg/ml intravenous solution MO	1	B vs D
topotecan hcl 1 mg/ml (1 ml), 4 mg, 4 mg/4 ml (1 mg/ml) vial; topotecan hcl 1 mg/ml vial; topotecan hcl 4 mg/4 ml vial DL	4	B vs D
toremifene citrate 60 mg tab DL	4	QL (30 per 30 days)
TORISEL 30 MG/3 ML (10 MG/ML) (FIRST DILUTION) INTRAVENOUS SOLUTION DL	4	PA,QL (8 per 28 days)
TOTECT 500 MG INTRAVENOUS SOLUTION DL	4	B vs D
TRAZIMERA 420 MG INTRAVENOUS SOLUTION DL	4	PA
TREANDA 100 MG, 25 MG INTRAVENOUS POWDER FOR SOLUTION DL	4	PA
tretinoin 10 mg capsule DL	4	
TRISENOX 2 MG/ML INTRAVENOUS SOLUTION DL	4	PA
TRUXIMA 10 MG/ML CONCENTRATE,INTRAVENOUS DL	4	PA
TUKYSA 150 MG TABLET DL	4	PA,QL (120 per 30 days)
TUKYSA 50 MG TABLET DL	4	PA,QL (300 per 30 days)
TURALIO 200 MG CAPSULE DL	4	PA,QL (120 per 30 days)
TYKERB 250 MG TABLET DL	4	PA,QL (150 per 30 days)
UNITUXIN 3.5 MG/ML INTRAVENOUS SOLUTION DL	4	PA
VALCHLOR 0.016 % TOPICAL GEL DL	4	PA,QL (60 per 28 days)
valrubicin 200 mg/5 ml vial DL	4	PA,QL (80 per 28 days)
VALSTAR 40 MG/ML INTRAVESICAL SOLUTION DL	4	PA,QL (80 per 28 days)
VECTIBIX 100 MG/5 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML) INTRAVENOUS SOLUTION DL	4	PA
VELCADE 3.5 MG SOLUTION FOR INJECTION DL	4	PA
VENCLEXTA 10 MG TABLET MO	2	PA,QL (56 per 28 days)
VENCLEXTA 100 MG TABLET DL	4	PA,QL (180 per 30 days)
VENCLEXTA 50 MG TABLET MO	2	PA,QL (28 per 28 days)
VENCLEXTA STARTING PACK 10 MG-50 MG-100 MG TABLETS IN A DOSE PACK DL	4	PA,QL (42 per 28 days)
VERZENIO 100 MG, 150 MG, 200 MG, 50 MG TABLET DL	4	PA,QL (60 per 30 days)
VIDAZA 100 MG SOLUTION FOR INJECTION DL	4	PA
vinblastine 1 mg/ml vial MO	1	B vs D
vincasar pfs 1 mg/ml, 2 mg/2 ml intravenous solution MO	1	B vs D
vincristine 1 mg/ml, 2 mg/2 ml vial MO	1	B vs D
vinorelbine 10 mg/ml, 50 mg/5 ml vial MO	1	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VISTOGARD 10 GRAM ORAL GRANULES IN PACKET DL	4	QL (20 per 365 days)
VITRAKVI 100 MG CAPSULE DL	4	PA,QL (60 per 30 days)
VITRAKVI 20 MG/ML ORAL SOLUTION DL	4	PA,QL (300 per 30 days)
VITRAKVI 25 MG CAPSULE DL	4	PA,QL (180 per 30 days)
VIZIMPRO 15 MG, 30 MG, 45 MG TABLET DL	4	PA,QL (30 per 30 days)
VOTRIENT 200 MG TABLET DL	4	PA,QL (120 per 30 days)
VYXEOS 44 MG-100 MG INTRAVENOUS SOLUTION DL	4	PA
XALKORI 200 MG, 250 MG CAPSULE DL	4	PA,QL (60 per 30 days)
XOSPATA 40 MG TABLET DL	4	PA,QL (90 per 30 days)
XPOVIO 100 MG/WEEK (20 MG X 5) TABLET DL	4	PA,QL (20 per 28 days)
XPOVIO 40 MG TWICE WEEKLY (80 MG/WEEK) (20 MG X 4) TABLET; XPOVIO 40MG TWICE WEEK (80 MG/WEEK), 80 MG/WEEK (20 MG X 4) TABLET DL	4	PA,QL (16 per 28 days)
XPOVIO 40 MG/WEEK (20 MG X 2) TABLET DL	4	PA,QL (8 per 28 days)
XPOVIO 60 MG TWICE WEEKLY (120 MG/WEEK) (20 MG X 6) TABLET DL	4	PA,QL (24 per 28 days)
XPOVIO 60 MG/WEEK (20 MG X 3) TABLET DL	4	PA,QL (12 per 28 days)
XPOVIO 80 MG TWICE WEEKLY (160 MG/WEEK) (20 MG X 8) TABLET DL	4	PA,QL (32 per 28 days)
XTANDI 40 MG CAPSULE DL, LA	4	PA,QL (120 per 30 days)
YERVOY 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML) INTRAVENOUS SOLUTION DL	4	PA
YONDELIS 1 MG INTRAVENOUS SOLUTION DL	4	PA
YONSA 125 MG TABLET DL	4	PA,QL (120 per 30 days)
ZALTRAP 100 MG/4 ML (25 MG/ML), 200 MG/8 ML (25 MG/ML) INTRAVENOUS SOLUTION DL	4	PA
ZANOSAR 1 GRAM INTRAVENOUS SOLUTION MO	3	B vs D
ZEJULA 100 MG CAPSULE DL	4	PA,QL (90 per 30 days)
ZELBORAF 240 MG TABLET DL	4	PA,QL (240 per 30 days)
ZEPZELCA 4 MG INTRAVENOUS SOLUTION DL	4	PA
ZINECARD 250 MG, 500 MG VIAL DL	4	B vs D
ZIRABEV 25 MG/ML INTRAVENOUS SOLUTION DL	4	PA
ZOLINZA 100 MG CAPSULE DL	4	PA,QL (120 per 30 days)
ZYDELIG 100 MG, 150 MG TABLET DL	4	PA,QL (60 per 30 days)
ZYKADIA 150 MG CAPSULE DL	4	PA,QL (150 per 30 days)
ZYKADIA 150 MG TABLET DL	4	PA,QL (150 per 30 days)
ZYTIGA 250 MG TABLET DL	4	PA,QL (120 per 30 days)
ZYTIGA 500 MG TABLET DL	4	PA,QL (60 per 30 days)
Antiparasitics		
albendazole 200 mg tablet DL	4	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ALBENZA 200 MG TABLET DL	4	
ALINIA 100 MG/5 ML ORAL SUSPENSION DL	4	QL (150 per 30 days)
ALINIA 500 MG TABLET DL	4	QL (40 per 30 days)
<i>atovaquone 750 mg/5 ml susp</i> DL	4	
<i>atovaquone-proguanil 250-100; atovaquone-proguanil 62.5-25</i> MO	1	
<i>benznidazole 100 mg tablet</i> MO	3	QL (240 per 365 days)
<i>benznidazole 12.5 mg tablet</i> MO	3	QL (720 per 365 days)
BILTRICIDE 600 MG TABLET DL	4	PA
<i>chloroquine ph 250 mg, 500 mg tablet</i> MO	1	
COARTEM 20 MG-120 MG TABLET MO	3	QL (24 per 30 days)
DARAPRIM 25 MG TABLET DL	4	PA,QL (90 per 30 days)
EGATEN 250 MG TABLET MO	3	
<i>emverm 100 mg chewable tablet</i> DL	4	
<i>hydroxychloroquine 200 mg tab</i> MO	1	
IMPAVIDO 50 MG CAPSULE DL	4	QL (84 per 28 days)
<i>ivermectin 3 mg tablet</i> MO	1	
KRINTAFEL 150 MG TABLET MO	2	QL (4 per 180 days)
MALARONE 250 MG-100 MG TABLET MO	3	PA
MALARONE PEDIATRIC 62.5 MG-25 MG TABLET MO	3	PA
<i>mefloquine hcl 250 mg tablet</i> MO	1	
MEPRON 750 MG/5 ML ORAL SUSPENSION DL	4	
NEBUPENT 300 MG SOLUTION FOR INHALATION MO	3	B vs D
PENTAM 300 MG SOLUTION FOR INJECTION MO	3	
<i>pentamidine 300 mg inhal powdr</i> MO	1	B vs D
<i>pentamidine 300 mg vial</i> MO	1	
PLAQUENIL 200 MG TABLET MO	3	PA
<i>praziquantel 600 mg tablet</i> MO	1	
<i>primaquine 26.3 mg tablet</i> MO	1	
<i>pyrimethamine 25 mg tablet</i> DL	4	QL (90 per 30 days)
QUALAQUIN 324 MG CAPSULE MO	3	PA,QL (42 per 7 days)
<i>quinine sulfate 324 mg capsule</i> MO	1	PA,QL (42 per 7 days)
SKLICE 0.5 % LOTION MO	3	QL (117 per 30 days)
STROMECTOL 3 MG TABLET MO	3	
ANTIPARKINSON AGENTS		
<i>amantadine 100 mg capsule</i> MO	1	
<i>amantadine 100 mg tablet</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>amantadine 50 mg/5 ml solution</i> MO	1	
APOKYN 10 MG/ML SUBCUTANEOUS CARTRIDGE DL	4	PA,QL (84 per 28 days)
AZILECT 0.5 MG, 1 MG TABLET DL	4	PA,QL (30 per 30 days)
<i>benztropine 2 mg/2 ml ampule</i> MO	1	
<i>benztropine mes 0.5 mg, 1 mg, 2 mg tab; benztropine mes 0.5 mg, 1 mg, 2 mg tablet</i> MO	1	
<i>bromocriptine 2.5 mg tablet</i> MO	1	
<i>bromocriptine 5 mg capsule</i> MO	1	QL (600 per 30 days)
<i>carbidopa 25 mg tablet</i> MO	1	
<i>carbidopa-levo 10-100 mg, 25-100 mg, 25-250 mg odt; carbidopa-levodopa 10-100 tab; carbidopa-levodopa 25-100 tab; carbidopa-levodopa 25-250 tab</i> MO	1	
<i>carbidopa-levo er 25-100 tab; carbidopa-levo er 50-200 tab</i> MO	1	
<i>carbidopa-levodopa 100 mg-enta; carbidopa-levodopa 125 mg-enta; carbidopa-levodopa 150 mg-enta; carbidopa-levodopa 50 mg-enta; carbidopa-levodopa 75 mg-enta</i> MO	1	QL (240 per 30 days)
<i>carbidopa-levodopa 200 mg-enta</i> MO	1	
COGENTIN 1 MG/ML INJECTION SOLUTION MO	3	
COMTAN 200 MG TABLET DL	4	PA,QL (300 per 30 days)
DUOPA 4.63 MG-20 MG/ML SUSPENSION IN J-TUBE PUMP DL	4	PA,QL (2800 per 28 days)
<i>entacapone 200 mg tablet</i> MO	1	QL (300 per 30 days)
GOCOVRI 137 MG CAPSULE,EXTENDED RELEASE DL	4	PA,QL (60 per 30 days)
GOCOVRI 68.5 MG CAPSULE,EXTENDED RELEASE DL	4	PA,QL (30 per 30 days)
INBRIJA 42 MG CAPSULE WITH INHALATION DEVICE; INBRIJA 42 MG CAPSULES FOR INHALATION DL	4	PA,QL (300 per 30 days)
KYNMOBI 10 MG, 10-15-20-25-30 MG, 15 MG, 20 MG, 25 MG, 30 MG SUBLINGUAL FILM; KYNMOBI 10 MG-15 MG-20 MG-25 MG-30 MG SUBLINGUAL FILM DL	4	PA,QL (150 per 30 days)
LODOSYN 25 MG TABLET DL	4	PA
MIRAPEX 0.125 MG, 0.25 MG, 0.5 MG, 0.75 MG, 1 MG, 1.5 MG TABLET MO	3	ST
MIRAPEX ER 0.375 MG, 0.75 MG, 1.5 MG, 2.25 MG, 3 MG, 3.75 MG, 4.5 MG TABLET,EXTENDED RELEASE DL	4	ST,QL (30 per 30 days)
NEUPRO 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH MO	3	QL (30 per 30 days)
NOURIANZ 20 MG, 40 MG TABLET DL	4	PA,QL (30 per 30 days)
ONGENTYS 50 MG CAPSULE MO	3	PA,QL (30 per 30 days)
OSMOLEX ER 129 MG, 193 MG, 258 MG TABLET, EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OSMOLEX ER 322 MG/DAY (129 MG AND 193 MG) TABLET, EXTENDED RELEASE MO	3	PA,QL (60 per 30 days)
PARLODEL 2.5 MG TABLET MO	3	PA
PARLODEL 5 MG CAPSULE MO	3	PA,QL (600 per 30 days)
pramipexole 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg tablet MO	1	
pramipexole er 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, 4.5 mg tablet MO	1	ST,QL (30 per 30 days)
rasagiline mesylate 0.5 mg, 1 mg tab MO	1	QL (30 per 30 days)
REQUIP 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG, 5 MG TABLET MO	3	ST
REQUIP XL 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET; REQUIP XL 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET,EXTENDED RELEASE MO	3	ST,QL (90 per 30 days)
ropinirole hcl 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg tablet MO	1	
ropinirole hcl er 12 mg, 2 mg, 4 mg, 6 mg, 8 mg tablet MO	1	ST,QL (90 per 30 days)
RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE; RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE MO	3	ST,QL (360 per 30 days)
RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE MO	3	ST,QL (270 per 30 days)
RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE MO	3	ST,QL (300 per 30 days)
selegiline hcl 5 mg capsule MO	1	
selegiline hcl 5 mg tablet MO	1	
SINEMET 10 MG-100 MG TABLET; SINEMET 25 MG-100 MG TABLET; SINEMET 25 MG-250 MG TABLET MO	3	PA
SINEMET CR 25-100 TABLET; SINEMET CR 50-200 TABLET MO	3	PA
STALEVO 100 25 MG-100 MG-200 MG TABLET DL	4	PA,QL (240 per 30 days)
STALEVO 125 31.25 MG-125 MG-200 MG TABLET DL	4	PA,QL (240 per 30 days)
STALEVO 150 37.5 MG-150 MG-200 MG TABLET DL	4	PA,QL (240 per 30 days)
STALEVO 200 50 MG-200 MG-200 MG TABLET DL	4	PA
STALEVO 50 12.5 MG-50 MG-200 MG TABLET DL	4	PA,QL (240 per 30 days)
STALEVO 75 18.75 MG-75 MG-200 MG TABLET DL	4	PA,QL (240 per 30 days)
TASMAR 100 MG TABLET DL	4	PA
tolcapone 100 mg tablet DL	4	PA
trihexyphenidyl 2 mg, 5 mg tablet MO	1	
trihexyphenidyl 2 mg/5 ml elx MO	1	
XADAGO 100 MG, 50 MG TABLET DL	4	PA,QL (30 per 30 days)
ZELAPAR 1.25 MG DISINTEGRATING TABLET DL	4	
Antipsychotics		
ABILIFY 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG TABLET DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ABILIFY MAINTENA 300 MG, 400 MG INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE DL	4	QL (1 per 28 days)
ABILIFY MAINTENA 300 MG, 400 MG SUSPENSION,EXTENDED REL. INTRAMUSCULAR SYRINGE DL	4	QL (1 per 28 days)
ABILIFY MYCITE 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG TABLET WITH SENSOR AND PATCH DL	4	PA,QL (30 per 30 days)
<i>aripiprazole 1 mg/ml solution</i> DL	4	QL (750 per 30 days)
<i>aripiprazole 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg tablet</i> MO	1	
<i>aripiprazole odt 10 mg, 15 mg tablet</i> DL	4	QL (60 per 30 days)
ARISTADA 1,064 MG/3.9 ML SUSPENSION, EXTEND.REL. IM SYRINGE MO	4	QL (3.9 per 56 days)
ARISTADA 441 MG/1.6 ML SUSPENSION, EXTEND.REL. IM SYRINGE DL	4	QL (1.6 per 28 days)
ARISTADA 662 MG/2.4 ML SUSPENSION, EXTEND.REL. IM SYRINGE DL	4	QL (2.4 per 28 days)
ARISTADA 882 MG/3.2 ML SUSPENSION, EXTEND.REL. IM SYRINGE DL	4	QL (3.2 per 28 days)
ARISTADA INITIO 675 MG/2.4 ML SUSPENSION, EXTEND.REL. IM SYRINGE DL	4	QL (2.4 per 42 days)
CAPLYTA 42 MG CAPSULE DL	4	PA,QL (30 per 30 days)
<i>chlorpromazine 10 mg, 25 mg tablet</i> MO	1	B vs D
<i>chlorpromazine 100 mg, 200 mg, 50 mg tablet</i> MO	1	
<i>chlorpromazine 25 mg/ml amp</i> MO	1	
<i>clozapine 100 mg tablet</i> MO	1	QL (270 per 30 days)
<i>clozapine 200 mg tablet</i> MO	1	QL (135 per 30 days)
<i>clozapine 25 mg tablet</i> MO	1	QL (1080 per 30 days)
<i>clozapine 50 mg tablet</i> MO	1	
<i>clozapine odt 100 mg tablet</i> MO	1	PA,QL (270 per 30 days)
<i>clozapine odt 12.5 mg tablet</i> MO	1	PA
<i>clozapine odt 150 mg tablet</i> MO	1	PA,QL (180 per 30 days)
<i>clozapine odt 200 mg tablet</i> MO	1	PA,QL (135 per 30 days)
<i>clozapine odt 25 mg tablet</i> MO	1	PA,QL (1080 per 30 days)
CLOZARIL 100 MG TABLET DL	4	QL (270 per 30 days)
CLOZARIL 200 MG TABLET DL	4	QL (135 per 30 days)
CLOZARIL 25 MG TABLET DL	4	QL (1080 per 30 days)
CLOZARIL 50 MG TABLET DL	4	
<i>droperidol 5 mg/2 ml vial</i> MO	1	
FANAPT 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET DL	4	PA,QL (60 per 30 days)
FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK DL	3	PA,QL (60 per 30 days)
FAZACLO 100 MG ODT DL	4	PA,QL (270 per 30 days)
FAZACLO 12.5 MG ODT DL	4	PA
FAZACLO 150 MG ODT DL	4	PA,QL (180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
FAZACLO 200 MG ODT DL	4	PA,QL (135 per 30 days)
FAZACLO 25 MG ODT DL	4	PA,QL (1080 per 30 days)
fluphenazine dec 125 mg/5 ml MO	1	
fluphenazine 1 mg, 10 mg, 2.5 mg, 5 mg tablet MO	1	
fluphenazine 2.5 mg/5 ml elix MO	1	
fluphenazine 2.5 mg/ml vial MO	1	
fluphenazine 5 mg/ml conc MO	1	
GEODON 20 MG, 40 MG, 60 MG, 80 MG CAPSULE DL	4	PA
GEODON 20 MG/ML (FINAL CONCENTRATION) INTRAMUSCULAR SOLUTION MO	3	PA
HALDOL 5 MG/ML INJECTION SOLUTION MO	3	
HALDOL DECANOATE 100 MG/ML, 50 MG/ML INTRAMUSCULAR SOLUTION MO	3	PA
haloperidol 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg tablet MO	1	
haloperidol dec 100 mg/ml, 50 mg/ml amp; haloperidol decan 100 mg/ml, 50 mg/ml amp MO	1	
haloperidol lac 2 mg/ml conc MO	1	
haloperidol lac 5 mg/ml syring MO	1	
haloperidol lac 5 mg/ml vial MO	1	
INVEGA 1.5 MG, 3 MG, 9 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (30 per 30 days)
INVEGA 6 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (60 per 30 days)
INVEGA SUSTENNA 117 MG/0.75 ML, 234 MG/1.5 ML, 78 MG/0.5 ML INTRAMUSCULAR SYRINGE DL	4	QL (1.5 per 28 days)
INVEGA SUSTENNA 156 MG/ML INTRAMUSCULAR SYRINGE DL	4	QL (1 per 28 days)
INVEGA SUSTENNA 39 MG/0.25 ML INTRAMUSCULAR SYRINGE MO	3	QL (1.5 per 28 days)
INVEGA TRINZA 273 MG/0.875 ML INTRAMUSCULAR SYRINGE MO	4	QL (0.87 per 90 days)
INVEGA TRINZA 410 MG/1.315 ML INTRAMUSCULAR SYRINGE MO	4	QL (1.31 per 90 days)
INVEGA TRINZA 546 MG/1.75 ML INTRAMUSCULAR SYRINGE MO	4	QL (1.75 per 90 days)
INVEGA TRINZA 819 MG/2.625 ML INTRAMUSCULAR SYRINGE MO	4	QL (2.62 per 90 days)
LATUDA 120 MG, 20 MG, 40 MG, 60 MG TABLET DL	4	PA,QL (30 per 30 days)
LATUDA 80 MG TABLET DL	4	PA,QL (60 per 30 days)
loxapine 10 mg, 25 mg, 5 mg, 50 mg capsule MO	1	
molindone hcl 10 mg tablet MO	1	PA,QL (240 per 30 days)
molindone hcl 25 mg tablet MO	1	PA,QL (270 per 30 days)
molindone hcl 5 mg tablet MO	1	PA,QL (360 per 30 days)
NUPLAZID 10 MG TABLET DL	4	PA,QL (30 per 30 days)
NUPLAZID 17 MG TABLET DL	4	PA,QL (60 per 30 days)
NUPLAZID 34 MG CAPSULE DL	4	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
olanzapine 10 mg vial MO	1	
olanzapine 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg tablet MO	1	
olanzapine odt 10 mg, 5 mg tablet MO	1	QL (30 per 30 days)
olanzapine odt 15 mg, 20 mg tablet MO	1	QL (60 per 30 days)
ORAP 2 MG TABLET MO	3	
paliperidone er 1.5 mg, 3 mg, 9 mg tablet MO	1	QL (30 per 30 days)
paliperidone er 6 mg tablet MO	1	QL (60 per 30 days)
perphenazine 16 mg, 2 mg, 4 mg, 8 mg tablet MO	1	
PERSERIS 120 MG, 90 MG ABDOMINAL SUBCUTANEOUS EXTEND RELEASE SUSP SYRINGE KIT DL	4	QL (1 per 28 days)
pimozide 1 mg, 2 mg tablet MO	1	
quetiapine er 150 mg tablet MO	1	QL (90 per 30 days)
quetiapine er 200 mg tablet MO	1	QL (30 per 30 days)
quetiapine er 300 mg, 400 mg tablet MO	1	QL (60 per 30 days)
quetiapine er 50 mg tablet MO	1	QL (120 per 30 days)
quetiapine fumarate 100 mg tab MO	1	QL (90 per 30 days)
quetiapine fumarate 200 mg, 25 mg, 50 mg tab MO	1	QL (120 per 30 days)
quetiapine fumarate 300 mg, 400 mg tab MO	1	QL (60 per 30 days)
REXULTI 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG TABLET DL	4	PA,QL (30 per 30 days)
RISPERDAL 0.25 MG, 1 MG, 2 MG, 3 MG, 4 MG TABLET DL	4	QL (60 per 30 days)
RISPERDAL 0.5 MG TABLET DL	4	QL (120 per 30 days)
RISPERDAL 1 MG/ML ORAL SOLUTION DL	4	
RISPERDAL CONSTA 12.5 MG/2 ML, 25 MG/2 ML INTRAMUSCULAR SUSP,EXTENDED RELEASE MO	3	QL (2 per 28 days)
RISPERDAL CONSTA 37.5 MG/2 ML, 50 MG/2 ML INTRAMUSCULAR SUSP,EXTENDED RELEASE DL	4	QL (2 per 28 days)
risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg odt; risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg tablet MO	1	QL (60 per 30 days)
risperidone 0.5 mg odt; risperidone 0.5 mg tablet MO	1	QL (120 per 30 days)
risperidone 1 mg/ml solution MO	1	
SAPHRIS 10 MG, 2.5 MG, 5 MG SUBLINGUAL TABLET DL	4	PA,QL (60 per 30 days)
SECUADO 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH DL	4	PA,QL (30 per 30 days)
SEROQUEL 100 MG TABLET MO	3	QL (90 per 30 days)
SEROQUEL 200 MG, 25 MG, 50 MG TABLET MO	3	QL (120 per 30 days)
SEROQUEL 300 MG, 400 MG TABLET MO	3	QL (60 per 30 days)
SEROQUEL XR 150 MG TABLET,EXTENDED RELEASE MO	3	PA,QL (90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SEROQUEL XR 200 MG TABLET,EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
SEROQUEL XR 300 MG, 400 MG TABLET,EXTENDED RELEASE MO	3	PA,QL (60 per 30 days)
SEROQUEL XR 50 MG TABLET,EXTENDED RELEASE MO	3	PA,QL (120 per 30 days)
SEROQUEL XR 50 MG(3)-200 MG(1)-300 MG(11) TABLET, ER 24 HR DOSE PACK MO	3	PA,QL (15 per 30 days)
<i>thioridazine 10 mg, 100 mg, 25 mg, 50 mg tablet</i> MO	1	
<i>thiothixene 1 mg, 10 mg, 2 mg, 5 mg capsule</i> MO	1	
<i>trifluoperazine 1 mg, 10 mg, 2 mg, 5 mg tablet</i> MO	1	
VERSACLOZ 50 MG/ML ORAL SUSPENSION DL	4	PA,QL (540 per 30 days)
VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK MO	3	PA
VRAYLAR 1.5 MG, 3 MG, 4.5 MG, 6 MG CAPSULE DL	4	PA,QL (30 per 30 days)
<i>ziprasidone hcl 20 mg, 40 mg, 60 mg, 80 mg capsule</i> MO	1	
<i>ziprasidone 20 mg/ml vial</i> MO	1	
ZYPREXA 10 MG INTRAMUSCULAR SOLUTION MO	3	
ZYPREXA 10 MG, 15 MG, 2.5 MG, 20 MG, 5 MG, 7.5 MG TABLET DL	4	
ZYPREXA RELPREVV 210 MG INTRAMUSCULAR SUSPENSION DL	4	QL (4 per 28 days)
ZYPREXA RELPREVV 300 MG INTRAMUSCULAR SUSPENSION DL	4	QL (2 per 28 days)
ZYPREXA RELPREVV 405 MG INTRAMUSCULAR SUSPENSION DL	4	QL (1 per 28 days)
ZYPREXA ZYDIS 10 MG, 5 MG DISINTEGRATING TABLET DL	4	QL (30 per 30 days)
ZYPREXA ZYDIS 15 MG, 20 MG DISINTEGRATING TABLET DL	4	QL (60 per 30 days)
Antispasticity Agents		
<i>baclofen 10 mg, 20 mg tablet</i> MO	1	
<i>baclofen 5 mg tablet</i> MO	1	QL (90 per 30 days)
DANTRIUM 20 MG INTRAVENOUS SOLUTION MO	3	
DANTRIUM 25 MG, 50 MG CAPSULE MO	3	
<i>dantrolene sodium 100 mg, 25 mg, 50 mg cap</i> MO	1	
<i>dantrolene sodium 20 mg vial</i> MO	1	
<i>revonto 20 mg intravenous solution</i> MO	1	
<i>tizanidine hcl 2 mg, 4 mg tablet</i> MO	1	
<i>tizanidine hcl 2 mg, 4 mg, 6 mg capsule</i> MO	1	ST
ZANAFLEX 2 MG, 4 MG, 6 MG CAPSULE MO	3	ST
ZANAFLEX 4 MG TABLET MO	3	ST
Antivirals		
<i>abacavir 20 mg/ml solution</i> MO	1	QL (960 per 30 days)
<i>abacavir 300 mg tablet</i> MO	1	QL (60 per 30 days)
<i>abacavir-lamivudine 600-300 mg</i> MO	1	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
abacavir-lamivudine-zidov tab DL	4	QL (60 per 30 days)
acyclovir 200 mg capsule MO	1	
acyclovir 200 mg/5 ml susp MO	1	
acyclovir 400 mg, 800 mg tablet MO	1	
acyclovir 5% cream DL	4	PA,QL (5 per 30 days)
acyclovir 5% ointment MO	1	PA,QL (30 per 30 days)
acyclovir 1,000 mg/20 ml vial; acyclovir sodium 1 gm vial; acyclovir sodium 1,000 mg, 50 mg/ml, 500 mg vial MO	1	B vs D
adefovir dipivoxil 10 mg tab DL	4	
APTIVUS 250 MG CAPSULE DL	4	QL (120 per 30 days)
APTIVUS (WITH VITAMIN E) 100 MG/ML ORAL SOLUTION DL	4	QL (285 per 28 days)
atazanavir sulfate 150 mg, 200 mg cap MO	1	QL (60 per 30 days)
atazanavir sulfate 300 mg cap MO	1	QL (30 per 30 days)
ATRIPLA 600 MG-200 MG-300 MG TABLET DL	4	QL (30 per 30 days)
BARACLUDE 0.05 MG/ML ORAL SOLUTION MO	3	QL (630 per 30 days)
BARACLUDE 0.5 MG, 1 MG TABLET DL	4	PA,QL (30 per 30 days)
BIKTARVY 50 MG-200 MG-25 MG TABLET DL	4	QL (30 per 30 days)
cidofovir 375 mg/5 ml vial MO	1	
CIMDUO 300 MG-300 MG TABLET DL	4	QL (30 per 30 days)
COMBIVIR 150 MG-300 MG TABLET DL	4	QL (60 per 30 days)
COMPLERA 200 MG-25 MG-300 MG TABLET DL	4	QL (30 per 30 days)
CRIXIVAN 200 MG CAPSULE MO	2	QL (450 per 30 days)
CRIXIVAN 400 MG CAPSULE MO	3	QL (270 per 30 days)
CYTOVENE 500 MG INTRAVENOUS SOLUTION DL	4	B vs D
DAKLINZA 30 MG, 60 MG, 90 MG TABLET DL	4	PA,QL (28 per 28 days)
DELSTRIGO 100 MG-300 MG-300 MG TABLET DL	4	QL (30 per 30 days)
DENAVIR 1 % TOPICAL CREAM DL	4	PA
DESCOVY 200 MG-25 MG TABLET DL	4	QL (30 per 30 days)
didanosine dr 125 mg capsule MO	1	QL (90 per 30 days)
didanosine dr 200 mg capsule MO	1	QL (60 per 30 days)
didanosine dr 250 mg, 400 mg capsule MO	1	QL (30 per 30 days)
DOVATO 50 MG-300 MG TABLET DL	4	QL (30 per 30 days)
EDURANT 25 MG TABLET DL	4	QL (30 per 30 days)
efavirenz 200 mg capsule MO	1	QL (120 per 30 days)
efavirenz 50 mg capsule MO	1	QL (480 per 30 days)
efavirenz 600 mg tablet MO	1	QL (30 per 30 days)
EMTRIVA 10 MG/ML ORAL SOLUTION MO	3	QL (680 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EMTRIVA 200 MG CAPSULE MO	3	QL (30 per 30 days)
<i>entecavir 0.5 mg, 1 mg tablet</i> MO	1	QL (30 per 30 days)
EPCLUSA 400 MG-100 MG TABLET DL	4	PA,QL (28 per 28 days)
EPIVIR 10 MG/ML ORAL SOLUTION MO	3	QL (900 per 30 days)
EPIVIR 150 MG TABLET MO	3	QL (60 per 30 days)
EPIVIR 300 MG TABLET MO	3	QL (30 per 30 days)
EPIVIR HBV 100 MG TABLET MO	3	QL (90 per 30 days)
EPIVIR HBV 25 MG/5 ML (5 MG/ML) ORAL SOLUTION MO	3	
EPZICOM 600 MG-300 MG TABLET DL	4	QL (30 per 30 days)
EVOTAZ 300 MG-150 MG TABLET DL	4	QL (30 per 30 days)
<i>famciclovir 125 mg, 250 mg, 500 mg tablet</i> MO	1	QL (90 per 30 days)
FLUMADINE 100 MG TABLET MO	3	
<i>fosamprenavir 700 mg tablet</i> DL	4	QL (120 per 30 days)
FOSCAVIR 24 MG/ML INTRAVENOUS SOLUTION MO	3	B vs D
FUZEON 90 MG SUBCUTANEOUS SOLUTION DL	4	QL (60 per 30 days)
<i>ganciclovir 50 mg/ml, 500 mg vial; ganciclovir 500 mg/10 ml vial</i> DL	4	B vs D
GENVOYA 150 MG-150 MG-200 MG-10 MG TABLET DL	4	QL (30 per 30 days)
HARVONI 33.75 MG-150 MG ORAL PELLETS IN PACKET DL	4	PA,QL (28 per 28 days)
HARVONI 45 MG-200 MG ORAL PELLETS IN PACKET DL	4	PA,QL (56 per 28 days)
HARVONI 45 MG-200 MG TABLET; HARVONI 90 MG-400 MG TABLET DL	4	PA,QL (28 per 28 days)
HEPSERA 10 MG TABLET DL	4	
INTELENCE 100 MG, 25 MG TABLET DL	4	QL (120 per 30 days)
INTELENCE 200 MG TABLET DL	4	QL (60 per 30 days)
INVIRASE 200 MG CAPSULE DL	4	QL (300 per 30 days)
INVIRASE 500 MG TABLET DL	4	QL (120 per 30 days)
ISENTRESS 100 MG CHEWABLE TABLET DL	4	QL (180 per 30 days)
ISENTRESS 100 MG ORAL POWDER PACKET MO	2	QL (300 per 30 days)
ISENTRESS 25 MG CHEWABLE TABLET MO	3	QL (180 per 30 days)
ISENTRESS 400 MG TABLET DL	4	QL (120 per 30 days)
ISENTRESS HD 600 MG TABLET DL	4	QL (60 per 30 days)
JULUCA 50 MG-25 MG TABLET DL	4	QL (30 per 30 days)
KALETRA 100 MG-25 MG TABLET DL	3	QL (300 per 30 days)
KALETRA 200 MG-50 MG TABLET DL	4	QL (150 per 30 days)
KALETRA 400 MG-100 MG/5 ML ORAL SOLUTION DL	4	
<i>lamivudine 10 mg/ml oral soln</i> MO	1	QL (900 per 30 days)
<i>lamivudine 150 mg tablet</i> MO	1	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
lamivudine 300 mg tablet MO	1	QL (30 per 30 days)
lamivudine hbv 100 mg tablet MO	1	QL (90 per 30 days)
lamivudine-zidovudine tablet MO	1	QL (60 per 30 days)
ledipasvir-sofosbuvir 90-400mg DL	4	PA,QL (28 per 28 days)
LEXIVA 50 MG/ML ORAL SUSPENSION MO	3	QL (1575 per 28 days)
LEXIVA 700 MG TABLET DL	4	QL (120 per 30 days)
lopinavir-ritonavir 80-20mg/ml MO	1	
MAVYRET 100 MG-40 MG TABLET DL	4	PA,QL (84 per 28 days)
moderiba 200 mg tablet DL	4	QL (168 per 28 days)
nevirapine 200 mg tablet MO	1	QL (60 per 30 days)
nevirapine 50 mg/5 ml susp MO	1	QL (1200 per 30 days)
nevirapine er 100 mg tablet MO	1	QL (120 per 30 days)
nevirapine er 400 mg tablet MO	1	QL (30 per 30 days)
NORVIR 100 MG ORAL POWDER PACKET MO	3	QL (360 per 30 days)
NORVIR 100 MG TABLET MO	3	QL (360 per 30 days)
NORVIR 80 MG/ML ORAL SOLUTION MO	3	QL (480 per 30 days)
ODEFSEY 200 MG-25 MG-25 MG TABLET DL	4	QL (30 per 30 days)
oseltamivir 6 mg/ml suspension MO	1	QL (1440 per 365 days)
oseltamivir phos 30 mg capsule MO	1	QL (224 per 365 days)
oseltamivir phos 45 mg, 75 mg capsule MO	1	QL (112 per 365 days)
PIFELTRO 100 MG TABLET DL	4	QL (60 per 30 days)
PREVMIS 240 MG, 480 MG TABLET DL	4	PA,QL (28 per 28 days)
PREVMIS 240 MG/12 ML INTRAVENOUS SOLUTION DL	4	PA,QL (336 per 28 days)
PREVMIS 480 MG/24 ML INTRAVENOUS SOLUTION DL	4	PA,QL (672 per 28 days)
PREZCOBIX 800 MG-150 MG TABLET DL	4	QL (30 per 30 days)
PREZISTA 100 MG/ML ORAL SUSPENSION DL	4	QL (360 per 30 days)
PREZISTA 150 MG TABLET DL	4	QL (240 per 30 days)
PREZISTA 600 MG TABLET DL	4	QL (60 per 30 days)
PREZISTA 75 MG TABLET MO	3	QL (480 per 30 days)
PREZISTA 800 MG TABLET DL	4	QL (30 per 30 days)
REBETOL 40 MG/ML SOLUTION MO	3	QL (1000 per 30 days)
RELENZA DISKHALER 5 MG/ACTUATION POWDER FOR INHALATION MO	3	QL (60 per 180 days)
RESCRIPTOR 100 MG TABLET MO	3	QL (360 per 30 days)
RESCRIPTOR 200 MG TABLET MO	3	QL (180 per 30 days)
RETROVIR 10 MG/ML INTRAVENOUS SOLUTION MO	3	
RETROVIR 10 MG/ML ORAL SYRUP MO	3	QL (1680 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RETROVIR 100 MG CAPSULE MO	3	QL (180 per 30 days)
REYATAZ 150 MG, 200 MG CAPSULE DL	4	QL (60 per 30 days)
REYATAZ 300 MG CAPSULE DL	4	QL (30 per 30 days)
REYATAZ 50 MG ORAL POWDER PACKET MO	3	
<i>ribasphere 200 mg capsule</i> DL	4	QL (168 per 28 days)
<i>ribasphere 200 mg tablet</i> MO	1	QL (168 per 28 days)
<i>ribasphere 400 mg tablet</i> MO	1	QL (112 per 30 days)
<i>ribasphere 600 mg tablet</i> MO	1	
RIBASPHERE RIBAPAK 600-400 MG; RIBASPHERE RIBAPAK 600-600 MG DL	4	
<i>ribavirin 200 mg capsule</i> MO	1	QL (168 per 28 days)
<i>ribavirin 200 mg tablet</i> MO	1	QL (168 per 28 days)
<i>rimantadine hcl 100 mg tablet</i> MO	1	
<i>ritonavir 100 mg tablet</i> MO	1	QL (360 per 30 days)
RUKOBIA 600 MG TABLET,EXTENDED RELEASE DL	4	QL (60 per 30 days)
SELZENTRY 150 MG, 25 MG TABLET DL	4	QL (240 per 30 days)
SELZENTRY 20 MG/ML ORAL SOLUTION DL	4	QL (1800 per 30 days)
SELZENTRY 300 MG, 75 MG TABLET DL	4	QL (120 per 30 days)
SITAVIG 50 MG BUCCAL TABLET MO	3	PA,QL (1 per 28 days)
SOVALDI 150 MG ORAL PELLETS IN PACKET DL	4	PA,QL (28 per 28 days)
SOVALDI 200 MG ORAL PELLETS IN PACKET DL	4	PA,QL (56 per 28 days)
SOVALDI 200 MG, 400 MG TABLET DL	4	PA,QL (28 per 28 days)
<i>stavudine 15 mg, 20 mg capsule</i> MO	1	QL (120 per 30 days)
<i>stavudine 30 mg, 40 mg capsule</i> MO	1	QL (60 per 30 days)
STRIBILD 150 MG-150 MG-200 MG-300 MG TABLET DL	4	QL (30 per 30 days)
SUSTIVA 200 MG CAPSULE DL	4	QL (120 per 30 days)
SUSTIVA 50 MG CAPSULE DL	4	QL (480 per 30 days)
SUSTIVA 600 MG TABLET DL	4	QL (30 per 30 days)
SYMFI 600 MG-300 MG-300 MG TABLET DL	4	QL (30 per 30 days)
SYMFI LO 400 MG-300 MG-300 MG TABLET DL	4	QL (30 per 30 days)
SYMTUZA 800 MG-150 MG-200 MG-10 MG TABLET DL	4	QL (30 per 30 days)
TAMIFLU 30 MG CAPSULE MO	3	PA,QL (224 per 365 days)
TAMIFLU 45 MG, 75 MG CAPSULE MO	3	PA,QL (112 per 365 days)
TAMIFLU 6 MG/ML ORAL SUSPENSION MO	3	PA,QL (1440 per 365 days)
TEMIXYS 300 MG-300 MG TABLET DL	4	QL (30 per 30 days)
<i>tenofovir disop fum 300 mg tb</i> MO	1	QL (30 per 30 days)
TIVICAY 10 MG TABLET DL	3	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TIVICAY 25 MG, 50 MG TABLET DL	4	QL (60 per 30 days)
TIVICAY PD 5 MG TABLET FOR ORAL SUSPENSION DL	4	QL (180 per 30 days)
TRIUMEQ 600 MG-50 MG-300 MG TABLET DL	4	QL (30 per 30 days)
TRIZIVIR 300 MG-150 MG-300 MG TABLET DL	4	QL (60 per 30 days)
TROGARZO 200 MG/1.33 ML (150 MG/ML) INTRAVENOUS SOLUTION DL	4	
TRUVADA 100 MG-150 MG TABLET; TRUVADA 133 MG-200 MG TABLET; TRUVADA 167 MG-250 MG TABLET; TRUVADA 200 MG-300 MG TABLET DL	4	QL (30 per 30 days)
TYBOST 150 MG TABLET MO	3	QL (30 per 30 days)
<i>valacyclovir hcl 1 gram, 500 mg tablet</i> MO	1	
VALCYTE 450 MG TABLET DL	4	PA,QL (120 per 30 days)
VALCYTE 50 MG/ML ORAL SOLUTION DL	4	PA,QL (1056 per 30 days)
<i>valganciclovir 450 mg tablet</i> DL	4	QL (120 per 30 days)
<i>valganciclovir hcl 50 mg/ml</i> DL	4	QL (1056 per 30 days)
VALTREX 1 GRAM, 500 MG TABLET MO	3	PA
VEMLIDY 25 MG TABLET DL, LA	4	QL (30 per 30 days)
VIDEX 2 GM PEDIATRIC SOLN MO	3	QL (1200 per 30 days)
VIDEX 4 GM PEDIATRIC SOLN MO	3	QL (1200 per 30 days)
VIDEX EC 125 MG CAPSULE MO	3	QL (90 per 30 days)
VIDEX EC 200 MG CAPSULE MO	3	QL (60 per 30 days)
VIDEX EC 250 MG, 400 MG CAPSULE MO	3	QL (30 per 30 days)
VIEKIRA PAK 12.5 MG-75 MG-50 MG/250 MG TABLETS IN A DOSE PACK DL	4	PA,QL (112 per 28 days)
VIRACEPT 250 MG TABLET DL	4	QL (300 per 30 days)
VIRACEPT 625 MG TABLET DL	4	QL (120 per 30 days)
VIRAMUNE 200 MG TABLET DL	4	QL (60 per 30 days)
VIRAMUNE 50 MG/5 ML ORAL SUSPENSION DL	4	QL (1200 per 30 days)
VIRAMUNE XR 100 MG TABLET DL	4	QL (120 per 30 days)
VIRAMUNE XR 400 MG TABLET,EXTENDED RELEASE DL	4	QL (30 per 30 days)
VIREAD 150 MG, 200 MG, 250 MG, 300 MG TABLET DL	4	QL (30 per 30 days)
VIREAD 40 MG/SCOOP (40 MG/GRAM) ORAL POWDER DL	4	QL (240 per 30 days)
VOSEVI 400 MG-100 MG-100 MG TABLET DL	4	PA,QL (28 per 28 days)
XERESE 5 %-1 % TOPICAL CREAM DL	4	QL (5 per 30 days)
XOFLUZA 20 MG, 40 MG TABLET MO	3	QL (10 per 365 days)
ZEPATIER 50 MG-100 MG TABLET DL	4	PA,QL (28 per 28 days)
ZERIT 1 MG/ML SOLUTION MO	3	QL (2400 per 30 days)
ZERIT 15 MG, 20 MG CAPSULE MO	3	QL (120 per 30 days)
ZERIT 30 MG, 40 MG CAPSULE MO	3	QL (60 per 30 days)
ZIAGEN 20 MG/ML ORAL SOLUTION MO	3	QL (960 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZIAGEN 300 MG TABLET MO	3	QL (60 per 30 days)
zidovudine 100 mg capsule MO	1	QL (180 per 30 days)
zidovudine 300 mg tablet MO	1	QL (60 per 30 days)
zidovudine 50 mg/5 ml syrup MO	1	QL (1680 per 28 days)
ZIRGAN 0.15 % EYE GEL MO	3	QL (5 per 30 days)
ZOVIRAX 200 MG CAPSULE MO	3	PA
ZOVIRAX 200 MG/5 ML ORAL SUSPENSION MO	3	PA
ZOVIRAX 400 MG, 800 MG TABLET MO	3	PA
ZOVIRAX 5 % TOPICAL CREAM DL	4	PA,QL (5 per 30 days)
ZOVIRAX 5 % TOPICAL OINTMENT DL	4	PA,QL (30 per 30 days)
Anxiolytics		
alprazolam 0.25 mg, 0.5 mg, 1 mg tablet DL	1	QL (120 per 30 days)
alprazolam 2 mg tablet DL	1	QL (150 per 30 days)
alprazolam er 0.5 mg, 1 mg, 2 mg, 3 mg tablet DL	1	QL (60 per 30 days)
alprazolam odt 0.25 mg, 0.5 mg, 1 mg, 2 mg tab DL	1	
alprazolam intensol 1 mg/ml oral concentrate DL	1	
ATIVAN 0.5 MG, 1 MG TABLET DL	4	PA,QL (90 per 30 days)
ATIVAN 2 MG TABLET DL	4	PA,QL (150 per 30 days)
ATIVAN 2 MG/ML, 4 MG/ML INJECTION SOLUTION DL	3	PA
bupirone hcl 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg tablet MO	1	
chlordiazepoxide 10 mg, 25 mg, 5 mg capsule DL	1	QL (120 per 30 days)
clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg dis tab; clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg dis tablet; clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg odt; clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg tablet DL	1	
clorazepate 15 mg, 3.75 mg, 7.5 mg tablet DL	1	
diazepam 10 mg tablet DL	1	QL (120 per 30 days)
diazepam 10 mg/2 ml carpject DL	1	
diazepam 2 mg, 5 mg tablet DL	1	QL (90 per 30 days)
diazepam 5 mg/5 ml solution DL	1	QL (1200 per 30 days)
diazepam 5 mg/ml oral conc DL	1	QL (240 per 30 days)
diazepam 50 mg/10 ml vial DL	1	
diazepam intensol 5 mg/ml oral concentrate DL	1	QL (240 per 30 days)
doxepin 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg capsule MO	1	
doxepin 10 mg/ml oral conc MO	1	
hydroxyzine 10 mg/5 ml, 25 mg/ml, 50 mg/ml soln; hydroxyzine 10 mg/5 ml, 25 mg/ml, 50 mg/ml vial MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
hydroxyzine hcl 10 mg, 25 mg, 50 mg tablet ^{MO}	1	
KLONOPIN 0.5 MG, 1 MG, 2 MG TABLET ^{DL}	3	PA
lorazepam 0.5 mg, 1 mg tablet ^{DL}	1	QL (90 per 30 days)
lorazepam 2 mg tablet ^{DL}	1	QL (150 per 30 days)
lorazepam 2 mg/ml oral concent ^{DL}	1	QL (150 per 30 days)
lorazepam 2 mg/ml, 4 mg/ml carpject ^{DL}	1	
lorazepam 2 mg/ml, 4 mg/ml vial ^{DL}	1	
lorazepam intensol 2 mg/ml oral concentrate ^{DL}	1	QL (150 per 30 days)
meprobamate 200 mg, 400 mg tablet ^{MO}	1	
oxazepam 10 mg, 15 mg, 30 mg capsule ^{DL}	1	
TRANXENE T-TAB 7.5 MG TABLET ^{DL}	4	PA
VALIUM 10 MG TABLET ^{DL}	3	PA,QL (120 per 30 days)
VALIUM 2 MG, 5 MG TABLET ^{DL}	3	PA,QL (90 per 30 days)
XANAX 0.25 MG, 0.5 MG, 1 MG TABLET ^{DL}	4	PA,QL (120 per 30 days)
XANAX 2 MG TABLET ^{DL}	4	PA,QL (150 per 30 days)
XANAX XR 0.5 MG, 1 MG, 2 MG, 3 MG TABLET,EXTENDED RELEASE ^{DL}	3	PA,QL (60 per 30 days)
Bipolar Agents		
lithium carbonate 150 mg, 300 mg, 600 mg cap ^{MO}	1	
lithium carbonate 300 mg tab ^{MO}	1	
lithium carbonate er 300 mg, 450 mg tb ^{MO}	1	
lithium 8 meq/5 ml solution ^{MO}	1	
LITHOBID 300 MG TABLET,EXTENDED RELEASE ^{DL}	4	
Blood Glucose Regulators		
acarbose 100 mg, 25 mg, 50 mg tablet ^{MO}	1	
ACTOPLUS MET 15 MG-500 MG TABLET; ACTOPLUS MET 15 MG-850 MG TABLET ^{MO}	3	PA,QL (90 per 30 days)
ACTOPLUS MET XR 15 MG-1,000 MG TABLET,EXTENDED RELEASE ^{MO}	3	QL (60 per 30 days)
ACTOPLUS MET XR 30-1,000 MG TB ^{MO}	3	QL (30 per 30 days)
ACTOS 15 MG, 30 MG, 45 MG TABLET ^{MO}	3	PA,QL (30 per 30 days)
ADLYXIN 10 MCG/0.2 ML- 20 MCG/0.2 ML, 20 MCG/0.2 ML SUBCUTANEOUS PEN INJECTOR; ADLYXIN 10 MCG/0.2 ML-20 MCG/0.2 ML SUBCUTANEOUS PEN INJECTOR ^{MO}	3	ST,QL (6 per 28 days)
ADMELOG SOLOSTAR U-100 INSULIN LISPRO 100 UNIT/ML SUBCUTANEOUS PEN ^{MO}	3	ST
ADMELOG U-100 INSULIN LISPRO 100 UNIT/ML SUBCUTANEOUS SOLUTION ^{MO}	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AFREZZA (REGULAR INSULIN) 8 UNIT (90)/12 UNIT (90) CARTRIDGE,INHALER; AFREZZA 4 UNIT (60)/8 UNIT (60)/12 UNIT (60) CARTRIDGE WITH INHALER; AFREZZA 4 UNIT (90)/8 UNIT (90) CARTRIDGE WITH INHALER DL	4	PA,QL (180 per 30 days)
AFREZZA 12 UNIT, 4 UNIT, 8 UNIT CARTRIDGE WITH INHALER DL	4	PA,QL (90 per 30 days)
AMARYL 1 MG, 2 MG, 4 MG TABLET MO	3	PA
APIDRA SOLOSTAR U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS PEN MO	3	ST
APIDRA U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO	3	ST
AVANDIA 2 MG, 4 MG TABLET MO	3	QL (60 per 30 days)
BAQSIMI 3 MG/ACTUATION NASAL SPRAY MO	2	
BASAGLAR KWIKPEN U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS MO	3	PA
BYDUREON 2 MG VIAL MO	3	QL (4 per 28 days)
BYDUREON 2 MG/0.65 ML SUBCUTANEOUS PEN INJECTOR MO	3	QL (4 per 28 days)
BYDUREON BCISE 2 MG/0.85 ML SUBCUTANEOUS AUTO-INJECTOR MO	3	QL (3.4 per 28 days)
BYETTA 10 MCG/DOSE(250 MCG/ML)2.4 ML SUBCUTANEOUS PEN INJECTOR; BYETTA 5 MCG/DOSE (250 MCG/ML)1.2 ML SUBCUTANEOUS PEN INJECTOR DL	4	ST,QL (2.4 per 30 days)
<i>chlorpropamide 100 mg, 250 mg tablet</i> MO	1	
CYCLOSET 0.8 MG TABLET MO	3	ST,QL (180 per 30 days)
<i>diazoxide 50 mg/ml oral susp</i> DL	4	
DUETACT 30 MG-2 MG TABLET; DUETACT 30 MG-4 MG TABLET MO	3	QL (30 per 30 days)
FARXIGA 10 MG, 5 MG TABLET MO	3	QL (30 per 30 days)
FIASP FLEXTOUCH U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS PEN MO	2	
FIASP PENFILL U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS CARTRIDGE MO	2	
FIASP U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO	2	
FORTAMET 1,000 MG TABLET,EXTENDED RELEASE DL	4	ST,QL (60 per 30 days)
FORTAMET 500 MG TABLET,EXTENDED RELEASE DL	4	ST,QL (150 per 30 days)
<i>glimepiride 1 mg, 2 mg, 4 mg tablet</i> MO	1	
<i>glipizide 10 mg, 5 mg tablet</i> MO	1	
<i>glipizide er 10 mg, 2.5 mg, 5 mg tablet; glipizide xl 10 mg, 2.5 mg, 5 mg tablet</i> MO	1	
<i>glipizide-metformin 2.5-250 mg, 2.5-500 mg, 5-500 mg</i> MO	1	
GLUCAGEN HYPOKIT 1 MG INJECTION MO	2	
GLUCAGON (HCL) EMERGENCY KIT 1 MG SOLUTION FOR INJECTION MO	3	ST
GLUCAGON EMERGENCY KIT (HUMAN-RECOMB) 1 MG SOLUTION FOR INJECTION MO	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GLUCOPHAGE 1,000 MG, 500 MG, 850 MG TABLET MO	3	PA
GLUCOPHAGE XR 500 MG TABLET,EXTENDED RELEASE MO	3	PA,QL (120 per 30 days)
GLUCOPHAGE XR 750 MG TABLET,EXTENDED RELEASE MO	3	PA,QL (60 per 30 days)
GLUCOTROL 10 MG, 5 MG TABLET MO	3	
GLUCOTROL XL 10 MG, 2.5 MG, 5 MG TABLET,EXTENDED RELEASE MO	3	
GLUMETZA 1,000 MG TABLET,EXTENDED RELEASE DL	4	ST,QL (60 per 30 days)
GLUMETZA 500 MG TABLET,EXTENDED RELEASE DL	4	ST,QL (120 per 30 days)
glyburide 1.25 mg, 2.5 mg, 5 mg tablet MO	1	
glyburide micro 1.5 mg, 3 mg, 6 mg tab; glyburide micro 1.5 mg, 3 mg, 6 mg tablet MO	1	
glyburid-metformin 1.25-250 mg, 2.5-500 mg, 5-500 mg; glyburide-metformin 1.25-250 mg, 2.5-500 mg, 5-500 mg MO	1	
GLYNASE 1.5 MG, 3 MG, 6 MG TABLET MO	3	
GLYSET 100 MG, 25 MG, 50 MG TABLET MO	3	
GLYXAMBI 10 MG-5 MG TABLET; GLYXAMBI 25 MG-5 MG TABLET MO	2	QL (30 per 30 days)
GVOKE HYPOPEN 1-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML SUBCUTANEOUS AUTO-INJECTOR MO	2	
GVOKE HYPOPEN 2-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML SUBCUTANEOUS AUTO-INJECTOR MO	2	
GVOKE PFS 1-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML SUBCUTANEOUS SYRINGE MO	2	
GVOKE PFS 2-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML SUBCUTANEOUS SYRINGE MO	2	
HUMALOG JUNIOR KWIKPEN (U-100) 100 UNIT/ML SUBCUTANEOUS HALF-UNIT PEN MO	3	ST
HUMALOG KWIKPEN (U-100) INSULIN 100 UNIT/ML, 200 UNIT/ML (3 ML) SUBCUTANEOUS; HUMALOG KWIKPEN U-200 INSULIN 100 UNIT/ML, 200 UNIT/ML (3 ML) SUBCUTANEOUS MO	3	ST
HUMALOG MIX 50-50 (U-100) INSULIN 100 UNIT/ML SUBCUTANEOUS SUSPENSION MO	3	ST
HUMALOG MIX 50-50 KWIKPEN U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS PEN MO	3	ST
HUMALOG MIX 75-25 KWIKPEN U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS PEN MO	3	ST
HUMALOG MIX 75-25 (U-100) INSULIN 100 UNIT/ML SUBCUTANEOUS SUSPENSION MO	3	ST
HUMALOG U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS CARTRIDGE MO	3	ST
HUMALOG U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO	3	ST
HUMULIN 70/30 U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SUSPENSION MO	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HUMULIN 70/30 U-100 INSULIN KWIKPEN 100 UNIT/ML SUBCUTANEOUS MO	3	ST
HUMULIN N NPH U-100 INSULIN KWIKPEN 100 UNIT/ML (3 ML) SUBCUTANEOUS MO	3	ST
HUMULIN N NPH U-100 INSULIN (ISOPHANE SUSP) 100 UNIT/ML SUBCUTANEOUS MO	3	ST
HUMULIN R REGULAR U-100 INSULIN 100 UNIT/ML INJECTION SOLUTION MO	3	ST
HUMULIN R U-500 (CONCENTRATED) INSULIN 500 UNIT/ML SUBCUTANEOUS SOLN DL	4	
HUMULIN R U-500 (CONC) INSULIN KWIKPEN 500 UNIT/ML (3 ML) SUBCUTANEOUS DL	4	
INSULIN ASPART PROT-INSULN ASP MO	2	
INSULIN ASPART 100 UNIT/ML CRT MO	2	
INSULIN ASPART 100 UNIT/ML PEN MO	2	
INSULIN ASPART 100 UNIT/ML VL MO	2	
INSULIN LISPRO 100 UNIT/ML PEN; INSULIN LISPRO JR 100 UNIT/ML MO	3	ST
INSULIN LISPRO 100 UNIT/ML VL MO	3	ST
INSULIN LISPRO MIX 75-25 KWKPN MO	3	ST
INVOKAMET 150 MG-1,000 MG TABLET; INVOKAMET 150 MG-500 MG TABLET; INVOKAMET 50 MG-1,000 MG TABLET; INVOKAMET 50 MG-500 MG TABLET MO	2	QL (60 per 30 days)
INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE; INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE; INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE; INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE MO	2	QL (60 per 30 days)
INVOKANA 100 MG, 300 MG TABLET MO	2	QL (30 per 30 days)
JANUMET 50 MG-1,000 MG TABLET; JANUMET 50 MG-500 MG TABLET MO	2	QL (60 per 30 days)
JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE MO	2	QL (30 per 30 days)
JANUMET XR 50 MG-1,000 MG TABLET,EXTENDED RELEASE; JANUMET XR 50 MG-500 MG TABLET,EXTENDED RELEASE MO	2	QL (60 per 30 days)
JANUVIA 100 MG, 25 MG, 50 MG TABLET MO	2	QL (30 per 30 days)
JARDIANCE 10 MG, 25 MG TABLET MO	2	QL (30 per 30 days)
JENTADUETO 2.5 MG-1,000 MG TABLET; JENTADUETO 2.5 MG-500 MG TABLET; JENTADUETO 2.5 MG-850 MG TABLET MO	2	QL (60 per 30 days)
JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE MO	2	QL (60 per 30 days)
JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE MO	2	QL (30 per 30 days)
KAZANO 12.5 MG-1,000 MG TABLET; KAZANO 12.5 MG-500 MG TABLET MO	3	PA,QL (60 per 30 days)
KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE MO	3	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE; KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE MO	3	QL (30 per 30 days)
LANTUS SOLOSTAR U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS PEN MO	2	
LANTUS U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO	2	
LEVEMIR FLEXTOUCH U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS PEN MO	2	
LEVEMIR U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO	2	
LYUMJEV KWIKPEN U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS MO	3	ST
LYUMJEV KWIKPEN U-200 INSULIN 200 UNIT/ML (3 ML) SUBCUTANEOUS MO	3	ST
LYUMJEV U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO	3	ST
<i>metformin er 1,000 mg gastr-tb; metformin er 1,000 mg osm-tab</i> DL	4	ST,QL (60 per 30 days)
<i>metformin er 500 mg gastrc-tb</i> DL	4	ST,QL (120 per 30 days)
<i>metformin er 500 mg osmotic tb</i> DL	4	ST,QL (150 per 30 days)
<i>metformin hcl 1,000 mg, 500 mg, 850 mg tablet</i> MO	1	
<i>metformin hcl er 500 mg tablet</i> MO	1	QL (120 per 30 days)
<i>metformin hcl er 750 mg tablet</i> MO	1	QL (60 per 30 days)
<i>miglitol 100 mg, 25 mg, 50 mg tablet</i> MO	1	
<i>nateglinide 120 mg, 60 mg tablet</i> MO	1	
NESINA 12.5 MG, 25 MG, 6.25 MG TABLET MO	3	PA,QL (30 per 30 days)
NOVOLIN 70-30 FLEXPEN U-100 INSULIN 100 UNIT/ML (70-30) SUBCUTANEOUS MO	2	
NOVOLIN 70/30 U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SUSPENSION MO	2	
NOVOLIN N FLEXPEN 100 UNIT/ML (3 ML) SUBCUTANEOUS INSULIN PEN MO	2	
NOVOLIN N NPH U-100 INSULIN ISOPHANE 100 UNIT/ML SUBCUTANEOUS SUSP MO	2	
NOVOLIN R FLEXPEN 100 UNIT/ML (3 ML) SUBCUTANEOUS INSULIN PEN MO	2	
NOVOLIN R REGULAR U-100 INSULIN 100 UNIT/ML INJECTION SOLUTION MO	2	
NOVOLOG FLEXPEN U-100 INSULIN ASPART 100 UNIT/ML (3 ML) SUBCUTANEOUS MO	2	
NOVOLOG MIX 70-30 U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO	2	
NOVOLOG MIX 70-30 FLEXPEN U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS PEN MO	2	
NOVOLOG PENFILL U-100 INSULIN ASPART 100 UNIT/ML SUBCUTANEOUS CARTRIDG MO	2	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NOVOLOG U-100 INSULIN ASPART 100 UNIT/ML SUBCUTANEOUS SOLUTION MO	2	
ONGLYZA 2.5 MG, 5 MG TABLET MO	3	QL (30 per 30 days)
OSENI 12.5 MG-15 MG TABLET; OSENI 12.5 MG-30 MG TABLET; OSENI 12.5 MG-45 MG TABLET; OSENI 25 MG-15 MG TABLET; OSENI 25 MG-30 MG TABLET; OSENI 25 MG-45 MG TABLET MO	3	PA,QL (30 per 30 days)
OZEMPIC 0.25 MG OR 0.5 MG (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR MO	2	QL (1.5 per 28 days)
OZEMPIC 1 MG/DOSE (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR MO	2	QL (3 per 28 days)
<i>pioglitazone hcl 15 mg, 30 mg, 45 mg tablet</i> MO	1	QL (30 per 30 days)
<i>pioglitazone-glimepiride 30-2; pioglitazone-glimepiride 30-4</i> MO	1	QL (30 per 30 days)
<i>pioglitazone-metformin 15-500; pioglitazone-metformin 15-850</i> MO	1	QL (90 per 30 days)
PRANDIN 1 MG, 2 MG TABLET MO	3	
PRECOSE 100 MG, 25 MG, 50 MG TABLET MO	3	
PROGLYCEM 50 MG/ML ORAL SUSPENSION DL	4	
QTERN 10 MG-5 MG TABLET; QTERN 5 MG-5 MG TABLET MO	3	PA,QL (30 per 30 days)
<i>repaglinide 0.5 mg, 1 mg, 2 mg tablet</i> MO	1	
<i>repaglinide-metformin 1-500 mg, 2-500 mg</i> MO	1	
RIOMET 500 MG/5 ML ORAL SOLUTION MO	3	QL (750 per 30 days)
RIOMET ER 500 MG/5 ML ORAL SUSPENSION,EXTENDED RELEASE MO	3	QL (750 per 30 days)
RYBELSUS 14 MG, 3 MG, 7 MG TABLET MO	2	QL (30 per 30 days)
SEGLUROMET 2.5 MG-1,000 MG TABLET; SEGLUROMET 2.5 MG-500 MG TABLET; SEGLUROMET 7.5 MG-1,000 MG TABLET; SEGLUROMET 7.5 MG-500 MG TABLET MO	3	PA,QL (60 per 30 days)
SEMGLEE PEN U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS MO	3	PA
SEMGLEE U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO	3	PA
SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN MO	2	QL (15 per 24 days)
STARLIX 120 MG, 60 MG TABLET MO	3	PA
STEGLATRO 15 MG, 5 MG TABLET MO	3	PA,QL (30 per 30 days)
STEGLUJAN 15 MG-100 MG TABLET; STEGLUJAN 5 MG-100 MG TABLET MO	3	PA,QL (30 per 30 days)
SYMLINPEN 120 2,700 MCG/2.7 ML SUBCUTANEOUS PEN INJECTOR DL	4	QL (10.8 per 30 days)
SYMLINPEN 60 1,500 MCG/1.5 ML SUBCUTANEOUS PEN INJECTOR DL	4	QL (10.5 per 28 days)
SYNJARDY 12.5 MG-1,000 MG TABLET; SYNJARDY 12.5 MG-500 MG TABLET; SYNJARDY 5 MG-1,000 MG TABLET; SYNJARDY 5 MG-500 MG TABLET MO	2	QL (60 per 30 days)
SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE; SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE MO	2	QL (30 per 30 days)
SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE; SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE MO	2	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
tolazamide 250 mg, 500 mg tablet MO	1	
tolbutamide 500 mg tablet MO	1	
TOUJEO MAX U-300 SOLOSTAR 300 UNIT/ML (3 ML) SUBCUTANEOUS INSULIN PEN MO	2	
TOUJEO SOLOSTAR U-300 INSULIN 300 UNIT/ML (1.5 ML) SUBCUTANEOUS PEN MO	2	
TRADJENTA 5 MG TABLET MO	2	QL (30 per 30 days)
TRESIBA FLEXTOUCH U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS PEN MO	2	
TRESIBA FLEXTOUCH U-200 INSULIN 200 UNIT/ML (3 ML) SUBCUTANEOUS PEN MO	2	
TRESIBA U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION MO	2	
TRIJARDY XR 10 MG-5 MG-1,000 MG TABLET, EXTENDED RELEASE; TRIJARDY XR 25 MG-5 MG-1,000 MG TABLET, EXTENDED RELEASE MO	2	QL (30 per 30 days)
TRIJARDY XR 12.5 MG-2.5 MG-1,000 MG TABLET, EXTENDED RELEASE; TRIJARDY XR 5 MG-2.5 MG-1,000 MG TABLET, EXTENDED RELEASE MO	2	QL (60 per 30 days)
TRULICITY 0.75 MG/0.5 ML, 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR MO	2	QL (2 per 28 days)
VICTOZA 2-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR MO	2	QL (9 per 30 days)
VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR MO	2	QL (9 per 30 days)
XIGDUO XR 10 MG-1,000 MG TABLET,EXTENDED RELEASE; XIGDUO XR 10 MG-500 MG TABLET,EXTENDED RELEASE; XIGDUO XR 5 MG-500 MG TABLET,EXTENDED RELEASE MO	3	QL (30 per 30 days)
XIGDUO XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE; XIGDUO XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE MO	3	QL (60 per 30 days)
XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN MO	2	QL (15 per 30 days)
BLOOD PRODUCTS AND MODIFIERS		
AGGRASTAT CONCENTRATE 250 MCG/ML INTRAVENOUS MO	3	
AGGRASTAT 12.5 MG/250 ML (50 MCG/ML), 5 MG/100 ML (50 MCG/ML) IN 0.9 % SODIUM CHLORIDE IV; AGGRASTAT 12.5 MG/250 ML (50 MCG/ML), 5 MG/100 ML (50 MCG/ML) IN ISO-OSMOTIC SODIUM CHLORIDE IV MO	3	
AGGRENOX 25 MG-200 MG CAPSULE, EXTENDED RELEASE MO	3	ST,QL (60 per 30 days)
AGRYLIN 0.5 MG CAPSULE MO	3	PA
AMICAR 1,000 MG, 500 MG TABLET DL	4	PA
AMICAR 250 MG/ML (25 %) ORAL SOLUTION DL	4	
aminocaproic acid 0.25 gram/ml DL	4	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>aminocaproic acid 1,000 mg, 500 mg tab</i> DL	4	
<i>aminocaproic acid 5 g/20 ml vl</i> MO	1	
<i>anagrelide hcl 0.5 mg, 1 mg capsule</i> MO	1	
ARANESP 10 MCG/0.4 ML, 40 MCG/0.4 ML (IN POLYSORBATE) INJECTION SYRINGE MO	3	PA,QL (1.6 per 30 days)
ARANESP 100 MCG/0.5 ML (IN POLYSORBATE) INJECTION SYRINGE DL	4	PA,QL (2 per 30 days)
ARANESP 100 MCG/ML, 200 MCG/ML, 300 MCG/ML (IN POLYSORBATE) INJECTION DL	4	PA,QL (4 per 30 days)
ARANESP 150 MCG/0.3 ML (IN POLYSORBATE) INJECTION SYRINGE DL	4	PA,QL (1.2 per 30 days)
ARANESP 150 MCG/0.75 ML (IN POLYSORBATE) INJECTION DL	4	PA,QL (3 per 30 days)
ARANESP 200 MCG/0.4 ML (IN POLYSORBATE) INJECTION SYRINGE DL	4	PA,QL (1.6 per 30 days)
ARANESP 25 MCG/0.42 ML (IN POLYSORBATE) INJECTION SYRINGE MO	3	PA,QL (1.68 per 30 days)
ARANESP 25 MCG/ML, 40 MCG/ML, 60 MCG/ML (IN POLYSORBATE) INJECTION MO	3	PA,QL (4 per 30 days)
ARANESP 300 MCG/0.6 ML (IN POLYSORBATE) INJECTION SYRINGE DL	4	PA,QL (2.4 per 30 days)
ARANESP 500 MCG/ML (IN POLYSORBATE) INJECTION SYRINGE DL	4	PA,QL (4 per 30 days)
ARANESP 60 MCG/0.3 ML (IN POLYSORBATE) INJECTION SYRINGE MO	3	PA,QL (1.2 per 30 days)
ARIXTRA 10 MG/0.8 ML SUBCUTANEOUS SOLUTION SYRINGE DL	4	PA,QL (24 per 30 days)
ARIXTRA 2.5 MG/0.5 ML SUBCUTANEOUS SOLUTION SYRINGE DL	4	PA,QL (15 per 30 days)
ARIXTRA 5 MG/0.4 ML SUBCUTANEOUS SOLUTION SYRINGE DL	4	PA,QL (12 per 30 days)
ARIXTRA 7.5 MG/0.6 ML SUBCUTANEOUS SOLUTION SYRINGE DL	4	PA,QL (18 per 30 days)
<i>aspirin-dipyridam er 25-200 mg</i> MO	1	ST,QL (60 per 30 days)
BEVYXXA 40 MG, 80 MG CAPSULE MO	3	PA,QL (41 per 41 days)
BRILINTA 60 MG, 90 MG TABLET MO	2	QL (60 per 30 days)
CABLIVI 11 MG INJECTION KIT DL	4	PA,QL (30 per 30 days)
<i>cilostazol 100 mg, 50 mg tablet</i> MO	1	
<i>clopidogrel 300 mg tablet</i> MO	1	
<i>clopidogrel 75 mg tablet</i> MO	1	QL (30 per 30 days)
COUMADIN 1 MG, 10 MG, 2 MG, 2.5 MG, 3 MG, 4 MG, 5 MG, 6 MG, 7.5 MG TABLET MO	3	
CYKLOKAPRON 1,000 MG/10 ML (100 MG/ML) INTRAVENOUS SOLUTION DL	4	PA
<i>dipyridamole 25 mg, 50 mg, 75 mg tablet</i> MO	1	
DOPTELET (10 TAB PACK) 20 MG TABLET DL	4	PA,QL (60 per 30 days)
DOPTELET (15 TAB PACK) 20 MG TABLET DL	4	PA,QL (60 per 30 days)
DOPTELET (30 TAB PACK) 20 MG TABLET DL	4	PA,QL (60 per 30 days)
EFFIENT 10 MG, 5 MG TABLET MO	3	PA,QL (30 per 30 days)
ELIQUIS 2.5 MG TABLET MO	2	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ELIQUIS 5 MG TABLET MO	2	QL (74 per 30 days)
ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG (74 TABLETS) IN DOSE PACK MO	2	QL (74 per 30 days)
enoxaparin 100 mg/ml, 150 mg/ml syringe MO	1	QL (28 per 28 days)
enoxaparin 120 mg/0.8 ml, 80 mg/0.8 ml syr MO	1	QL (22.4 per 28 days)
enoxaparin 30 mg/0.3 ml, 60 mg/0.6 ml syr MO	1	QL (16.8 per 28 days)
enoxaparin 300 mg/3 ml vial MO	1	QL (84 per 28 days)
enoxaparin 40 mg/0.4 ml syr MO	1	QL (11.2 per 28 days)
EPOGEN 10,000 UNIT/ML, 20,000 UNIT/ML INJECTION SOLUTION DL	4	PA,QL (14 per 30 days)
EPOGEN 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML INJECTION SOLUTION MO	3	PA,QL (14 per 30 days)
EPOGEN 20,000 UNIT/2 ML INJECTION SOLUTION MO	3	PA,QL (28 per 30 days)
eptifibatide 200 mg/100 ml vl; eptifibatide 75 mg/100 ml vial MO	1	
fondaparinux 10 mg/0.8 ml syr DL	4	QL (24 per 30 days)
fondaparinux 2.5 mg/0.5 ml syr DL	4	QL (15 per 30 days)
fondaparinux 5 mg/0.4 ml syr DL	4	QL (12 per 30 days)
fondaparinux 7.5 mg/0.6 ml syr DL	4	QL (18 per 30 days)
FRAGMIN 10,000 ANTI-XA UNIT/ML SUBCUTANEOUS SYRINGE DL	4	QL (30 per 30 days)
FRAGMIN 12,500 ANTI-XA UNIT/0.5 ML SUBCUTANEOUS SYRINGE DL	4	QL (15 per 30 days)
FRAGMIN 15,000 ANTI-XA UNIT/0.6 ML SUBCUTANEOUS SYRINGE DL	4	QL (18 per 30 days)
FRAGMIN 18,000 ANTI-XA UNIT/0.72 ML SUBCUTANEOUS SYRINGE DL	4	QL (21.6 per 30 days)
FRAGMIN 2,500 ANTI-XA UNIT/0.2 ML, 5,000 ANTI-XA UNIT/0.2 ML SUBCUTANEOUS SYRINGE DL	4	QL (6 per 30 days)
FRAGMIN 25,000 ANTI-XA UNIT/ML SUBCUTANEOUS SOLUTION DL	4	QL (22.8 per 30 days)
FRAGMIN 7,500 ANTI-XA UNIT/0.3 ML SUBCUTANEOUS SYRINGE DL	4	QL (9 per 30 days)
FULPHILA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (1.2 per 28 days)
GRANIX 300 MCG/0.5 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (7 per 28 days)
GRANIX 300 MCG/ML SUBCUTANEOUS SOLUTION DL	4	PA,QL (14 per 28 days)
GRANIX 480 MCG/0.8 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (11.2 per 28 days)
GRANIX 480 MCG/1.6 ML SUBCUTANEOUS SOLUTION DL	4	PA,QL (22.4 per 28 days)
heparin 5,000 unit/ml carpuct MO	1	
heparin sod 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml vial; heparin sod 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml vl MO	1	
heparin sod 5,000 unit/ml syrg MO	1	
heparin 2,000 unit/2 ml vial; heparin sod 1,000 unit/ml, 5,000 unit/0.5 ml MO	1	
heparin sod 5,000 unit/0.5 ml, 5,000 unit/ml; heparin sod 5,000 unit/0.5 ml, 5,000 unit/ml syrg MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
INTEGRILIN 0.75 MG/ML, 2 MG/ML INTRAVENOUS SOLUTION MO	3	
<i>gantoven</i> 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg tablet MO	1	
KENGREAL 50 MG INTRAVENOUS SOLUTION DL	4	
LEUKINE 250 MCG SOLUTION FOR INJECTION DL	4	PA
LOVENOX 100 MG/ML, 150 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (28 per 28 days)
LOVENOX 120 MG/0.8 ML, 80 MG/0.8 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (22.4 per 28 days)
LOVENOX 30 MG/0.3 ML, 60 MG/0.6 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (16.8 per 28 days)
LOVENOX 300 MG/3 ML SUBCUTANEOUS SOLUTION DL	4	PA,QL (84 per 28 days)
LOVENOX 40 MG/0.4 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (11.2 per 28 days)
LYSTEDA 650 MG TABLET MO	3	QL (30 per 5 days)
MIRCERA 100 MCG/0.3 ML INJECTION SYRINGE DL	4	PA,QL (1.2 per 28 days)
MIRCERA 150 MCG/0.3 ML, 200 MCG/0.3 ML, 30 MCG/0.3 ML INJECTION SYRINGE DL	4	PA,QL (0.6 per 28 days)
MIRCERA 50 MCG/0.3 ML, 75 MCG/0.3 ML INJECTION SYRINGE DL	4	PA,QL (0.9 per 28 days)
MOZOBIL 24 MG/1.2 ML (20 MG/ML) SUBCUTANEOUS SOLUTION DL	4	PA,QL (9.6 per 30 days)
MULPLETA 3 MG TABLET DL	4	PA,QL (7 per 30 days)
NEULASTA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE; NEULASTA 6 MG/0.6 ML WITH WEARABLE SUBCUTANEOUS INJECTOR DL	4	PA,QL (1.2 per 28 days)
NEUPOGEN 300 MCG/0.5 ML INJECTION SYRINGE DL	4	PA,QL (7 per 30 days)
NEUPOGEN 300 MCG/ML INJECTION SOLUTION DL	4	PA,QL (14 per 30 days)
NEUPOGEN 480 MCG/0.8 ML INJECTION SYRINGE DL	4	PA,QL (11.2 per 30 days)
NEUPOGEN 480 MCG/1.6 ML INJECTION SOLUTION DL	4	PA,QL (22.4 per 30 days)
NIVESTYM 300 MCG/0.5 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (7 per 30 days)
NIVESTYM 300 MCG/ML INJECTION SOLUTION DL	4	PA,QL (14 per 30 days)
NIVESTYM 480 MCG/0.8 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (11.2 per 30 days)
NIVESTYM 480 MCG/1.6 ML INJECTION SOLUTION DL	4	PA,QL (22.4 per 30 days)
PLAVIX 300 MG TABLET MO	3	PA
PLAVIX 75 MG TABLET MO	3	PA,QL (30 per 30 days)
PRADAXA 110 MG, 150 MG, 75 MG CAPSULE MO	3	QL (60 per 30 days)
<i>prasugrel</i> 10 mg, 5 mg tablet MO	1	QL (30 per 30 days)
PROCRIT 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML INJECTION SOLUTION MO	3	PA,QL (14 per 30 days)
PROCRIT 20,000 UNIT/2 ML INJECTION SOLUTION MO	3	PA,QL (28 per 30 days)
PROMACTA 12.5 MG ORAL POWDER PACKET DL, LA	4	PA,QL (360 per 30 days)
PROMACTA 12.5 MG, 75 MG TABLET DL, LA	4	PA,QL (60 per 30 days)
PROMACTA 25 MG ORAL POWDER PACKET DL, LA	4	PA,QL (180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROMACTA 25 MG TABLET DL, LA	4	PA,QL (30 per 30 days)
PROMACTA 50 MG TABLET DL, LA	4	PA,QL (90 per 30 days)
REBLOZYL 25 MG, 75 MG SUBCUTANEOUS SOLUTION DL	4	PA
REOPRO 10 MG/5 ML VIAL DL	4	
RETACRIT 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML INJECTION SOLUTION MO	3	PA,QL (14 per 30 days)
RIASTAP 1 GRAM (900 MG-1,300 MG) INTRAVENOUS SOLUTION MO	3	
SAVAYSA 15 MG, 30 MG, 60 MG TABLET MO	3	PA,QL (30 per 30 days)
TAVALISSE 100 MG, 150 MG TABLET DL	4	PA,QL (60 per 30 days)
<i>tranexamic acid 1,000 mg/10 ml</i> MO	1	PA
<i>tranexamic acid 650 mg tablet</i> MO	1	QL (30 per 5 days)
UDENYCA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (1.2 per 28 days)
<i>warfarin sodium 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg tablet</i> MO	1	
XARELTO 10 MG, 20 MG TABLET MO	2	QL (30 per 30 days)
XARELTO 15 MG, 2.5 MG TABLET MO	2	QL (60 per 30 days)
XARELTO DVT-PE TREATMENT 30-DAY STARTER 15 MG(42)-20 MG(9) TABLET PACK MO	2	QL (51 per 30 days)
YOSPRALA 325 MG-40 MG TABLET,IMMEDIATE AND DELAY RELEASE; YOSPRALA 81 MG-40 MG TABLET,IMMEDIATE AND DELAY RELEASE MO	3	PA,QL (30 per 30 days)
ZARXIO 300 MCG/0.5 ML INJECTION SYRINGE DL	4	PA,QL (7 per 30 days)
ZARXIO 480 MCG/0.8 ML INJECTION SYRINGE DL	4	PA,QL (11.2 per 30 days)
ZIEXTENZO 6 MG/0.6 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (1.2 per 28 days)
ZONTIVITY 2.08 MG TABLET MO	3	PA,QL (30 per 30 days)
Cardiovascular Agents		
ACCUPRIL 10 MG, 20 MG, 40 MG, 5 MG TABLET MO	3	
ACCURETIC 10 MG-12.5 MG TABLET; ACCURETIC 20 MG-12.5 MG TABLET; ACCURETIC 20 MG-25 MG TABLET MO	3	
<i>acebutolol 200 mg, 400 mg capsule</i> MO	1	
<i>acetazolamide 125 mg, 250 mg tablet</i> MO	1	
<i>acetazolamide er 500 mg cap</i> MO	1	
<i>acetazolamide sod 500 mg vial</i> MO	1	
ADALAT CC 30 MG, 60 MG, 90 MG TABLET,EXTENDED RELEASE MO	3	QL (60 per 30 days)
<i>adenosine 12 mg/4 ml vial</i> MO	1	
<i>adenosine 6 mg/2 ml syringe</i> MO	1	
<i>afeditab cr 30 mg, 60 mg tablet</i> MO	1	QL (60 per 30 days)
ALDACTAZIDE 25 MG-25 MG TABLET; ALDACTAZIDE 50 MG-50 MG TABLET MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ALDACTONE 100 MG, 25 MG, 50 MG TABLET MO	3	
aliskiren 150 mg, 300 mg tablet MO	1	QL (30 per 30 days)
ALTACE 1.25 MG, 10 MG, 2.5 MG, 5 MG CAPSULE MO	3	PA
ALTOPREV 20 MG, 40 MG, 60 MG TABLET,EXTENDED RELEASE DL	4	ST,QL (30 per 30 days)
amiloride hcl 5 mg tablet MO	1	
amiloride hcl-hctz 5-50 mg tab MO	1	
amiodarone 150 mg/3 ml syringe MO	1	
amiodarone 900 mg/18 ml vial MO	1	
amiodarone hcl 100 mg, 200 mg tablet MO	1	
amiodarone hcl 400 mg tablet MO	1	QL (60 per 30 days)
amlodipine besylate 10 mg tab MO	1	QL (60 per 30 days)
amlodipine besylate 2.5 mg, 5 mg tab MO	1	QL (30 per 30 days)
amlodipine-atorvast 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg MO	1	QL (30 per 30 days)
amlodipine-benazepril 10-20 mg, 2.5-10 mg, 5-10 mg, 5-20 mg; amlodipine-benazepril 2.5-10 MO	1	QL (60 per 30 days)
amlodipine-benazepril 10-40 mg, 5-40 mg MO	1	QL (30 per 30 days)
amlodipine-olmesartan 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg MO	1	QL (30 per 30 days)
amlodipine-valsartan 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg MO	1	QL (30 per 30 days)
amlod-vals-hctz 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg; amlod-vals-hctz 10-160-12.5mg MO	1	QL (30 per 30 days)
ANTARA 30 MG, 90 MG CAPSULE MO	3	QL (30 per 30 days)
ATACAND 16 MG, 4 MG, 8 MG TABLET MO	3	ST,QL (60 per 30 days)
ATACAND 32 MG TABLET MO	3	ST,QL (30 per 30 days)
ATACAND HCT 16 MG-12.5 MG TABLET; ATACAND HCT 32 MG-12.5 MG TABLET; ATACAND HCT 32 MG-25 MG TABLET MO	3	ST,QL (30 per 30 days)
atenolol 100 mg, 25 mg, 50 mg tablet MO	1	
atenolol-chlorthalidone 100-25; atenolol-chlorthalidone 50-25 MO	1	
atorvastatin 10 mg, 20 mg, 40 mg, 80 mg tablet MO	1	
AVALIDE 150 MG-12.5 MG TABLET MO	3	PA,QL (60 per 30 days)
AVALIDE 300 MG-12.5 MG TABLET MO	3	PA,QL (30 per 30 days)
AVAPRO 150 MG, 300 MG, 75 MG TABLET MO	3	PA,QL (30 per 30 days)
AZOR 10 MG-20 MG TABLET; AZOR 10 MG-40 MG TABLET; AZOR 5 MG-20 MG TABLET; AZOR 5 MG-40 MG TABLET MO	3	PA,QL (30 per 30 days)
benazepril hcl 10 mg, 20 mg, 40 mg, 5 mg tablet MO	1	
benazepril-hctz 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg tab MO	1	
BENICAR 20 MG, 40 MG, 5 MG TABLET MO	3	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BENICAR HCT 20 MG-12.5 MG TABLET; BENICAR HCT 40 MG-12.5 MG TABLET; BENICAR HCT 40 MG-25 MG TABLET MO	3	PA,QL (30 per 30 days)
BETAPACE 120 MG, 160 MG, 240 MG, 80 MG TABLET DL	4	PA
BETAPACE AF 120 MG, 160 MG, 80 MG TABLET DL	4	PA
<i>betaxolol 10 mg, 20 mg tablet</i> MO	1	
BIDIL 20 MG-37.5 MG TABLET MO	3	QL (180 per 30 days)
BIORPHEN 0.1 MG/ML INTRAVENOUS SOLUTION MO	3	
<i>bisoprolol fumarate 10 mg, 5 mg tab</i> MO	1	
<i>bisoprolol-hctz 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg tab; bisoprolol-hctz 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg tb</i> MO	1	
<i>bretylum 500 mg/10 ml vial</i> MO	1	
BREVIBLOC 100 MG/10 ML (10 MG/ML) INTRAVENOUS SOLUTION MO	3	
BREVIBLOC 2,000 MG/100 ML, 2,500 MG/250 ML (10 MG/ML) (20 MG/ML) IN SODIUM CHLORIDE (ISO-OSM) IV; BREVIBLOC 2,000 MG/100 ML, 2,500 MG/250 ML (10 MG/ML) IN SODIUM CHLORIDE (ISO-OSM) IV MO	3	
<i>bumetanide 0.5 mg, 1 mg, 2 mg tablet</i> MO	1	
<i>bumetanide 1 mg/4 ml vial</i> MO	1	
BYSTOLIC 10 MG TABLET MO	2	QL (120 per 30 days)
BYSTOLIC 2.5 MG, 5 MG TABLET MO	2	QL (30 per 30 days)
BYSTOLIC 20 MG TABLET MO	2	QL (60 per 30 days)
BYVALSON 5 MG-80 MG TABLET MO	3	ST,QL (30 per 30 days)
CADUET 10 MG-10 MG TABLET; CADUET 10 MG-20 MG TABLET; CADUET 10 MG-40 MG TABLET; CADUET 10 MG-80 MG TABLET; CADUET 5 MG-10 MG TABLET; CADUET 5 MG-20 MG TABLET; CADUET 5 MG-40 MG TABLET; CADUET 5 MG-80 MG TABLET MO	3	PA,QL (30 per 30 days)
CALAN 120 MG TABLET MO	3	QL (120 per 30 days)
CALAN SR 120 MG TABLET,EXTENDED RELEASE MO	3	QL (30 per 30 days)
CALAN SR 180 MG, 240 MG TABLET,EXTENDED RELEASE MO	3	
<i>candesartan cilexetil 16 mg, 4 mg, 8 mg tab; candesartan cilexetil 16 mg, 4 mg, 8 mg tb</i> MO	1	QL (60 per 30 days)
<i>candesartan cilexetil 32 mg tb</i> MO	1	QL (30 per 30 days)
<i>candesartan-hctz 16-12.5 mg, 32-12.5 mg, 32-25 mg tab; candesartan-hctz 16-12.5 mg, 32-12.5 mg, 32-25 mg tb</i> MO	1	QL (30 per 30 days)
<i>captopril 100 mg, 12.5 mg, 25 mg, 50 mg tablet</i> MO	1	
<i>captopril-hctz 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg tablet</i> MO	1	
CARDIZEM 120 MG, 30 MG, 60 MG TABLET MO	3	
CARDIZEM CD 120 MG, 180 MG, 240 MG CAPSULE,EXTENDED RELEASE DL	4	PA,QL (60 per 30 days)
CARDIZEM CD 300 MG, 360 MG CAPSULE,EXTENDED RELEASE DL	4	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CARDIZEM LA 120 MG, 300 MG, 360 MG, 420 MG TABLET,EXTENDED RELEASE MO	3	QL (30 per 30 days)
CARDIZEM LA 180 MG, 240 MG TABLET,EXTENDED RELEASE MO	3	QL (60 per 30 days)
CARDURA 1 MG, 2 MG, 4 MG, 8 MG TABLET MO	3	
CARDURA XL 4 MG, 8 MG TABLET,EXTENDED RELEASE MO	3	QL (30 per 30 days)
CAROSPIR 25 MG/5 ML ORAL SUSPENSION DL	4	PA,QL (450 per 30 days)
<i>cartia xt 120 mg, 180 mg, 240 mg capsule,extended release</i> MO	1	QL (60 per 30 days)
<i>cartia xt 300 mg capsule,extended release</i> MO	1	QL (30 per 30 days)
<i>carvedilol 12.5 mg, 25 mg, 3.125 mg, 6.25 mg tablet</i> MO	1	
<i>carvedilol er 10 mg, 20 mg, 40 mg, 80 mg capsule</i> MO	1	QL (30 per 30 days)
CATAPRES 0.1 MG, 0.2 MG, 0.3 MG TABLET MO	3	
CATAPRES-TTS-1 0.1 MG/24 HR TRANSDERMAL PATCH MO	3	PA,QL (4 per 28 days)
CATAPRES-TTS-2 0.2 MG/24 HR TRANSDERMAL PATCH MO	3	PA,QL (4 per 28 days)
CATAPRES-TTS-3 0.3 MG/24 HR TRANSDERMAL PATCH MO	3	PA,QL (4 per 28 days)
<i>chlorothiazide 250 mg, 500 mg tablet</i> MO	1	
<i>chlorothiazide sod 500 mg vial</i> MO	1	
<i>chlorthalidone 25 mg, 50 mg tablet</i> MO	1	
<i>cholestyramine packet; cholestyramine powder</i> MO	1	
<i>cholestyramine light 4 gram oral powder; cholestyramine light 4 gram powder for susp in a packet</i> MO	1	
CLEVIPREX 25 MG/50 ML, 50 MG/100 ML INTRAVENOUS EMULSION MO	3	
<i>clonidine 0.1 mg/day patch; clonidine 0.2 mg/day patch; clonidine 0.3 mg/day patch</i> MO	1	QL (4 per 28 days)
<i>clonidine hcl 0.1 mg, 0.2 mg, 0.3 mg tablet</i> MO	1	
<i>colesevelam 625 mg tablet</i> MO	1	PA,QL (180 per 30 days)
<i>colesevelam hcl 3.75 g packet</i> MO	1	PA,QL (30 per 30 days)
COLESTID 1 GRAM TABLET MO	3	
COLESTID 5 GRAM ORAL GRANULES MO	3	QL (1000 per 30 days)
COLESTID 5 GRAM ORAL PACKET MO	3	
COLESTID FLAVORED 5 GRAM ORAL GRANULES MO	3	QL (1000 per 30 days)
COLESTID FLAVORED 7.5 GRAM PACKET MO	3	
<i>colestipol hcl granules</i> MO	1	QL (1000 per 30 days)
<i>colestipol hcl granules packet</i> MO	1	
<i>colestipol micronized 1 gm tab</i> MO	1	
COREG 12.5 MG, 25 MG, 3.125 MG, 6.25 MG TABLET MO	3	PA
COREG CR 10 MG, 20 MG, 40 MG, 80 MG CAPSULE, EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
CORGARD 20 MG, 40 MG, 80 MG TABLET MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CORLANOR 5 MG, 7.5 MG TABLET MO	3	PA,QL (60 per 30 days)
CORLANOR 5 MG/5 ML ORAL SOLUTION MO	3	PA,QL (560 per 28 days)
CORLOPAM 10 MG/ML INTRAVENOUS SOLUTION MO	3	
CORVERT 0.1 MG/ML INTRAVENOUS SOLUTION MO	3	
CORZIDE 40-5 TABLET; CORZIDE 80-5 TABLET MO	3	
COZAAR 100 MG, 25 MG, 50 MG TABLET MO	3	PA,QL (60 per 30 days)
CRESTOR 10 MG, 20 MG, 40 MG, 5 MG TABLET MO	3	PA
DEMADEX 10 MG TABLET MO	3	
DEMSEER 250 MG CAPSULE DL	4	
DIBENZYLIN 10 MG CAPSULE DL	4	
digitek 125 mcg (0.125 mg), 250 mcg (0.25 mg) tablet MO	1	QL (30 per 30 days)
digox 125 mcg (0.125 mg), 250 mcg (0.25 mg) tablet MO	1	QL (30 per 30 days)
digoxin 0.05 mg/ml solution; digoxin 500 mcg/2 ml ampule MO	1	
digoxin 125 mcg tablet; digoxin 250 mcg tablet MO	1	QL (30 per 30 days)
DILATRATE-SR 40 MG CAPSULE, EXTENDED RELEASE MO	3	
dilt-xr 120 mg, 180 mg, 240 mg capsule, extended release MO	1	QL (60 per 30 days)
diltiazem 100 mg, 5 mg/ml add-van vial; diltiazem 125 mg/25 ml vial MO	1	
diltiazem 120 mg, 30 mg, 60 mg, 90 mg tablet MO	1	
diltiazem 12hr er 120 mg cap MO	1	QL (90 per 30 days)
diltiazem 12hr er 60 mg, 90 mg cap MO	1	QL (180 per 30 days)
diltiazem 24h er(cd) 120 mg, 180 mg, 240 mg cp; diltiazem 24hr er 120 mg, 180 mg, 240 mg cap MO	1	QL (60 per 30 days)
diltiazem 24h er(cd) 300 mg, 360 mg, 420 mg cp; diltiazem 24hr er 300 mg, 360 mg, 420 mg cap MO	1	QL (30 per 30 days)
diltiazem 24h er(la) 180 mg, 240 mg tb MO	1	QL (60 per 30 days)
diltiazem 24h er(la) 300 mg, 360 mg, 420 mg tb MO	1	QL (30 per 30 days)
diltiazem 24h er(xr) 120 mg, 180 mg, 240 mg cp MO	1	QL (60 per 30 days)
DIOVAN 160 MG, 320 MG, 40 MG, 80 MG TABLET MO	3	PA,QL (60 per 30 days)
DIOVAN HCT 160 MG-12.5 MG TABLET; DIOVAN HCT 160 MG-25 MG TABLET; DIOVAN HCT 320 MG-12.5 MG TABLET; DIOVAN HCT 320 MG-25 MG TABLET; DIOVAN HCT 80 MG-12.5 MG TABLET MO	3	PA,QL (30 per 30 days)
disopyramide 100 mg, 150 mg capsule MO	1	
DIURIL 250 MG/5 ML ORAL SUSPENSION MO	3	
DIURIL 500 MG INTRAVENOUS SOLUTION MO	3	
dobutamine 12.5 mg/ml vial; dobutamine 250 mg/20 ml vial MO	1	B vs D
dobutamine 1,000 mg/250 ml d5w; dobutamine 250 mg/250 ml-d5w; dobutamine 500 mg/250 ml d5w MO	1	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
dofetilide 125 mcg, 250 mcg, 500 mcg capsule MO	1	
dopamine 160 mg/ml vial; dopamine 200 mg/5 ml vial; dopamine 400 mg/10 ml vial; dopamine 80 mg/ml vial MO	1	B vs D
dopamine 200 mg-d5w 250 ml; dopamine 400 mg-d5w 500 ml; dopamine 400 mg/250 ml-d5w bag; dopamine 800 mg/250 ml-d5w bag; dopamine 800 mg/500 ml-d5w bag MO	1	B vs D
doxazosin mesylate 1 mg, 2 mg, 4 mg, 8 mg tab MO	1	
DUTOPROL 100 MG-12.5 MG TABLET,EXTENDED RELEASE MO	3	QL (120 per 30 days)
DUTOPROL 25 MG-12.5 MG TABLET,EXTENDED RELEASE; DUTOPROL 50 MG-12.5 MG TABLET,EXTENDED RELEASE MO	3	QL (60 per 30 days)
DYAZIDE 37.5 MG-25 MG CAPSULE MO	3	
DYRENIUM 100 MG, 50 MG CAPSULE MO	3	
EDARBI 40 MG, 80 MG TABLET MO	3	ST,QL (30 per 30 days)
EDARBYCLOR 40 MG-12.5 MG TABLET; EDARBYCLOR 40 MG-25 MG TABLET MO	3	ST,QL (30 per 30 days)
EDECIN 25 MG TABLET DL	4	QL (480 per 30 days)
enalapril maleate 10 mg, 2.5 mg, 20 mg, 5 mg tab; enalapril maleate 10 mg, 2.5 mg, 20 mg, 5 mg tablet MO	1	
enalapril-hctz 10-25 mg, 5-12.5 mg tab; enalapril-hctz 10-25 mg, 5-12.5 mg tablet MO	1	
enalaprilat 1.25 mg/ml vial MO	1	
ENTRESTO 24 MG-26 MG TABLET; ENTRESTO 49 MG-51 MG TABLET; ENTRESTO 97 MG-103 MG TABLET MO	2	QL (60 per 30 days)
EPANED 1 MG/ML ORAL SOLUTION MO	3	
eplerenone 25 mg, 50 mg tablet MO	1	
eprosartan mesylate 600 mg tab MO	1	QL (60 per 30 days)
esmolol hcl 100 mg/10 ml vial MO	1	
esmolol 2,000 mg/100 ml, 2,500 mg/250 ml (10 mg/ml)-nacl; esmolol 2,500 mg/250 ml-nacl MO	1	
ethacrynic acid 50 mg vial MO	1	
ethacrynic acid 25 mg tablet DL	4	QL (480 per 30 days)
EXFORGE 10 MG-160 MG TABLET; EXFORGE 10 MG-320 MG TABLET; EXFORGE 5 MG-160 MG TABLET; EXFORGE 5 MG-320 MG TABLET MO	3	PA,QL (30 per 30 days)
EXFORGE HCT 10 MG-160 MG-12.5 MG TABLET; EXFORGE HCT 10 MG-160 MG-25 MG TABLET; EXFORGE HCT 10 MG-320 MG-25 MG TABLET; EXFORGE HCT 5 MG-160 MG-12.5 MG TABLET; EXFORGE HCT 5 MG-160 MG-25 MG TABLET MO	3	PA,QL (30 per 30 days)
EZALLOR SPRINKLE 10 MG, 20 MG, 40 MG, 5 MG CAPSULE MO	3	ST,QL (30 per 30 days)
ezetimibe 10 mg tablet MO	1	QL (30 per 30 days)
ezetimibe-simvastatin 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg MO	1	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
felodipine er 10 mg, 2.5 mg, 5 mg tablet MO	1	QL (30 per 30 days)
fenofibrate 120 mg, 160 mg tablet MO	1	QL (30 per 30 days)
fenofibrate 150 mg capsule MO	1	QL (30 per 30 days)
fenofibrate 40 mg, 54 mg tablet MO	1	QL (60 per 30 days)
fenofibrate 50 mg capsule MO	1	QL (60 per 30 days)
fenofibrate 130 mg, 43 mg capsule MO	1	ST,QL (30 per 30 days)
fenofibrate 134 mg, 200 mg capsule MO	1	QL (30 per 30 days)
fenofibrate 67 mg capsule MO	1	QL (60 per 30 days)
fenofibrate 145 mg, 160 mg tablet MO	1	QL (30 per 30 days)
fenofibrate 48 mg tablet MO	1	QL (60 per 30 days)
fenofibric acid 105 mg, 35 mg tablet MO	2	QL (30 per 30 days)
fenofibric acid dr 135 mg, 45 mg cap MO	1	QL (30 per 30 days)
FENOGLIDE 120 MG TABLET DL	4	QL (30 per 30 days)
FENOGLIDE 40 MG TABLET DL	4	QL (60 per 30 days)
FIBRICOR 105 MG, 35 MG TABLET MO	3	QL (30 per 30 days)
flecainide acetate 100 mg, 150 mg, 50 mg tab MO	1	
FLOLIPID 20 MG/5 ML (4 MG/ML), 40 MG/5 ML (8 MG/ML) ORAL SUSPENSION MO	3	ST,QL (150 per 30 days)
fluvastatin er 80 mg tablet MO	1	ST,QL (30 per 30 days)
fluvastatin sodium 20 mg, 40 mg cap MO	1	ST,QL (60 per 30 days)
fosinopril sodium 10 mg, 20 mg, 40 mg tab MO	1	
fosinopril-hctz 10-12.5 mg, 20-12.5 mg tab MO	1	
furosemide 10 mg/ml, 40 mg/5 ml (8 mg/ml) solution; furosemide 40 mg/4 ml vial; furosemide 40 mg/5 ml soln MO	1	
furosemide 100 mg/10 ml syringe MO	1	
furosemide 20 mg, 40 mg, 80 mg tablet MO	1	
gemfibrozil 600 mg tablet MO	1	QL (60 per 30 days)
GONITRO 400 MCG SUBLINGUAL POWDER IN A PACKET MO	3	
guanfacine 1 mg, 2 mg tablet MO	1	
HEMANGEOL 4.28 MG/ML ORAL SOLUTION MO	3	
hydralazine 10 mg, 100 mg, 25 mg, 50 mg tablet MO	1	
hydralazine 20 mg/ml vial MO	1	
hydrochlorothiazide 12.5 mg cp MO	1	
hydrochlorothiazide 12.5 mg, 25 mg, 50 mg tab; hydrochlorothiazide 12.5 mg, 25 mg, 50 mg tb MO	1	
HYZAAR 100 MG-12.5 MG TABLET; HYZAAR 100 MG-25 MG TABLET; HYZAAR 50 MG-12.5 MG TABLET MO	3	PA,QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ibutilide fum 1 mg/10 ml vial</i> MO	1	
<i>indapamide 1.25 mg, 2.5 mg tablet</i> MO	1	
INDERAL LA 120 MG, 160 MG, 60 MG, 80 MG CAPSULE,EXTENDED RELEASE DL	4	PA
INNOPRAN XL 120 MG, 80 MG CAPSULE,EXTENDED RELEASE DL	4	
INSPIRA 25 MG, 50 MG TABLET MO	3	PA
<i>irbesartan 150 mg, 300 mg, 75 mg tablet</i> MO	1	QL (30 per 30 days)
<i>irbesartan-hctz 150-12.5 mg tb</i> MO	1	QL (60 per 30 days)
<i>irbesartan-hctz 300-12.5 mg tb</i> MO	1	QL (30 per 30 days)
<i>isochron 40 mg tablet,extended release</i> MO	1	
ISORDIL 40 MG TABLET DL	4	
ISORDIL TITRADOSE 5 MG TABLET DL	4	PA
<i>isosorbide dinitr er 40 mg tab</i> MO	1	
<i>isosorbide dinitrate 10 mg, 20 mg, 30 mg, 5 mg tab</i> MO	1	
<i>isosorbide dinitrate 40 mg tab</i> DL	4	
<i>isosorbide mononit 10 mg, 20 mg tab</i> MO	1	
<i>isosorbide mononit er 120 mg, 30 mg, 60 mg; isosorbide mononit er 120 mg, 30 mg, 60 mg tb</i> MO	1	
<i>isradipine 2.5 mg, 5 mg capsule</i> MO	1	
ISUPREL 0.2 MG/ML INJECTION SOLUTION MO	3	
JUXTAPID 10 MG, 30 MG, 40 MG, 5 MG, 60 MG CAPSULE DL	4	PA,QL (28 per 28 days)
JUXTAPID 20 MG CAPSULE DL	4	PA,QL (84 per 28 days)
KAPSPARGO SPRINKLE 100 MG, 25 MG, 50 MG CAPSULE,EXTENDED RELEASE MO	3	ST,QL (30 per 30 days)
KAPSPARGO SPRINKLE 200 MG CAPSULE,EXTENDED RELEASE MO	3	ST,QL (60 per 30 days)
KATERZIA 1 MG/ML ORAL SUSPENSION MO	3	QL (300 per 30 days)
<i>labetalol hcl 100 mg, 200 mg, 300 mg tablet</i> MO	1	
<i>labetalol hcl 100 mg/20 ml vl</i> MO	1	
LANOXIN 125 MCG (0.125 MG), 187.5 MCG (0.1875 MG), 250 MCG (0.25 MG), 62.5 MCG (0.0625 MG) TABLET; LANOXIN 187.5 MCG TABLET MO	3	QL (30 per 30 days)
LANOXIN 250 MCG/ML (0.25 MG/ML), 500 MCG/2 ML (0.5 MG/2 ML) INJECTION SOLUTION; LANOXIN 500 MCG/2 ML (250 MCG/ML) (0.5 MG/2 ML) INJECTION SOLUTION MO	3	
LANOXIN PEDIATRIC 100 MCG/ML (0.1 MG/ML) INJECTION SOLUTION MO	3	
LASIX 20 MG, 40 MG, 80 MG TABLET MO	3	
LESCOL 20 MG, 40 MG CAPSULE MO	3	ST,QL (60 per 30 days)
LESCOL XL 80 MG TABLET,EXTENDED RELEASE MO	3	ST,QL (30 per 30 days)
LEVOPHED 1 MG/ML INTRAVENOUS SOLUTION MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>lidocaine hcl 2% vial</i> ^{MO}	1	
<i>lidocaine 0.4% in d5w 250 ml; lidocaine 0.8% in d5w soln</i> ^{MO}	1	
LIPITOR 10 MG, 20 MG, 40 MG, 80 MG TABLET ^{MO}	3	PA
LIPOFEN 150 MG CAPSULE ^{MO}	3	QL (30 per 30 days)
LIPOFEN 50 MG CAPSULE ^{MO}	3	QL (60 per 30 days)
<i>lisinopril 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg tablet</i> ^{MO}	1	
<i>lisinopril-hctz 10-12.5 mg, 20-12.5 mg, 20-25 mg tab</i> ^{MO}	1	
LIVALO 1 MG, 2 MG, 4 MG TABLET ^{MO}	3	ST,QL (30 per 30 days)
LOPID 600 MG TABLET ^{MO}	3	PA,QL (60 per 30 days)
LOPRESSOR 100 MG, 50 MG TABLET ^{MO}	3	
LOPRESSOR 5 MG/5 ML INTRAVENOUS SOLUTION ^{MO}	3	
LOPRESSOR HCT 50 MG-25 MG TABLET ^{MO}	3	
<i>losartan potassium 100 mg, 25 mg, 50 mg tab</i> ^{MO}	1	QL (60 per 30 days)
<i>losartan-hctz 100-12.5 mg, 100-25 mg, 50-12.5 mg tab</i> ^{MO}	1	QL (60 per 30 days)
LOTENSIN 10 MG, 20 MG, 40 MG TABLET ^{MO}	3	
LOTENSIN HCT 10 MG-12.5 MG TABLET; LOTENSIN HCT 20 MG-12.5 MG TABLET; LOTENSIN HCT 20 MG-25 MG TABLET ^{MO}	3	
LOTREL 10 MG-20 MG CAPSULE; LOTREL 5 MG-10 MG CAPSULE; LOTREL 5 MG-20 MG CAPSULE ^{MO}	3	PA,QL (60 per 30 days)
LOTREL 10 MG-40 MG CAPSULE; LOTREL 5 MG-40 MG CAPSULE ^{MO}	3	PA,QL (30 per 30 days)
<i>lovastatin 10 mg, 20 mg, 40 mg tablet</i> ^{MO}	1	
LOVAZA 1 GRAM CAPSULE ^{MO}	3	PA,QL (120 per 30 days)
<i>mannitol 10% iv solution</i> ^{MO}	1	
<i>mannitol 20% iv solution</i> ^{MO}	1	
<i>mannitol 25% vial</i> ^{MO}	1	
<i>mannitol 5% iv solution</i> ^{MO}	1	
<i>matzim la 180 mg, 240 mg tablet,extended release</i> ^{MO}	1	QL (60 per 30 days)
<i>matzim la 300 mg, 360 mg, 420 mg tablet,extended release</i> ^{MO}	1	QL (30 per 30 days)
MAXZIDE 75 MG-50 MG TABLET ^{MO}	3	PA
MAXZIDE-25MG 37.5 MG-25 MG TABLET ^{MO}	3	PA
<i>methazolamide 25 mg, 50 mg tablet</i> ^{MO}	1	
<i>methyclothiazide 5 mg tablet</i> ^{MO}	1	
<i>methyl dopa 250 mg, 500 mg tablet</i> ^{MO}	1	
<i>methyl dopa-hctz 250-15 mg, 250-25 mg tab</i> ^{MO}	1	
<i>methyl dopate 250 mg/5 ml vial</i> ^{MO}	1	
<i>metolazone 10 mg, 2.5 mg, 5 mg tablet</i> ^{MO}	1	
<i>metoprolol succ er 100 mg, 200 mg, 25 mg, 50 mg tab</i> ^{MO}	1	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
metoprolol-hctz 100-25 mg, 100-50 mg, 50-25 mg tab ^{MO}	1	
metoprolol 5 mg/5 ml carpject ^{MO}	1	
metoprolol tart 5 mg/5 ml vial ^{MO}	1	
metoprolol tartrate 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg tab; metoprolol tartrate 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg tb ^{MO}	1	
metirosine 250 mg capsule ^{DL}	4	
mexiletine 150 mg, 200 mg, 250 mg capsule ^{MO}	1	
MICARDIS 20 MG, 40 MG TABLET ^{MO}	3	ST,QL (30 per 30 days)
MICARDIS 80 MG TABLET ^{MO}	3	ST,QL (60 per 30 days)
MICARDIS HCT 40 MG-12.5 MG TABLET; MICARDIS HCT 80 MG-25 MG TABLET ^{MO}	3	ST,QL (30 per 30 days)
MICARDIS HCT 80 MG-12.5 MG TABLET ^{MO}	3	ST,QL (60 per 30 days)
MICROZIDE 12.5 MG CAPSULE ^{MO}	3	
midodrine hcl 10 mg, 2.5 mg, 5 mg tablet ^{MO}	1	
milrinone lact 20 mg/20 ml vl ^{MO}	1	B vs D
milrinone-d5w 20 mg/100 ml; milrinone-d5w 40 mg/200 ml ^{MO}	1	B vs D
MINIPRESS 1 MG, 2 MG, 5 MG CAPSULE ^{MO}	3	
minitran 0.1 mg/hr, 0.2 mg/hr, 0.6 mg/hr transdermal 24 hour patch ^{MO}	1	QL (30 per 30 days)
minitran 0.4 mg/hr transdermal 24 hour patch ^{MO}	1	QL (60 per 30 days)
minoxidil 10 mg, 2.5 mg tablet ^{MO}	1	
moexipril hcl 15 mg, 7.5 mg tablet ^{MO}	1	
moexipril-hctz 15-12.5 mg, 15-25 mg, 7.5-12.5 mg tab; moexipril-hctz 15-12.5 mg, 15-25 mg, 7.5-12.5 mg tablet ^{MO}	1	
MULTAQ 400 MG TABLET ^{MO}	2	QL (60 per 30 days)
nadolol 20 mg, 40 mg, 80 mg tablet ^{MO}	1	
nadolol-bendroflu 40-5 mg, 80-5 mg tab ^{MO}	1	
NATRECOR 1.5 MG VIAL ^{MO}	3	
NEXLETOL 180 MG TABLET ^{MO}	3	PA,QL (30 per 30 days)
NEXLIZET 180 MG-10 MG TABLET ^{MO}	3	PA,QL (30 per 30 days)
NEXTERONE 150 MG/100 ML (1.5 MG/ML), 360 MG/200 ML (1.8 MG/ML) INTRAVENOUS SOLUTION ^{MO}	3	
niacin er 1,000 mg, 500 mg, 750 mg tablet ^{MO}	1	
niacor 500 mg tablet ^{MO}	1	
NIASPAN 1,000 MG, 500 MG, 750 MG TABLET,EXTENDED RELEASE ^{MO}	3	PA
nicardipine 20 mg, 30 mg capsule ^{MO}	1	
nicardipine 25 mg/10 ml ampule ^{MO}	1	
nifedipine 10 mg, 20 mg capsule ^{MO}	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>nifedipine er 30 mg, 60 mg, 90 mg tablet</i> MO	1	QL (60 per 30 days)
<i>nimodipine 30 mg capsule</i> MO	1	
<i>nisoldipine er 17 mg, 20 mg, 34 mg, 40 mg, 8.5 mg tablet</i> MO	1	QL (30 per 30 days)
<i>nisoldipine er 25.5 mg, 30 mg tablet</i> MO	1	QL (60 per 30 days)
NITRO-BID 2 % TRANSDERMAL OINTMENT MO	1	
NITRO-DUR 0.1 MG/HR, 0.2 MG/HR, 0.6 MG/HR TRANSDERMAL 24 HOUR PATCH DL	4	QL (30 per 30 days)
NITRO-DUR 0.3 MG/HR, 0.8 MG/HR TRANSDERMAL 24 HOUR PATCH DL	4	
NITRO-DUR 0.4 MG/HR TRANSDERMAL 24 HOUR PATCH DL	4	QL (60 per 30 days)
<i>nitroglycerin 0.1 mg/hr, 0.2 mg/hr, 0.6 mg/hr patch</i> MO	1	QL (30 per 30 days)
<i>nitroglycerin 0.3 mg, 0.4 mg, 0.6 mg tablet sl</i> MO	1	
<i>nitroglycerin 0.4 mg/hr patch</i> MO	1	QL (60 per 30 days)
<i>nitroglycerin 5 mg/ml vial</i> MO	1	
<i>nitroglycerin lingual 400 mcg</i> MO	1	
<i>ntg 0.2 mg/ml in d5w; ntg 100 mg/250 ml in d5w; ntg 200 mg/500 ml in d5w; ntg 25 mg/250 ml in d5w; ntg 50 mg/500 ml in d5w</i> MO	1	
NITROLINGUAL 400 MCG/SPRAY MO	3	
NITROSTAT 0.3 MG, 0.4 MG, 0.6 MG SUBLINGUAL TABLET MO	2	
<i>norepinephrine 4 mg/4 ml vial</i> MO	1	
NORPACE 100 MG, 150 MG CAPSULE MO	3	
NORPACE CR 100 MG, 150 MG CAPSULE, EXTENDED RELEASE MO	3	
NORTHERA 100 MG, 200 MG CAPSULE DL	4	PA, QL (90 per 30 days)
NORTHERA 300 MG CAPSULE DL	4	PA, QL (180 per 30 days)
NORVASC 10 MG TABLET MO	3	PA, QL (60 per 30 days)
NORVASC 2.5 MG, 5 MG TABLET MO	3	PA, QL (30 per 30 days)
NYMALIZE 30 MG/10 ML SOLUTION DL	4	QL (1260 per 28 days)
NYMALIZE 30 MG/5 ML ORAL SYRINGE (FOR ORAL USE ONLY) DL	4	QL (630 per 28 days)
NYMALIZE 60 MG/10 ML ORAL SYRINGE (FOR ORAL USE ONLY) DL	4	QL (1260 per 28 days)
NYMALIZE 60 MG/20 ML SOLUTION DL	4	QL (2838 per 28 days)
<i>olmesartan medoxomil 20 mg, 40 mg, 5 mg tab</i> MO	1	QL (30 per 30 days)
<i>olmsrtn-amldpn-hctz 20-5-12.5; olmsrtn-amldpn-hctz 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg; olmsrtn-amldpn-hctz 40-10-12.5; olmsrtn-amldpn-hctz 40-10-25mg; olmsrtn-amldpn-hctz 40-5-12.5</i> MO	1	QL (30 per 30 days)
<i>olmesartan-hctz 20-12.5 mg, 40-12.5 mg, 40-25 mg tab</i> MO	1	QL (30 per 30 days)
<i>omega-3 ethyl esters 1 gm cap</i> MO	1	QL (120 per 30 days)
OSMITROL 10 % INTRAVENOUS SOLUTION MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OSMITROL 15 % INTRAVENOUS SOLUTION MO	3	
OSMITROL 20 % INTRAVENOUS SOLUTION MO	3	
OSMITROL 5 % INTRAVENOUS SOLUTION MO	3	
PACERONE 100 MG TABLET MO	1	
<i>pacerone 200 mg tablet</i> MO	1	
PACERONE 400 MG TABLET MO	1	QL (60 per 30 days)
<i>pentoxifylline er 400 mg tab</i> MO	1	
<i>perindopril erbumine 2 mg, 4 mg, 8 mg tab</i> MO	1	
<i>phenoxybenzamine hcl 10 mg cap</i> DL	4	
<i>phenylephrine 100 mg/10 ml vl</i> MO	1	
<i>pindolol 10 mg, 5 mg tablet</i> MO	1	
PRALUENT PEN 150 MG/ML, 75 MG/ML SUBCUTANEOUS PEN INJECTOR MO	3	PA,QL (2 per 28 days)
PRAVACHOL 20 MG, 40 MG, 80 MG TABLET MO	3	PA
<i>pravastatin sodium 10 mg, 20 mg, 40 mg, 80 mg tab</i> MO	1	
<i>prazosin 1 mg, 2 mg, 5 mg capsule</i> MO	1	
PRESTALIA 14 MG-10 MG TABLET; PRESTALIA 3.5 MG-2.5 MG TABLET; PRESTALIA 7 MG-5 MG TABLET MO	3	QL (30 per 30 days)
<i>prevalite 4 gram oral powder; prevalite 4 gram powder for susp in a packet</i> MO	1	
PRINIVIL 10 MG, 20 MG, 5 MG TABLET MO	3	
<i>procainamide 1 gram/10 ml vial; procainamide 1,000 mg/2 ml vl</i> MO	1	
PROCARDIA 10 MG CAPSULE MO	3	PA
PROCARDIA XL 30 MG, 60 MG, 90 MG TABLET, EXTENDED RELEASE MO	3	PA,QL (60 per 30 days)
<i>propafenone hcl 150 mg, 225 mg, 300 mg tab; propafenone hcl 150 mg, 225 mg, 300 mg tablet</i> MO	1	
<i>propafenone hcl er 225 mg, 325 mg cap</i> MO	1	QL (60 per 30 days)
<i>propafenone hcl er 425 mg cap</i> MO	1	
<i>propranolol 1 mg/ml, 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml) vial; propranolol 20 mg/5 ml soln; propranolol 40 mg/5 ml soln</i> MO	1	
<i>propranolol 10 mg, 20 mg, 40 mg, 60 mg, 80 mg tablet</i> MO	1	
<i>propranolol er 120 mg, 160 mg, 60 mg, 80 mg capsule</i> MO	1	
<i>propranolol-hctz 40-25 mg, 80-25 mg tab</i> MO	1	
QBRELIS 1 MG/ML ORAL SOLUTION DL	4	QL (1200 per 30 days)
QUESTRAN 4 GRAM ORAL POWDER; QUESTRAN 4 GRAM POWDER FOR SUSP IN A PACKET MO	1	
QUESTRAN LIGHT 4 GRAM ORAL POWDER MO	1	
<i>quinapril 10 mg, 20 mg, 40 mg, 5 mg tablet</i> MO	1	
<i>quinapril-hctz 10-12.5 mg, 20-12.5 mg, 20-25 mg tab</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>quinidine gluc 80 mg/ml vial</i> ^{MO}	1	
<i>quinidine gluc er 324 mg tab</i> ^{MO}	1	
<i>quinidine sulfate 200 mg, 300 mg tab</i> ^{MO}	1	
<i>ramipril 1.25 mg, 10 mg, 2.5 mg, 5 mg capsule</i> ^{MO}	1	
RANEXA 1,000 MG, 500 MG TABLET,EXTENDED RELEASE ^{MO}	3	PA,QL (120 per 30 days)
<i>ranolazine er 1,000 mg, 500 mg tablet</i> ^{MO}	1	QL (120 per 30 days)
REPATHA PUSHTRONEX 420 MG/3.5 ML SUBCUTANEOUS WEARABLE INJECTOR ^{MO}	2	PA,QL (3.5 per 28 days)
REPATHA SURECLICK 140 MG/ML SUBCUTANEOUS PEN INJECTOR ^{MO}	2	PA,QL (3 per 28 days)
REPATHA SYRINGE 140 MG/ML SUBCUTANEOUS SYRINGE ^{MO}	2	PA,QL (3 per 28 days)
RESECTISOL 5% SOLUTION ^{MO}	3	
<i>rosuvastatin calcium 10 mg, 20 mg, 40 mg, 5 mg tab</i> ^{MO}	1	
RYTHMOL SR 225 MG CAPSULE,EXTENDED RELEASE ^{MO}	3	PA,QL (60 per 30 days)
RYTHMOL SR 325 MG CAPSULE,EXTENDED RELEASE ^{DL}	4	PA,QL (60 per 30 days)
RYTHMOL SR 425 MG CAPSULE,EXTENDED RELEASE ^{DL}	4	PA
<i>simvastatin 10 mg, 20 mg, 40 mg, 5 mg, 80 mg tablet</i> ^{MO}	1	
SODIUM EDECRIN 50 MG INTRAVENOUS SOLUTION ^{MO}	3	
<i>sorine 120 mg, 160 mg, 240 mg, 80 mg tablet</i> ^{MO}	1	
<i>sotalol 120 mg, 160 mg, 240 mg, 80 mg tablet</i> ^{MO}	1	
<i>sotalol hcl 150 mg/10 ml vial</i> ^{MO}	1	
<i>sotalol of 120 mg, 160 mg, 80 mg tablet</i> ^{MO}	1	
SOTYLIZE 5 MG/ML ORAL SOLUTION ^{MO}	3	
<i>spironolactone-hctz 25-25 tab</i> ^{MO}	1	
<i>spironolactone 100 mg, 25 mg, 50 mg tablet</i> ^{MO}	1	
SULAR 17 MG, 34 MG, 8.5 MG TABLET,EXTENDED RELEASE ^{DL}	4	PA,QL (30 per 30 days)
TARKA 2 MG-180 MG TABLET, EXTENDED RELEASE; TARKA 2 MG-240 MG TABLET, EXTENDED RELEASE; TARKA 4 MG-240 MG TABLET, EXTENDED RELEASE ^{MO}	3	
<i>taztia xt 120 mg, 180 mg, 240 mg capsule,extended release</i> ^{MO}	1	QL (60 per 30 days)
<i>taztia xt 300 mg, 360 mg capsule,extended release</i> ^{MO}	1	QL (30 per 30 days)
TEKTURNA 150 MG, 300 MG TABLET ^{MO}	3	PA,QL (30 per 30 days)
TEKTURNA HCT 150 MG-12.5 MG TABLET; TEKTURNA HCT 150 MG-25 MG TABLET; TEKTURNA HCT 300 MG-12.5 MG TABLET; TEKTURNA HCT 300 MG-25 MG TABLET ^{MO}	2	QL (30 per 30 days)
<i>telmisartan 20 mg, 40 mg tablet</i> ^{MO}	1	QL (30 per 30 days)
<i>telmisartan 80 mg tablet</i> ^{MO}	1	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
telmisartan-amlodipine 40-10; telmisartan-amlodipine 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg; telmisartan-amlodipine 80-10 ^{MO}	1	QL (30 per 30 days)
telmisartan-hctz 40-12.5 mg, 80-25 mg tab; telmisartan-hctz 40-12.5 mg, 80-25 mg tb ^{MO}	1	ST,QL (30 per 30 days)
telmisartan-hctz 80-12.5 mg tb ^{MO}	1	ST,QL (60 per 30 days)
TENORETIC 100 100 MG-25 MG TABLET ^{MO}	3	
TENORETIC 50 50 MG-25 MG TABLET ^{MO}	3	PA
TENORMIN 100 MG, 25 MG, 50 MG TABLET ^{MO}	3	
terazosin 1 mg, 10 mg, 2 mg, 5 mg capsule ^{MO}	1	
tiadylt er 120 mg, 180 mg, 240 mg capsule,extended release ^{MO}	1	QL (60 per 30 days)
tiadylt er 300 mg, 360 mg, 420 mg capsule,extended release ^{MO}	1	QL (30 per 30 days)
TIAZAC 120 MG, 180 MG, 240 MG CAPSULE,EXTENDED RELEASE ^{MO}	3	QL (60 per 30 days)
TIAZAC 300 MG, 360 MG, 420 MG CAPSULE,EXTENDED RELEASE ^{MO}	3	QL (30 per 30 days)
TIKOSYN 125 MCG, 250 MCG, 500 MCG CAPSULE ^{DL}	4	PA
timolol maleate 10 mg, 20 mg, 5 mg tablet ^{MO}	1	
TOPROL XL 100 MG, 200 MG, 25 MG, 50 MG TABLET,EXTENDED RELEASE ^{MO}	3	QL (60 per 30 days)
torse mide 10 mg, 100 mg, 20 mg, 5 mg tablet ^{MO}	1	
trandolapril 1 mg, 2 mg, 4 mg tablet ^{MO}	1	
trandolapr-verapam er 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg ^{MO}	1	
triamterene 100 mg, 50 mg capsule ^{MO}	1	
triamterene-hctz 37.5-25 mg, 50-25 mg cap; triamterene-hctz 37.5-25 mg, 50-25 mg cp ^{MO}	1	
triamterene-hctz 37.5-25 mg, 75-50 mg tab; triamterene-hctz 37.5-25 mg, 75-50 mg tb ^{MO}	1	
TRIBENZOR 20 MG-5 MG-12.5 MG TABLET; TRIBENZOR 40 MG-10 MG-12.5 MG TABLET; TRIBENZOR 40 MG-10 MG-25 MG TABLET; TRIBENZOR 40 MG-5 MG-12.5 MG TABLET; TRIBENZOR 40 MG-5 MG-25 MG TABLET ^{MO}	3	PA,QL (30 per 30 days)
TRICOR 145 MG TABLET ^{MO}	3	PA,QL (30 per 30 days)
TRICOR 48 MG TABLET ^{MO}	3	PA,QL (60 per 30 days)
TRIGLIDE 160 MG TABLET ^{MO}	3	QL (30 per 30 days)
triklo 1 gm capsule ^{MO}	1	QL (120 per 30 days)
TRILIPIX 135 MG, 45 MG CAPSULE,DELAYED RELEASE ^{MO}	3	PA,QL (30 per 30 days)
TWYNSTA 40 MG-10 MG TABLET; TWYNSTA 40 MG-5 MG TABLET; TWYNSTA 80 MG-10 MG TABLET; TWYNSTA 80 MG-5 MG TABLET ^{MO}	3	PA,QL (30 per 30 days)
valsartan 160 mg, 320 mg, 40 mg, 80 mg tablet ^{MO}	1	QL (60 per 30 days)
valsartan-hctz 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg tab ^{MO}	1	QL (30 per 30 days)
VASCEPA 0.5 GRAM CAPSULE ^{MO}	3	PA,QL (240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VASCEPA 1 GRAM CAPSULE MO	3	PA,QL (120 per 30 days)
VASERETIC 10 MG-25 MG TABLET MO	3	
VASOTEC 10 MG, 2.5 MG, 20 MG, 5 MG TABLET DL	4	PA
VAZCULEP 10 MG/ML INJECTION SOLUTION MO	3	
vecamyl 2.5 mg tablet DL	4	QL (300 per 30 days)
verapamil 10 mg/4 ml syringe MO	1	
verapamil 120 mg, 180 mg, 240 mg, 360 mg cap pellet; verapamil sr 120 mg, 180 mg, 240 mg, 360 mg capsule MO	1	QL (60 per 30 days)
verapamil 120 mg, 40 mg, 80 mg tablet MO	1	QL (120 per 30 days)
verapamil 5 mg/2 ml ampul MO	1	
verapamil er 120 mg tablet MO	1	QL (30 per 30 days)
verapamil er 180 mg, 240 mg tablet MO	1	
verapamil er pm 100 mg, 300 mg capsule MO	1	QL (30 per 30 days)
verapamil er pm 200 mg capsule MO	1	QL (60 per 30 days)
VERELAN 120 MG, 180 MG, 240 MG, 360 MG CAPSULE,EXTENDED RELEASE MO	3	QL (60 per 30 days)
VERELAN PM 100 MG, 300 MG CAPSULE, EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
VERELAN PM 200 MG CAPSULE, EXTENDED RELEASE MO	3	PA,QL (60 per 30 days)
VYTORIN 10 MG-10 MG TABLET MO	3	PA,QL (30 per 30 days)
VYTORIN 10 MG-20 MG TABLET MO	3	PA,QL (30 per 30 days)
VYTORIN 10 MG-40 MG TABLET MO	3	PA,QL (30 per 30 days)
VYTORIN 10 MG-80 MG TABLET MO	3	PA,QL (30 per 30 days)
WELCHOL 3.75 GRAM ORAL POWDER PACKET MO	3	PA,QL (30 per 30 days)
WELCHOL 625 MG TABLET MO	3	PA,QL (180 per 30 days)
ZESTORETIC 10 MG-12.5 MG TABLET; ZESTORETIC 20 MG-12.5 MG TABLET; ZESTORETIC 20 MG-25 MG TABLET MO	3	
ZESTRIL 10 MG, 2.5 MG, 20 MG, 30 MG, 40 MG, 5 MG TABLET MO	3	PA
ZETIA 10 MG TABLET MO	3	PA,QL (30 per 30 days)
ZIAC 10 MG-6.25 MG TABLET; ZIAC 2.5 MG-6.25 MG TABLET; ZIAC 5 MG-6.25 MG TABLET MO	3	PA
ZOCOR 10 MG, 20 MG, 40 MG, 80 MG TABLET MO	3	PA
ZYPITAMAG 1 MG, 2 MG, 4 MG TABLET MO	3	ST,QL (30 per 30 days)
Central Nervous System Agents		
ADDERALL 10 MG, 12.5 MG, 15 MG, 20 MG, 5 MG, 7.5 MG TABLET MO	1	PA,QL (90 per 30 days)
ADDERALL 30 MG TABLET MO	1	PA,QL (60 per 30 days)
ADDERALL XR 10 MG, 15 MG, 5 MG CAPSULE,EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
ADDERALL XR 20 MG, 25 MG, 30 MG CAPSULE,EXTENDED RELEASE MO	3	PA,QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ADZENYS ER 1.25 MG/ML SUSPENSION, EXTENDED RELEASE 24HR MO	3	QL (450 per 30 days)
ADZENYS XR-ODT 12.5 MG, 15.7 MG, 18.8 MG, 3.1 MG, 6.3 MG, 9.4 MG EXTENDED RELEASE DISINTEGRATING TABLET MO	3	QL (30 per 30 days)
<i>amphetamine er 1.25 mg/ml susp</i> MO	3	QL (450 per 30 days)
<i>amphetamine sulfate 10 mg, 5 mg tab</i> MO	1	QL (90 per 30 days)
AMPYRA 10 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (60 per 30 days)
APTENSIO XR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG CAPSULE,EXTENDED RELEASE SPRINKLE MO	3	QL (30 per 30 days)
<i>atomoxetine hcl 10 mg, 18 mg, 25 mg, 40 mg capsule</i> MO	1	QL (60 per 30 days)
<i>atomoxetine hcl 100 mg, 60 mg, 80 mg capsule</i> MO	1	QL (30 per 30 days)
AUBAGIO 14 MG, 7 MG TABLET DL, LA	4	PA,QL (30 per 30 days)
AUSTEDO 12 MG, 9 MG TABLET DL	4	PA,QL (120 per 30 days)
AUSTEDO 6 MG TABLET DL	4	PA,QL (60 per 30 days)
AVONEX 30 MCG/0.5 ML INTRAMUSCULAR PEN KIT DL	4	PA,QL (1 per 28 days)
AVONEX 30 MCG/0.5 ML INTRAMUSCULAR SYRINGE KIT DL	4	PA,QL (1 per 28 days)
AVONEX 30 MCG VIAL KIT DL	4	PA,QL (4 per 28 days)
BAFIERTAM 95 MG CAPSULE,DELAYED RELEASE DL	4	PA,QL (120 per 30 days)
BETASERON 0.3 MG SUBCUTANEOUS KIT DL	4	PA,QL (15 per 30 days)
<i>clonidine hcl er 0.1 mg tablet</i> MO	1	QL (120 per 30 days)
CONCERTA 18 MG, 27 MG, 54 MG TABLET,EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
CONCERTA 36 MG TABLET,EXTENDED RELEASE MO	3	PA,QL (60 per 30 days)
COPAXONE 20 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (30 per 30 days)
COPAXONE 40 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (12 per 28 days)
COTEMPLA XR-ODT 17.3 MG, 8.6 MG EXTENDED RELEASE DISINTEGRATING TABLET MO	3	QL (30 per 30 days)
COTEMPLA XR-ODT 25.9 MG EXTENDED RELEASE DISINTEGRATING TABLET MO	3	QL (60 per 30 days)
<i>dalfampridine er 10 mg tablet</i> MO	1	PA,QL (60 per 30 days)
DAYTRANA 10 MG/9 HR, 15 MG/9 HR, 20 MG/9 HR, 30 MG/9 HR DAILY PATCH MO	3	QL (30 per 30 days)
DESOXYN 5 MG TABLET DL	4	PA,QL (150 per 30 days)
DEXEDRINE SPANSULE 10 MG CAPSULE,EXTENDED RELEASE DL	4	PA,QL (180 per 30 days)
DEXEDRINE SPANSULE 15 MG CAPSULE,EXTENDED RELEASE DL	4	PA,QL (120 per 30 days)
DEXEDRINE SPANSULE 5 MG CAPSULE,EXTENDED RELEASE DL	4	PA,QL (60 per 30 days)
<i>dexmethylphenidate 10 mg, 2.5 mg, 5 mg tab</i> MO	1	QL (60 per 30 days)
<i>dexmethylphenidate er 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 5 mg cap; dexmethylphenidate er 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 5 mg cp</i> MO	1	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
dextroamphetamine 10 mg tab MO	1	QL (180 per 30 days)
dextroamphetamine 5 mg tab MO	1	QL (150 per 30 days)
dextroamphetamine 5 mg/5 ml MO	1	QL (1800 per 30 days)
dextroamphetamine er 10 mg cap MO	1	QL (180 per 30 days)
dextroamphetamine er 15 mg cap MO	1	QL (120 per 30 days)
dextroamphetamine er 5 mg cap MO	1	QL (60 per 30 days)
dextroamp-amphet er 10 mg, 15 mg, 5 mg cap MO	1	QL (30 per 30 days)
dextroamp-amphet er 20 mg, 25 mg, 30 mg cap MO	1	QL (60 per 30 days)
dextroamp-amphetam 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg tab; dextroamp-amphetamin 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg tab; dextroamp-amphetamine 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg tab MO	1	QL (90 per 30 days)
dextroamp-amphetamin 30 mg tab MO	1	QL (60 per 30 days)
DYANAVEL XR 2.5 MG/ML ORAL 24 HR EXTENDED RELEASE SUSPENSION MO	3	QL (240 per 30 days)
EVEKEO 10 MG, 5 MG TABLET MO	1	QL (90 per 30 days)
EVEKEO ODT 10 MG, 5 MG DISINTEGRATING TABLET MO	3	QL (90 per 30 days)
EVEKEO ODT 15 MG, 20 MG DISINTEGRATING TABLET MO	3	QL (60 per 30 days)
EXTAVIA 0.3 MG SUBCUTANEOUS KIT DL	4	PA,QL (15 per 30 days)
EXTAVIA 0.3 MG SUBCUTANEOUS SOLUTION DL	4	PA,QL (15 per 30 days)
FIRDAPSE 10 MG TABLET DL	4	PA,QL (240 per 30 days)
FOCALIN 10 MG, 2.5 MG, 5 MG TABLET MO	3	PA,QL (60 per 30 days)
FOCALIN XR 10 MG, 15 MG, 20 MG, 25 MG, 30 MG, 35 MG, 40 MG, 5 MG CAPSULE,EXTENDED RELEASE MO	3	QL (30 per 30 days)
GILENYA 0.25 MG, 0.5 MG CAPSULE DL	4	PA,QL (30 per 30 days)
glatiramer 20 mg/ml syringe DL	4	PA,QL (30 per 30 days)
glatiramer 40 mg/ml syringe DL	4	PA,QL (12 per 28 days)
glatopa 20 mg/ml subcutaneous syringe DL	4	PA,QL (30 per 30 days)
glatopa 40 mg/ml subcutaneous syringe DL	4	PA,QL (12 per 28 days)
GRALISE 300 MG TABLET,EXTENDED RELEASE DL	4	ST,QL (30 per 30 days)
GRALISE 600 MG TABLET,EXTENDED RELEASE DL	4	ST,QL (90 per 30 days)
GRALISE 30-DAY STARTER PACK DL	4	ST,QL (78 per 30 days)
guanfacine hcl er 1 mg, 2 mg, 3 mg, 4 mg tablet MO	1	QL (30 per 30 days)
HORIZANT ER 300 MG, 600 MG TABLET,EXTENDED RELEASE MO	3	PA,QL (60 per 30 days)
INGREZZA 40 MG, 80 MG CAPSULE DL	4	PA,QL (30 per 30 days)
INGREZZA INITIATION PACK 40 MG (7)-80 MG (21) CAPSULES IN A DOSE PACK DL	4	PA,QL (28 per 28 days)
INTUNIV ER 1 MG, 2 MG, 3 MG, 4 MG TABLET,EXTENDED RELEASE MO	3	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
JORNAY PM 100 MG, 20 MG, 40 MG, 60 MG, 80 MG CAPSULE, DELAYED RELEASE, EXTENDED RELEASE SPRINKLE MO	3	QL (30 per 30 days)
KAPVAY 0.1 MG TABLET, EXTENDED RELEASE MO	3	QL (120 per 30 days)
LEMTRADA 12 MG/1.2 ML INTRAVENOUS SOLUTION DL	4	PA, QL (6 per 365 days)
LYRICA 100 MG, 150 MG, 200 MG, 25 MG, 50 MG, 75 MG CAPSULE MO	3	QL (90 per 30 days)
LYRICA 20 MG/ML ORAL SOLUTION MO	3	QL (900 per 30 days)
LYRICA 225 MG, 300 MG CAPSULE MO	3	QL (60 per 30 days)
LYRICA CR 165 MG, 82.5 MG TABLET, EXTENDED RELEASE MO	3	PA, QL (30 per 30 days)
LYRICA CR 330 MG TABLET, EXTENDED RELEASE MO	3	PA, QL (60 per 30 days)
MAVENCLAD (10 TABLET PACK) 10 MG TABLET DL	4	PA, QL (40 per 365 days)
MAVENCLAD (4 TABLET PACK) 10 MG TABLET DL	4	PA, QL (40 per 365 days)
MAVENCLAD (5 TABLET PACK) 10 MG TABLET DL	4	PA, QL (40 per 365 days)
MAVENCLAD (6 TABLET PACK) 10 MG TABLET DL	4	PA, QL (40 per 365 days)
MAVENCLAD (7 TABLET PACK) 10 MG TABLET DL	4	PA, QL (40 per 365 days)
MAVENCLAD (8 TABLET PACK) 10 MG TABLET DL	4	PA, QL (40 per 365 days)
MAVENCLAD (9 TABLET PACK) 10 MG TABLET DL	4	PA, QL (40 per 365 days)
MAYZENT 0.25 MG TABLET DL	4	PA, QL (120 per 30 days)
MAYZENT 2 MG TABLET DL	4	PA, QL (30 per 30 days)
MAYZENT STARTER PACK 0.25 MG (12 TABS) TABLETS DL	4	PA, QL (12 per 30 days)
<i>metadate er 20 mg tablet, extended release</i> MO	1	QL (90 per 30 days)
<i>methamphetamine 5 mg tablet</i> DL	4	QL (150 per 30 days)
METHYLIN 10 MG/5 ML ORAL SOLUTION MO	3	PA, QL (900 per 30 days)
METHYLIN 5 MG/5 ML ORAL SOLUTION MO	3	PA, QL (1800 per 30 days)
<i>methylphenidate 10 mg chew tab</i> MO	1	QL (180 per 30 days)
<i>methylphenidate 10 mg, 20 mg, 5 mg tablet</i> MO	1	QL (90 per 30 days)
<i>methylphenidate 10 mg/5 ml sol</i> MO	1	QL (900 per 30 days)
<i>methylphenidate 2.5 mg, 5 mg chew tab; methylphenidate 2.5 mg, 5 mg chew tb</i> MO	1	QL (150 per 30 days)
<i>methylphenidate 5 mg/5 ml soln</i> MO	1	QL (1800 per 30 days)
<i>methylphenidate cd 10 mg, 20 mg, 40 mg, 50 mg, 60 mg cap;</i> <i>methylphenidate la 10 mg, 20 mg, 40 mg, 50 mg, 60 mg cap</i> MO	1	QL (30 per 30 days)
<i>methylphenidate cd 20 mg, 30 mg cap; methylphenidate la 20 mg, 30 mg cap</i> MO	1	QL (60 per 30 days)
<i>methylphenidate er 10 mg tab</i> MO	1	QL (180 per 30 days)
<i>methylphenidate er 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg cap</i> MO	3	QL (30 per 30 days)
<i>methylphenidate er 18 mg, 27 mg, 54 mg, 72 mg tab</i> MO	1	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>methylphenidate er 20 mg tab</i> MO	1	QL (90 per 30 days)
<i>methylphenidate er 36 mg tab</i> MO	1	QL (60 per 30 days)
MYDAYIS 12.5 MG, 25 MG, 37.5 MG, 50 MG CAPSULE EXTENDED RELEASE 24 HR MO	3	QL (30 per 30 days)
NUEDEXTA 20 MG-10 MG CAPSULE DL	4	PA,QL (60 per 30 days)
OCREVUS 30 MG/ML INTRAVENOUS SOLUTION LA,MO	4	PA,QL (40 per 365 days)
PLEGRIDY 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML SUBCUTANEOUS PEN INJECTOR; PLEGRIDY 63 MCG/0.5 ML-94 MCG/0.5 ML SUBCUTANEOUS PEN INJECTOR DL	4	PA,QL (1 per 28 days)
PLEGRIDY 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML SUBCUTANEOUS SYRINGE; PLEGRIDY 63 MCG/0.5 ML-94 MCG/0.5 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (1 per 28 days)
<i>pregabalin 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg capsule</i> MO	1	QL (90 per 30 days)
<i>pregabalin 20 mg/ml solution</i> MO	1	QL (900 per 30 days)
<i>pregabalin 225 mg, 300 mg capsule</i> MO	1	QL (60 per 30 days)
<i>procentra 5 mg/5 ml oral solution</i> DL	4	QL (1800 per 30 days)
QUILLICHEW ER 20 MG, 40 MG CHEWABLE TABLET, EXTENDED RELEASE; QUILLICHEW ER 20 MG, 40 MG CHEWABLE, EXTENDED RELEASE TABLET DL	4	QL (30 per 30 days)
QUILLICHEW ER 30 MG CHEWABLE TABLET, EXTENDED RELEASE DL	4	QL (60 per 30 days)
QUILLIVANT XR 5 MG/ML (25 MG/5 ML) ORAL SUSPENSION,EXTEND RELEASE 24HR MO	3	QL (360 per 30 days)
RADICAVA 30 MG/100 ML INTRAVENOUS PIGGYBACK DL, LA	4	PA
REBIF (WITH ALBUMIN) 22 MCG/0.5 ML, 44 MCG/0.5 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (6 per 28 days)
REBIF REBIDOSE 22 MCG/0.5 ML, 44 MCG/0.5 ML SUBCUTANEOUS PEN INJECTOR DL	4	PA,QL (6 per 28 days)
REBIF REBIDOSE 8.8 MCG/0.2 ML-22 MCG/0.5 ML (6) SUBCUTANEOUS PEN INJ. DL	4	PA,QL (4.2 per 28 days)
REBIF TITRATION PACK 8.8 MCG/0.2 ML-22 MCG/0.5 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (4.2 per 28 days)
<i>relexxii 72 mg tablet,extended release</i> MO	1	QL (30 per 30 days)
RILUTEK 50 MG TABLET DL	4	
<i>riluzole 50 mg tablet</i> MO	1	
RITALIN 10 MG, 20 MG, 5 MG TABLET MO	3	PA,QL (90 per 30 days)
RITALIN LA 10 MG, 20 MG, 40 MG CAPSULE,EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
RITALIN LA 30 MG CAPSULE,EXTENDED RELEASE MO	3	PA,QL (60 per 30 days)
RUZURGI 10 MG TABLET DL	4	PA,QL (300 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SAVELLA 100 MG, 12.5 MG, 12.5 MG (5)-25 MG(8)-50 MG(42), 25 MG, 50 MG TABLET; SAVELLA 12.5 MG (5)-25 MG(8)-50MG(42) TABLETS IN A DOSE PACK MO	2	QL (60 per 30 days)
STRATTERA 10 MG, 18 MG, 25 MG, 40 MG CAPSULE MO	3	PA,QL (60 per 30 days)
STRATTERA 100 MG, 60 MG, 80 MG CAPSULE MO	3	PA,QL (30 per 30 days)
TECFIDERA 120 MG (14)- 240 MG (46), 240 MG CAPSULE,DELAYED RELEASE; TECFIDERA 120 MG (14)-240 MG (46) CAPSULE,DELAYED RELEASE DL	4	PA,QL (60 per 30 days)
TECFIDERA 120 MG CAPSULE,DELAYED RELEASE DL	4	PA,QL (14 per 30 days)
tetrabenazine 12.5 mg tablet DL	4	PA,QL (240 per 30 days)
tetrabenazine 25 mg tablet DL	4	PA,QL (120 per 30 days)
TIGLUTIK 50 MG/10 ML ORAL SUSPENSION DL	4	PA,QL (600 per 30 days)
TYSABRI 300 MG/15 ML INTRAVENOUS SOLUTION DL	4	PA,QL (15 per 28 days)
VUMERITY 231 MG CAPSULE,DELAYED RELEASE DL	4	PA,QL (120 per 30 days)
VYVANSE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG CHEWABLE TABLET MO	3	PA,QL (30 per 30 days)
VYVANSE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG, 70 MG CAPSULE MO	3	PA,QL (30 per 30 days)
XENAZINE 12.5 MG TABLET DL	4	PA,QL (240 per 30 days)
XENAZINE 25 MG TABLET DL	4	PA,QL (120 per 30 days)
zenzedi 10 mg tablet MO	1	QL (180 per 30 days)
ZENZEDI 15 MG TABLET MO	1	QL (120 per 30 days)
ZENZEDI 2.5 MG, 20 MG, 7.5 MG TABLET MO	1	QL (90 per 30 days)
ZENZEDI 30 MG TABLET MO	1	QL (60 per 30 days)
zenzedi 5 mg tablet MO	1	QL (150 per 30 days)
Dental & Oral Agents		
cevimeline hcl 30 mg capsule MO	1	
chlorhexidine 0.12% rinse MO	1	
EVOXAC 30 MG CAPSULE MO	3	PA
KEPIVANCE 6.25 MG INTRAVENOUS SOLUTION DL	4	
oralone 0.1 % dental paste MO	1	
paroex oral rinse 0.12 % mouthwash MO	1	
periogard 0.12 % mouthwash MO	1	
pilocarpine hcl 5 mg, 7.5 mg tablet MO	1	
SALAGEN (PILOCARPINE) 5 MG, 7.5 MG TABLET MO	3	
triamcinolone 0.1% paste MO	1	
DERMATOLOGICAL AGENTS		
ABSORICA 10 MG, 20 MG, 25 MG, 30 MG, 35 MG CAPSULE DL	4	ST,QL (60 per 30 days)
ABSORICA 40 MG CAPSULE DL	4	ST,QL (120 per 30 days)
ABSORICA LD 16 MG, 24 MG, 8 MG CAPSULE DL	4	ST,QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ABSORICA LD 32 MG CAPSULE DL	4	ST,QL (120 per 30 days)
ACANYA 1.2 %-2.5 % TOPICAL GEL WITH PUMP MO	3	QL (50 per 30 days)
acitretin 10 mg capsule MO	1	PA,QL (90 per 30 days)
acitretin 17.5 mg capsule MO	1	PA,QL (60 per 30 days)
acitretin 25 mg capsule MO	1	PA
ACZONE 5 %, 7.5 % TOPICAL GEL; ACZONE 5 %, 7.5 % TOPICAL GEL WITH PUMP MO	3	QL (90 per 30 days)
adapalene 0.1% cream MO	1	QL (45 per 30 days)
adapalene 0.1% gel; adapalene 0.3% gel; adapalene 0.3% gel pump MO	1	QL (45 per 30 days)
adapalene 0.1% solution DL	4	QL (60 per 30 days)
adapalene 0.1% swab MO	1	QL (30 per 30 days)
adapalene-bnzyl perox 0.1-2.5% MO	1	QL (45 per 30 days)
AKLIEF 0.005 % TOPICAL CREAM MO	3	PA,QL (90 per 30 days)
AKTIPAK 3%-5% GEL POUCH MO	3	
ALA-CORT 1 % TOPICAL CREAM MO	1	QL (240 per 30 days)
ALA-SCALP 2 % LOTION MO	1	QL (236.8 per 30 days)
alclometasone dipr 0.05% oint MO	1	QL (240 per 30 days)
alclometasone dipro 0.05% crm MO	1	QL (240 per 30 days)
ALDARA 5 % TOPICAL CREAM PACKET MO	3	PA,QL (12 per 30 days)
ALTABAX 1 % TOPICAL OINTMENT MO	3	
ALTRENO 0.05 % LOTION MO	3	PA,QL (90 per 30 days)
amcinonide 0.1% cream MO	1	QL (120 per 30 days)
amcinonide 0.1% lotion MO	1	QL (120 per 30 days)
ammonium lactate 12% cream MO	1	
ammonium lactate 12% lotion MO	1	
amnesteem 10 mg, 20 mg capsule MO	1	QL (60 per 30 days)
amnesteem 40 mg capsule MO	1	QL (120 per 30 days)
AMZEEQ 4 % TOPICAL FOAM MO	3	PA,QL (30 per 30 days)
anusol-hc 2.5 % topical cream with perineal applicator MO	1	QL (60 per 30 days)
apexicon e 0.05 % topical cream MO	1	QL (60 per 30 days)
ARAZLO 0.045 % LOTION MO	3	PA
ATRALIN 0.05 % TOPICAL GEL MO	3	PA,QL (45 per 30 days)
AVITA 0.025 % TOPICAL CREAM MO	3	PA,QL (45 per 30 days)
AVITA 0.025 % TOPICAL GEL MO	3	PA,QL (45 per 30 days)
azelaic acid 15% gel MO	1	ST,QL (50 per 30 days)
AZELEX 20 % TOPICAL CREAM MO	3	QL (50 per 30 days)
BACTROBAN 2% CREAM MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BACTROBAN NASAL 2% OINTMENT MO	3	
BENZACLIN 1 %-5 % TOPICAL GEL MO	3	QL (50 per 30 days)
BENZACLIN PUMP 1 %-5 % TOPICAL GEL MO	3	QL (50 per 30 days)
BENZAMYCIN 3 %-5 % TOPICAL GEL MO	3	QL (46.6 per 30 days)
<i>besser 0.05 % lotion</i> MO	1	QL (240 per 30 days)
<i>betamethasone dp 0.05% crm</i> MO	1	QL (90 per 30 days)
<i>betamethasone dp 0.05% lot</i> MO	1	QL (120 per 30 days)
<i>betamethasone dp 0.05% oint</i> MO	1	QL (90 per 30 days)
<i>betamethasone va 0.1% cream</i> MO	1	QL (180 per 30 days)
<i>betamethasone va 0.1% lotion</i> MO	1	QL (120 per 30 days)
<i>betamethasone valer 0.1% ointm</i> MO	1	QL (180 per 30 days)
<i>betamethasone valer 0.12% foam</i> MO	1	QL (200 per 30 days)
<i>betamethasone dp aug 0.05% crm</i> MO	1	QL (100 per 30 days)
<i>betamethasone dp aug 0.05% gel</i> MO	1	QL (100 per 30 days)
<i>betamethasone dp aug 0.05% lot</i> MO	1	QL (120 per 30 days)
<i>betamethasone dp aug 0.05% oin</i> MO	1	QL (100 per 30 days)
BRYHALI 0.01 % LOTION MO	3	ST,QL (200 per 30 days)
<i>calcipotriene 0.005% cream</i> MO	1	PA,QL (120 per 30 days)
<i>calcipotriene 0.005% ointment</i> MO	1	QL (240 per 30 days)
<i>calcipotriene 0.005% solution</i> MO	1	QL (60 per 30 days)
<i>calcipotriene-betameth dp oint</i> DL	4	PA,QL (60 per 30 days)
<i>calcipotriene-betameth dp susp</i> MO	2	QL (420 per 30 days)
<i>calcitrene 0.005% ointment</i> MO	1	QL (240 per 30 days)
<i>calcitriol 3 mcg/g ointment</i> MO	1	ST,QL (800 per 28 days)
CAPEX 0.01 % SHAMPOO MO	3	QL (840 per 30 days)
CARAC 0.5 % TOPICAL CREAM DL	4	PA,QL (60 per 30 days)
CENTANY 2 % TOPICAL OINTMENT MO	3	
<i>claravis 10 mg, 20 mg, 30 mg capsule</i> MO	1	QL (60 per 30 days)
<i>claravis 40 mg capsule</i> MO	1	QL (120 per 30 days)
CLEOCIN T 1 % LOTION MO	3	QL (60 per 30 days)
CLEOCIN T 1 % SOLUTION MO	3	QL (60 per 30 days)
CLEOCIN T 1 % TOPICAL GEL MO	3	QL (60 per 30 days)
CLEOCIN T 1% PLEDGETS MO	3	
<i>clindacin etz 1 % topical swab</i> MO	1	
<i>clindacin p 1 % topical swab</i> MO	1	
CLINDAGEL 1 % TOPICAL GEL, ONCE DAILY DL	4	PA,QL (75 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
clindamycin ph 1% gel MO	1	QL (60 per 30 days)
clindamycin ph 1% solution MO	1	QL (60 per 30 days)
clindamycin phos 1% pledget MO	1	
clindamycin phosp 1% lotion MO	1	QL (60 per 30 days)
clindamycin phosphate 1% foam MO	1	QL (100 per 30 days)
clindamycin phosphate 1% gel MO	1	PA,QL (75 per 30 days)
clind ph-benzoyl pero 1.2-2.5%; clinda-benzoyl perox 1-5% pump;	1	QL (50 per 30 days)
clindamycin-benzoyl perox 1-5% MO		
clind ph-benzoyl perox 1.2-5% MO	1	QL (45 per 30 days)
clinda-tretinoin 1.2%-0.025% MO	1	QL (60 per 30 days)
clobetasol 0.05% cream MO	1	QL (120 per 30 days)
clobetasol 0.05% gel MO	1	QL (120 per 28 days)
clobetasol 0.05% ointment MO	1	QL (120 per 28 days)
clobetasol 0.05% shampoo MO	1	QL (240 per 30 days)
clobetasol 0.05% solution MO	1	QL (100 per 30 days)
clobetasol 0.05% topical lotn MO	1	QL (240 per 28 days)
clobetasol prop 0.05% foam MO	1	QL (100 per 28 days)
clobetasol prop 0.05% spray MO	1	QL (240 per 30 days)
clobetasol emollient 0.05% crm MO	1	QL (120 per 30 days)
clobetasol emulsion 0.05% foam MO	1	QL (100 per 30 days)
CLOBEX 0.05 % LOTION MO	3	ST,QL (240 per 28 days)
CLOBEX 0.05 % SHAMPOO MO	3	ST,QL (240 per 30 days)
CLOBEX 0.05 % TOPICAL SPRAY MO	3	ST,QL (240 per 30 days)
clocortolone pivalate 0.1% crm MO	1	QL (180 per 30 days)
clodan 0.05 % shampoo MO	1	QL (240 per 30 days)
CLODERM 0.1 % TOPICAL CREAM MO	3	PA,QL (180 per 30 days)
CONDYLOX 0.5 % TOPICAL GEL DL	4	
CORDRAN 0.025 % TOPICAL CREAM MO	3	ST,QL (240 per 30 days)
CORDRAN 0.05 % LOTION DL	4	ST,QL (240 per 30 days)
CORDRAN 0.05 % TOPICAL CREAM DL	4	ST,QL (240 per 30 days)
CORDRAN 0.05 % TOPICAL OINTMENT DL	4	ST,QL (240 per 30 days)
CORDRAN TAPE LARGE ROLL 4 MCG/CM2 DL	4	QL (2 per 30 days)
cormax 0.05% solution MO	1	QL (100 per 30 days)
CORTEF 10 MG, 20 MG, 5 MG TABLET MO	3	
CORTISPORIN 1 % TOPICAL OINTMENT MO	3	
CORTISPORIN 3.5 MG/G-10,000 UNIT/G-0.5 % TOPICAL CREAM MO	3	
crotan 10 % lotion DL	4	PA,QL (454 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CUTIVATE 0.05 % LOTION DL	4	PA,QL (240 per 30 days)
CUTIVATE 0.05 % TOPICAL CREAM DL	4	PA,QL (240 per 30 days)
<i>dapsone 5% gel; dapsone 7.5% gel pump</i> MO	1	QL (90 per 30 days)
DERMA-SMOOTHIE/FS BODY OIL 0.01 % MO	3	QL (118.28 per 30 days)
DERMA-SMOOTHIE/FS SCALP OIL 0.01 % MO	3	QL (118.28 per 30 days)
DERMATOP 0.1% OINTMENT MO	3	QL (240 per 30 days)
DESONATE 0.05 % TOPICAL GEL MO	3	QL (240 per 30 days)
<i>desonide 0.05% cream</i> MO	1	QL (240 per 30 days)
<i>desonide 0.05% gel</i> MO	1	QL (240 per 30 days)
<i>desonide 0.05% lotion</i> MO	1	QL (240 per 30 days)
<i>desonide 0.05% ointment</i> MO	1	QL (240 per 30 days)
DESOWEN 0.05 % LOTION MO	1	PA,QL (240 per 30 days)
DESOWEN 0.05 % TOPICAL CREAM MO	3	QL (240 per 30 days)
<i>desoximetasone 0.05% cream</i> MO	1	QL (240 per 30 days)
<i>desoximetasone 0.05% gel</i> MO	1	QL (240 per 30 days)
<i>desoximetasone 0.05% ointment</i> MO	1	QL (240 per 30 days)
<i>desoximetasone 0.25% cream</i> MO	1	QL (120 per 30 days)
<i>desoximetasone 0.25% ointment</i> MO	1	QL (120 per 30 days)
<i>desoximetasone 0.25% spray</i> MO	1	QL (100 per 30 days)
<i>diclofenac sodium 3% gel</i> MO	1	PA
DIFFERIN 0.1 % LOTION MO	3	QL (59 per 30 days)
DIFFERIN 0.1 % TOPICAL CREAM MO	3	PA,QL (45 per 30 days)
DIFFERIN 0.3 % TOPICAL GEL MO	3	PA,QL (45 per 30 days)
DIFFERIN 0.3 % TOPICAL GEL WITH PUMP MO	3	QL (45 per 30 days)
<i>diflorasone 0.05% cream</i> DL	4	QL (120 per 30 days)
<i>diflorasone 0.05% ointment</i> DL	4	QL (120 per 30 days)
DIPROLENE 0.05 % TOPICAL OINTMENT MO	3	QL (100 per 30 days)
DOVONEX 0.005 % TOPICAL CREAM DL	4	PA,QL (120 per 30 days)
<i>doxepin 5% cream</i> DL	4	PA,QL (45 per 30 days)
DUOBRII 0.01 %-0.045 % LOTION DL	4	PA,QL (200 per 28 days)
EFUDEX 5 % TOPICAL CREAM MO	3	PA
ELIDEL 1 % TOPICAL CREAM MO	3	PA,QL (100 per 30 days)
ELIMITE 5 % TOPICAL CREAM MO	3	
ELOCON 0.1% CREAM MO	3	QL (180 per 30 days)
ELOCON 0.1% OINTMENT MO	3	QL (180 per 30 days)
ENSTILAR 0.005 %-0.064 % TOPICAL FOAM MO	3	QL (120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EPIDUO 0.1 %-2.5 % TOPICAL GEL WITH PUMP MO	3	QL (45 per 30 days)
EPIDUO FORTE 0.3 %-2.5 % TOPICAL GEL WITH PUMP MO	3	QL (60 per 30 days)
EPIFOAM 1 %-1 % TOPICAL MO	1	
<i>ery pads 2 % topical swab</i> MO	1	QL (60 per 30 days)
ERYGEL 2 % TOPICAL MO	1	QL (60 per 30 days)
<i>erythromycin 2% gel</i> MO	1	QL (60 per 30 days)
<i>erythromycin 2% pledgets</i> MO	1	QL (60 per 30 days)
<i>erythromycin 2% solution</i> MO	1	QL (120 per 30 days)
<i>erythromycin-benzoyl gel</i> MO	1	QL (46.6 per 30 days)
EUCRISA 2 % TOPICAL OINTMENT MO	3	PA,QL (100 per 30 days)
EURAX 10 % LOTION MO	3	PA,QL (454 per 30 days)
EURAX 10 % TOPICAL CREAM MO	3	PA
EVOCLIN 1 % TOPICAL FOAM MO	3	PA,QL (100 per 30 days)
FABIOR 0.1 % TOPICAL FOAM DL	4	PA,QL (100 per 30 days)
FINACEA 15 % TOPICAL FOAM MO	3	ST,QL (50 per 30 days)
FINACEA 15 % TOPICAL GEL MO	3	ST,QL (50 per 30 days)
<i>fluocinolone 0.01% body oil</i> MO	1	QL (118.28 per 30 days)
<i>fluocinolone 0.01% cream; fluocinolone 0.025% cream</i> MO	1	QL (120 per 30 days)
<i>fluocinolone 0.01% solution</i> MO	1	QL (180 per 30 days)
<i>fluocinolone 0.025% ointment</i> MO	1	QL (120 per 30 days)
<i>fluocinolone 0.01% scalp oil</i> MO	1	QL (118.28 per 30 days)
<i>fluocinonide 0.05% cream</i> MO	1	QL (120 per 30 days)
<i>fluocinonide 0.05% gel</i> MO	1	QL (120 per 30 days)
<i>fluocinonide 0.05% ointment</i> MO	1	QL (120 per 30 days)
<i>fluocinonide 0.05% solution</i> MO	1	QL (120 per 30 days)
<i>fluocinonide 0.1% cream</i> MO	1	QL (120 per 28 days)
<i>fluocinonide-e 0.05 % topical cream</i> MO	1	QL (120 per 30 days)
<i>fluocinonide-e 0.05% cream</i> MO	1	QL (120 per 30 days)
FLUOROPLEX 1 % TOPICAL CREAM DL	4	
<i>fluorouracil 0.5% cream</i> DL	4	QL (60 per 30 days)
<i>fluorouracil 2% topical soln; fluorouracil 5% topical soln</i> MO	1	
<i>fluorouracil 5% cream</i> MO	1	
<i>flurandrenolide 0.05% cream</i> MO	1	QL (240 per 30 days)
<i>flurandrenolide 0.05% lotion</i> MO	1	QL (240 per 30 days)
<i>flurandrenolide 0.05% ointment</i> MO	1	QL (240 per 30 days)
<i>fluticasone prop 0.005% oint</i> MO	1	QL (240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>fluticasone prop 0.05% cream</i> MO	1	QL (240 per 30 days)
<i>fluticasone prop 0.05% lotion</i> MO	1	QL (240 per 30 days)
<i>halcinonide 0.1% cream</i> MO	1	QL (120 per 30 days)
<i>halobetasol prop 0.05% cream</i> MO	1	QL (100 per 30 days)
<i>halobetasol prop 0.05% foam</i> DL	4	PA,QL (100 per 30 days)
<i>halobetasol prop 0.05% ointmnt</i> MO	1	QL (100 per 30 days)
HALOG 0.1 % TOPICAL CREAM DL	4	QL (120 per 30 days)
HALOG 0.1 % TOPICAL OINTMENT DL	4	QL (120 per 30 days)
HALOG 0.1 % TOPICAL SOLUTION DL	4	QL (120 per 30 days)
<i>hydrocortisone 1% cream</i> MO	1	QL (28.4 per 30 days)
<i>hydrocortisone 1% cream; hydrocortisone 2.5% cream</i> MO	1	QL (240 per 30 days)
<i>hydrocortisone 1% ointment; hydrocortisone 2.5% ointment</i> MO	1	QL (240 per 30 days)
<i>hydrocortisone 10 mg, 20 mg, 5 mg tablet</i> MO	1	
<i>hydrocortisone 2.5% cream</i> MO	1	QL (60 per 30 days)
<i>hydrocortisone 2.5% lotion</i> MO	1	QL (236 per 30 days)
<i>hydrocort buty 0.1% lipid crm</i> MO	1	QL (240 per 30 days)
<i>hydrocortisone buty 0.1% cream</i> MO	1	QL (240 per 30 days)
<i>hydrocortisone butyr 0.1% lotn</i> MO	1	QL (236 per 30 days)
<i>hydrocortisone butyr 0.1% oint</i> MO	1	QL (180 per 30 days)
<i>hydrocortisone butyr 0.1% soln</i> MO	1	QL (240 per 30 days)
<i>hydrocortisone val 0.2% cream</i> MO	1	QL (240 per 30 days)
<i>hydrocortisone val 0.2% ointmt</i> MO	1	QL (240 per 30 days)
<i>hydrocortisone 1% absorbase</i> MO	1	QL (220 per 30 days)
<i>imiquimod 3.75% cream pump</i> DL	4	ST,QL (15 per 30 days)
<i>imiquimod 5% cream packet</i> MO	1	QL (12 per 30 days)
IMPOYZ 0.025 % TOPICAL CREAM MO	3	ST,QL (120 per 30 days)
<i>isotretinoin 10 mg, 20 mg, 30 mg capsule</i> MO	1	QL (60 per 30 days)
<i>isotretinoin 40 mg capsule</i> MO	1	QL (120 per 30 days)
<i>ivermectin 1% cream</i> MO	1	ST,QL (45 per 30 days)
LEXETTE 0.05 % TOPICAL FOAM DL	4	PA,QL (100 per 30 days)
<i>lindane 1% shampoo</i> MO	1	QL (60 per 30 days)
LOCOID 0.1 % LOTION MO	3	QL (236 per 30 days)
LOCOID 0.1% CREAM MO	3	QL (240 per 30 days)
LOCOID 0.1% SOLUTION MO	3	QL (240 per 30 days)
LOCOID LIPOCREAM 0.1 % TOPICAL MO	3	QL (240 per 30 days)
LUXIQ 0.12 % TOPICAL FOAM MO	3	ST,QL (200 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>mafenide acetate 50 gm powd pk</i> DL	4	
<i>malathion 0.5% lotion</i> MO	1	
<i>methoxsalen 10 mg softgel</i> DL	4	
MIRVASO 0.33 % TOPICAL GEL WITH PUMP; MIRVASO 0.33% GEL MO	3	ST,QL (30 per 30 days)
<i>mometasone furoate 0.1% cream</i> MO	1	QL (180 per 30 days)
<i>mometasone furoate 0.1% oint</i> MO	1	QL (180 per 30 days)
<i>mometasone furoate 0.1% soln</i> MO	1	QL (180 per 30 days)
<i>mupirocin 2% ointment</i> MO	1	
<i>mupirocin 2% cream</i> MO	1	
<i>myorisan 10 mg, 20 mg, 30 mg capsule</i> MO	1	QL (60 per 30 days)
<i>myorisan 40 mg capsule</i> MO	1	QL (120 per 30 days)
NATROBA 0.9 % TOPICAL SUSPENSION MO	3	QL (240 per 30 days)
NEO-SYNALAR 0.5 % (0.35 % BASE)-0.025 % TOPICAL CREAM MO	1	
<i>neuac 1.2 % (1 % base)-5 % topical gel</i> MO	1	QL (45 per 30 days)
<i>nolix 0.05 % lotion</i> MO	1	QL (240 per 30 days)
<i>nolix 0.05 % topical cream</i> MO	1	QL (240 per 30 days)
OLUX 0.05 % TOPICAL FOAM MO	3	PA,QL (100 per 28 days)
OLUX-E 0.05 % TOPICAL FOAM MO	3	PA,QL (100 per 30 days)
ONEXTON 1.2 % (1 % BASE)-3.75 % TOPICAL GEL MO	3	
ONEXTON 1.2 % (1 % BASE)-3.75 % TOPICAL GEL WITH PUMP MO	3	QL (50 per 30 days)
OTEZLA 30 MG TABLET DL	4	PA,QL (60 per 30 days)
OTEZLA STARTER 10 MG (4)-20 MG (4)-30 MG(19) TABLETS IN A DOSE PACK DL	4	PA,QL (27 per 30 days)
OTEZLA STARTER 10 MG (4)-20 MG (4)-30 MG(47) TABLETS IN A DOSE PACK DL	4	PA,QL (55 per 28 days)
OVIDE 0.5 % LOTION MO	3	PA
OXSORALEN ULTRA 10 MG LIQUID-FILLED,RAPID RELEASE CAPSULE DL	4	
PANDEL 0.1 % TOPICAL CREAM DL	4	QL (160 per 30 days)
<i>permethrin 5% cream</i> MO	1	
PICATO 0.015 % TOPICAL GEL MO	3	QL (3 per 30 days)
PICATO 0.05 % TOPICAL GEL MO	3	QL (2 per 30 days)
<i>pimecrolimus 1% cream</i> MO	1	QL (100 per 30 days)
<i>plixda 0.1% swab</i> MO	1	QL (30 per 30 days)
<i>podofilox 0.5% topical soln</i> MO	1	QL (7 per 30 days)
<i>prednicarbate 0.1% cream</i> MO	1	QL (240 per 30 days)
<i>prednicarbate 0.1% ointment</i> MO	1	QL (240 per 30 days)
<i>procto-med hc 2.5 % topical cream perineal applicator</i> MO	1	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>procto-pak 1 % topical cream perineal applicator</i> ^{MO}	1	QL (28.4 per 30 days)
<i>proctosol hc 2.5 % topical cream perineal applicator</i> ^{MO}	1	QL (60 per 30 days)
<i>proctozone-hc 2.5 % topical cream perineal applicator</i> ^{MO}	1	QL (60 per 30 days)
PROTOPIC 0.03 %, 0.1 % TOPICAL OINTMENT ^{DL}	4	QL (200 per 30 days)
PRUDOXIN 5 % TOPICAL CREAM ^{DL}	4	PA,QL (45 per 30 days)
<i>psorcon 0.05 % topical cream</i> ^{MO}	1	QL (120 per 30 days)
QBREXZA 2.4 % TOWELETTE ^{MO}	3	PA,QL (30 per 30 days)
REGRANEX 0.01 % TOPICAL GEL ^{DL}	4	PA
RETIN-A 0.01 %, 0.025 % TOPICAL GEL ^{MO}	3	PA,QL (45 per 30 days)
RETIN-A 0.025 %, 0.05 %, 0.1 % TOPICAL CREAM ^{MO}	3	PA,QL (45 per 30 days)
RETIN-A MICRO 0.04 %, 0.1 % TOPICAL GEL ^{DL}	4	PA,QL (45 per 30 days)
RETIN-A MICRO PUMP 0.04 %, 0.06 %, 0.08 %, 0.1 % TOPICAL GEL ^{DL}	4	PA,QL (50 per 30 days)
RHOFADE 1 % TOPICAL CREAM ^{MO}	3	ST,QL (30 per 30 days)
SANTYL 250 UNIT/GRAM TOPICAL OINTMENT ^{MO}	2	QL (180 per 30 days)
<i>selenium sulfide 2.5% lotion</i> ^{MO}	1	QL (120 per 30 days)
SERNIVO 0.05 % TOPICAL SPRAY WITH PUMP ^{DL}	4	PA,QL (120 per 28 days)
SILVADENE 1 % TOPICAL CREAM ^{MO}	2	
<i>silver sulfadiazine 1% cream</i> ^{MO}	1	
SOLARAZE 3 % TOPICAL GEL ^{MO}	3	PA
SOOLANTRA 1 % TOPICAL CREAM ^{MO}	3	ST,QL (45 per 30 days)
SORIATANE 10 MG CAPSULE ^{DL}	4	PA,QL (90 per 30 days)
SORIATANE 25 MG CAPSULE ^{DL}	4	PA
SORILUX 0.005 % TOPICAL FOAM ^{DL}	4	ST,QL (120 per 28 days)
SSD 1 % TOPICAL CREAM ^{MO}	1	
SULFAMYLON 50 GRAM TOPICAL PACKET ^{MO}	3	
SULFAMYLON 85 MG/G TOPICAL CREAM ^{MO}	3	
SYNALAR 0.01 % TOPICAL SOLUTION ^{MO}	3	QL (180 per 30 days)
TACLONEX 0.005 %-0.064 % TOPICAL OINTMENT ^{DL}	4	PA,QL (60 per 30 days)
TACLONEX 0.005 %-0.064 % TOPICAL SUSPENSION ^{MO}	2	QL (420 per 30 days)
<i>tacrolimus 0.03% ointment; tacrolimus 0.1% ointment</i> ^{MO}	1	QL (200 per 30 days)
<i>tazarotene 0.1% cream</i> ^{MO}	1	PA,QL (120 per 30 days)
TAZORAC 0.05 %, 0.1 % TOPICAL CREAM ^{DL}	4	PA,QL (120 per 30 days)
TAZORAC 0.05 %, 0.1 % TOPICAL GEL ^{MO}	3	PA,QL (200 per 30 days)
TEMOVATE 0.05 % TOPICAL CREAM ^{MO}	3	PA,QL (120 per 30 days)
TEMOVATE 0.05 % TOPICAL OINTMENT ^{MO}	3	PA,QL (120 per 28 days)
TEXACORT 2.5 % TOPICAL SOLUTION ^{MO}	1	QL (240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TOLAK 4 % TOPICAL CREAM MO	3	PA
TOPICORT 0.05 % TOPICAL CREAM MO	1	QL (240 per 30 days)
TOPICORT 0.05 % TOPICAL GEL MO	1	QL (240 per 30 days)
TOPICORT 0.05 % TOPICAL OINTMENT MO	3	QL (240 per 30 days)
TOPICORT 0.25 % TOPICAL CREAM MO	1	QL (120 per 30 days)
TOPICORT 0.25 % TOPICAL OINTMENT MO	1	QL (120 per 30 days)
TOPICORT 0.25 % TOPICAL SPRAY MO	3	QL (100 per 30 days)
<i>tovet emollient 0.05 % topical foam</i> MO	1	QL (100 per 30 days)
TRETIN-X 0.075 % TOPICAL CREAM MO	1	PA
<i>tretinoin 0.01% gel; tretinoin 0.025% gel; tretinoin 0.05% gel</i> MO	1	PA,QL (45 per 30 days)
<i>tretinoin 0.025% cream; tretinoin 0.05% cream; tretinoin 0.1% cream</i> MO	1	PA,QL (45 per 30 days)
<i>tretinoin gel micro 0.04% pump; tretinoin gel micro 0.1% pump</i> MO	1	PA,QL (50 per 30 days)
<i>tretinoin gel micro 0.04% tube; tretinoin gel micro 0.1% tube</i> MO	1	PA,QL (45 per 30 days)
TRIDESILON 0.05 % TOPICAL CREAM MO	3	QL (240 per 30 days)
ULTRAVATE 0.05 % LOTION DL	4	QL (120 per 30 days)
ULTRAVATE 0.05% CREAM DL	4	QL (100 per 30 days)
ULTRAVATE 0.05% OINTMENT DL	4	QL (100 per 30 days)
UVADEX 20 MCG/ML INJECTION SOLUTION MO	3	B vs D
VANOS 0.1 % TOPICAL CREAM MO	3	QL (120 per 28 days)
VECTICAL 3 MCG/GRAM TOPICAL OINTMENT DL	4	ST,QL (800 per 28 days)
VELTIN 1.2 %-0.025 % TOPICAL GEL MO	3	PA,QL (60 per 30 days)
VERDESO 0.05 % TOPICAL FOAM DL	4	QL (200 per 30 days)
VEREGEN 15 % TOPICAL OINTMENT DL	4	QL (30 per 30 days)
XEPI 1 % TOPICAL CREAM MO	3	PA
<i>zenatane 10 mg, 20 mg, 30 mg capsule</i> MO	1	QL (60 per 30 days)
<i>zenatane 40 mg capsule</i> MO	1	QL (120 per 30 days)
ZIANA 1.2 %-0.025 % TOPICAL GEL MO	3	PA,QL (60 per 30 days)
ZILXI 1.5 % TOPICAL FOAM MO	3	PA,QL (30 per 30 days)
ZONALON 5 % TOPICAL CREAM DL	4	PA,QL (45 per 30 days)
ZYCLARA 2.5 %, 3.75 % TOPICAL CREAM IN A PUMP DL	4	ST,QL (15 per 30 days)
ZYCLARA 3.75 % TOPICAL CREAM PACKET MO	3	ST,QL (28 per 28 days)
Electrolytes/Minerals/Metals/Vitamins		
AMINOSYN 10 % INTRAVENOUS SOLUTION MO	3	B vs D
AMINOSYN 7 % WITH ELECTROLYTES INTRAVENOUS SOLUTION MO	3	B vs D
AMINOSYN 8.5 % INTRAVENOUS SOLUTION MO	3	B vs D
AMINOSYN 8.5 % WITH ELECTROLYTES INTRAVENOUS SOLUTION MO	3	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AMINOSYN II 10 % INTRAVENOUS SOLUTION MO	3	B vs D
AMINOSYN II 15 % INTRAVENOUS SOLUTION MO	3	B vs D
AMINOSYN II 7 % INTRAVENOUS SOLUTION MO	3	B vs D
AMINOSYN II 8.5 % INTRAVENOUS SOLUTION MO	3	B vs D
AMINOSYN II 8.5 % WITH ELECTROLYTES INTRAVENOUS SOLUTION MO	3	B vs D
AMINOSYN M 3.5 % INTRAVENOUS SOLUTION MO	3	B vs D
AMINOSYN-HBC 7% INTRAVENOUS SOLUTION MO	3	B vs D
AMINOSYN-PF 10 % INTRAVENOUS SOLUTION MO	3	B vs D
AMINOSYN-PF 7 % (SULFITE-FREE) INTRAVENOUS SOLUTION MO	3	B vs D
AMINOSYN-RF 5.2 % INTRAVENOUS SOLUTION MO	3	B vs D
AURYXIA 210 MG IRON TABLET MO	3	PA,QL (360 per 30 days)
<i>bal-care dha 27 mg-1 mg-430 mg tablet-capsule, delayed release</i> MO	3	
<i>c-nate dha 28 mg iron-1 mg-200 mg capsule</i> MO	1	
<i>calcium acetate 667 mg gelcap</i> MO	1	
<i>calcium acetate 667 mg tablet</i> MO	1	
<i>calcium chloride 10% syringe</i> MO	1	
<i>calcium chloride 10% vial</i> MO	1	
<i>calcium gluc 1,000mg/50ml-nacl</i> MO	1	
<i>calcium gluc 1,000 mg/10 ml vl</i> MO	1	
CARBAGLU 200 MG DISPERSIBLE TABLET DL	4	PA
CARNITOR 100 MG/ML, 200 MG/ML INTRAVENOUS SOLUTION; CARNITOR 100 MG/ML, 200 MG/ML ORAL SOLUTION MO	3	
CARNITOR 330 MG TABLET MO	3	
CARNITOR (SUGAR-FREE) 100 MG/ML ORAL SOLUTION MO	3	
CHEMET 100 MG CAPSULE DL	4	
CITRANATAL B-CALM (FE GLUC) 20 MG IRON-1 MG-25 MG/25 MG TABLETS MO	3	
CLINIMIX 5 % IN 15 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO	3	B vs D
CLINIMIX 5 % IN 25 % DEXTROSE SULFITE-FREE INTRAVENOUS SOLUTION MO	3	B vs D
CLINIMIX 2.75%-5% SOLUTION MO	3	B vs D
CLINIMIX 4.25%-20% SOLUTION MO	3	B vs D
CLINIMIX 4.25 % IN 25 % DEXTROSE (SULFITE-FREE) INTRAVENOUS SOLUTION MO	3	B vs D
CLINIMIX 4.25 % IN 10 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO	3	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CLINIMIX 4.25 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO	3	B vs D
CLINIMIX 5 % IN 20 % DEXTROSE (SULFITE-FREE) INTRAVENOUS SOLUTION MO	3	B vs D
CLINIMIX E 2.75%-10% SOLUTION MO	3	B vs D
CLINIMIX E 2.75 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO	3	B vs D
CLINIMIX E 4.25 % IN 10 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO	3	B vs D
CLINIMIX E 4.25%-25% SOLUTION MO	3	B vs D
CLINIMIX E 4.25 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO	3	B vs D
CLINIMIX E 5 % IN 15 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO	3	B vs D
CLINIMIX E 5 % IN 20 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION MO	3	B vs D
CLINIMIX E 5%-25% SOLUTION MO	3	B vs D
CLINISOL SF 15 % INTRAVENOUS SOLUTION MO	1	B vs D
CLINOLIPID 20 % INTRAVENOUS EMULSION MO	3	B vs D
clovique 250 mg capsule DL	4	QL (240 per 30 days)
complete natal dha 29 mg-1 mg-250 mg-200 mg oral pack MO	1	
CUPRIMINE 250 MG CAPSULE DL	4	QL (600 per 30 days)
dextrose 10%-0.45% nacl iv sol MO	1	
dextrose 2.5%-0.45% nacl iv MO	1	
dextrose 5%-0.9% nacl iv soln MO	1	
dextrose 5%-0.45% nacl iv soln MO	1	
deferasirox 125 mg, 180 mg, 250 mg, 360 mg, 500 mg, 90 mg tablet; deferasirox 125 mg, 180 mg, 250 mg, 360 mg, 500 mg, 90 mg tb for susp DL	4	PA
deferasirox 180 mg, 360 mg, 90 mg granule DL	4	PA
deferoxamine 2 gram, 500 mg vial MO	1	B vs D
DEPEN TITRATABS 250 MG TABLET DL	4	
DESFERAL 2 GRAM, 500 MG SOLUTION FOR INJECTION MO	3	B vs D
dextrose 10%-0.2% nacl iv soln MO	1	
dextrose 10%-water iv solution MO	1	
dextrose 20%-water iv soln MO	1	
dextrose 25%-water syringe MO	1	
dextrose 30%-water iv soln MO	1	
dextrose 40%-water iv soln MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
dextrose 5%-water iv soln MO	1	
dextrose 5%-lr iv solution MO	1	
dextrose 5%-0.2% nacl iv soln MO	1	
dextrose 5%-0.3% nacl iv soln MO	1	
dextrose 50%-water syringe MO	1	
dextrose 50%-water vial MO	1	
dextrose 70%-water iv soln MO	1	
dothelle dha softgel MO	1	
DUET DHA WITH OMEGA-3 25 MG IRON-1 MG-400 MG ORAL PACK MO	3	
dextrose 5%-electrolyte 48 MO	1	
EXJADE 125 MG, 250 MG, 500 MG DISPERSIBLE TABLET DL, LA	4	PA
FERRIPROX 1,000 MG TABLET DL	4	PA,QL (300 per 30 days)
FERRIPROX 100 MG/ML ORAL SOLUTION DL	4	PA,QL (3600 per 30 days)
FERRIPROX 500 MG TABLET DL	4	PA,QL (720 per 30 days)
FERRIPROX (2 TIMES A DAY) 1,000 MG TABLET DL	4	PA,QL (300 per 30 days)
FOSRENOL 1,000 MG, 500 MG, 750 MG CHEWABLE TABLET DL	4	ST
FOSRENOL 1,000 MG, 750 MG ORAL POWDER PACKET DL	4	ST
FREAMINE HBC 6.9% IV SOLN MO	3	B vs D
FREAMINE III 10 % INTRAVENOUS SOLUTION MO	3	B vs D
GLYCOFOS 1 MMOL/ML INTRAVENOUS SOLUTION MO	1	
hemenatal ob + dha combo pack MO	1	
HEPATAMINE 8% INTRAVENOUS SOLUTION MO	3	B vs D
INTRALIPID 20 %, 30 % INTRAVENOUS EMULSION MO	3	B vs D
IONOSOL-B IN D5W INTRAVENOUS SOLUTION MO	3	
IONOSOL-MB IN D5W INTRAVENOUS SOLUTION MO	3	
ISOLYTE S PH 7.4 INTRAVENOUS SOLUTION MO	3	
ISOLYTE-P IN 5 % DEXTROSE INTRAVENOUS SOLUTION MO	3	
ISOLYTE-S INTRAVENOUS SOLUTION MO	3	
JADENU 180 MG, 360 MG, 90 MG TABLET DL	4	PA
JADENU SPRINKLE 180 MG, 360 MG, 90 MG ORAL GRANULES IN PACKET DL	4	PA
JYNARQUE 15 MG (AM)/15 MG (PM) TABLETS; JYNARQUE 30 MG (AM)/15 MG (PM) TABLETS; JYNARQUE 45 MG (AM)/15 MG (PM) TABLETS; JYNARQUE 60 MG (AM)/30 MG (PM) TABLETS; JYNARQUE 90 MG (AM)/30 MG (PM) TABLETS DL	4	PA,QL (56 per 28 days)
JYNARQUE 15 MG, 30 MG TABLET DL	4	PA,QL (60 per 30 days)
K-TAB 10 MEQ, 20 MEQ, 8 MEQ TABLET,EXTENDED RELEASE MO	3	
KABIVEN 3.31 %-9.8 %-3.9 % INTRAVENOUS EMULSION MO	3	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>kionex (with sorbitol) 15 gram-19.3 gram/60 ml oral suspension</i> ^{MO}	1	
<i>klor-con 20 meq oral packet</i> ^{MO}	1	QL (240 per 30 days)
KLOR-CON 10 MEQ TABLET,EXTENDED RELEASE ^{MO}	1	
KLOR-CON 8 MEQ TABLET,EXTENDED RELEASE ^{MO}	1	
<i>klor-con m10 meq tablet,extended release</i> ^{MO}	1	
KLOR-CON M15 MEQ TABLET,EXTENDED RELEASE ^{MO}	1	
<i>klor-con m20 meq tablet,extended release</i> ^{MO}	1	
<i>klor-con sprinkle er 8 meq cap</i> ^{MO}	1	
KOSHER PRENATAL PLUS IRON 30 MG IRON-1 MG TABLET ^{MO}	3	
<i>lactated ringers injection</i> ^{MO}	1	
<i>lanthanum carb 1,000 mg, 500 mg, 750 mg tab chew; lanthanum carb 1,000 mg, 500 mg, 750 mg tb chw</i> ^{DL}	4	ST
<i>levocarnitine 330 mg tablet</i> ^{MO}	1	
<i>levocarnitine sf 1 g/10 ml sol</i> ^{MO}	1	
<i>levocarnitine 1 g/10 ml soln</i> ^{MO}	1	
LOKELMA 10 GRAM, 5 GRAM ORAL POWDER PACKET ^{MO}	2	QL (30 per 30 days)
<i>m-natal plus 27 mg iron-1 mg tablet</i> ^{MO}	1	
<i>magnesium sulfate 50% syringe</i> ^{MO}	1	
<i>magnesium sulfate 50% vial</i> ^{MO}	1	
<i>magnesium sulf 1 g/100 ml-d5w</i> ^{MO}	1	
<i>magnesium sulf 2 g/50 ml bag; magnesium sulf 4 g/100 ml bag; magnesium sulf 4 g/50 ml bag</i> ^{MO}	1	
<i>magnesium sulf 20 g/500 ml bag; magnesium sulf 40 g/1,000 ml</i> ^{MO}	1	
NATACHEW (FE BIS-GLYCINATE) 28 MG IRON-1 MG TABLET ^{MO}	3	
NEPHRAMINE 5.4 % INTRAVENOUS SOLUTION ^{MO}	3	B vs D
NORMOSOL-M IN 5 % DEXTROSE INTRAVENOUS SOLUTION ^{MO}	3	
NORMOSOL-R INTRAVENOUS SOLUTION ^{MO}	3	
NORMOSOL-R IN 5 % DEXTROSE INTRAVENOUS SOLUTION ^{MO}	3	
NORMOSOL-R PH 7.4 INTRAVENOUS SOLUTION ^{MO}	3	
NUTRILIPID 20 % INTRAVENOUS EMULSION ^{MO}	3	B vs D
O-CAL PRENATAL 15 MG IRON-1,000 MCG TABLET ^{MO}	3	
OB COMPLETE ONE 40 MG-10 MG-1 MG-300 MG CAPSULE ^{MO}	3	
OB COMPLETE PETITE 35 MG IRON-5 MG IRON-1 MG CAPSULE ^{MO}	3	
OB COMPLETE PREMIER 30 MG-20 MG-1 MG TABLET ^{MO}	3	
OMEGAVEN 10 % INTRAVENOUS EMULSION ^{DL}	4	B vs D
<i>penicillamine 250 mg capsule</i> ^{DL}	4	QL (600 per 30 days)
<i>penicillamine 250 mg tablet</i> ^{DL}	4	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PERIKABIVEN 2.36 %-6.8 %-3.5 % INTRAVENOUS EMULSION MO	3	B vs D
PHOSLYRA 667 MG (169 MG CALCIUM)/5 ML ORAL SOLUTION MO	3	ST
PLASMA-LYTE 148 INTRAVENOUS SOLUTION MO	3	
PLASMA-LYTE A INTRAVENOUS SOLUTION MO	3	
plenamine 15 % intravenous solution MO	1	B vs D
prn ob+dha combo pack MO	1	
potassium acet 100 meq/50 ml MO	1	
d5w-1/2ns-kcl 10 meq/l, 20 meq/l, 30 meq/l, 40 meq/l iv sol; kcl 20 meq in d5w-0.45% nacl MO	1	
potassium cl 10% (20 meq/15ml) MO	1	QL (1125 per 30 days)
potassium cl 20 meq packet MO	1	QL (240 per 30 days)
potassium cl 20% (40 meq/15ml) MO	1	
potassium cl 40 meq/20 ml conc MO	1	
potassium cl er 10 meq, 20 meq tablet MO	1	
potassium cl er 10 meq, 20 meq, 8 meq tablet MO	1	
potassium cl er 10 meq, 8 meq capsule MO	1	
kcl 20 meq-ns 1,000 ml iv soln; kcl 40 meq-ns 1,000 ml iv soln MO	1	
d5w-kcl 20 meq/l, 30 meq/l, 40 meq/l iv solution; kcl 20 meq in d5w solution; kcl 40 meq in d5w solution MO	1	
kcl 20 meq in d5w-lact ringer; kcl 40 meq in d5w-lact ringer MO	1	
potassium cl 10 meq/100 ml, 10 meq/50 ml, 20 meq/100 ml, 20 meq/50 ml, 30 meq/100 ml, 40 meq/100 ml sol MO	1	
potassium cl 20 meq-0.45% nacl MO	1	
d5w-1/4ns-kcl 20 meq/l, 30 meq/l, 40 meq/l iv sol; kcl 20 meq in d5w-0.225% nacl MO	1	
kcl 20 meq in d5w-0.3% nacl MO	1	
kcl 20 meq in d5w-ns; kcl 40 meq in d5w-nacl 0.9% MO	1	
potassium citrate er 10 meq (1,080 mg), 15 meq, 5 meq (540 mg) tb; potassium citrate er 10 meq tb; potassium citrate er 5 meq tab MO	1	
pr natal 400 29 mg-1 mg-400 mg oral pack MO	1	
pr natal 400 ec 29 mg-1 mg-400 mg tablet-capsule, delayed release MO	1	
pr natal 430 29 mg iron-1 mg-430 mg oral pack MO	1	
pr natal 430 ec 29 mg-1 mg-430 mg tablet-capsule, delayed release MO	1	
PREMASOL 10 % INTRAVENOUS SOLUTION MO	1	B vs D
PREMASOL 6% IV SOLUTION MO	1	B vs D
PRENATA 29 MG IRON-1 MG CHEWABLE TABLET MO	3	
PRENATABS FA 29 MG-1 MG TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>prenatal plus (calcium carbonate) 27 mg iron-1 mg tablet</i> MO	1	
<i>prenatal plus dha 27 mg iron-1 mg-312 mg-250 mg oral pack</i> MO	3	
<i>prenatal vitamins plus low iron 27 mg iron-1 mg tablet</i> MO	1	
PRENATE ELITE 26 MG IRON-1 MG TABLET MO	3	
<i>preplus 27 mg iron-1 mg tablet</i> MO	1	
PROCALAMINE 3% INTRAVENOUS SOLUTION MO	3	B vs D
PROSOL 20 % INTRAVENOUS SOLUTION MO	3	B vs D
RENAGEL 800 MG TABLET DL	4	ST
REVELA 0.8 GRAM ORAL POWDER PACKET DL	4	PA,QL (540 per 30 days)
REVELA 2.4 GRAM ORAL POWDER PACKET DL	4	PA,QL (180 per 30 days)
REVELA 800 MG TABLET DL	4	PA,QL (540 per 30 days)
<i>ringer's iv solution</i> MO	1	
SAMSCA 15 MG, 30 MG TABLET DL	4	PA,QL (60 per 30 days)
<i>se-natal 19 chewable 29 mg iron-1 mg tablet</i> MO	1	
SELECT-OB 29 MG IRON-1 MG CHEWABLE TABLET MO	3	
SELECT-OB (FOLIC ACID) 29 MG IRON-1 MG CHEWABLE TABLET MO	3	
SELECT-OB + DHA 29 MG IRON-1 MG-250 MG ORAL PACK MO	3	
<i>sevelamer 0.8 gm powder packet</i> DL	4	QL (540 per 30 days)
<i>sevelamer 2.4 gm powder packet</i> DL	4	QL (180 per 30 days)
<i>sevelamer carbonate 800 mg tab</i> MO	1	QL (540 per 30 days)
<i>sevelamer hcl 400 mg, 800 mg tablet</i> MO	1	ST
SMOFLIPID 20 % INTRAVENOUS EMULSION MO	3	B vs D
<i>sodium acetate 40 meq/20 ml vl</i> MO	1	
<i>sodium bicarb 8.4% abboject</i> MO	1	
<i>sodium chloride 100 meq/40 ml</i> MO	1	
<i>saline 0.45% soln-excel con</i> MO	1	
<i>sodium chloride 0.45% soln</i> MO	1	
<i>sodium chloride 0.9% solution</i> MO	1	
<i>sodium chloride 0.9% vial</i> MO	1	
<i>sodium chloride 3% iv soln</i> MO	1	
<i>sodium chloride 5% iv soln</i> MO	1	
<i>sodium lactate 50 meq/10 ml vl</i> MO	1	
<i>sodium phosphate 3mm/ml vial</i> MO	1	
<i>sodium polystyrene sulfonate (sorbitol free) 15 gram/60 ml oral susp</i> MO	1	
<i>sodium polystyrene sulf powder</i> MO	1	
<i>sps 15 gm/60 ml suspension</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>sps 30 gm/120 ml enema; sps 50 gm/200 ml enema</i> MO	1	
SPS (WITH SORBITOL) 15 GRAM-20 GRAM/60 ML ORAL SUSPENSION MO	1	
SPS (WITH SORBITOL) 30 GRAM-40 GRAM/120 ML ENEMA MO	1	
SYPRINE 250 MG CAPSULE DL	4	PA,QL (240 per 30 days)
THAM 36 MG/ML (0.3 M) INTRAVENOUS SOLUTION MO	3	
<i>tolvaptan 30 mg tablet</i> DL	4	PA,QL (60 per 30 days)
TPN ELECTROLYTES 35 MEQ-20 MEQ-5 MEQ/20 ML INTRAVENOUS SOLUTION MO	3	
TRAVASOL 10 % INTRAVENOUS SOLUTION MO	3	B vs D
TRICARE 27 MG IRON-1 MG TABLET MO	1	
<i>trientine hcl 250 mg capsule</i> DL	4	QL (240 per 30 days)
<i>trinatal rx 1 60 mg iron-1 mg tablet</i> MO	1	
TRISTART DHA 31 MG IRON-1 MG-200 MG CAPSULE MO	3	
<i>triveen-duo dha 29 mg-1 mg-400 mg oral pack</i> MO	1	
TROPHAMINE 10 % INTRAVENOUS SOLUTION MO	3	B vs D
TROPHAMINE 6% IV SOLUTION MO	3	B vs D
UROCIT-K 10 10 MEQ (1,080 MG) TABLET,EXTENDED RELEASE MO	3	
UROCIT-K 15 15 MEQ (1,620 MG) TABLET,EXTENDED RELEASE MO	3	
UROCIT-K 5 5 MEQ (540 MG) TABLET,EXTENDED RELEASE MO	3	
VAPRISOL IN 5 % DEXTROSE 20 MG/100 ML INTRAVENOUS SOLUTION MO	3	
VELPHORO 500 MG CHEWABLE TABLET DL	4	ST
VELTASSA 16.8 GRAM, 25.2 GRAM, 8.4 GRAM ORAL POWDER PACKET DL	4	PA,QL (30 per 30 days)
<i>virt-c dha 35 mg-1 mg-200 mg capsule</i> MO	1	
<i>virt-nate dha 28 mg iron-1 mg-200 mg capsule</i> MO	1	
VITAFOL FE PLUS 90 MG IRON-1 MG-200 MG CAPSULE MO	3	
VITAFOL GUMMIES 3.33 MG IRON-0.33 MG CHEWABLE TABLET MO	3	
VITAFOL NANO 18 MG IRON-1 MG TABLET MO	3	
VITAFOL ULTRA 29 MG IRON-1 MG-200 MG CAPSULE MO	3	
VITAFOL-OB 65 MG-1 MG TABLET MO	3	
VITAFOL-OB+DHA 65 MG-1 MG-250 MG ORAL PACK MO	3	
VITAFOL-ONE 29 MG IRON-1 MG-200 MG CAPSULE MO	3	
VITAMED MD ONE RX 30 MG IRON-1 MG-200 MG CAPSULE MO	3	
VP-PNV-DHA 28 MG IRON-1 MG-200 MG CAPSULE MO	3	
Gastrointestinal Agents		
ACIPHEX 20 MG TABLET,DELAYED RELEASE MO	3	PA,QL (30 per 30 days)
ACIPHEX SPRINKLE 10 MG, 5 MG CAPSULE,DELAYED RELEASE DL	4	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ACTIGALL 300 MG CAPSULE MO	3	PA
AEMCOLO 194 MG TABLET, DELAYED RELEASE MO	3	PA, QL (12 per 30 days)
<i>alosetron hcl 0.5 mg, 1 mg tablet</i> DL	4	PA, QL (60 per 30 days)
AMITIZA 24 MCG, 8 MCG CAPSULE MO	3	PA, QL (60 per 30 days)
<i>lansoprazol-amoxicil-clarithro</i> MO	1	ST
<i>atropine 0.05 mg/ml, 0.1 mg/ml syringe; atropine 1 mg/10 ml syringe</i> MO	1	
BENTYL 10 MG/ML INTRAMUSCULAR SOLUTION MO	3	
CARAFATE 1 GRAM TABLET MO	3	
CARAFATE 100 MG/ML ORAL SUSPENSION MO	3	
CHENODAL 250 MG TABLET DL	4	PA
<i>cimetidine 200 mg, 300 mg, 400 mg, 800 mg tablet</i> MO	1	
<i>cimetidine 300 mg/5 ml soln</i> MO	1	
CLENPIQ 10 MG-3.5 GRAM-12 GRAM/160 ML ORAL SOLUTION MO	3	ST
COLYTE WITH FLAVOR PACKETS MO	3	ST
<i>constulose 10 gram/15 ml oral solution</i> MO	1	
CUVPOSA 1 MG/5 ML (0.2 MG/ML) ORAL SOLUTION MO	3	
CYTOTEC 100 MCG, 200 MCG TABLET DL	4	
DEXILANT 30 MG, 60 MG CAPSULE, DELAYED RELEASE MO	3	QL (30 per 30 days)
<i>dicyclomine 10 mg capsule</i> MO	1	
<i>dicyclomine 10 mg/5 ml, 10 mg/ml soln; dicyclomine 20 mg/2 ml vial</i> MO	1	
<i>dicyclomine 20 mg tablet</i> MO	1	
<i>diphenoxylat-atrop 2.5-0.025/5</i> MO	1	
<i>diphenoxylate-atrop 2.5-0.025</i> MO	1	
ENDARI 5 GRAM ORAL POWDER PACKET DL	4	PA, QL (180 per 30 days)
<i>enulose 10 gram/15 ml oral solution</i> MO	1	
<i>esomeprazole dr 10 mg, 20 mg, 40 mg packet</i> MO	1	QL (30 per 30 days)
<i>esomeprazole mag dr 20 mg, 40 mg cap</i> MO	1	QL (30 per 30 days)
<i>esomeprazole sodium 20 mg, 40 mg vial</i> MO	1	
<i>esomeprazole dr 49.3 mg cap</i> MO	3	QL (30 per 30 days)
<i>famotidine 20 mg, 40 mg tablet</i> MO	1	
<i>famotidine 40 mg/4 ml vial</i> MO	1	
<i>famotidine 40 mg/5 ml susp</i> MO	1	
<i>famotidine 20 mg/2 ml vial</i> MO	1	
<i>famotidine 20 mg piggyback</i> MO	1	
GATTEX 30-VIAL 5 MG SUBCUTANEOUS KIT DL, LA	4	PA
GATTEX ONE-VIAL 5 MG SUBCUTANEOUS KIT DL, LA	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>gavilyte-c</i> 240 gram-22.72 gram-6.72 gram-5.84 gram oral solution MO	1	
<i>gavilyte-g</i> 236 gram-22.74 gram-6.74 gram-5.86 gram oral solution MO	1	
<i>gavilyte-n</i> 420 gram oral solution MO	1	
<i>generlac</i> 10 gram/15 ml oral solution MO	1	
GLYCATE 1.5 MG TABLET MO	1	
<i>glycopyrrolate</i> 1 mg, 1.5 mg, 2 mg tablet MO	1	
<i>glycopyrrolate</i> 4 mg/20 ml vial MO	1	
<i>glycopyrrolate</i> 0.2 mg/ml syring MO	1	
GOLYTELY 227.1 GRAM-21.5 GRAM-6.36 GRAM ORAL POWDER PACKET MO	3	ST
GOLYTELY 236 GRAM-22.74 GRAM-6.74 GRAM-5.86 GRAM ORAL SOLUTION MO	3	ST
<i>helidac</i> 250 mg-500 mg-262.4 mg oral pack DL	4	PA,QL (224 per 30 days)
KRISTALOSE 10 GRAM, 20 GRAM ORAL PACKET MO	1	
<i>lactulose</i> 10 gm packet MO	1	
<i>lactulose</i> 10 gm/15 ml solution; <i>lactulose</i> 20 gm/30 ml solution MO	1	
<i>lansoprazole dr</i> 15 mg capsule MO	1	QL (60 per 30 days)
<i>lansoprazole dr</i> 30 mg capsule MO	1	QL (30 per 30 days)
<i>lansoprazole odt</i> 15 mg, 30 mg tablet MO	1	QL (30 per 30 days)
LINZESS 145 MCG, 290 MCG, 72 MCG CAPSULE MO	2	QL (30 per 30 days)
LOMOTIL 2.5 MG-0.025 MG TABLET MO	3	
<i>loperamide</i> 2 mg capsule MO	1	
LOTRONEX 0.5 MG, 1 MG TABLET DL	4	PA,QL (60 per 30 days)
<i>methscopolamine brom</i> 2.5 mg, 5 mg tab; <i>methscopolamine brom</i> 2.5 mg, 5 mg tb MO	1	
<i>misoprostol</i> 100 mcg, 200 mcg tablet MO	1	
MOTEGRITY 1 MG, 2 MG TABLET MO	3	PA,QL (30 per 30 days)
MOTOFEN 1 MG-0.025 MG TABLET MO	3	
MOVANTIK 12.5 MG, 25 MG TABLET MO	2	QL (30 per 30 days)
MOVIPREP 100 GRAM-7.5 GRAM-2.691 GRAM ORAL POWDER PACKET MO	3	ST
MYALEPT 5 MG/ML (FINAL CONCENTRATION) SUBCUTANEOUS SOLUTION DL	4	PA,QL (30 per 30 days)
MYTESI 125 MG TABLET,DELAYED RELEASE DL	4	PA,QL (60 per 30 days)
NEXIUM 20 MG, 40 MG CAPSULE,DELAYED RELEASE MO	3	PA,QL (30 per 30 days)
NEXIUM 40 MG INTRAVENOUS SOLUTION MO	3	PA
NEXIUM PACKET 10 MG, 2.5 MG, 20 MG, 40 MG, 5 MG GRANULES DELAYED RELEASE FOR SUSP MO	3	QL (30 per 30 days)
<i>nizatidine</i> 15 mg/ml solution MO	1	
<i>nizatidine</i> 150 mg, 300 mg capsule MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NULYTELY LEMON-LIME 420 GRAM ORAL SOLUTION MO	3	ST
NULYTELY WITH FLAVOR PACKS 420 GRAM ORAL SOLUTION MO	3	ST
NUTRESTORE POWDER PACKET DL	4	PA
OCALIVA 10 MG, 5 MG TABLET DL	4	PA,QL (30 per 30 days)
OMECLAMOX-PAK 20 MG-500 MG-500 MG (40) ORAL PACK MO	3	ST
omeppi 20 mg-1,100 mg capsule; omeppi 40 mg-1,100 mg capsule MO	1	ST,QL (30 per 30 days)
omeprazole dr 10 mg, 20 mg, 40 mg capsule MO	1	QL (60 per 30 days)
omeprazole-bicarb 20-1,100 cap; omeprazole-bicarb 40-1,100 cap MO	1	ST,QL (30 per 30 days)
omeprazole-bicarb 20-1,680 pkt; omeprazole-bicarb 40-1,680 pkt DL	4	ST,QL (30 per 30 days)
opium tincture 10 mg/ml MO	3	QL (180 per 30 days)
OSMOPREP 1.5 GRAM (1.102-0.398) TABLET MO	3	ST
pantoprazole 40 mg suspension MO	1	QL (30 per 30 days)
pantoprazole sod dr 20 mg, 40 mg tab MO	1	QL (60 per 30 days)
pantoprazole sodium 40 mg vial MO	1	
peg 3350 electrolyte soln; peg-3350 and electrolytes soln MO	1	
peg 3350-electrolyte solution MO	1	
peg-prep 5 mg-210 gram oral kit MO	1	
pepcid 20 mg, 40 mg tablet MO	3	PA
PEPCID 40 MG/5 ML ORAL SUSP MO	3	PA
PLENVU 140 GRAM-9 GRAM-5.2 GRAM POWDER PACK MO	3	ST
PREPOPIK 10 MG-3.5 GRAM-12 GRAM ORAL POWDER PACKET MO	3	ST
PREVACID 15 MG CAPSULE,DELAYED RELEASE MO	3	PA,QL (60 per 30 days)
PREVACID 30 MG CAPSULE,DELAYED RELEASE MO	3	PA,QL (30 per 30 days)
PREVACID SOLUTAB 15 MG, 30 MG DELAYED RELEASE,DISINTEGRATING TABLET MO	3	QL (30 per 30 days)
PRILOSEC 10 MG, 2.5 MG ORAL SUSPENSION,DELAYED RELEASE MO	3	
propantheline 15 mg tablet MO	1	
PROTONIX 20 MG, 40 MG TABLET,DELAYED RELEASE MO	3	PA,QL (60 per 30 days)
PROTONIX 40 MG GRANULES DELAYED-RELEASE PACKET MO	3	QL (30 per 30 days)
PROTONIX 40 MG INTRAVENOUS SOLUTION MO	3	PA
PYLERA 140 MG-125 MG-125 MG CAPSULE MO	3	QL (120 per 30 days)
rabeprazole sod dr 20 mg tab MO	1	QL (30 per 30 days)
RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SOLUTION MO	3	QL (36 per 30 days)
RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SYRINGE MO	3	QL (36 per 28 days)
RELISTOR 150 MG TABLET MO	3	QL (90 per 30 days)
RELISTOR 8 MG/0.4 ML SUBCUTANEOUS SYRINGE MO	3	QL (12 per 30 days)
ROBINUL 1 MG TABLET MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ROBINUL FORTE 2 MG TABLET MO	3	PA
<i>sucralfate 1 gm tablet</i> MO	1	
<i>sucralfate 1 gm/10 ml susp</i> MO	1	
SUPREP BOWEL PREP KIT 17.5 GRAM-3.13 GRAM-1.6 GRAM ORAL SOLUTION MO	2	
SYMPROIC 0.2 MG TABLET MO	3	PA,QL (30 per 30 days)
TALICIA 10 MG-250 MG-12.5 MG CAPSULE,IMMEDIATE - DELAY RELEASE MO	3	ST,QL (168 per 30 days)
<i>trilyte with flavor packets 420 gram oral solution</i> MO	1	
TRULANCE 3 MG TABLET MO	3	PA,QL (30 per 30 days)
URSO 250 250 MG TABLET MO	3	PA
URSO FORTE 500 MG TABLET DL	4	PA
<i>ursodiol 250 mg, 500 mg tablet</i> MO	1	
<i>ursodiol 300 mg capsule</i> MO	1	
VIBERZI 100 MG, 75 MG TABLET DL	4	PA,QL (60 per 30 days)
XERMELO 250 MG TABLET DL	4	PA,QL (84 per 28 days)
XIFAXAN 200 MG TABLET DL	4	PA,QL (9 per 30 days)
XIFAXAN 550 MG TABLET DL	4	PA,QL (84 per 28 days)
ZEGERID 20 MG-1,680 MG ORAL PACKET; ZEGERID 40 MG-1,680 MG ORAL PACKET DL	4	ST,QL (30 per 30 days)
ZEGERID 20 MG-1.1 GRAM CAPSULE; ZEGERID 40 MG-1.1 GRAM CAPSULE DL	4	ST,QL (30 per 30 days)
ZELNORM 6 MG TABLET MO	3	PA,QL (60 per 30 days)
ZINPLAVA 25 MG/ML INTRAVENOUS SOLUTION DL	4	PA
GENETIC/ENZYME/PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT		
ADAGEN 250 UNIT/ML VIAL DL	4	
ALDURAZYME 2.9 MG/5 ML INTRAVENOUS SOLUTION DL	4	PA
ARALAST NP 1,000 MG, 500 MG INTRAVENOUS SOLUTION DL, LA	4	PA
BUPHENYL 0.94 GRAM/GRAM ORAL POWDER DL	4	
BUPHENYL 500 MG TABLET DL	4	
CERDELGA 84 MG CAPSULE DL	4	PA
CEREZYME 400 UNIT INTRAVENOUS SOLUTION DL	4	PA
CHOLBAM 250 MG, 50 MG CAPSULE DL	4	PA,QL (120 per 30 days)
CREON 12,000-38,000-60,000 UNIT CAPSULE,DELAYED RELEASE; CREON 24,000-76,000-120,000 UNIT CAPSULE,DELAYED RELEASE; CREON 3,000 UNIT-9,500 UNIT-15,000 UNIT CAPSULE,DELAYED RELEASE; CREON 36,000 UNIT-114,000 UNIT-180,000 UNIT CAPSULE,DELAYED RELEASE; CREON 6,000-19,000-30,000 UNIT CAPSULE,DELAYED RELEASE MO	2	
CRYSVITA 10 MG/ML, 20 MG/ML SUBCUTANEOUS SOLUTION DL	4	PA,QL (2 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CRYSVITA 30 MG/ML SUBCUTANEOUS SOLUTION DL	4	PA,QL (6 per 28 days)
CYSTADANE 1 GRAM/1.7 ML ORAL POWDER DL	4	
CYSTAGON 150 MG, 50 MG CAPSULE MO	3	
ELAPRASE 6 MG/3 ML INTRAVENOUS SOLUTION DL	4	PA
ELELYSO 200 UNIT INTRAVENOUS SOLUTION DL	4	PA
FABRAZYME 35 MG, 5 MG INTRAVENOUS SOLUTION DL	4	PA
GALAFOLD 123 MG CAPSULE DL	4	PA,QL (14 per 28 days)
GLASSIA 1 GRAM/50 ML (2 %) INTRAVENOUS SOLUTION DL, LA	4	PA
KANUMA 2 MG/ML INTRAVENOUS SOLUTION DL	4	PA
KEVEYIS 50 MG TABLET DL	4	PA,QL (120 per 30 days)
KUVAN 100 MG SOLUBLE TABLET DL	4	PA
KUVAN 100 MG, 500 MG ORAL POWDER PACKET DL	4	PA
LUMIZYME 50 MG INTRAVENOUS SOLUTION DL	4	PA
MEPSEVII 2 MG/ML INTRAVENOUS SOLUTION DL	4	PA
<i>miglustat 100 mg capsule</i> DL	4	PA,QL (90 per 30 days)
NAGLAZYME 5 MG/5 ML INTRAVENOUS SOLUTION DL	4	PA
<i>nitisinone 10 mg, 2 mg, 5 mg capsule</i> DL	4	
NITYR 10 MG, 2 MG, 5 MG TABLET DL	4	
ORFADIN 10 MG, 2 MG, 20 MG, 5 MG CAPSULE DL	4	
ORFADIN 4 MG/ML ORAL SUSPENSION DL	4	
PALYNZIQ 10 MG/0.5 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (15 per 30 days)
PALYNZIQ 2.5 MG/0.5 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (4 per 28 days)
PALYNZIQ 20 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (30 per 30 days)
PANCREAZE 10,500 UNIT-35,500 UNIT-61,500 UNIT CAPSULE,DELAYED RELEASE; PANCREAZE 16,800 UNIT-56,800 UNIT-98,400 UNIT CAPSULE,DELAYED RELEASE; PANCREAZE 2,600 UNIT-6,200 UNIT-10,850 UNIT CAPSULE,DELAYED RELEASE; PANCREAZE 21,000 UNIT-54,700 UNIT-83,900 UNIT CAPSULE,DELAYED RELEASE; PANCREAZE 4,200 UNIT-14,200 UNIT-24,600 UNIT CAPSULE,DELAYED RELEASE DL	4	ST
PERTZYE 16,000 UNIT-57,500 UNIT-60,500 UNIT CAPSULE,DELAYED RELEASE; PERTZYE 24,000-86,250-90,750 UNIT CAPSULE,DELAYED RELEASE; PERTZYE 4,000 UNIT-14,375 UNIT-15,125 UNIT CAPSULE,DELAYED RELEASE; PERTZYE 8,000 UNIT-28,750 UNIT-30,250 UNIT CAPSULE,DELAYED RELEASE DL	4	ST
PROCYSBI 25 MG CAPSULE,DELAYED RELEASE SPRINKLE DL	4	PA,QL (120 per 30 days)
PROCYSBI 300 MG ORAL DR GRANULES IN PACKET DL	4	PA,QL (210 per 30 days)
PROCYSBI 75 MG CAPSULE,DELAYED RELEASE SPRINKLE DL	4	PA,QL (780 per 30 days)
PROCYSBI 75 MG ORAL DR GRANULES IN PACKET DL	4	PA,QL (780 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROLASTIN-C 1,000 MG (+-)/20 ML INTRAVENOUS SOLUTION; PROLASTIN-C 1,000 MG, 1,000 MG (+-)/20 ML INTRAVENOUS POWDER FOR SOLUTION DL, LA	4	PA
RAVICTI 1.1 GRAM/ML ORAL LIQUID DL	4	PA,QL (525 per 30 days)
REVENCOVI 2.4 MG/1.5 ML (1.6 MG/ML) INTRAMUSCULAR SOLUTION DL	4	
<i>sodium phenylbutyrate 500mg tb</i> DL	4	
<i>sodium phenylbutyrate powder</i> DL	4	
STRENSIQ 18 MG/0.45 ML, 28 MG/0.7 ML, 40 MG/ML, 80 MG/0.8 ML SUBCUTANEOUS SOLUTION DL	4	PA
SUCRAID 8,500 UNIT/ML ORAL SOLUTION DL	4	
TEGSEDI 284 MG/1.5 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (6 per 28 days)
VIOKACE 10,440 UNIT-39,150 UNIT-39,150 UNIT TABLET; VIOKACE 20,880 UNIT-78,300 UNIT-78,300 UNIT TABLET DL	4	ST
VPRIV 400 UNIT INTRAVENOUS SOLUTION DL	4	PA
VYNDAMAX 61 MG CAPSULE DL	4	PA,QL (30 per 30 days)
VYENDAQEL 20 MG CAPSULE DL	4	PA,QL (120 per 30 days)
VYONDYS-53 50 MG/ML INTRAVENOUS SOLUTION DL	4	PA
XURIDEN 2 GRAM ORAL GRANULES IN PACKET DL	4	PA,QL (120 per 30 days)
ZAVESCA 100 MG CAPSULE DL	4	PA,QL (90 per 30 days)
ZEMAIRA 1,000 MG INTRAVENOUS SOLUTION DL, LA	4	PA
ZENPEP 10,000 UNIT-32,000 UNIT-42,000 UNIT CAPSULE, DELAYED RELEASE; ZENPEP 15,000 UNIT-47,000 UNIT-63,000 UNIT CAPSULE, DELAYED RELEASE; ZENPEP 20,000 UNIT-63,000 UNIT-84,000 UNIT CAPSULE, DELAYED RELEASE; ZENPEP 25,000 UNIT-79,000 UNIT-105,000 UNIT CAPSULE, DELAYED RELEASE; ZENPEP 3,000 UNIT-10,000 UNIT-14,000 UNIT CAPSULE, DELAYED RELEASE; ZENPEP 40,000 UNIT-126,000 UNIT-168,000 UNIT CAPSULE, DELAYED RELEASE; ZENPEP 5,000 UNIT-17,000 UNIT-24,000 UNIT CAPSULE, DELAYED RELEASE MO	3	
Genitourinary Agents		
<i>alfuzosin hcl er 10 mg tablet</i> MO	1	
AVODART 0.5 MG CAPSULE MO	3	PA,QL (30 per 30 days)
<i>bethanechol 10 mg, 25 mg, 5 mg, 50 mg tablet</i> MO	1	
CIALIS 2.5 MG, 5 MG TABLET MO	3	PA
<i>darifenacin er 15 mg, 7.5 mg tablet</i> MO	1	ST,QL (30 per 30 days)
DETROL 1 MG, 2 MG TABLET MO	3	PA,QL (60 per 30 days)
DETROL LA 2 MG, 4 MG CAPSULE, EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
DITROPAN XL 10 MG, 5 MG TABLET, EXTENDED RELEASE MO	3	PA,QL (60 per 30 days)
<i>dutasteride 0.5 mg capsule</i> MO	1	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>dutasteride-tamsulosin 0.5-0.4</i> MO	1	QL (30 per 30 days)
ELMIRON 100 MG CAPSULE DL	4	QL (90 per 30 days)
ENABLEX 15 MG, 7.5 MG TABLET MO	3	ST,QL (30 per 30 days)
<i>finasteride 5 mg tablet</i> MO	1	QL (30 per 30 days)
<i>flavoxate hcl 100 mg tablet</i> MO	1	
FLOMAX 0.4 MG CAPSULE MO	3	
GELNIQUE 10 % (100 MG/GRAM), 100 MG/GRAM (10 %) TRANSDERMAL GEL PACKET; GELNIQUE 10% GEL PUMP MO	3	ST,QL (30 per 30 days)
JALYN 0.5 MG-0.4 MG CAPSULE, EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
MYRBETRIQ 25 MG, 50 MG TABLET,EXTENDED RELEASE MO	2	QL (30 per 30 days)
<i>oxybutynin 5 mg tablet</i> MO	1	
<i>oxybutynin 5 mg/5 ml syrup</i> MO	1	
<i>oxybutynin cl er 10 mg, 15 mg, 5 mg tablet</i> MO	1	QL (60 per 30 days)
OXYTROL 3.9 MG/24 HR TRANSDERMAL PATCH MO	3	ST,QL (8 per 28 days)
PROSCAR 5 MG TABLET MO	3	PA,QL (30 per 30 days)
RAPAFLO 4 MG, 8 MG CAPSULE MO	3	PA,QL (30 per 30 days)
<i>silodosin 4 mg, 8 mg capsule</i> MO	1	QL (30 per 30 days)
<i>solifenacin 10 mg, 5 mg tablet</i> MO	1	QL (30 per 30 days)
<i>tadalafil 2.5 mg, 5 mg tablet</i> MO	1	PA
<i>tamsulosin hcl 0.4 mg capsule</i> MO	1	
THIOLA 100 MG TABLET DL	4	
THIOLA EC 100 MG, 300 MG TABLET,DELAYED RELEASE DL	4	
<i>tolterodine tart er 2 mg, 4 mg cap</i> MO	1	QL (30 per 30 days)
<i>tolterodine tartrate 1 mg, 2 mg tab</i> MO	1	QL (60 per 30 days)
TOVIAZ 4 MG, 8 MG TABLET,EXTENDED RELEASE MO	2	QL (30 per 30 days)
<i>tropium chloride 20 mg tablet</i> MO	1	
<i>tropium chloride er 60 mg cap</i> MO	1	QL (30 per 30 days)
URECHOLINE 10 MG, 25 MG, 5 MG, 50 MG TABLET MO	1	PA
UROXATRAL 10 MG TABLET,EXTENDED RELEASE MO	3	
VESICARE 10 MG, 5 MG TABLET MO	3	PA,QL (30 per 30 days)
Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)		
<i>a-hydrocort 100 mg solution for injection</i> MO	1	
ACTHAR 80 UNIT/ML INJECTION GEL DL, LA	4	PA,QL (30 per 30 days)
ARISTOSPAN INTRA-ARTICULAR 20 MG/ML SUSPENSION FOR INJECTION MO	3	
ARISTOSPAN INTRALESIONAL 5 MG/ML SUSPENSION FOR INJECTION MO	3	
<i>betamethasone sp-ac 30 mg/5 ml</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CELESTONE SOLUSPAN 6 MG/ML SUSPENSION FOR INJECTION ^{MO}	3	
cortisone 25 mg tablet ^{MO}	1	
decadron 0.5 mg, 0.75 mg, 4 mg, 6 mg tablet ^{MO}	1	
decadron 0.5 mg/5 ml elixir ^{MO}	1	
DEPO-MEDROL 20 MG/ML, 40 MG/ML, 80 MG/ML SUSPENSION FOR INJECTION ^{MO}	3	
dexabliss 1.5 mg (39 tabs) tablets in a dose pack ^{MO}	1	
dexamethasone 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 1.5 mg (21 tabs), 1.5 mg (35 tabs), 1.5 mg (51 tabs), 2 mg, 4 mg, 6 mg tablet; dexamethasone 10 day 1.5 mg tb; dexamethasone 13 day 1.5 mg tb; dexamethasone 6 day 1.5 mg tab ^{MO}	1	
dexamethasone 0.5 mg/5 ml elx ^{MO}	1	
dexamethasone 0.5 mg/5 ml liq ^{MO}	1	
dexamethasone intensol 1 mg/ml drops (concentrate) ^{MO}	1	
dexamethasone 10 mg/ml syringe ^{MO}	1	
dexamethasone 10 mg/ml vial ^{MO}	1	
dexamethasone 10 mg/ml, 4 mg/ml vial ^{MO}	1	
dexamethasone 4 mg/ml syringe ^{MO}	1	
DEXPAK 10 DAY 1.5 MG TABLET ^{MO}	1	
DEXPAK 13 DAY 1.5 MG TABLET ^{MO}	1	
DEXPAK 6 DAY 1.5 MG TABLET ^{MO}	1	
DXEVO 1.5 MG (39 TABS) TABLETS IN A DOSE PACK ^{MO}	1	
EMFLAZA 18 MG, 30 MG, 36 MG, 6 MG TABLET ^{DL}	4	PA
EMFLAZA 22.75 MG/ML ORAL SUSPENSION ^{DL}	4	PA
fludrocortisone 0.1 mg tablet ^{MO}	1	
HEMADY 20 MG TABLET ^{MO}	3	PA, QL (24 per 28 days)
hidex 1.5 mg (21 tabs) tablets in a dose pack ^{MO}	1	
KENALOG 0.147 MG/GRAM TOPICAL AEROSOL ^{MO}	3	QL (200 per 30 days)
KENALOG 10 MG/ML, 40 MG/ML SUSPENSION FOR INJECTION ^{MO}	3	
KENALOG-80 80 MG/ML SUSPENSION FOR INJECTION ^{MO}	3	
MEDROL 16 MG, 2 MG, 32 MG, 4 MG, 8 MG TABLET ^{MO}	3	B vs D
MEDROL (PAK) 4 MG TABLETS IN A DOSE PACK ^{MO}	3	
methylprednisolone 16 mg, 32 mg, 4 mg, 8 mg tab; methylprednisolone 16 mg, 32 mg, 4 mg, 8 mg tablet ^{MO}	1	B vs D
methylprednisolone 4 mg dosepk ^{MO}	1	
methylprednisolone 40 mg/ml, 80 mg/ml vl ^{MO}	1	
methylprednisolone ss 1 gm vl; methylprednisolone ss 1,000 mg, 125 mg, 40 mg, 500 mg; methylprednisolone ss 1,000 mg, 125 mg, 40 mg, 500 mg vl ^{MO}	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
micort hc 2.5% cream MO	1	
MICORT-HC 2.5% CREAM MO	1	
millipred 5 mg tablet MO	1	B vs D
millipred dp 5 mg (21 tabs), 5 mg (48 tabs) tablets in a dose pack MO	1	
ORAPRED ODT 10 MG, 15 MG, 30 MG DISINTEGRATING TABLET MO	3	
PEDIAPRED 5 MG BASE/5 ML (6.7 MG/5 ML) ORAL SOLUTION MO	3	
prednisolone 15 mg/5 ml soln MO	1	
prednisolone 10 mg/5 ml, 15 mg/5 ml (3 mg/ml), 20 mg/5 ml (4 mg/ml), 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml) soln; prednisolone 15 mg/5 ml soln; prednisolone 20 mg/5 ml soln; prednisolone 5 mg/5 ml soln;	1	
prednisolone sod ph 25 mg/5 ml MO		
prednisolone odt 10 mg, 15 mg, 30 mg tablet MO	1	
prednisone 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg tablet MO	1	B vs D
prednisone 10 mg, 5 mg tab dose pack MO	1	
prednisone 5 mg/5 ml solution MO	1	B vs D
prednisone intensol 5 mg/ml oral concentrate MO	1	B vs D
RAYOS 1 MG, 2 MG, 5 MG TABLET, DELAYED RELEASE DL	4	B vs D
SOLU-CORTEF 100 MG SOLUTION FOR INJECTION MO	3	
SOLU-CORTEF ACT-O-VIAL (PF) 1,000 MG/8 ML, 100 MG/2 ML, 250 MG/2 ML, 500 MG/4 ML SOLUTION FOR INJECTION MO	3	
SOLU-MEDROL 1,000 MG, 2 GRAM, 500 MG INTRAVENOUS SOLUTION MO	3	
SOLU-MEDROL (PF) 1,000 MG/8 ML, 125 MG/2 ML, 40 MG/ML, 500 MG/4 ML INTRAVENOUS SOLUTION; SOLU-MEDROL (PF) 1,000 MG/8 ML, 125 MG/2 ML, 40 MG/ML, 500 MG/4 ML SOLUTION FOR INJECTION MO	3	
taperdex 1.5 mg (21 tabs), 1.5 mg (27 tabs), 1.5 mg (49 tabs) tablets in a dose pack MO	1	
triamcinolone 0.025% cream; triamcinolone 0.1% cream; triamcinolone 0.5% cream MO	1	
triamcinolone 0.025% lotion; triamcinolone 0.1% lotion MO	1	
triamcinolone 0.025% oint; triamcinolone 0.1% ointment; triamcinolone 0.5% ointment MO	1	
triamcinolone 0.05% ointment DL	4	
triamcinolone 0.147 mg/g spray MO	1	QL (200 per 30 days)
triamcinolone acet 40 mg/ml vl MO	1	
trianex 0.05 % topical ointment DL	4	
triderm 0.1 %, 0.5 % topical cream MO	1	
VERIPRED 20 20 MG/5 ML (4 MG/ML) ORAL SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZCORT 1.5 MG (25 TABS) TABLETS IN A DOSE PACK MO	1	
ZILRETTA 32 MG INTRA-ARTICULAR SUSPENSION,EXTENDED RELEASE MO	3	PA
Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary)		
CHORIONIC GONAD 10,000 UNIT VL DL	4	PA
DDAVP 0.01% NASAL SPRAY MO	3	PA,QL (25 per 30 days)
DDAVP 0.1 MG TABLET DL	4	PA,QL (180 per 30 days)
DDAVP 0.1 MG/ML (REFRIGERATE), 4 MCG/ML INJECTION SOLUTION; DDAVP 0.1 MG/ML (REFRIGERATE), 4 MCG/ML NASAL SOLUTION MO	3	PA
DDAVP 0.2 MG TABLET DL	4	PA
<i>desmopressin 0.01% solution; desmopressin 10 mcg/0.1 ml spr</i> MO	1	QL (25 per 30 days)
<i>desmopressin ac 4 mcg/ml vial</i> MO	1	
<i>desmopressin acetate 0.1 mg tb</i> MO	1	QL (180 per 30 days)
<i>desmopressin acetate 0.2 mg tb</i> MO	1	
EGRIFTA 1 MG VIAL DL	4	PA,QL (60 per 30 days)
EGRIFTA SV 2 MG SUBCUTANEOUS SOLUTION DL	4	PA,QL (30 per 30 days)
GENOTROPIN 12 MG/ML (36 UNIT/ML), 5 MG/ML (15 UNIT/ML) SUBCUTANEOUS CARTRIDGE DL	4	PA
GENOTROPIN MINIQUICK 0.2 MG/0.25 ML, 0.4 MG/0.25 ML, 0.6 MG/0.25 ML, 0.8 MG/0.25 ML, 1 MG/0.25 ML, 1.2 MG/0.25 ML, 1.4 MG/0.25 ML, 1.6 MG/0.25 ML, 1.8 MG/0.25 ML, 2 MG/0.25 ML SUBCUTANEOUS SYRINGE DL	4	PA
HUMATROPE 12 MG (36 UNIT), 24 MG (72 UNIT), 6 MG (18 UNIT) INJECTION CARTRIDGE DL	4	PA
HUMATROPE 5 MG (15 UNIT) SOLUTION FOR INJECTION DL	4	PA
INCRELEX 10 MG/ML SUBCUTANEOUS SOLUTION DL	4	PA
NOCDURNA (MEN) 55.3 MCG DISINTEGRATING TABLET,SUBLINGUAL MO	3	PA,QL (30 per 30 days)
NOCDURNA (WOMEN) 27.7 MCG DISINTEGRATING TABLET,SUBLINGUAL MO	3	PA,QL (30 per 30 days)
NORDITROPIN FLEXPRO 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) SUBCUTANEOUS PEN INJECTOR DL	4	PA
NOVAREL 10,000 UNIT, 5,000 UNIT INTRAMUSCULAR SOLUTION MO	3	PA
NUTROPIN AQ NUSPIN 10 MG/2 ML (5 MG/ML), 20 MG/2 ML (10 MG/ML), 5 MG/2 ML (2.5 MG/ML) SUBCUTANEOUS PEN INJECTOR DL	4	PA
OMNITROPE 10 MG/1.5 ML (6.7 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) SUBCUTANEOUS CARTRIDGE DL	4	PA
OMNITROPE 5.8 MG SUBCUTANEOUS SOLUTION DL	4	PA
PREGNYL 10,000 UNIT INTRAMUSCULAR SOLUTION MO	3	PA
SAIZEN 5 MG SUBCUTANEOUS SOLUTION DL	4	PA,QL (28 per 28 days)
SAIZEN 8.8 MG SUBCUTANEOUS SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SAIZEN SAIZENPREP 8.8 MG/1.51 ML (FINAL CONC.) SUBCUTANEOUS CARTRIDGE DL	4	PA
SEROSTIM 4 MG, 5 MG, 6 MG SUBCUTANEOUS SOLUTION DL	4	PA,QL (28 per 28 days)
STIMATE 1.5 MG/ML NASAL SPRAY DL	4	
ZOMACTON 10 MG SUBCUTANEOUS SOLUTION DL	4	PA
ZOMACTON 5 MG SUBCUTANEOUS SOLUTION DL	4	PA,QL (28 per 28 days)
ZORBTIVE 8.8 MG SUBCUTANEOUS SOLUTION DL	4	PA
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PROSTAGLANDINS)		
<i>carboprost 250 mcg/ml vial</i> MO	1	
HEMABATE 250 MCG/ML INTRAMUSCULAR SOLUTION MO	3	
Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)		
ACTIVELLA 0.5-0.1 MG, 1-0.5 MG TABLET; ACTIVELLA 1 MG-0.5 MG TABLET MO	3	
<i>afirmelle 0.1 mg-20 mcg tablet</i> MO	1	
ALORA 0.025 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR TRANSDERMAL PATCH MO	3	QL (8 per 28 days)
<i>altavera (28) 0.15 mg-0.03 mg tablet</i> MO	1	
<i>alyacen 1/35 (28) 1 mg-35 mcg tablet</i> MO	1	
<i>alyacen 7/7/7 (28) 0.5 mg/0.75 mg/1 mg-35 mcg tablet</i> MO	1	
<i>amabelz 0.5 mg-0.1 mg tablet; amabelz 1 mg-0.5 mg tablet</i> MO	1	
<i>amethia 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack</i> MO	1	QL (91 per 90 days)
<i>amethia lo 0.10 mg-20 mcg (84)/10 mcg(7) tablets,3 month dose pack</i> MO	1	QL (91 per 90 days)
<i>amethyst (28) 90 mcg-20 mcg tablet</i> MO	1	
ANADROL-50 50 MG TABLET DL	4	
ANDRODERM 2 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH MO	3	PA,QL (90 per 30 days)
ANDRODERM 4 MG/24 HR TRANSDERMAL 24 HOUR PATCH MO	3	PA,QL (30 per 30 days)
ANDROGEL 1 % (25 MG/2.5 GRAM) TRANSDERMAL GEL PACKET; ANDROGEL 1 % (25 MG/2.5GRAM), 1 % (50 MG/5 GRAM) TRANSDERMAL GEL PACKET DL	4	PA,QL (300 per 30 days)
ANDROGEL 1.62 % (20.25 MG/1.25 GRAM) TRANSDERMAL GEL PACKET DL	4	PA,QL (37.5 per 30 days)
ANDROGEL 1.62 % (40.5 MG/2.5 GRAM) TRANSDERMAL GEL PACKET DL	4	PA,QL (150 per 30 days)
ANDROGEL 20.25 MG/1.25 GRAM (1.62 %) TRANSDERMAL GEL PUMP MO	3	PA,QL (150 per 30 days)
ANDROID 10 MG CAPSULE DL	4	
ANGELIQ 0.25 MG-0.5 MG TABLET; ANGELIQ 0.5 MG-1 MG TABLET MO	3	
ANNOVERA 0.15 MG-0.013 MG/24 HR VAGINAL RING MO	3	QL (1 per 365 days)
<i>apri 0.15 mg-0.03 mg tablet</i> MO	1	
<i>aranelle (28) 0.5 mg/1 mg/0.5 mg-35 mcg tablet</i> MO	1	
<i>ashlyna 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack</i> MO	1	QL (91 per 90 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>aubra</i> 0.1 mg-20 mcg tablet MO	1	
<i>aubra eq</i> 0.1 mg-20 mcg tablet MO	1	
<i>aurovela</i> 1.5/30 (21) 1.5 mg-30 mcg tablet MO	1	
<i>aurovela</i> 1/20 (21) 1 mg-20 mcg tablet MO	1	
<i>aurovela</i> 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet MO	1	
<i>aurovela fe</i> 1-20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet MO	1	
<i>aurovela fe</i> 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet MO	1	
AVEED 750 MG/3 ML (250MG/ML) INTRAMUSCULAR SOLUTION DL	4	PA,QL (3 per 70 days)
<i>aviane</i> 0.1 mg-20 mcg tablet MO	1	
AXIRON 30 MG/ACTUATION SOLN MO	3	PA,QL (180 per 30 days)
AYGESTIN 5 MG TABLET MO	1	
<i>ayuna</i> 0.15 mg-0.03 mg tablet MO	1	
<i>azurette</i> (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO	1	
BALCOLTRA 0.1 MG-0.02 MG(21)/36.5 MG(7) TABLET MO	3	
<i>balziva</i> (28) 0.4 mg-35 mcg tablet MO	1	
<i>bekyree</i> (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO	1	
BEYAZ (28) 3 MG-0.02 MG-0.451 MG (24)/0.451 MG (4) TABLET MO	3	
BIJUVA 1 MG-100 MG CAPSULE MO	3	QL (30 per 30 days)
<i>blisovi</i> 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet MO	1	
<i>blisovi fe</i> 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet MO	1	
<i>blisovi fe</i> 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet MO	1	
<i>briellyn</i> 0.4 mg-35 mcg tablet MO	1	
<i>camila</i> 0.35 mg tablet MO	1	
<i>camrese</i> 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack MO	3	QL (91 per 90 days)
<i>camrese lo</i> 0.10 mg-20 mcg (84)/10 mcg(7) tablets,3 month dose pack MO	1	QL (91 per 90 days)
<i>caziant</i> (28) 0.1 mg/0.125 mg/0.15 mg-25 mcg tablet MO	1	
<i>charlotte</i> 24 fe 1 mg-20 mcg (24)/75 mg (4) chewable tablet MO	1	
<i>chateal</i> (28) 0.15 mg-0.03 mg tablet MO	1	
<i>chateal eq</i> (28) 0.15 mg-0.03 mg tablet MO	1	
CLIMARA 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.06 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR TRANSDERMAL PATCH MO	3	QL (4 per 28 days)
CLIMARA PRO 0.045 MG-0.015 MG/24 HR TRANSDERMAL PATCH MO	3	QL (4 per 28 days)
COMBIPATCH 0.05 MG-0.14 MG/24 HR TRANSDERMAL; COMBIPATCH 0.05 MG-0.25 MG/24 HR TRANSDERMAL MO	3	QL (8 per 28 days)
CRINONE 4 %, 8 % VAGINAL GEL MO	3	
<i>cryselle</i> (28) 0.3 mg-30 mcg tablet MO	1	
<i>cyclafem</i> 1/35 (28) 1 mg-35 mcg tablet MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>cyclafem 7/7/7 (28) 0.5 mg/0.75 mg/1 mg-35 mcg tablet</i> ^{MO}	1	
<i>cyred 0.15 mg-0.03 mg tablet</i> ^{MO}	1	
<i>cyred eq 0.15 mg-0.03 mg tablet</i> ^{MO}	1	
<i>danazol 100 mg, 200 mg, 50 mg capsule</i> ^{MO}	1	
<i>dasetta 1/35 (28) 1 mg-35 mcg tablet</i> ^{MO}	1	
<i>dasetta 7/7/7 (28) 0.5 mg(7)/0.75 mg(7)/1 mg(7)-35 mcg tablet</i> ^{MO}	1	
<i>daysee 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack</i> ^{MO}	1	QL (91 per 90 days)
<i>deblitane 0.35 mg tablet</i> ^{MO}	1	
DELESTROGEN 10 MG/ML, 20 MG/ML, 40 MG/ML INTRAMUSCULAR OIL ^{MO}	3	
DEPO-ESTRADIOL 5 MG/ML INTRAMUSCULAR OIL ^{MO}	1	QL (5 per 30 days)
DEPO-PROVERA 150 MG/ML INTRAMUSCULAR SUSPENSION ^{MO}	3	QL (1 per 90 days)
DEPO-PROVERA 150 MG/ML INTRAMUSCULAR SYRINGE ^{MO}	3	QL (1 per 90 days)
DEPO-PROVERA 400 MG/ML INTRAMUSCULAR SUSPENSION ^{MO}	3	
DEPO-SUBQ PROVERA 104 104 MG/0.65 ML SUBCUTANEOUS SYRINGE ^{MO}	3	QL (0.65 per 90 days)
DEPO-TESTOSTERONE 100 MG/ML, 200 MG/ML INTRAMUSCULAR OIL ^{MO}	1	
<i>desogestr-eth estrad eth estra</i> ^{MO}	1	
<i>desogest-eth estra 0.15-0.03mg</i> ^{MO}	1	
DIVIGEL 0.25 MG/0.25 GRAM (0.1 %), 0.5 MG/0.5 GRAM (0.1 %), 0.75 MG/0.75 GRAM (0.1%), 1 MG/GRAM (0.1 %), 1.25 MG/1.25 GRAM (0.1 %) TRANSDERMAL GEL PACKET ^{MO}	3	
<i>dotti 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr transdermal patch</i> ^{MO}	1	QL (8 per 28 days)
<i>dros-ee-levomef 3-0.02-0.451; dros-ee-levomef 3-0.03-0.451</i> ^{MO}	1	
<i>drosiprone-ee 3-0.02 mg, 3-0.03 mg tab</i> ^{MO}	1	
DUAVEE 0.45 MG-20 MG TABLET ^{MO}	3	PA,QL (30 per 30 days)
ELESTRIN 0.87 GRAM/ACTUATION (0.06%) TRANSDERMAL GEL PUMP ^{MO}	3	QL (52 per 30 days)
<i>elinest 0.3 mg-30 mcg tablet</i> ^{MO}	1	
ELLA 30 MG TABLET ^{MO}	2	QL (1 per 30 days)
<i>eluryng 0.12 mg-0.015 mg/24 hr vaginal ring</i> ^{MO}	1	QL (1 per 28 days)
<i>emoquette 0.15 mg-0.03 mg tablet</i> ^{MO}	1	
ENDOMETRIN 100 MG VAGINAL INSERT ^{DL}	4	
<i>enpresse 50-30 (6)/75-40(5)/125-30(10) tablet</i> ^{MO}	1	
<i>enskyce 0.15 mg-0.03 mg tablet</i> ^{MO}	1	
<i>errin 0.35 mg tablet</i> ^{MO}	1	
<i>estarylla 0.25 mg-35 mcg tablet</i> ^{MO}	1	
ESTRACE 0.01% (0.1 MG/GRAM) VAGINAL CREAM ^{MO}	3	PA
ESTRACE 0.5 MG, 1 MG, 2 MG TABLET ^{MO}	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
estradiol 0.01% cream MO	1	
estradiol 0.025 mg patch(1/wk); estradiol 0.0375mg patch(1/wk); estradiol 0.05 mg patch (1/wk); estradiol 0.06 mg patch (1/wk); estradiol 0.075 mg patch(1/wk); estradiol 0.1 mg patch (1/wk) MO	1	QL (4 per 28 days)
estradiol 0.025 mg patch(2/wk); estradiol 0.0375mg patch(2/wk); estradiol 0.05 mg patch (2/wk); estradiol 0.075 mg patch(2/wk); estradiol 0.1 mg patch (2/wk) MO	1	QL (8 per 28 days)
estradiol 0.5 mg, 1 mg, 10 mcg, 2 mg tablet; estradiol 0.5 mg, 1 mg, 10 mcg, 2 mg vaginal insrt MO	1	
estradiol valerate 100 mg/5 ml; estradiol valerate 200 mg/5 ml MO	1	
estradiol-noreth 0.5-0.1 mg, 1-0.5 mg tab; estradiol-noreth 0.5-0.1 mg, 1-0.5 mg tb MO	1	
ESTRING 2 MG (7.5 MCG/24 HOUR) VAGINAL RING MO	3	QL (1 per 90 days)
ESTROGEL 1.25 GRAM/ACTUATION (0.06%) TRANSDERMAL GEL PUMP MO	3	
ESTROSTEP FE-28 1-20 (5)/1-30(7)/1MG-35MCG(9) TABLET MO	3	
ethynodiol-eth estra 1mg-35mcg; ethynodiol-eth estra 1mg-50mcg MO	1	
etonogestrel-ee vaginal ring MO	1	QL (1 per 28 days)
EVAMIST 1.53 MG/SPRAY (1.7 %) TRANSDERMAL SPRAY MO	3	
EVISTA 60 MG TABLET MO	3	PA,QL (30 per 30 days)
falmina (28) 0.1 mg-20 mcg tablet MO	1	
fayosim 0.15 mg-20 mcg/0.15 mg-25 mcg tablets,3 month dose pack MO	1	QL (91 per 90 days)
FEMHRT LOW DOSE 0.5 MG-2.5 MCG TABLET MO	3	
FEMRING 0.05 MG/24 HR, 0.1 MG/24 HR VAGINAL MO	3	QL (1 per 90 days)
femynor 0.25 mg-35 mcg tablet MO	1	
FORTESTA 10 MG/0.5 GRAM/ACTUATION TRANSDERMAL GEL PUMP MO	3	PA,QL (120 per 30 days)
fyavolv 0.5 mg-2.5 mcg tablet; fyavolv 1 mg-5 mcg tablet MO	1	
GENERESS FE 0.8 MG-25 MCG (24)/75 MG (4) CHEWABLE TABLET MO	3	
gianvi (28) 3 mg-0.02 mg tablet MO	1	
hailey 1.5 mg-30 mcg tablet MO	1	
hailey 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet MO	1	
hailey fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet MO	1	
hailey fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet MO	1	
heather 0.35 mg tablet MO	1	
hydroxyprogest 250 mg/ml vial DL	4	PA
hydroxyprogest 1,250 mg/5 ml DL	4	PA
hydroxyprogesterone 1.25 g/5ml DL	4	PA
incassia 0.35 mg tablet MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
introvale 0.15 mg-30 mcg (91) tablets,3 month dose pack ^{MO}	1	QL (91 per 90 days)
isibloom 0.15 mg-0.03 mg tablet ^{MO}	1	
jaimiess 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack ^{MO}	1	QL (91 per 90 days)
jasmiel (28) 3 mg-0.02 mg tablet ^{MO}	1	
jencycla 0.35 mg tablet ^{MO}	1	
jevantique lo 0.5 mg-2.5 mcg ^{MO}	3	
jinteli 1 mg-5 mcg tablet ^{MO}	1	
jolessa 0.15 mg-30 mcg (91) tablets,3 month dose pack ^{MO}	1	QL (91 per 90 days)
jolivette tablet ^{MO}	1	
juleber 0.15 mg-0.03 mg tablet ^{MO}	1	
junel 1.5/30 (21) 1.5 mg-30 mcg tablet ^{MO}	1	
junel 1/20 (21) 1 mg-20 mcg tablet ^{MO}	1	
junel fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet ^{MO}	1	
junel fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet ^{MO}	1	
junel fe 24 1 mg-20 mcg (24)/75 mg (4) tablet ^{MO}	1	
kaitlib fe 0.8 mg-25 mcg (24)/75 mg (4) chewable tablet ^{MO}	1	
kalliga 0.15 mg-0.03 mg tablet ^{MO}	1	
kariva (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet ^{MO}	1	
kelnor 1-50 1 mg-50 mcg tablet ^{MO}	1	
kelnor 1/35 (28) 1 mg-35 mcg tablet ^{MO}	1	
kurvelo (28) 0.15 mg-0.03 mg tablet ^{MO}	1	
levono-e estrad 0.15-0.03-0.01; levonor-e estrad 0.1-0.02-0.01; levonorg 0.15mg-ee 20-25-30mcg ^{MO}	1	QL (91 per 90 days)
larin 1.5/30 (21) 1.5 mg-30 mcg tablet ^{MO}	1	
larin 1/20 (21) 1 mg-20 mcg tablet ^{MO}	1	
larin 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet ^{MO}	1	
larin fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet ^{MO}	1	
larin fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet ^{MO}	1	
larissia 0.1 mg-20 mcg tablet ^{MO}	1	
LAYOLIS FE 0.8 MG-25 MCG (24)/75 MG (4) CHEWABLE TABLET ^{MO}	3	
leena 28 0.5 mg/1 mg/0.5 mg-35 mcg tablet ^{MO}	1	
lessina 0.1 mg-20 mcg tablet ^{MO}	1	
levonest (28) 50-30 (6)/75-40(5)/125-30(10) tablet ^{MO}	1	
levonor-eth estrad triphasic ^{MO}	1	
levonor-eth estra 0.09-0.02 mg; levonor-eth estrad 0.1-0.02 mg; levonor-eth estrad 0.15-0.03 ^{MO}	1	
levonor-eth estrad 0.15-0.03 ^{MO}	1	QL (91 per 90 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
levora-28 0.15 mg-0.03 mg tablet MO	1	
lillow (28) 0.15 mg-0.03 mg tablet MO	1	
LO LOESTRIN FE 1 MG-10 MCG (24)/10 MCG (2) TABLET MO	3	
lo-zumandimine (28) 3 mg-0.02 mg tablet MO	1	
LOESTRIN 1.5/30 (21) 1.5 MG-30 MCG TABLET MO	1	
LOESTRIN 1/20 (21) 1 MG-20 MCG TABLET MO	1	
LOESTRIN FE 1.5/30 (28-DAY) 1.5 MG-30 MCG (21)/75 MG (7) TABLET MO	1	
LOESTRIN FE 1/20 (28-DAY) 1 MG-20 MCG (21)/75 MG (7) TABLET MO	1	
lojaimiess 0.10 mg-20 mcg (84)/10 mcg(7) tablets,3 month dose pack MO	1	QL (91 per 90 days)
lopreeza 0.5 mg-0.1 mg tablet; lopreeza 1 mg-0.5 mg tablet MO	1	
loryna (28) 3 mg-0.02 mg tablet MO	1	
LOSEASONIQUE 0.10 MG-20 MCG (84)/10 MCG(7) TABLETS,3 MONTH DOSE PACK MO	3	QL (91 per 90 days)
low-ogestrel (28) 0.3 mg-30 mcg tablet MO	1	
lutera (28) 0.1 mg-20 mcg tablet MO	1	
lyza 0.35 mg tablet MO	1	
MAKENA 250 MG/ML, 250 MG/ML (1 ML) INTRAMUSCULAR OIL DL	4	PA
MAKENA (PF) 275 MG/1.1 ML SUBCUTANEOUS AUTO-INJECTOR DL	4	PA
marlissa (28) 0.15 mg-0.03 mg tablet MO	1	
medroxyprogesterone 10 mg, 2.5 mg, 5 mg tab MO	1	
medroxyprogesterone 150 mg/ml MO	1	QL (1 per 90 days)
MEGACE ES 625 MG/5 ML SUSP MO	3	
megestrol 20 mg, 40 mg tablet MO	1	
megestrol 625 mg/5 ml susp; megestrol acet 40 mg/ml susp; megestrol acet 400 mg/10 ml MO	1	
melodetta 24 fe 1 mg-20 mcg (24)/75 mg (4) chewable tablet MO	1	
MENEST 0.3 MG, 0.625 MG, 1.25 MG TABLET MO	1	
MENOSTAR 14 MCG/24 HR TRANSDERMAL PATCH MO	3	QL (8 per 28 days)
METHITEST 10 MG TABLET DL	4	
methyltestosterone 10 mg cap DL	4	
mibelas 24 fe 1 mg-20 mcg (24)/75 mg (4) chewable tablet MO	1	
microgestin 1.5/30 (21) 1.5 mg-30 mcg tablet MO	1	
microgestin 1/20 (21) 1 mg-20 mcg tablet MO	1	
MICROGESTIN 24 FE 1 MG-20 MCG MO	3	
microgestin fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet MO	1	
microgestin fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet MO	1	
mili 0.25 mg-35 mcg tablet MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>mimvey 1 mg-0.5 mg tablet</i> MO	1	
<i>mimvey lo 0.5-0.1 mg tablet</i> MO	1	
MINASTRIN 24 FE 1 MG-20 MCG (24)/75 MG (4) CHEWABLE TABLET MO	3	
MINIVELLE 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR TRANSDERMAL PATCH MO	3	QL (8 per 28 days)
MIRCETTE (28) 0.15 MG-0.02 MG (21)/0.01 MG (5) TABLET MO	1	
<i>mono-lyyah 0.25 mg-35 mcg tablet</i> MO	1	
<i>mononessa 28 tablet</i> MO	1	
<i>myzilra-28 tablet</i> MO	1	
NATAZIA 3 MG/2 MG-2 MG/2 MG-3 MG/1 MG TABLET MO	3	
NATESTO 5.5 MG/0.122 GRAM PER ACTUATION NASAL GEL PUMP MO	3	PA,QL (21.96 per 30 days)
<i>necon 0.5/35 (28) 0.5 mg-35 mcg tablet</i> MO	1	
<i>nikki (28) 3 mg-0.02 mg tablet</i> MO	1	
<i>nora-be 0.35 mg tablet</i> MO	1	
<i>noret-estr-fe 0.4-0.035(21)-75; norethin-estra-fe 0.8-0.025 mg</i> MO	1	
<i>norethindrone 0.35 mg tablet</i> MO	1	
<i>norethin-ee 1.5-0.03 mg(21) tb; norethin-eth estrad 1 mg-5 mcg; norethind-eth estrad 0.5-2.5; norethind-eth estrad 1-0.02 mg</i> MO	1	
<i>norethindrone 5 mg tablet</i> MO	1	
<i>noreth-ee-fe 1.5-0.03mg(21)-75; noreth-estrad-fe 1-0.02(21)-75; noreth-estrad-fe 1-0.02(24)-75</i> MO	1	
<i>noreth-estrad-fe 1-0.02(24)-75</i> MO	1	
<i>norg-ee 0.18-0.215-0.25/0.025; norg-ee 0.18-0.215-0.25/0.035; norg-ethin estra 0.25-0.035 mg</i> MO	1	
<i>norlyda 0.35 mg tablet</i> MO	1	
<i>nortrel 0.5/35 (28) 0.5 mg-35 mcg tablet</i> MO	1	
<i>nortrel 1/35 (21) 1 mg-35 mcg tablet</i> MO	1	
<i>nortrel 1/35 (28) 1 mg-35 mcg tablet</i> MO	1	
<i>nortrel 7/7/7 (28) 0.5 mg/0.75 mg/1 mg-35 mcg tablet</i> MO	1	
NUVARING 0.12 MG-0.015 MG/24 HR VAGINAL MO	3	QL (1 per 28 days)
<i>ocella 3 mg-0.03 mg tablet</i> MO	1	
<i>ogestrel tablet</i> MO	1	
<i>orsythia 0.1 mg-20 mcg tablet</i> MO	1	
ORTHO MICRONOR 0.35 MG TABLET MO	3	
ORTHO TRI-CYCLEN (28) 0.18 MG(7)/0.215 MG(7)/0.25 MG(7)-35 MCG TABLET MO	3	
ORTHO TRI-CYCLEN LO TABLET MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ORTHO-CYCLEN 28 TABLET MO	3	
ORTHO-NOVUM 1/35 (28) 1 MG-35 MCG TABLET MO	3	
ORTHO-NOVUM 7/7/7 (28) 0.5 MG/0.75 MG/1 MG-35 MCG TABLET MO	3	
OSPHENA 60 MG TABLET MO	2	PA
oxandrolone 10 mg tablet DL	4	PA,QL (60 per 30 days)
oxandrolone 2.5 mg tablet MO	1	PA,QL (120 per 30 days)
philith 0.4 mg-35 mcg tablet MO	1	
pimtrex (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO	1	
pirmella 0.5/0.75/1 mg-35 mcg tablet; pirmella 1 mg-35 mcg tablet MO	1	
portia 28 0.15 mg-0.03 mg tablet MO	1	
PREFEST 1 MG (15)/1 MG-0.09 MG (15) TABLET MO	1	
PREMARIN 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG TABLET MO	3	
PREMARIN 0.625 MG/GRAM VAGINAL CREAM MO	2	
PREMARIN 25 MG SOLUTION FOR INJECTION MO	3	
PREMPHASE 0.625 MG(14)/0.625 MG-5MG(14) TABLET MO	3	
PREMPRO 0.3 MG-1.5 MG TABLET; PREMPRO 0.45 MG-1.5 MG TABLET; PREMPRO 0.625 MG-2.5 MG TABLET; PREMPRO 0.625 MG-5 MG TABLET MO	3	
previfem 0.25 mg-35 mcg tablet MO	1	
progesterone 500 mg/10 ml vial MO	1	
progesterone 100 mg, 200 mg capsule MO	1	
PROMETRIUM 100 MG, 200 MG CAPSULE DL	4	
PROVERA 10 MG, 2.5 MG, 5 MG TABLET MO	3	
QUARTETTE 0.15 MG-20 MCG/0.15 MG-25 MCG TABLETS,3 MONTH DOSE PACK MO	3	QL (91 per 90 days)
quasense 0.15-0.03 mg tablet MO	1	QL (91 per 90 days)
rajani 28 tablet MO	1	
raloxifene hcl 60 mg tablet MO	1	QL (30 per 30 days)
reclipsen (28) 0.15 mg-0.03 mg tablet MO	1	
rivelsa 0.15 mg-20 mcg/0.15 mg-25 mcg tablets,3 month dose pack MO	1	QL (91 per 90 days)
SAFYRAL 3 MG-0.03 MG-0.451 MG (21)/0.451 MG (7) TABLET MO	3	
SEASONIQUE 0.15 MG-30 MCG (84)/10 MCG(7) TABLETS,3 MONTH DOSE PACK MO	3	QL (91 per 90 days)
setlakin 0.15 mg-30 mcg (91) tablets,3 month dose pack MO	1	QL (91 per 90 days)
sharobel 0.35 mg tablet MO	1	
simliya (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO	1	
simpesse 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack MO	1	QL (91 per 90 days)
SLYND 4 MG (28) TABLET MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
sprintec (28) 0.25 mg-35 mcg tablet MO	1	
sronyx 0.1 mg-20 mcg tablet MO	1	
STRIANT 30 MG MUCOADHESIVE DL	4	PA
syeda 3 mg-0.03 mg tablet MO	1	
tarina 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet MO	1	
tarina fe 1-20 eq (28) 1 mg-20 mcg (21)/75 mg (7) tablet MO	1	
tarina fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet MO	1	
TAYTULLA 1 MG-20 MCG (24)/75 MG (4) CAPSULE MO	3	
TESTIM 50 MG/5 GRAM (1 %) TRANSDERMAL GEL MO	3	PA,QL (300 per 30 days)
testosterone 1.62% (2.5 g) pkt; testosterone 1.62% gel pump MO	1	PA,QL (150 per 30 days)
testosterone 1.62%(1.25 g) pkt MO	1	PA,QL (37.5 per 30 days)
testosterone 10 mg gel pump MO	3	PA,QL (120 per 30 days)
testosterone 12.5 mg/1.25 gram; testosterone 25 mg/2.5 gm pkt; testosterone 50 mg/5 gram gel; testosterone 50 mg/5 gram pkt MO	3	PA,QL (300 per 30 days)
testosterone 30 mg/1.5 ml pump MO	3	PA,QL (180 per 30 days)
testosteron cyp 1,000 mg/10 ml; testosterone cyp 100 mg/ml, 200 mg/ml MO	1	
testosteron enan 1,000 mg/5 ml MO	1	QL (24 per 90 days)
TESTRED 10 MG CAPSULE DL	4	
tilia fe 1-20 (5)/1-30(7)/1mg-35mcg(9) tablet MO	1	
tri femynor (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO	1	
tri-estarylla (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO	1	
tri-legest fe 1-20 (5)/1-30(7)/1mg-35mcg(9) tablet MO	1	
tri-linyah (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO	1	
tri-lo-estarylla 0.18 mg/0.215 mg/0.25 mg-25 mcg tablet MO	1	
tri-lo-marzia 0.18 mg/0.215 mg/0.25 mg-25 mcg tablet MO	1	
tri-lo-mili 0.18/0.215/0.25 mg-25 mcg tablet MO	1	
tri-lo-sprintec 0.18 mg/0.215 mg/0.25 mg-25 mcg tablet MO	1	
tri-mili (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO	1	
TRI-NORINYL 28 TABLET MO	3	
tri-previfem (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO	1	
tri-sprintec (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO	1	
tri-vylibra (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet MO	1	
tri-vylibra lo 0.18/0.215/0.25 mg-25 mcg tablet MO	1	
trinessa tablet MO	1	
trinessa lo tablet MO	1	
trivora (28) 50-30 (6)/75-40(5)/125-30(10) tablet MO	1	
tulana 0.35 mg tablet MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
tydemy 3 mg-0.03 mg-0.451 mg (21)(7) tablet MO	1	
VAGIFEM 10 MCG VAGINAL TABLET MO	3	PA
velivet triphasic regimen (28) 0.1 mg/0.125 mg/0.15 mg-25 mcg tablet MO	1	
vienva 0.1 mg-20 mcg tablet MO	1	
viorele (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO	1	
VIVELLE-DOT 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR TRANSDERMAL PATCH MO	3	QL (8 per 28 days)
VOGELXO 1 % (50 MG/5 GRAM), 12.5 MG/ 1.25 GRAM (1 %), 50 MG/5 GRAM (1 %) TRANSDERMAL GEL; VOGELXO 1 % (50 MG/5 GRAM), 12.5 MG/ 1.25 GRAM (1 %), 50 MG/5 GRAM (1 %) TRANSDERMAL GEL PACKET; VOGELXO 12.5 MG/1.25 GRAM PER PUMP ACTUATION (1 %) TRANSDERMAL GEL MO	3	PA,QL (300 per 30 days)
volnea (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet MO	1	
vyfemla (28) 0.4 mg-35 mcg tablet MO	1	
vylibra 0.25 mg-35 mcg tablet MO	1	
wera (28) 0.5 mg-35 mcg tablet MO	1	
wymzya fe 0.4 mg-35 mcg (21)/75 mg (7) chewable tablet MO	1	
xulane 150 mcg-35 mcg/24 hr transdermal patch MO	1	QL (3 per 28 days)
XYOSTED 100 MG/0.5 ML, 50 MG/0.5 ML, 75 MG/0.5 ML SUBCUTANEOUS AUTO-INJECTOR MO	3	PA,QL (2 per 28 days)
YASMIN (28) 3 MG-0.03 MG TABLET MO	3	
YAZ (28) 3 MG-0.02 MG TABLET MO	3	
yuvafem 10 mcg vaginal tablet MO	1	
zarah 3 mg-0.03 mg tablet MO	1	
zovia 1/35e (28) 1 mg-35 mcg tablet MO	1	
zumandimine (28) 3 mg-0.03 mg tablet MO	1	
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (THYROID)		
ARMOUR THYROID 120 MG, 15 MG, 180 MG, 240 MG, 30 MG, 300 MG, 60 MG, 90 MG TABLET MO	2	
CYTOMEL 25 MCG, 5 MCG, 50 MCG TABLET MO	3	
EUTHYROX 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	1	
LEVO-T 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	2	
levothyroxine 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg tablet MO	1	
levothyroxine 100 mcg, 200 mcg, 500 mcg vial MO	1	
levothyroxine 100 mcg/5 ml vl; levothyroxine 200 mcg/5 ml vl; levothyroxine 500 mcg/5 ml vl DL	4	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LEVOXYL 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	1	
<i>liothyronine sod 10 mcg/ml vl</i> MO	1	
<i>liothyronine sod 25 mcg, 5 mcg, 50 mcg tab</i> MO	1	
SYNTHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	2	
THYROLAR-1 12.5 MCG-50 MCG TABLET MO	1	
THYROLAR-1/2 6.25 MCG-25 MCG TABLET MO	1	
THYROLAR-1/4 3.1 MCG-12.5 MCG TABLET MO	1	
THYROLAR-2 25 MCG-100 MCG TABLET MO	1	
THYROLAR-3 37.5 MCG-150 MCG TABLET MO	1	
TIROSINT 100 MCG, 112 MCG, 125 MCG, 13 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG CAPSULE MO	3	
TIROSINT-SOL 100 MCG/ML, 112 MCG/ML, 125 MCG/ML, 13 MCG/ML, 137 MCG/ML, 150 MCG/ML, 175 MCG/ML, 200 MCG/ML, 25 MCG/ML, 50 MCG/ML, 75 MCG/ML, 88 MCG/ML ORAL SOLUTION MO	3	
TRIOSTAT 10 MCG/ML INTRAVENOUS SOLUTION MO	3	
UNITHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	2	
Hormonal Agents, Suppressant (Adrenal)		
LYSODREN 500 MG TABLET DL	4	
HORMONAL AGENTS, SUPPRESSANT (PITUITARY)		
BYNFEZIA 2,500 MCG/ML SUBCUTANEOUS PEN INJECTOR DL	4	PA
<i>cabergoline 0.5 mg tablet</i> MO	1	QL (16 per 28 days)
ELIGARD 7.5 MG (1 MONTH) SUBCUTANEOUS SYRINGE MO	3	PA
ELIGARD 22.5 MG (3 MONTH) SUBCUTANEOUS SYRINGE MO	3	PA
ELIGARD 30 MG (4 MONTH) SUBCUTANEOUS SYRINGE MO	3	PA
ELIGARD 45 MG (6 MONTH) SUBCUTANEOUS SYRINGE MO	3	PA
FENSOLVI 45 MG SUBCUTANEOUS SYRINGE MO	4	PA,QL (1 per 180 days)
FIRMAGON 120 MG SUBCUTANEOUS SOLUTION DL	4	PA
FIRMAGON KIT WITH DILUENT SYRINGE 120 MG SUBCUTANEOUS SOLUTION DL	4	PA
FIRMAGON KIT WITH DILUENT SYRINGE 80 MG SUBCUTANEOUS SOLUTION MO	3	PA
<i>leuprolide 2wk 14 mg/2.8 ml kt</i> MO	1	B vs D
LUPANETA PACK (1 MONTH) 3.75 MG IM SYRINGE AND 5 MG (30) TABLETS,KIT DL	4	PA,QL (1 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LUPANETA PACK (3 MONTH) 11.25 MG IM SYRINGE AND 5 MG (90) TABLETS, KIT MO	4	PA, QL (1 per 90 days)
LUPRON DEPOT 3.75 MG INTRAMUSCULAR SYRINGE KIT MO	3	PA, QL (1 per 30 days)
LUPRON DEPOT 7.5 MG INTRAMUSCULAR SYRINGE KIT DL	4	PA, QL (1 per 30 days)
LUPRON DEPOT 11.25 MG, 22.5 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT MO	3	PA, QL (1 per 90 days)
LUPRON DEPOT 30 MG (4 MONTH) INTRAMUSCULAR SYRINGE KIT MO	3	PA, QL (1 per 112 days)
LUPRON DEPOT (6 MONTH) 45 MG INTRAMUSCULAR SYRINGE KIT MO	4	PA, QL (1 per 168 days)
LUPRON DEPOT-PED 11.25 MG, 15 MG, 7.5 MG (PED) INTRAMUSCULAR KIT DL	4	PA, QL (1 per 28 days)
LUPRON DEPOT-PED 11.25 MG, 30 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT MO	4	PA, QL (1 per 90 days)
MYCAPSSA 20 MG CAPSULE, DELAYED RELEASE DL	4	PA, QL (112 per 28 days)
octreotide 1,000 mcg/ml, 100 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml vial; octreotide acet 0.05 mg/ml v; octreotide acet 1,000 mcg/ml, 100 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml v MO	1	PA
octreotide acet 100 mcg/ml syr; octreotide acet 50 mcg/ml syr; octreotide acet 500 mcg/ml syr MO	1	PA
ORILISSA 150 MG TABLET DL	4	PA, QL (28 per 28 days)
ORILISSA 200 MG TABLET DL	4	PA, QL (56 per 28 days)
SANDOSTATIN 100 MCG/ML, 50 MCG/ML, 500 MCG/ML INJECTION SOLUTION DL	4	PA
SANDOSTATIN LAR DEPOT 10 MG, 20 MG, 30 MG INTRAMUSCULAR SUSP, EXTENDED RELEASE DL	4	PA
SIGNIFOR 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) SUBCUTANEOUS SOLUTION DL	4	PA, QL (60 per 30 days)
SOMATULINE DEPOT 120 MG/0.5 ML SUBCUTANEOUS SYRINGE DL	4	PA, QL (0.5 per 28 days)
SOMATULINE DEPOT 60 MG/0.2 ML SUBCUTANEOUS SYRINGE DL	4	PA, QL (0.2 per 28 days)
SOMATULINE DEPOT 90 MG/0.3 ML SUBCUTANEOUS SYRINGE DL	4	PA, QL (0.3 per 28 days)
SOMAVERT 10 MG, 15 MG, 20 MG SUBCUTANEOUS SOLUTION DL	4	PA, QL (60 per 30 days)
SOMAVERT 25 MG, 30 MG SUBCUTANEOUS SOLUTION DL	4	PA, QL (30 per 30 days)
SYNAREL 2 MG/ML NASAL SPRAY DL	4	
TRELSTAR 11.25 MG, 22.5 MG INTRAMUSCULAR SUSPENSION MO	4	PA
TRELSTAR 3.75 MG INTRAMUSCULAR SUSPENSION DL	4	PA
TRIPTODUR 22.5 MG INTRAMUSCULAR SUSPENSION MO	4	PA, QL (1 per 168 days)
ZOLADEX 10.8 MG SUBCUTANEOUS IMPLANT MO	3	PA, QL (1 per 84 days)
ZOLADEX 3.6 MG SUBCUTANEOUS IMPLANT MO	3	PA, QL (1 per 28 days)
Hormonal Agents, Suppressant (Thyroid)		
methimazole 10 mg, 5 mg tablet MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>propylthiouracil 50 mg tablet</i> MO	1	
TAPAZOLE 10 MG, 5 MG TABLET MO	1	
IMMUNOLOGICAL AGENTS		
ACTEMRA 162 MG/0.9 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (3.6 per 28 days)
ACTEMRA ACTPEN 162 MG/0.9 ML SUBCUTANEOUS PEN INJECTOR DL	4	PA,QL (3.6 per 28 days)
ACTHIB (PF) 10 MCG/0.5 ML INTRAMUSCULAR SOLUTION DL	3	
ACTIMMUNE 100 MCG (2 MILLION UNIT)/0.5 ML SUBCUTANEOUS SOLUTION DL	4	PA
ADACEL (TDAP ADOLESN/ADULT)(PF)2 LF-(2.5-5-3-5)-5 LF/0.5 ML IM SYRINGE DL	2	
ADACEL (TDAP ADOLESN/ADULT)(PF)2LF-(2.5-5-3-5MCG)-5 LF/0.5 ML IM SUSP DL	2	
ARAVA 10 MG, 20 MG TABLET DL	4	PA,QL (30 per 30 days)
ARCALYST 220 MG SUBCUTANEOUS SOLUTION DL	4	PA
ASCENIV 10 % INTRAVENOUS SOLUTION DL	4	PA
ASTAGRAF XL 0.5 MG, 1 MG, 5 MG CAPSULE,EXTENDED RELEASE MO	3	B vs D
ATGAM 50 MG/ML INTRAVENOUS SOLUTION DL	4	PA
AVSOLA 100 MG INTRAVENOUS SOLUTION DL	4	PA
AZASAN 100 MG, 75 MG TABLET MO	1	B vs D
<i>azathioprine 50 mg tablet</i> MO	1	B vs D
<i>azathioprine sod 100 mg vial</i> MO	1	B vs D
BCG VACCINE (TICE STRAIN) VIAL DL	3	
BENLYSTA 120 MG INTRAVENOUS SOLUTION DL	4	PA,QL (20 per 28 days)
BENLYSTA 200 MG/ML SUBCUTANEOUS AUTO-INJECTOR DL	4	PA,QL (4 per 28 days)
BENLYSTA 200 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (4 per 28 days)
BENLYSTA 400 MG INTRAVENOUS SOLUTION DL	4	PA,QL (6 per 28 days)
BERINERT 500 UNIT (10 ML) INTRAVENOUS KIT DL	4	PA,QL (15 per 30 days)
BERINERT 500 UNIT (10 ML) INTRAVENOUS SOLUTION DL	4	PA,QL (15 per 30 days)
BEXSERO 50 MCG-50 MCG-50 MCG-25 MCG/0.5 ML INTRAMUSCULAR SYRINGE DL	3	
BIVIGAM 10 % INTRAVENOUS SOLUTION DL	4	PA
BOOSTRIX TDAP 2.5 LF UNIT-8 MCG-5 LF/0.5 ML INTRAMUSCULAR SUSPENSION DL	2	
BOOSTRIX TDAP 2.5 LF UNIT-8 MCG-5 LF/0.5 ML INTRAMUSCULAR SYRINGE DL	2	
CELLCEPT 200 MG/ML ORAL SUSPENSION DL	4	B vs D
CELLCEPT 250 MG CAPSULE DL	4	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CELLCEPT 500 MG TABLET DL	4	B vs D
CELLCEPT INTRAVENOUS 500 MG INTRAVENOUS SOLUTION MO	3	B vs D
CIMZIA 400 MG/2 ML (200 MG/ML X 2) SUBCUTANEOUS SYRINGE KIT DL	4	PA,QL (3 per 30 days)
CIMZIA POWDER FOR RECON 400 MG (200 MG X 2 VIALS) SUBCUTANEOUS KIT DL	4	PA,QL (3 per 30 days)
CIMZIA STARTER KIT 400 MG/2 ML (200 MG/ML X2) SUBCUTANEOUS SYRINGE KIT DL	4	PA,QL (3 per 30 days)
CINRYZE 500 UNIT (5 ML) INTRAVENOUS SOLUTION DL	4	PA,QL (20 per 30 days)
COSENTYX 150 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (4 per 28 days)
COSENTYX 300 MG/2 SYRINGES (150 MG/ML) SUBCUTANEOUS DL	4	PA,QL (4 per 28 days)
COSENTYX PEN 150 MG/ML SUBCUTANEOUS DL	4	PA,QL (4 per 28 days)
COSENTYX PEN 300 MG/2 PENS (150 MG/ML) SUBCUTANEOUS DL	4	PA,QL (4 per 28 days)
CUTAQUIG 16.5 % SUBCUTANEOUS SOLUTION DL	4	PA
<i>cyclosporine 100 mg, 25 mg capsule</i> MO	1	B vs D
<i>cyclosporine modified 100 mg, 25 mg, 50 mg</i> MO	1	B vs D
<i>cyclosporine modified 100mg/ml</i> MO	1	B vs D
CYTOGAM 50 MG/ML INTRAVENOUS SOLUTION DL	4	PA
DAPTACEL (DTAP PEDIATRIC) (PF) 15 LF UNIT-10 MCG-5 LF/0.5 ML IM SUSP DL	3	
DUPIXENT 300 MG/2 ML SUBCUTANEOUS PEN INJECTOR DL	4	PA,QL (6 per 28 days)
DUPIXENT 200 MG/1.14 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (3.42 per 28 days)
DUPIXENT 300 MG/2 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (6 per 28 days)
ENBREL 25 MG (1 ML), 25 MG/0.5 ML SUBCUTANEOUS POWDER FOR SOLUTION; ENBREL 25 MG (1 ML), 25 MG/0.5 ML SUBCUTANEOUS SOLUTION DL	4	PA,QL (8 per 28 days)
ENBREL 25 MG/0.5 ML (0.5 ML) SUBCUTANEOUS SYRINGE; ENBREL 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) SUBCUTANEOUS SYRINGE DL	4	PA,QL (8 per 28 days)
ENBREL MINI 50 MG/ML (1 ML) SUBCUTANEOUS CARTRIDGE DL	4	PA,QL (8 per 28 days)
ENBREL SURECLICK 50 MG/ML (1 ML) SUBCUTANEOUS PEN INJECTOR DL	4	PA,QL (8 per 28 days)
ENGERIX-B (PF) 20 MCG/ML INTRAMUSCULAR SUSPENSION DL	3	B vs D
ENGERIX-B (PF) 20 MCG/ML INTRAMUSCULAR SYRINGE DL	3	B vs D
ENGERIX-B PEDIATRIC (PF) 10 MCG/0.5 ML INTRAMUSCULAR SYRINGE DL	3	B vs D
ENSPRYNG 120 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (2 per 28 days)
ENTYVIO 300 MG INTRAVENOUS SOLUTION DL	4	PA,QL (8 per 365 days)
ENVARUSUS XR 0.75 MG, 1 MG, 4 MG TABLET,EXTENDED RELEASE MO	3	PA
<i>everolimus 0.25 mg tablet</i> MO	4	B vs D,QL (60 per 30 days)
<i>everolimus 0.5 mg tablet</i> DL	4	B vs D,QL (120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
everolimus 0.75 mg tablet DL	4	B vs D,QL (60 per 30 days)
FIRAZYR 30 MG/3 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (9 per 30 days)
FLEBOGAMMA DIF 10 %, 5 % INTRAVENOUS SOLUTION DL	4	PA
GAMASTAN 15 %-18 % RANGE INTRAMUSCULAR SOLUTION DL	4	PA
GAMASTAN S/D 15 %-18 % RANGE INTRAMUSCULAR SOLUTION DL	4	PA
GAMMAGARD LIQUID 10 % INJECTION SOLUTION DL	4	PA
GAMMAGARD S-D (IGA < 1 MCG/ML) 10 GRAM, 5 GRAM INTRAVENOUS SOLUTION DL	4	PA
GAMMAKED 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 5 GRAM/50 ML (10 %) INJECTION SOLUTION; GAMMAKED 2.5 GRAM/25 ML VIAL DL	4	PA
GAMMAPLEX 10 % INTRAVENOUS SOLUTION DL	4	PA
GAMMAPLEX (WITH SORBITOL) 5 % INTRAVENOUS SOLUTION DL	4	PA
GAMUNEX-C 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 40 GRAM/400 ML (10 %), 5 GRAM/50 ML (10 %) INJECTION SOLUTION DL	4	PA
GARDASIL 9 (PF) 0.5 ML INTRAMUSCULAR SUSPENSION DL	3	QL (1.5 per 365 days)
GARDASIL 9 (PF) 0.5 ML INTRAMUSCULAR SYRINGE DL	3	QL (1.5 per 365 days)
gengraf 100 mg, 25 mg capsule MO	1	B vs D
gengraf 100 mg/ml oral solution MO	1	B vs D
HAEGARDA 2,000 UNIT, 3,000 UNIT SUBCUTANEOUS SOLUTION DL	4	PA,QL (24 per 28 days)
HAVRIX (PF) 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML INTRAMUSCULAR SUSPENSION; HAVRIX 720 UNITS/0.5 ML VIAL DL	3	
HAVRIX (PF) 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML INTRAMUSCULAR SYRINGE DL	3	
HIBERIX (PF) 10 MCG/0.5 ML INTRAMUSCULAR SOLUTION DL	3	
HIZENTRA 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SUBCUTANEOUS SOLUTION DL	4	PA
HIZENTRA 1 GRAM/5 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SUBCUTANEOUS SYRINGE DL	4	PA
HUMIRA 10 MG/0.2 ML SUBCUTANEOUS SYRINGE KIT DL	4	PA,QL (2 per 28 days)
HUMIRA 20 MG/0.4 ML, 40 MG/0.8 ML SUBCUTANEOUS SYRINGE KIT DL	4	PA,QL (6 per 28 days)
HUMIRA PEDI CROHN 40 MG/0.8 ML DL	4	PA,QL (6 per 28 days)
HUMIRA PEN 40 MG/0.8 ML SUBCUTANEOUS KIT DL	4	PA,QL (6 per 28 days)
HUMIRA PEN CROHN'S-ULC COLITIS-HID SUP STARTER 40 MG/0.8 ML SUBCUT KIT DL	4	PA,QL (6 per 28 days)
HUMIRA PEN PSORIASIS-UVEITIS-ADOL HID SUP START 40 MG/0.8 ML SUBCUT KT DL	4	PA,QL (6 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HUMIRA(CF) 10 MG/0.1 ML SUBCUTANEOUS SYRINGE KIT DL	4	PA,QL (2 per 28 days)
HUMIRA(CF) 20 MG/0.2 ML, 40 MG/0.4 ML SUBCUTANEOUS SYRINGE KIT DL	4	PA,QL (6 per 28 days)
HUMIRA(CF) PEDI CROHN'S START 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML SUBCUT SYR KIT; HUMIRA(CF) PEDIATRIC CROHN'S STARTER 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML SUBCUT SYRINGE KIT DL	4	PA,QL (6 per 28 days)
HUMIRA(CF) PEN 40 MG/0.4 ML, 80 MG/0.8 ML SUBCUTANEOUS KIT DL	4	PA,QL (6 per 28 days)
HUMIRA(CF) PEN CROHN'S-ULC COLITIS-HID SUP STRT 80 MG/0.8 ML SUBCUT KT DL	4	PA,QL (6 per 28 days)
HUMIRA(CF) PEN PS-UV-ADOL HS 80 MG/0.8 ML(1)-40 MG/0.4 ML(2)SUBCUT KIT DL	4	PA,QL (6 per 28 days)
HYPERRAB (PF) 300 UNIT/ML INTRAMUSCULAR SOLUTION DL	4	B vs D
HYPERRAB S/D (PF) 150 UNIT/ML INTRAMUSCULAR SOLUTION DL	4	B vs D
HYPERTET S/D (PF) 250 UNIT INTRAMUSCULAR SYRINGE MO	3	B vs D
<i>icatibant 30 mg/3 ml syringe</i> DL	4	PA,QL (9 per 30 days)
ILUMYA 100 MG/ML SUBCUTANEOUS SYRINGE MO	4	PA,QL (6 per 365 days)
IMOGAM RABIES-HT (PF) 150 UNIT/ML INTRAMUSCULAR SOLUTION MO	3	B vs D
IMOVAX RABIES VACCINE (PF) 2.5 UNIT INTRAMUSCULAR SOLUTION DL	2	B vs D
IMURAN 50 MG TABLET MO	3	PA
INFANRIX (DTAP) (PF) 25 LF UNIT-58 MCG-10 LF/0.5ML INTRAMUSCULAR SUSP DL	3	
INFANRIX (DTAP)(PF) 25 LF UNIT-58MCG-10 LF/0.5ML INTRAMUSCULAR SYRINGE DL	3	
INFLECTRA 100 MG INTRAVENOUS SOLUTION DL	4	PA
INTRON A 10 MILLION UNIT (1 ML), 18 MILLION UNIT (1 ML), 50 MILLION UNIT (1 ML) SOLUTION FOR INJECTION MO	3	PA
INTRON A 10 MILLION UNIT/ML, 6 MILLION UNIT/ML INJECTION SOLUTION DL	4	PA
IPOL 40 UNIT-8 UNIT-32 UNIT/0.5 ML SUSPENSION FOR INJECTION DL	3	
IXIARO (PF) 6 MCG/0.5 ML INTRAMUSCULAR SYRINGE DL	3	
KEDRAB (PF) 150 UNIT/ML INTRAMUSCULAR SOLUTION DL	4	B vs D
KEVZARA 150 MG/1.14 ML, 200 MG/1.14 ML SUBCUTANEOUS PEN INJECTOR DL	4	PA,QL (2.28 per 28 days)
KEVZARA 150 MG/1.14 ML, 200 MG/1.14 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (2.28 per 28 days)
KINERET 100 MG/0.67 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (20.1 per 30 days)
KINRIX (PF) 25 LF-58 MCG-10 LF/0.5 ML INTRAMUSCULAR SUSPENSION DL	3	
KINRIX (PF) 25 LF-58 MCG-10 LF/0.5 ML INTRAMUSCULAR SYRINGE DL	3	
<i>leflunomide 10 mg, 20 mg tablet</i> MO	1	QL (30 per 30 days)
M-M-R II (PF) 1,000-12,500 TCID50/0.5 ML SUBCUTANEOUS SOLUTION DL	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MENACTRA (PF) 4 MCG/0.5 ML INTRAMUSCULAR SOLUTION DL	3	
MENVEO A-C-Y-W-135-DIP (PF) 10 MCG-5 MCG/0.5 ML INTRAMUSCULAR KIT DL	3	
<i>methotrexate 2.5 mg tablet</i> MO	1	B vs D
<i>methotrexate 50 mg/2 ml vial</i> MO	1	
<i>methotrexate 1 gm vial; methotrexate 50 mg/2 ml vial</i> MO	1	
MONJUVI 200 MG INTRAVENOUS SOLUTION DL	4	PA
<i>mycophenolate 200 mg/ml susp</i> MO	1	B vs D
<i>mycophenolate 250 mg capsule</i> MO	1	B vs D
<i>mycophenolate 500 mg tablet</i> MO	1	B vs D
<i>mycophenolate 500 mg vial</i> MO	1	B vs D
<i>mycophenolic acid dr 180 mg, 360 mg tb</i> MO	1	B vs D
MYFORTIC 180 MG TABLET, DELAYED RELEASE MO	3	B vs D
MYFORTIC 360 MG TABLET, DELAYED RELEASE DL	4	B vs D
NEORAL 100 MG, 25 MG CAPSULE MO	3	B vs D
NEORAL 100 MG/ML ORAL SOLUTION MO	3	B vs D
OCTAGAM 10 %, 5 % INTRAVENOUS SOLUTION DL	4	PA
OLUMIANT 1 MG, 2 MG TABLET DL	4	PA, QL (30 per 30 days)
ORENCIA 125 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA, QL (4 per 28 days)
ORENCIA 50 MG/0.4 ML SUBCUTANEOUS SYRINGE DL	4	PA, QL (1.6 per 28 days)
ORENCIA 87.5 MG/0.7 ML SUBCUTANEOUS SYRINGE DL	4	PA, QL (2.8 per 28 days)
ORENCIA CLICKJECT 125 MG/ML SUBCUTANEOUS AUTO-INJECTOR DL	4	PA, QL (4 per 28 days)
OTREXUP (PF) 10 MG/0.4 ML, 12.5 MG/0.4 ML, 15 MG/0.4 ML, 17.5 MG/0.4 ML, 20 MG/0.4 ML, 22.5 MG/0.4 ML, 25 MG/0.4 ML SUBCUTANEOUS AUTO-INJECTOR DL	4	PA, QL (1.6 per 28 days)
PANZYGA 10 % INTRAVENOUS SOLUTION DL	4	PA
PEDIARIX (PF) 10 MCG-25 LF-25 MCG-10 LF/0.5 ML INTRAMUSCULAR SYRINGE DL	3	
PEDVAX HIB (PF) 7.5 MCG/0.5 ML INTRAMUSCULAR SOLUTION DL	3	
PEGASYS 180 MCG/0.5 ML SUBCUTANEOUS SYRINGE DL	4	PA, QL (2 per 28 days)
PEGASYS 180 MCG/ML SUBCUTANEOUS SOLUTION DL	4	PA, QL (4 per 28 days)
PEGASYS PROCLICK 135 MCG/0.5; PEGASYS PROCLICK 180 MCG/0.5 DL	4	PA, QL (2 per 28 days)
PEGINTRON 50 MCG/0.5 ML SUBCUTANEOUS KIT DL	4	PA, QL (4 per 28 days)
PENTACEL (PF) 15 LF UNIT-20 MCG-5 LF /0.5 ML INTRAMUSCULAR KIT; PENTACEL (PF) 15 LF-48 MCG-62 DU-10 MCG/0.5 ML INTRAMUSCULAR KIT DL	3	
PRIVIGEN 10 % INTRAVENOUS SOLUTION DL	4	PA
PROGRAF 0.2 MG, 1 MG ORAL GRANULES IN PACKET MO	3	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROGRAF 0.5 MG, 1 MG, 5 MG CAPSULE MO	3	B vs D
PROQUAD (PF) 10EXP3-4.3-3-3.99TCID50/0.5ML SUBCUTANEOUS SUSPENSION DL	3	
QUADRACEL (PF) 15 LF-48 MCG-5 LF UNIT/0.5 ML INTRAMUSCULAR SUSPENSION DL	3	
RABAVERT (PF) 2.5 UNIT INTRAMUSCULAR SUSPENSION DL	2	B vs D
RAPAMUNE 0.5 MG, 1 MG, 2 MG TABLET DL	4	B vs D
RAPAMUNE 1 MG/ML ORAL SOLUTION DL	4	B vs D
RASUVO (PF) 10 MG/0.2 ML SUBCUTANEOUS AUTO-INJECTOR MO	3	PA,QL (0.8 per 28 days)
RASUVO (PF) 12.5 MG/0.25 ML SUBCUTANEOUS AUTO-INJECTOR MO	3	PA,QL (1 per 28 days)
RASUVO (PF) 15 MG/0.3 ML SUBCUTANEOUS AUTO-INJECTOR MO	3	PA,QL (1.2 per 28 days)
RASUVO (PF) 17.5 MG/0.35 ML SUBCUTANEOUS AUTO-INJECTOR MO	3	PA,QL (1.4 per 28 days)
RASUVO (PF) 20 MG/0.4 ML SUBCUTANEOUS AUTO-INJECTOR MO	3	PA,QL (1.6 per 28 days)
RASUVO (PF) 22.5 MG/0.45 ML SUBCUTANEOUS AUTO-INJECTOR MO	3	PA,QL (1.8 per 28 days)
RASUVO (PF) 25 MG/0.5 ML SUBCUTANEOUS AUTO-INJECTOR MO	3	PA,QL (2 per 28 days)
RASUVO (PF) 30 MG/0.6 ML SUBCUTANEOUS AUTO-INJECTOR MO	3	PA,QL (2.4 per 28 days)
RASUVO (PF) 7.5 MG/0.15 ML SUBCUTANEOUS AUTO-INJECTOR MO	3	PA,QL (0.6 per 28 days)
RECOMBIVAX HB (PF) 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML INTRAMUSCULAR SUSPENSION DL	3	B vs D
RECOMBIVAX HB (PF) 10 MCG/ML, 5 MCG/0.5 ML INTRAMUSCULAR SYRINGE DL	3	B vs D
REMICADE 100 MG INTRAVENOUS SOLUTION DL	4	PA
RENFLIXIS 100 MG INTRAVENOUS SOLUTION DL	4	PA
RHOPHYLAC 1,500 UNIT (300 MCG)/2 ML INJECTION SYRINGE DL	4	
RIDAURA 3 MG CAPSULE DL	4	
RINVOQ 15 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (30 per 30 days)
ROTARIX 10EXP6 CCID50/ML SUSPENSION DL	3	
ROTATEQ VACCINE 2 ML ORAL SOLUTION DL	3	
RUCONEST 2,100 UNIT INTRAVENOUS SOLUTION DL	4	PA,QL (8 per 28 days)
SANDIMMUNE 100 MG, 25 MG CAPSULE MO	3	B vs D
SANDIMMUNE 100 MG/ML ORAL SOLUTION MO	3	B vs D
SHINGRIX (PF) 50 MCG/0.5 ML INTRAMUSCULAR SUSPENSION, KIT DL	2	QL (2 per 999 days)
SILIQ 210 MG/1.5 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (4.5 per 28 days)
SIMPONI 100 MG/ML SUBCUTANEOUS PEN INJECTOR DL	4	PA,QL (3 per 28 days)
SIMPONI 100 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (3 per 28 days)
SIMPONI 50 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR DL	4	PA,QL (0.5 per 30 days)
SIMPONI 50 MG/0.5 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (0.5 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SIMPONI ARIA 12.5 MG/ML INTRAVENOUS SOLUTION DL	4	PA,QL (20 per 28 days)
SIMULECT 10 MG, 20 MG INTRAVENOUS SOLUTION DL	4	B vs D
<i>sirolimus 0.5 mg, 1 mg, 2 mg tablet</i> MO	1	B vs D
<i>sirolimus 1 mg/ml solution</i> MO	1	B vs D
SKYRIZI 150 MG/1.66 ML (75 MG/0.83 ML X 2) SUBCUTANEOUS SYRINGE KIT MO	4	PA,QL (6 per 365 days)
SKYRIZI 75 MG/0.83 ML SUBCUTANEOUS SYRINGE MO	4	PA,QL (9.96 per 365 days)
STELARA 130 MG/26 ML INTRAVENOUS SOLUTION DL	4	PA,QL (104 per 30 days)
STELARA 45 MG/0.5 ML SUBCUTANEOUS SOLUTION DL	4	PA,QL (1.5 per 84 days)
STELARA 45 MG/0.5 ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (1.5 per 84 days)
STELARA 90 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (3 per 84 days)
SYLATRON 200 MCG, 300 MCG, 600 MCG KIT; SYLATRON 200 MCG, 300 MCG, 600 MCG SUBCUTANEOUS KIT DL	4	PA,QL (4 per 28 days)
SYLVANT 100 MG, 400 MG INTRAVENOUS SOLUTION DL	4	PA
<i>tacrolimus 0.5 mg, 1 mg, 5 mg capsule</i> MO	1	B vs D
TAKHZYRO 300 MG/2 ML (150 MG/ML) SUBCUTANEOUS SOLUTION DL	4	PA,QL (4 per 28 days)
TALTZ AUTOINJECTOR 80 MG/ML SUBCUTANEOUS DL	4	PA,QL (4 per 28 days)
TALTZ AUTOINJECTOR (2 PACK) 80 MG/ML SUBCUTANEOUS DL	4	PA,QL (4 per 28 days)
TALTZ AUTOINJECTOR (3 PACK) 80 MG/ML SUBCUTANEOUS DL	4	PA,QL (4 per 28 days)
TALTZ SYRINGE 80 MG/ML SUBCUTANEOUS DL	4	PA,QL (4 per 28 days)
TDVAX 2 LF UNIT-2 LF UNIT/0.5 ML INTRAMUSCULAR SUSPENSION DL	3	
TENIVAC (PF) 5 LF UNIT-2 LF UNIT/0.5 ML INTRAMUSCULAR SUSPENSION DL	3	
TENIVAC (PF) 5 LF UNIT-2 LF UNIT/0.5 ML INTRAMUSCULAR SYRINGE DL	3	
DIPHTHERIA-TETANUS TOXOIDS-PED DL	3	
THYMOGLOBULIN 25 MG INTRAVENOUS SOLUTION MO	3	PA
TREMFYA 100 MG/ML SUBCUTANEOUS AUTO-INJECTOR DL	4	PA,QL (8 per 365 days)
TREMFYA 100 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (8 per 365 days)
TREXALL 10 MG, 15 MG, 5 MG, 7.5 MG TABLET MO	1	B vs D
TRUMENBA 120 MCG/0.5 ML INTRAMUSCULAR SYRINGE DL	3	
TWINRIX (PF) 720 ELISA UNIT-20 MCG/ML INTRAMUSCULAR SYRINGE DL	3	
TYPHIM VI 25 MCG/0.5 ML INTRAMUSCULAR SOLUTION DL	3	
TYPHIM VI 25 MCG/0.5 ML INTRAMUSCULAR SYRINGE DL	3	
VAQTA (PF) 25 UNIT/0.5 ML, 50 UNIT/ML INTRAMUSCULAR SUSPENSION DL	3	
VAQTA (PF) 25 UNIT/0.5 ML, 50 UNIT/ML INTRAMUSCULAR SYRINGE DL	3	
VARIVAX (PF) 1,350 UNIT/0.5 ML SUBCUTANEOUS SUSPENSION DL	2	
VARIZIG 125 UNIT/1.2 ML INTRAMUSCULAR SOLUTION DL	4	PA,QL (12 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
WINRHO SDF 1,500 UNIT (300 MCG)/1.3 ML, 15000 UNIT(3000 MCG)/13 ML, 2,500 UNIT (500 MCG)/2.2 ML, 5,000 UNIT(1000 MCG)/4.4 ML INJECTION SOLUTION; WINRHO SDF 15,000 UNIT (3,000 MCG)/13 ML INJECTION SOLUTION; WINRHO SDF 5,000 UNIT (1,000 MCG)/4.4 ML INJECTION SOLUTION DL	4	B vs D
XATMEP 2.5 MG/ML ORAL SOLUTION MO	3	PA
XELJANZ 10 MG, 5 MG TABLET DL	4	PA,QL (60 per 30 days)
XELJANZ XR 11 MG, 22 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (30 per 30 days)
XEMBIFY 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SUBCUTANEOUS SOLUTION DL	4	PA
XOLAIR 150 MG SUBCUTANEOUS SOLUTION DL, LA	4	PA,QL (6 per 28 days)
XOLAIR 150 MG/ML SUBCUTANEOUS SYRINGE DL, LA	4	PA,QL (6 per 28 days)
XOLAIR 75 MG/0.5 ML SUBCUTANEOUS SYRINGE DL, LA	4	PA,QL (3 per 28 days)
YF-VAX (PF) 10 EXP4.74 UNIT/0.5 ML SUBCUTANEOUS SUSPENSION DL	3	
ZORTRESS 0.25 MG, 0.75 MG, 1 MG TABLET DL	4	B vs D,QL (60 per 30 days)
ZORTRESS 0.5 MG TABLET DL	4	B vs D,QL (120 per 30 days)
ZOSTAVAX (PF) 19,400 UNIT/0.65 ML SUBCUTANEOUS SUSPENSION DL	3	QL (1 per 365 days)
Inflammatory Bowel Disease Agents		
APRISO 0.375 GRAM CAPSULE,EXTENDED RELEASE MO	3	ST,QL (120 per 30 days)
ASACOL HD 800 MG TABLET,DELAYED RELEASE DL	4	ST,QL (180 per 30 days)
AZULFIDINE 500 MG TABLET MO	3	
AZULFIDINE EN-TABS 500 MG TABLET,DELAYED RELEASE MO	3	
<i>balsalazide disodium 750 mg cp</i> MO	1	
<i>budesonide ec 3 mg capsule</i> MO	1	PA
<i>budesonide er 9 mg tablet</i> DL	4	PA,QL (30 per 30 days)
CANASA 1,000 MG RECTAL SUPPOSITORY DL	4	ST,QL (30 per 30 days)
COLAZAL 750 MG CAPSULE DL	4	PA
<i>colocort 100 mg/60 ml enema</i> MO	1	
CORTENEMA 100 MG/60 ML MO	3	
CORTIFOAM 10 % (80 MG) RECTAL MO	3	
DELZICOL 400 MG CAPSULE (DR TABLETS INSIDE) MO	3	ST,QL (180 per 30 days)
DIPENTUM 250 MG CAPSULE DL	4	ST,QL (120 per 30 days)
ENTOCORT EC 3 MG CAPSULE,DELAYED,EXTENDED RELEASE DL	4	PA
<i>hydrocortisone 100 mg/60 ml</i> MO	1	
LIALDA 1.2 GRAM TABLET,DELAYED RELEASE MO	3	ST,QL (120 per 30 days)
<i>mesalamine 1,000 mg supp</i> MO	1	ST,QL (30 per 30 days)
<i>mesalamine 4 gm/60 ml enema</i> MO	1	QL (1800 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
mesalamine 800 mg dr tablet ^{MO}	1	ST,QL (180 per 30 days)
mesalamine dr 1.2 gm tablet ^{MO}	1	QL (120 per 30 days)
mesalamine dr 400 mg capsule ^{MO}	1	ST,QL (180 per 30 days)
mesalamine er 0.375 gram cap ^{MO}	1	ST,QL (120 per 30 days)
ORTIKOS 6 MG, 9 MG CAPSULE,EXTENDED RELEASE ^{DL}	4	PA,QL (30 per 30 days)
PENTASA 250 MG CAPSULE,CONTROLLED RELEASE ^{DL}	4	ST,QL (150 per 30 days)
PENTASA 500 MG CAPSULE,CONTROLLED RELEASE ^{DL}	4	ST,QL (300 per 30 days)
PROCTOFOAM HC 1 %-1 % ^{MO}	1	
ROWASA 4 GRAM/60 ML ENEMA ^{MO}	3	QL (1800 per 30 days)
SFROWASA 4 GRAM/60 ML ENEMA ^{MO}	3	QL (1800 per 30 days)
sulfasalazine 500 mg tablet; sulfasalazine dr 500 mg tab ^{MO}	1	
UCERIS 2 MG/ACTUATION RECTAL FOAM ^{DL}	4	PA
UCERIS 9 MG TABLET, EXTENDED RELEASE ^{DL}	4	PA,QL (30 per 30 days)
METABOLIC BONE DISEASE AGENTS		
ACTONEL 150 MG TABLET ^{MO}	3	PA,QL (1 per 30 days)
ACTONEL 35 MG TABLET ^{MO}	3	PA,QL (4 per 28 days)
ACTONEL 5 MG TABLET ^{MO}	3	PA,QL (30 per 30 days)
alendronate sod 70 mg/75 ml ^{MO}	1	QL (300 per 30 days)
alendronate sodium 10 mg, 40 mg, 5 mg tab; alendronate sodium 10 mg, 40 mg, 5 mg tablet ^{MO}	1	QL (30 per 30 days)
alendronate sodium 35 mg, 70 mg tab ^{MO}	1	QL (4 per 28 days)
ATELVIA 35 MG TABLET,DELAYED RELEASE ^{MO}	3	PA,QL (4 per 28 days)
BINOSTO 70 MG EFFERVESCENT TABLET ^{MO}	3	ST,QL (4 per 28 days)
BONIVA 150 MG TABLET ^{MO}	3	PA,QL (1 per 28 days)
BONIVA 3 MG/3 ML INTRAVENOUS SYRINGE ^{MO}	3	PA,QL (3 per 90 days)
calcitonin-salmon 200 units sp ^{MO}	1	QL (3.7 per 28 days)
calcitriol 0.25 mcg, 0.5 mcg capsule ^{MO}	1	
calcitriol 1 mcg/ml ampul; calcitriol 1 mcg/ml solution ^{MO}	1	
cinacalcet hcl 30 mg, 60 mg tablet ^{MO}	1	QL (60 per 30 days)
cinacalcet hcl 90 mg tablet ^{MO}	1	QL (120 per 30 days)
doxercalciferol 0.5 mcg, 1 mcg, 2.5 mcg cap; doxercalciferol 0.5 mcg, 1 mcg, 2.5 mcg capsule ^{MO}	1	
doxercalciferol 4 mcg/2 ml vl ^{MO}	1	
etidronate disodium 200 mg, 400 mg tab ^{MO}	1	
EVENITY 105 MG/1.17 ML, 210MG/2.34ML (105MG/1.17MLX2) SUBCUTANEOUS SYRINGE; EVENITY 210 MG/2.34 ML (105 MG/1.17 ML X 2) SUBCUTANEOUS SYRINGE ^{DL}	4	PA,QL (2.34 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
FORTEO 20 MCG/DOSE (600 MCG/2.4 ML) SUBCUTANEOUS PEN INJECTOR MO	3	PA,QL (2.4 per 28 days)
FOSAMAX 70 MG TABLET MO	3	PA,QL (4 per 28 days)
FOSAMAX PLUS D 70 MG-2,800 UNIT TABLET; FOSAMAX PLUS D 70 MG-5,600 UNIT TABLET MO	3	ST,QL (4 per 28 days)
HECTOROL 2 MCG/ML INTRAVENOUS SOLUTION MO	2	
HECTOROL 4 MCG/2 ML INTRAVENOUS SOLUTION MO	3	
<i>ibandronate 3 mg/3 ml syringe</i> MO	1	PA,QL (3 per 90 days)
<i>ibandronate 3 mg/3 ml vial</i> MO	1	PA,QL (3 per 90 days)
<i>ibandronate sodium 150 mg tab</i> MO	1	QL (1 per 28 days)
MIACALCIN 200 UNIT/ML INJECTION SOLUTION DL	4	
NATPARA 100 MCG/DOSE, 25 MCG/DOSE, 50 MCG/DOSE, 75 MCG/DOSE SUBCUTANEOUS CARTRIDGE DL	4	PA,QL (2 per 28 days)
<i>pamidronate 30 mg/10 ml vial</i> MO	1	B vs D,QL (30 per 21 days)
<i>pamidronate 60 mg/10 ml vial; pamidronate 90 mg/10 ml vial</i> MO	1	B vs D,QL (10 per 21 days)
<i>paricalcitol 1 mcg, 2 mcg capsule</i> MO	1	QL (30 per 30 days)
<i>paricalcitol 2 mcg/ml vial</i> MO	1	QL (24 per 30 days)
<i>paricalcitol 4 mcg capsule</i> MO	1	QL (12 per 30 days)
<i>paricalcitol 5 mcg/ml vial</i> MO	1	QL (48 per 28 days)
PROLIA 60 MG/ML SUBCUTANEOUS SYRINGE MO	3	B vs D,QL (1 per 180 days)
RAYALDEE 30 MCG CAPSULE,EXTENDED RELEASE DL, LA	4	PA,QL (60 per 30 days)
RECLAST 5 MG/100 ML INTRAVENOUS PIGGYBACK MO	3	PA,QL (100 per 365 days)
<i>risedronate sod dr 35 mg tab; risedronate sodium 35 mg tab</i> MO	1	QL (4 per 28 days)
<i>risedronate sodium 150 mg tab</i> MO	1	QL (1 per 30 days)
<i>risedronate sodium 30 mg, 5 mg tab; risedronate sodium 30 mg, 5 mg tablet</i> MO	1	QL (30 per 30 days)
ROCALTROL 0.25 MCG, 0.5 MCG CAPSULE MO	3	
ROCALTROL 1 MCG/ML ORAL SOLUTION MO	3	
SENSIPAR 30 MG, 60 MG TABLET DL	4	PA,QL (60 per 30 days)
SENSIPAR 90 MG TABLET DL	4	PA,QL (120 per 30 days)
TYMLOS 80 MCG/DOSE (3,120 MCG/1.56 ML) SUBCUTANEOUS PEN INJECTOR DL	4	PA,QL (1.56 per 30 days)
XGEVA 120 MG/1.7 ML (70 MG/ML) SUBCUTANEOUS SOLUTION DL	4	PA,QL (1.7 per 28 days)
ZEMPLAR 1 MCG, 2 MCG CAPSULE MO	3	QL (30 per 30 days)
ZEMPLAR 2 MCG/ML INTRAVENOUS SOLUTION DL	4	QL (24 per 30 days)
ZEMPLAR 5 MCG/ML INTRAVENOUS SOLUTION DL	4	QL (48 per 28 days)
<i>zoledronic acid 4 mg/100 ml</i> MO	1	B vs D,QL (300 per 21 days)
<i>zoledronic acid 4 mg vial</i> MO	1	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
zoledronic acid 4 mg/5 ml vial MO	1	B vs D,QL (15 per 21 days)
zoledronic acid 4 mg/100 ml MO	1	B vs D,QL (300 per 21 days)
zoledronic acid 5 mg/100 ml MO	1	PA,QL (100 per 365 days)
ZOMETA 4 MG/100 ML INJECTION DL	4	B vs D,QL (300 per 21 days)
ZOMETA 4 MG/5 ML VIAL DL	4	B vs D,QL (15 per 21 days)
MISCELLANEOUS THERAPEUTIC AGENTS		
1ST TIER UNIFINE PENTIPS 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE MO	1	
1ST TIER UNIFINE PENTIPS PLUS 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE MO	1	
ABOUTTIME PEN NEEDLE 30 GAUGE X 5/16", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" MO	1	
ACETADOTE 200 MG/ML (20 %) INTRAVENOUS SOLUTION MO	3	
acetic acid 0.25% irrig soln MO	1	
acetylcysteine 6 gram/30 ml vial MO	1	
ADAKVEO 10 MG/ML INTRAVENOUS SOLUTION DL	4	PA
ADVOCATE PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 33 GAUGE X 5/32" MO	1	
ADVOCATE SYRINGES 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16"; ADVOCATE SYRINGES 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" MO	1	
ALCOHOL PADS MO	1	
ALCOHOL PREP PADS MO	1	
ALCOHOL SWAB MO	1	
ALCOHOL WIPES MO	1	
AMMONUL 10 %-10 % INTRAVENOUS SOLUTION DL	4	
ASSURE ID DUO-SHIELD 30 GAUGE X 3/16", 30 GAUGE X 5/16" NEEDLE MO	1	
ASSURE ID INSULIN SAFETY 0.5 ML 29 GAUGE X 1/2", 0.5 ML 31 GAUGE X 15/64", 1 ML 29 GAUGE X 1/2", 1 ML 31 GAUGE X 15/64" SYRINGE MO	1	
ASSURE ID PEN NEEDLE 30 GAUGE X 3/16", 30 GAUGE X 5/16", 31 GAUGE X 3/16" MO	1	
AUTOJECT 2 INJECTION DEVICE SUBCUTANEOUS INSULIN PEN MO	1	
AUTOPEN 1 TO 21 UNITS SUBCUTANEOUS MO	1	
AUTOPEN 2 TO 42 UNITS SUBCUTANEOUS MO	1	
BAL IN OIL 100 MG/ML INTRAMUSCULAR SOLUTION MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BAND-AID GAUZE PADS 2" X 2" BANDAGE MO	1	
BD ALCOHOL SWABS MO	1	
BD AUTOSHIELD DUO PEN NEEDLE 30 GAUGE X 3/16" MO	1	
BD ECLIPSE LUER-LOK 1 ML 30 GAUGE X 1/2" SYRINGE MO	1	
BD INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.5 ML 29 GAUGE X 1/2", 1 ML 25 GAUGE X 5/8", 1 ML 25 X 1", 1 ML 26 X 1/2", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" MO	1	
BD INSULIN SYRINGE HALF UNIT ULTRA-FINE 0.3 ML 31 GAUGE X 5/16" MO	1	
BD INSULIN SYRINGE MICRO-FINE 1 ML 28 GAUGE X 1/2" MO	1	
BD INSULIN SYRINGE SAFETY-LOK 1 ML 29 GAUGE X 1/2" MO	1	
BD INSULIN SYRINGE SLIP TIP 1 ML MO	1	
BD INSULIN SYRINGE U-500 1/2 ML 31 GAUGE X 15/64" MO	1	
BD INSULIN SYRINGE ULTRA-FINE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16"; BD INSULIN SYRINGE ULTRA-FINE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16" MO	1	
BD LO-DOSE MICRO-FINE IV 1/2 ML 28 GAUGE X 1/2" SYRINGE MO	1	
BD LO-DOSE ULTRA-FINE 0.5 ML 29 GAUGE X 1/2" SYRINGE MO	1	
BD NANO 2ND GEN PEN NEEDLE 32 GAUGE X 5/32" MO	1	
BD SAFETYGLIDE INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 1 ML 29 GAUGE X 1/2", 1 ML 31 GAUGE X 15/64" MO	1	
BD SAFETYGLIDE SYRINGE 1 ML 27 GAUGE X 5/8" MO	1	
BD ULTRA-FINE MICRO PEN NEEDLE 32 GAUGE X 1/4" MO	1	
BD ULTRA-FINE MINI PEN NEEDLE 31 GAUGE X 3/16" MO	1	
BD ULTRA-FINE NANO PEN NEEDLE 32 GAUGE X 5/32" MO	1	
BD ULTRA-FINE ORIGINAL PEN NEEDLE 29 GAUGE X 1/2" MO	1	
BD ULTRA-FINE SHORT PEN NEEDLE 31 GAUGE X 5/16" MO	1	
BD VEO INSULIN SYRINGE HALF UNIT ULTRA-FINE 0.3 ML 31 GAUGE X 15/64" MO	1	
BD VEO INSULIN SYRINGE ULTRA-FINE 0.3 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 15/64", 1/2 ML 31 GAUGE X 15/64" MO	1	
BORDERED GAUZE 2" X 2" BANDAGE MO	1	
CAFCIT 60 MG/3 ML (20 MG/ML) INTRAVENOUS SOLUTION MO	3	
<i>caffeine cit 60 mg/3 ml oral; caffeine cit 60 mg/3 ml vial</i> MO	1	
<i>calcium disodium versenate 200 mg/ml injection solution</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CAREFINE PEN NEEDLE 29 GAUGE X 1/2", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/32" MO	1	
CARETOUCH ALCOHOL PREP PAD TOPICAL PADS MO	1	
CARETOUCH INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 X 5/16", 1 ML 29 GAUGE X 5/16, 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; CARETOUCH INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 X 5/16", 1 ML 29 GAUGE X 5/16, 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16"; CARETOUCH INSULIN SYRINGE 1 ML 28 GAUGE X 5/16" MO	1	
CARETOUCH PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 3/16", 32 GAUGE X 5/32" MO	1	
CERVIDIL 10 MG VAGINAL INSERT, CONTROLLED RELEASE MO	3	
CINVANTI 7.2 MG/ML INTRAVENOUS EMULSION MO	3	PA, QL (36 per 28 days)
CLARINEX-D 12 HOUR 2.5 MG-120 MG TABLET, EXTENDED RELEASE MO	3	ST, QL (60 per 30 days)
CLICKFINE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16", 32 GAUGE X 5/32" MO	1	
COMFORT EZ INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2"; COMFORT EZ INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" MO	1	
COMFORT EZ PEN NEEDLES 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 1/4", 33 GAUGE X 3/16", 33 GAUGE X 5/16", 33 GAUGE X 5/32" MO	1	
CURITY ALCOHOL SWABS MO	1	
CURITY GAUZE 2" X 2" BANDAGE MO	1	
DEFITELIO 80 MG/ML INTRAVENOUS SOLUTION DL	4	PA
DERMACEA 2" X 2" BANDAGE MO	1	
DOJOLVI 8.3 KCAL/ML ORAL LIQUID DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DROPLET INSULIN SYRINGE HALF UNIT 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 0.5 ML 31 GAUGE X 5/16", 0.5ML 30 GAUGE X 15/64"; DROPLET INSULIN SYRINGE HALF UNIT 0.5 ML 30 GAUGE X 15/64" MO	1	
DROPLET INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 15/64", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 15/64", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16; DROPLET INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 15/64", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 15/64", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16" MO	1	
DROPLET MICRON PEN NEEDLE 34 GAUGE X 9/64" MO	1	
DROPLET PEN NEEDLE 29 GAUGE X 1/2", 29 GAUGE X 3/8", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/16", 32 GAUGE X 5/32" MO	1	
DROPSAFE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16" MO	1	
DROXIA 200 MG, 300 MG, 400 MG CAPSULE MO	2	
EASY COMFORT ALCOHOL PAD TOPICAL PADS MO	1	
EASY COMFORT INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1 ML 32 GAUGE X 5/16", 1/2 ML 32 GAUGE X 5/16"; EASY COMFORT INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1 ML 32 GAUGE X 5/16", 1/2 ML 32 GAUGE X 5/16" MO	1	
EASY COMFORT PEN NEEDLES 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 1/4", 33 GAUGE X 3/16", 33 GAUGE X 5/32" MO	1	
EASY GLIDE INSULIN SYRINGE 0.3 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 15/64", 1/2 ML 31 GAUGE X 15/64" MO	1	
EASY GLIDE PEN NEEDLE 33 GAUGE X 5/32" MO	1	
EASY TOUCH 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/32" NEEDLE MO	1	
EASY TOUCH ALCOHOL PREP PADS MO	1	
EASY TOUCH FLIPLOCK INSULIN 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" SYRINGE; EASY TOUCH FLIPLOCK INSULIN SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EASY TOUCH INSULIN SAFETY SYRINGE 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2" MO	1	
EASY TOUCH INSULIN SYRINGE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2"; EASY TOUCH INSULIN SYRINGE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" MO	1	
EASY TOUCH LUER LOCK INSULIN 1 ML SYRINGE MO	1	
EASY TOUCH PEN NEEDLE 30 GAUGE X 5/16" MO	1	
EASY TOUCH SAFETY PEN NEEDLE 29 GAUGE X 3/16", 30 GAUGE X 3/16" MO	1	
EASY TOUCH SHEATHLOCK INSULIN 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" SYRINGE; EASY TOUCH SHEATHLOCK INSULIN SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" MO	1	
EASY TOUCH UNI-SLIP 1 ML SYRINGE MO	1	
EXEL INSULIN 0.3 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" SYRINGE; EXEL INSULIN 0.3 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" SYRINGE MO	1	
<i>flumazenil 0.5 mg/5 ml vial</i> MO	1	
<i>fomepizole 1.5 gm/1.5 ml vial</i> MO	1	
FREESTYLE PRECISION 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 SYRINGE; FREESTYLE PRECISION 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" SYRINGE MO	1	
GAUZE PADS 2"X2" MO	1	
GAUZE PAD 2" X 2" BANDAGE MO	1	
GIVLAARI 189 MG/ML SUBCUTANEOUS SOLUTION DL	4	PA
HEALTHWISE INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; HEALTHWISE INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" MO	1	
HEALTHWISE PEN NEEDLE 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HEALTHY ACCENTS UNIFINE PENTIP 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE MO	1	
HUMAPEN LUXURA HD MO	1	
INCONTROL ALCOHOL PADS MO	1	
INCONTROL PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" MO	1	
INSULIN SYR 0.3ML 31GX1/4(1/2) MO	1	
INSULIN SYRINGE 0.5 ML 29 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" MO	1	
INSULIN SYRINGE MICROFINE 1 ML 27 GAUGE X 5/8", 1/2 ML 28 GAUGE X 1/2" MO	1	
BD LUER-LOK SYRINGE 1 ML MO	1	
BD INSULIN SYR 1 ML 28GX1/2"; INSULIN 1 ML SYRINGE; INSULIN 1/2 ML SYRINGE; INSULIN 3/10 ML SYRINGE; INSULIN SYRIN 0.3 ML 30GX1/2"; INSULIN SYRIN 0.3 ML 31GX5/16"; INSULIN SYRIN 0.5 ML 30GX1/2"; INSULIN SYRING 0.5 ML 27GX1/2"; INSULIN SYRINGE 0.3 ML 31GX1/4; INSULIN SYRINGE 0.5 ML 31GX1/4; INSULIN SYRINGE 1 ML 27GX1/2"; INSULIN SYRINGE 1 ML 30GX1/2"; INSULIN SYRINGE 1 ML 31GX1/4"; INSULIN SYRINGE 1 ML 31GX5/16"; KMART VALU PLUS SYR 1/2 ML; PREFERRED PLUS SYRINGE 0.5 ML; PREFERRED PLUS SYRINGE 1 ML; RELI-ON INSULIN 0.3 ML SYR; RELI-ON INSULIN 1 ML SYR; RELION INS SYR 0.3 ML 31GX6MM; RELION INS SYR 0.5 ML 31GX6MM; RELION INS SYR 1 ML 31GX15/64"; TERUMO INS SYRINGE U100-1 ML; ULTICARE INS SYR 1 ML 29GX1/2"; ULTICARE SYR 0.3 ML 30GX5/16"; ULTICARE SYR 0.5 ML 29GX1/2"; ULTICARE SYR 0.5 ML 30GX5/16"; ULTICARE SYR 0.5 ML 31GX5/16"; ULTICARE SYR 1 ML 30GX5/16"; ULTICARE SYRIN 0.3 ML 29GX1/2"; ULTICARE SYRIN 0.5 ML 28GX1/2" MO	1	
INSUPEN 29 GAUGE X 1/2", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 5/32" NEEDLE MO	1	
ISTURISA 1 MG TABLET DL	4	PA,QL (240 per 30 days)
ISTURISA 10 MG TABLET DL	4	PA,QL (180 per 30 days)
ISTURISA 5 MG TABLET DL	4	PA,QL (60 per 30 days)
IV PREP WIPES MEDICATED MO	1	
KORLYM 300 MG TABLET DL	4	PA,QL (120 per 30 days)
<i>lactated ringers irrigation</i> MO	1	
LITE TOUCH INSULIN PEN NEEDLES 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16" MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LITE TOUCH INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 GAUGE; LITE TOUCH INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 GAUGE"; LITE TOUCH INSULIN SYRINGE 1/2 ML 29 MO	1	
LITHOSTAT 250 MG TABLET DL	4	
MAGELLAN INSULIN SAFETY SYRINGE 0.3 ML 29 X 1/2", 0.5 ML 29 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16" MO	1	
MAGELLAN SYRINGE 0.3 ML 30 X 5/16", 0.5 ML 30 GAUGE X 5/16" MO	1	
MAXI-COMFORT INSULIN SYRINGE 1 ML 28 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" MO	1	
MAXICOMFORT II PEN NEEDLE 31 GAUGE X 1/4" MO	1	
MAXICOMFORT INSULIN SYRINGE 1 ML 27 GAUGE X 1/2", 1/2 ML 27 GAUGE X 1/2" MO	1	
MAXICOMFORT SAFETY PEN NEEDLE 29 GAUGE X 3/16", 29 GAUGE X 5/16" MO	1	
<i>methergine 0.2 mg tablet</i> DL	4	
<i>methylergonovine 0.2 mg tablet</i> MO	1	
<i>methylergonovine 0.2 mg/ml amp</i> MO	1	
MICRODOT INSULIN PEN NEEDLE 31 GAUGE X 1/4", 32 GAUGE X 5/32", 33 GAUGE X 5/32" MO	1	
MINI ULTRA-THIN II 31 GAUGE X 3/16" NEEDLE MO	1	
MONOJECT INSULIN SAFETY SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 29 GAUGE X 1/2" MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MONOJECT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 25 GAUGE X 5/8", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2"; MONOJECT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 25 GAUGE X 5/8", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2"; MONOJECT INSULIN SYRINGE 1 ML MO	1	
MONOJECT SYRINGE 1/2 ML 28 GAUGE MO	1	
MONOJECT ULTRA COMFORT INSULIN 1/2 ML 28 GAUGE SYRINGE MO	1	
neomy-polymyxin b 40 mg/ml amp MO	1	
NOVOFINE 32 32 GAUGE X 1/4" NEEDLE MO	1	
NOVOFINE AUTOCOVER 30 GAUGE X 1/3" NEEDLE MO	1	
NOVOFINE PLUS 32 GAUGE X 1/6" NEEDLE MO	1	
NOVOPEN ECHO SUBCUTANEOUS MO	1	
NOVOTWIST 32 GAUGE X 1/5" NEEDLE MO	1	
NURTEC ODT 75 MG DISINTEGRATING TABLET DL	4	PA,QL (8 per 30 days)
OMNIPOD DASH 5 PACK INSULIN POD SUBCUTANEOUS CARTRIDGE MO	2	
OMNIPOD INSULIN MANAGEMENT MO	2	
OMNIPOD INSULIN REFILL SUBCUTANEOUS CARTRIDGE MO	2	
ORIAHNN 300-1-0.5 MG(AM)/300 MG(PM) CAPSULES DL	4	PA,QL (56 per 28 days)
OXBRYTA 500 MG TABLET DL	4	PA,QL (90 per 30 days)
oxytocin 10 unit/ml vial MO	1	
PEN NEEDLE 29 GAUGE X 1/2", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" MO	1	
COMFORT POINT PEN NDL 31GX1/3"; COMFORT POINT PEN NDL 31GX1/6"; FIFTY50 PEN 31G X 3/16" NEEDLE; FIFTY50 PEN NEEDLE 32G X 1/4"; KRO PEN NEEDLE 4MM X 33G; PEN NEEDLE 12MM 29G; PEN NEEDLE 30G X 8MM; PEN NEEDLE 32G X 3/16"; PEN NEEDLE 32G X 5/32"; PEN NEEDLE 8MM 31G; PEN NEEDLES 6MM 31G MO	1	
PENTIPS 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE MO	1	
PHYSIOLYTE 140 MEQ-5 MEQ-3 MEQ-98 MEQ/L IRRIGATION SOLUTION MO	1	
PHYSIOSOL IRRIGATION 140 MEQ-5 MEQ-3 MEQ-98 MEQ/L SOLUTION MO	1	
PITOCIN 10 UNIT/ML INJECTION SOLUTION MO	3	
PREVENT DROPSAFE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16" MO	1	
PRIALT 100 MCG/ML, 25 MCG/ML INTRATHECAL SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PRO COMFORT ALCOHOL PADS MO	1	
PRO COMFORT INSULIN SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; PRO COMFORT INSULIN SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" MO	1	
PRO COMFORT PEN NEEDLE 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/32" MO	1	
PRODIGY INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2" MO	1	
<i>promethazine vc 6.25 mg-5 mg/5 ml oral syrup</i> MO	1	
<i>promethazine-phenylephrine syr</i> MO	1	
<i>protamine 250 mg/25 ml vial</i> MO	1	
PURE COMFORT ALCOHOL PADS MO	1	
PURE COMFORT PEN NEEDLE 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/16", 32 GAUGE X 5/32" MO	1	
RECTIV 0.4 % (W/W) OINTMENT MO	3	QL (30 per 30 days)
RELION NEEDLES 31 GAUGE X 1/4" MO	1	
RELION PEN NEEDLES 32 GAUGE X 5/32" MO	1	
RENACIDIN 1980.6 MG-59.4MG-980.4MG/30ML IRRIGATION SOLUTION MO	3	
<i>ribavirin 6 gm inhalation vial</i> DL	4	B vs D
RIMSO-50 50 % INTRAVESICAL SOLUTION DL	4	
<i>ringers irrigation solution</i> MO	1	
SAFESNAP INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" MO	1	
SAFETY PEN NEEDLE 31 GAUGE X 3/16" MO	1	
SEMPREX-D 8 MG-60 MG CAPSULE MO	3	
SIKLOS 1,000 MG TABLET DL	4	PA
SIKLOS 100 MG TABLET MO	3	PA
<i>sod phenylacet-sod benzoate vl</i> DL	4	
<i>sodium chloride 0.9% irrig.</i> MO	1	
<i>sorbitol-mannitol irrig</i> MO	1	
SURE COMFORT ALCOHOL PREP PADS MO	1	
SURE COMFORT INSULIN SYRINGE U-100 0.5 ML 29 GAUGE X 1/2" MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SURE COMFORT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 1/4", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 1/4", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 31 GAUGE X 1/4"; SURE COMFORT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 1/4", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 1/4", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 31 GAUGE X 1/4" MO	1	
SURE COMFORT PEN NEEDLE 29 GAUGE X 1/2", 30 GAUGE X 5/16", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/32" MO	1	
SURE-FINE PEN NEEDLES 29 GAUGE X 1/2", 31 GAUGE X 3/16", 31 GAUGE X 5/16" MO	1	
SURE-JECT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2"; SURE-JECT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" MO	1	
SURE-PREP ALCOHOL PREP PADS MO	1	
SYNAGIS 100 MG/ML, 50 MG/0.5 ML INTRAMUSCULAR SOLUTION DL	4	PA
TECHLITE INSULIN SYRINGE HALF UNIT 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 0.5 ML 31 GAUGE X 5/16" MO	1	
TECHLITE INSULIN SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16; TECHLITE INSULIN SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16" MO	1	
TECHLITE PEN NEEDLE 29 GAUGE X 1/2", 29 GAUGE X 3/8", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/16", 32 GAUGE X 5/32" MO	1	
TEPEZZA 500 MG INTRAVENOUS SOLUTION DL	4	PA
TERUMO INSULIN SYRINGE 0.3 ML 30 X 3/8", 0.5 ML 29 GAUGE X 1/2", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 X 3/8" MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
THINPRO INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 X 3/8", 0.3 ML 31 X 3/8", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 31 X 3/8", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 3/8", 1 ML 31 X 3/8", 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 X 3/8" MO	1	
TOPCARE CLICKFINE 31 GAUGE X 1/4", 31 GAUGE X 5/16" NEEDLE MO	1	
TOPCARE ULTRA COMFORT 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 SYRINGE; TOPCARE ULTRA COMFORT 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" SYRINGE MO	1	
TRUE COMFORT ALCOHOL PADS MO	1	
TRUE COMFORT INSULIN SYRINGE 0.5 ML 31 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16; TRUE COMFORT INSULIN SYRINGE 0.5 ML 31 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" MO	1	
TRUE COMFORT PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 3/16", 32 GAUGE X 5/32" MO	1	
TRUEPLUS INSULIN 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" SYRINGE; TRUEPLUS INSULIN 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" SYRINGE MO	1	
TRUEPLUS PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" MO	1	
UBRELVY 100 MG, 50 MG TABLET DL	4	PA,QL (8 per 30 days)
ULTICARE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16 SYRINGE; ULTICARE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16" SYRINGE MO	1	
ULTICARE INSULIN SYRINGE HALF UNIT 0.3 ML 31 GAUGE X 1/4" MO	1	
ULTICARE INSULIN SYRINGE 0.3 ML 31 GAUGE X 1/4", 1 ML 31 GAUGE X 1/4", 1/2 ML 31 GAUGE X 1/4" MO	1	
ULTICARE PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/32" MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ULTIGUARD SAFE PACK 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/32" NEEDLE MO	1	
ULTILET ALCOHOL SWAB MO	1	
ULTILET INSULIN SYRINGE 0.3 ML 29 GAUGE, 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; ULTILET INSULIN SYRINGE 0.3 ML 29 GAUGE, 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16"; ULTILET INSULIN SYRINGE 1/2 ML 29 MO	1	
ULTILET PEN NEEDLE 29 GAUGE, 32 GAUGE X 5/32" MO	1	
ULTRA COMFORT INSULIN SYRINGE HALF UNIT 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" MO	1	
ULTRA COMFORT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30, 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 GAUGE; ULTRA COMFORT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30, 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 GAUGE"; ULTRA COMFORT INSULIN SYRINGE 1/2 ML 29 MO	1	
ULTRA FLO INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2" MO	1	
ULTRA FLO PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 3/16" MO	1	
ULTRA THIN PEN NEEDLE 32 GAUGE X 5/32" MO	1	
ULTRA-THIN II (SHORT) INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; ULTRA-THIN II (SHORT) INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" MO	1	
ULTRA-THIN II (SHORT) PEN NDL 31 GAUGE X 5/16" NEEDLE MO	1	
ULTRA-THIN II INSULIN PEN NEEDLES 29 GAUGE X 1/2" MO	1	
ULTRA-THIN II INSULIN SYRINGE 0.5 ML 29 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ULTRACARE INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; ULTRACARE INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" MO	1	
ULTRACARE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/32", 33 GAUGE X 5/32" MO	1	
UNIFINE PENTIPS 29 GAUGE, 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/32", 33 GAUGE X 5/32" NEEDLE MO	1	
UNIFINE PENTIPS MAXFLOW 30 GAUGE X 3/16" NEEDLE MO	1	
UNIFINE PENTIPS PLUS 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 5/32" NEEDLE MO	1	
UNIFINE PENTIPS PLUS MAXFLOW 30 GAUGE X 3/16" NEEDLE MO	1	
UNIFINE SAFECONTROL 30 GAUGE X 3/16", 30 GAUGE X 5/16" NEEDLE MO	1	
V-GO 20 DEVICE MO	2	
V-GO 30 DEVICE MO	2	
V-GO 40 DEVICE MO	2	
VANISHPOINT INSULIN SYRINGE 1 ML 30 GAUGE X 3/16" MO	1	
VANISHPOINT SYRINGE 0.5 ML 30 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" MO	1	
VERIFINE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16", 32 GAUGE X 3/16", 32 GAUGE X 5/32" MO	1	
VIRAZOLE 6 GRAM SOLUTION FOR INHALATION DL	4	B vs D
<i>sterile water for irrigation</i> MO	1	
WEBCOL TOPICAL PADS MO	1	
XENICAL 120 MG CAPSULE MO	3	PA
OPHTHALMIC AGENTS		
ACULAR 0.5 % EYE DROPS MO	3	ST
ACULAR LS 0.4 % EYE DROPS MO	3	ST
ACUVAIL (PF) 0.45 % EYE DROPS IN A DROPPERETTE MO	3	ST
<i>ak-poly-bac 500 unit-10,000 unit/gram eye ointment</i> MO	1	
AKTEN (PF) 3.5 % EYE GEL MO	3	
ALCAINE 0.5 % EYE DROPS MO	1	
ALOCRIL 2 % EYE DROPS MO	3	
ALOMIDE 0.1 % EYE DROPS MO	3	
ALPHAGAN P 0.1 % EYE DROPS MO	2	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ALPHAGAN P 0.15 % EYE DROPS MO	3	PA
ALREX 0.2 % EYE DROPS,SUSPENSION MO	3	ST
<i>apraclonidine hcl 0.5% drops</i> MO	1	
<i>atropine 1% eye drops</i> MO	1	
AZASITE 1 % EYE DROPS MO	3	ST,QL (2.5 per 25 days)
<i>azelastine hcl 0.05% drops</i> MO	1	
AZOPT 1 % EYE DROPS,SUSPENSION MO	3	ST,QL (10 per 28 days)
BACIGUENT 500 UNIT/GRAM EYE OINTMENT MO	1	
<i>bacitracin 500 unit/gm ophth</i> MO	1	
<i>bacitracin-polymyxin eye oint</i> MO	1	
<i>balanced salt intraocular solution</i> MO	1	
BEPREVE 1.5 % EYE DROPS MO	3	ST,QL (5 per 25 days)
BESIVANCE 0.6 % EYE DROPS,SUSPENSION MO	3	ST
BETADINE OPHTHALMIC PREP 5 % SOLUTION MO	3	
<i>betaxolol hcl 0.5% eye drop</i> MO	1	
BETIMOL 0.25 %, 0.5 % EYE DROPS MO	3	ST
BETOPTIC S 0.25 % EYE DROPS,SUSPENSION MO	3	ST
<i>bimatoprost 0.03% eye drops</i> MO	1	QL (2.5 per 25 days)
BLEPH-10 10 % EYE DROPS MO	1	
BLEPHAMIDE 10 %-0.2 % EYE DROPS,SUSPENSION MO	3	
BLEPHAMIDE S.O.P. 10 %-0.2 % EYE OINTMENT MO	1	
<i>brimonidine 0.2% eye drop; brimonidine tartrate 0.15% drp</i> MO	1	
<i>bromfenac sodium 0.09% eye drp</i> MO	1	QL (1.7 per 30 days)
BROMSITE 0.075 % EYE DROPS MO	3	ST,QL (5 per 30 days)
BSS INTRAOCULAR SOLUTION MO	3	
BSS PLUS INTRAOCULAR SOLUTION MO	3	
<i>carteolol hcl 1% eye drops</i> MO	1	
CEQUA 0.09 % EYE DROPS IN A DROPPERETTE MO	3	PA,QL (60 per 30 days)
CILOXAN 0.3 % EYE DROPS MO	3	
CILOXAN 0.3 % EYE OINTMENT MO	3	
<i>ciprofloxacin 0.3% eye drop</i> MO	1	
COMBIGAN 0.2 %-0.5 % EYE DROPS MO	2	QL (5 per 25 days)
COSOPT 22.3 MG-6.8 MG/ML EYE DROPS MO	3	ST,QL (10 per 30 days)
COSOPT (PF) 2 %-0.5 % EYE DROPS IN A DROPPERETTE MO	3	ST,QL (60 per 30 days)
<i>cromolyn 4% eye drops</i> MO	1	
CYSTARAN 0.44 % EYE DROPS DL	4	PA,QL (60 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>dexamethasone 0.1% eye drop</i> MO	1	
DEXTENZA 0.4 MG INTRACANALICULAR INSERT MO	3	B vs D,QL (1 per 30 days)
<i>diclofenac 0.1% eye drops</i> MO	1	
<i>dorzolamide hcl 2% eye drops</i> MO	1	QL (10 per 30 days)
<i>dorzolamide-timolol eye drops</i> MO	1	QL (10 per 30 days)
<i>dorzolamide-timolol 2%-0.5%</i> MO	1	ST,QL (60 per 30 days)
DUREZOL 0.05 % EYE DROPS MO	2	
DURYSTA 10 MCG INTRACAMERAL IMPLANT DL	4	PA,QL (2 per 365 days)
ELESTAT 0.05% EYE DROPS MO	3	ST,QL (5 per 25 days)
EMADINE 0.05% EYE DROPS MO	3	ST
<i>epinastine hcl 0.05% eye drops</i> MO	1	ST,QL (5 per 25 days)
<i>erythromycin 0.5% eye ointment</i> MO	1	
FLAREX 0.1 % EYE DROPS,SUSPENSION MO	3	ST
<i>fluorometholone 0.1% drops</i> MO	1	
<i>flurbiprofen 0.03% eye drop</i> MO	1	
FML FORTE 0.25 % EYE DROPS,SUSPENSION MO	3	ST
FML LIQUIFILM 0.1 % EYE DROPS,SUSPENSION MO	3	ST
FML S.O.P. 0.1 % EYE OINTMENT MO	3	ST
<i>gatifloxacin 0.5% eye drops</i> MO	1	QL (2.5 per 25 days)
<i>gentak 0.3 % (3 mg/gram) eye ointment</i> MO	1	
<i>gentamicin 3 mg/ml eye drop</i> MO	1	
ILEVRO 0.3 % EYE DROPS,SUSPENSION MO	2	QL (3 per 30 days)
INVELTYS 1 % EYE DROPS,SUSPENSION MO	3	ST
IOPIDINE 0.5% EYE DROPS MO	3	PA
IOPIDINE 1 % EYE DROPS IN A DROPPERETTE MO	3	
ISOPTO CARPINE 1 %, 2 %, 4 % EYE DROPS MO	3	
ISTALOL 0.5 % EYE DROPS MO	3	
<i>ketorolac 0.4% ophth solution; ketorolac 0.5% ophth solution</i> MO	1	
LACRISERT 5 MG EYE INSERTS MO	3	
LASTACFT 0.25 % EYE DROPS MO	3	ST
<i>latanoprost 0.005% eye drops</i> MO	1	QL (5 per 25 days)
<i>levobunolol 0.5% eye drops</i> MO	1	
<i>levofloxacin 0.5% eye drops</i> MO	1	
LOTEMAX 0.5 % EYE DROPS,SUSPENSION; LOTEMAX 0.5 % EYE GEL DROPS MO	3	ST
LOTEMAX 0.5 % EYE OINTMENT MO	3	ST
LOTEMAX SM 0.38 % EYE GEL DROPS MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
loteprednol etabonate 0.5% drp MO	1	ST
LUMIGAN 0.01 % EYE DROPS MO	2	QL (2.5 per 25 days)
MAXIDEX 0.1 % EYE DROPS,SUSPENSION MO	3	ST
MAXITROL 3.5 MG/G-10,000 UNIT/G-0.1 % EYE OINTMENT MO	3	
MAXITROL 3.5 MG/ML-10,000 UNIT/ML-0.1% EYE DROPS,SUSPENSION MO	1	
metipranolol 0.3% eye drops MO	1	
MIOSTAT 0.01 % INTRAOCULAR SOLUTION MO	3	
MOXEZA 0.5 % EYE DROPS MO	3	ST
moxifloxacin 0.5% eye drops MO	1	ST
moxifloxacin 0.5% eye drops MO	1	
NATACYN 5 % EYE DROPS,SUSPENSION MO	3	
neo-polycin 3.5 mg-400 unit-10,000 unit/g eye ointment MO	1	
neo-polycin hc 3.5 mg-400-10,000 unit/g-1 % eye ointment MO	1	
neo-bacit-poly-hc eye ointment MO	1	
neomyc-bacit-polymix eye oint MO	1	
neomyc-polym-dexamet eye ointm MO	1	
neomyc-polym-dexameth eye drop MO	1	
neomyc-polym-gramicid eye drop MO	1	
neomycin-poly-hc eye drops MO	1	
NEVANAC 0.1 % EYE DROPS,SUSPENSION MO	3	ST
OCUFLOX 0.3 % EYE DROPS MO	3	
ofloxacin 0.3% eye drops MO	1	
olopatadine hcl 0.1% eye drops MO	1	ST
olopatadine hcl 0.2% eye drop MO	1	
OMNIPRED 1% EYE DROPS MO	3	ST
OXERVATE 0.002 % EYE DROPS DL	4	PA,QL (112 per 365 days)
PATADAY 0.2 % EYE DROPS MO	3	ST
PATANOL 0.1% EYE DROPS MO	3	ST
PAZEO 0.7 % EYE DROPS MO	2	QL (2.5 per 25 days)
PHOSPHOLINE IODIDE 0.125 % EYE DROPS MO	3	
MO pilocarpine 1% eye drops; pilocarpine 2% eye drops; pilocarpine 4% eye drops	1	
polycin 500 unit-10,000 unit/gram eye ointment MO	1	
polymyxin b-tmp eye drops MO	1	
POLYTRIM 10,000 UNIT-1 MG/ML EYE DROPS MO	3	
PRED FORTE 1 % EYE DROPS,SUSPENSION MO	3	ST
PRED MILD 0.12 % EYE DROPS,SUSPENSION MO	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PRED-G 0.3 %-1 % EYE DROPS,SUSPENSION MO	3	
PRED-G S.O.P. 0.3 %-0.6 % EYE OINTMENT MO	3	
<i>prednisolone ac 1% eye drop</i> MO	1	
<i>prednisolone sod 1% eye drop</i> MO	1	
PROLENSA 0.07 % EYE DROPS MO	3	ST,QL (3 per 30 days)
<i>proparacaine 0.5% eye drops</i> MO	1	
RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE MO	2	QL (60 per 30 days)
RESTASIS MULTIDOSE 0.05 % EYE DROPS MO	2	QL (5.5 per 25 days)
RHOPRESSA 0.02 % EYE DROPS MO	2	ST,QL (2.5 per 25 days)
ROCKLATAN 0.02 %-0.005 % EYE DROPS MO	2	ST,QL (2.5 per 25 days)
SIMBRINZA 1 %-0.2 % EYE DROPS,SUSPENSION MO	3	ST,QL (16 per 30 days)
<i>sulfacetamide 10% eye drops</i> MO	1	
<i>sulf-pred 10-0.23% eye drops</i> MO	1	
<i>timolol 0.25% gfs gel-solution; timolol 0.5% gfs gel-solution</i> MO	1	
<i>timolol 0.5% eye drop; timolol maleate 0.25% eye drop; timolol maleate 0.5% eye drops</i> MO	1	
TIMOPTIC 0.25 %, 0.5 % EYE DROPS MO	3	ST
TIMOPTIC OCUDOSE (PF) 0.25 %, 0.5 % EYE DROPS IN A DROPPERETTE MO	3	ST
TIMOPTIC-XE 0.25 %, 0.5 % EYE GEL MO	3	PA
TOBRADEX 0.3 %-0.1 % EYE DROPS,SUSPENSION MO	3	
TOBRADEX 0.3 %-0.1 % EYE OINTMENT MO	3	
TOBRADEX ST 0.3 %-0.05 % EYE DROPS,SUSPENSION MO	3	
<i>tobramycin 0.3% eye drop</i> MO	1	
<i>tobramycin-dexameth ophth susp</i> MO	1	
TOBREX 0.3 % EYE DROPS MO	3	
TOBREX 0.3 % EYE OINTMENT MO	3	
TRAVATAN Z 0.004 % EYE DROPS MO	3	ST,QL (2.5 per 25 days)
<i>travoprost 0.004% eye drop</i> MO	1	QL (2.5 per 25 days)
<i>trifluridine 1% eye drops</i> MO	1	
TRUSOPT 2 % EYE DROPS MO	3	QL (10 per 30 days)
VIGAMOX 0.5 % EYE DROPS MO	3	PA
VYZULTA 0.024 % EYE DROPS MO	3	QL (5 per 30 days)
XALATAN 0.005 % EYE DROPS MO	3	PA,QL (5 per 25 days)
XELPROS 0.005 % EYE DROP EMULSION MO	3	ST,QL (2.5 per 25 days)
XIIDRA 5 % EYE DROPS IN A DROPPERETTE MO	3	PA,QL (60 per 30 days)
ZERVIAE 0.24 % EYE DROPS IN A DROPPERETTE MO	3	ST,QL (60 per 30 days)
ZIOPTAN (PF) 0.0015 % EYE DROPS IN A DROPPERETTE MO	3	ST,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZYLET 0.3 %-0.5 % EYE DROPS,SUSPENSION MO	3	
ZYMAXID 0.5 % EYE DROPS MO	3	ST,QL (2.5 per 25 days)
Otic Agents		
CIPRO HC 0.2 %-1 % EAR DROPS,SUSPENSION MO	3	
CIPRODEX 0.3 %-0.1 % EAR DROPS,SUSPENSION MO	3	
<i>ciprofloxacin 0.2% otic soln</i> MO	1	
<i>ciproflox-dexameth otic susp</i> MO	1	
<i>ciproflox-fluocinoln 0.3-0.025%</i> MO	3	
COLY-MYCIN S OTIC SUSP DROP MO	3	
CORTISPORIN-TC 3.3 MG-3 MG-10 MG-0.5 MG/ML EAR DROPS,SUSPENSION MO	3	
DERMOTIC OIL 0.01 % EAR DROPS MO	3	
<i>flac otic (ear) oil 0.01 % drops</i> MO	1	
<i>fluocinolone oil 0.01% ear drp</i> MO	1	
<i>hydrocortison-acetic acid soln</i> MO	1	
<i>neomycin-polymyxin-hc ear soln</i> MO	1	
<i>neomycin-polymyxin-hc ear susp</i> MO	1	
<i>ofloxacin 0.3% ear drops</i> MO	1	
OTOVEL 0.3 %-0.025 % (0.25 ML) EAR SOLUTION MO	3	
Respiratory Tract/Pulmonary Agents		
ACCOLATE 10 MG, 20 MG TABLET MO	3	PA,QL (60 per 30 days)
<i>acetylcysteine 10% vial; acetylcysteine 20% vial</i> MO	1	B vs D
ADCIRCA 20 MG TABLET DL	4	PA,QL (60 per 30 days)
ADEMPAS 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG TABLET DL	4	PA,QL (90 per 30 days)
ADRENALIN 1 MG/ML, 1 MG/ML (1 ML) INJECTION SOLUTION MO	3	
ADVAIR DISKUS 100 MCG-50 MCG/DOSE POWDER FOR INHALATION; ADVAIR DISKUS 250 MCG-50 MCG/DOSE POWDER FOR INHALATION; ADVAIR DISKUS 500 MCG-50 MCG/DOSE POWDER FOR INHALATION MO	2	QL (60 per 30 days)
ADVAIR HFA 115 MCG-21 MCG/ACTUATION AEROSOL INHALER; ADVAIR HFA 230 MCG-21 MCG/ACTUATION AEROSOL INHALER; ADVAIR HFA 45 MCG-21 MCG/ACTUATION AEROSOL INHALER MO	2	QL (12 per 30 days)
AIRDUO DIGIHALER 113 MCG-14 MCG/ACTUATION, 232-14 MCG/ACTUATION, 55-14 MCG/ACTUATION BREATH ACT,POWDER SENSOR; AIRDUO DIGIHALER 232 MCG-14 MCG/ACTUATION BREATH ACT,POWDER SENSOR; AIRDUO DIGIHALER 55 MCG-14 MCG/ACTUATION BREATH ACT,POWDER SENSOR MO	3	ST,QL (1 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AIRDUO RESPICLICK 113 MCG-14 MCG/ACTUATION BREATH ACTIVATED; AIRDUO RESPICLICK 232 MCG-14 MCG/ACTUATION BREATH ACTIVATED; AIRDUO RESPICLICK 55 MCG-14 MCG/ACTUATION BREATH ACTIVATED MO	3	ST,QL (1 per 30 days)
albuterol 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml sol; albuterol 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml solution; albuterol sul 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml sol; albuterol sul 2.5 mg/3 ml soln MO	1	B vs D
albuterol hfa 90 mcg inhaler MO	1	QL (36 per 30 days)
albuterol sulf 2 mg/5 ml syrup MO	1	
albuterol sulfate 2 mg tab MO	1	QL (120 per 30 days)
albuterol sulfate 4 mg tab MO	1	
albuterol sulfate er 4 mg, 8 mg tab MO	1	
ALVESCO 160 MCG/ACTUATION, 80 MCG/ACTUATION AEROSOL INHALER MO	3	ST,QL (18.3 per 28 days)
alyq 20 mg tablet MO	1	PA,QL (60 per 30 days)
ambrisentan 10 mg, 5 mg tablet DL	4	PA,QL (30 per 30 days)
aminophylline 250 mg/10 ml, 500 mg/20 ml vial MO	1	
ANORO ELLIPTA 62.5 MCG-25 MCG/ACTUATION POWDER FOR INHALATION MO	3	PA,QL (60 per 30 days)
ARCAPTA NEOHALER 75 MCG CAPSULE WITH INHALATION DEVICE MO	3	PA,QL (30 per 30 days)
ARMONAIR RESPICLICK 113 MCG; ARMONAIR RESPICLICK 113 MCG/ACTUATION, 232 MCG/ACTUATION, 55 MCG/ACTUATION BREATH ACTIVATED POWDER INHALER MO	3	ST,QL (1 per 30 days)
ARNUITY ELLIPTA 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION POWDER FOR INHALATION MO	2	QL (30 per 30 days)
ASMANEX HFA 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION AEROSOL INHALER MO	3	ST,QL (13 per 30 days)
ASMANEX TWISTHALER 110 MCG/ACTUATION(30 DOSES) BREATH ACTIVATED INHALR; ASMANEX TWISTHALER 220 MCG/ACTUATION(120 DOSES) BREATH ACTIVATED INHLR; ASMANEX TWISTHALER 220 MCG/ACTUATION(14 DOSES) BREATH ACTIVATED INHALR; ASMANEX TWISTHALER 220 MCG/ACTUATION(30 DOSES) BREATH ACTIVATED INHALR; ASMANEX TWISTHALER 220 MCG/ACTUATION(60 DOSES) BREATH ACTIVATED INHALR MO	3	ST,QL (1 per 28 days)
ATROVENT HFA 17 MCG/ACTUATION AEROSOL INHALER MO	3	QL (25.8 per 30 days)
azelastine 0.1% (137 mcg) spry MO	1	QL (30 per 25 days)
azelastine 0.15% nasal spray MO	1	QL (30 per 25 days)
azelastin-flutic 137-50mcg spr MO	1	ST,QL (23 per 28 days)
BECONASE AQ 42 MCG (0.042 %) NASAL SPRAY MO	3	ST,QL (50 per 30 days)
BEVESPI AEROSPHERE 9 MCG-4.8 MCG HFA AEROSOL INHALER MO	3	QL (10.7 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>bosentan 125 mg, 62.5 mg tablet</i> DL	4	PA,QL (60 per 30 days)
BREO ELLIPTA 100 MCG-25 MCG/DOSE POWDER FOR INHALATION; BREO ELLIPTA 200 MCG-25 MCG/DOSE POWDER FOR INHALATION MO	2	QL (60 per 30 days)
BREZTRI AEROSPHERE 160 MCG-9MCG-4.8MCG/ACTUATION HFA AEROSOL INHALER MO	2	QL (10.7 per 30 days)
BROVANA 15 MCG/2 ML SOLUTION FOR NEBULIZATION DL	4	PA,QL (120 per 30 days)
<i>budesonide 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml inh susp; budesonide 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml susp</i> MO	1	B vs D
<i>carbinoxamine 4 mg/5 ml liquid</i> MO	1	
<i>carbinoxamine maleate 4 mg tab</i> MO	1	
<i>carbinoxamine maleate 6 mg tab</i> MO	1	QL (120 per 30 days)
CAYSTON 75 MG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL (84 per 28 days)
<i>cetirizine hcl 1 mg/ml soln</i> MO	1	QL (300 per 30 days)
CINQAIR 10 MG/ML INTRAVENOUS SOLUTION DL	4	PA
CLARINEX 0.5 MG/ML (2.5 MG/5) MO	3	ST,QL (300 per 30 days)
CLARINEX 5 MG TABLET MO	3	PA,QL (30 per 30 days)
<i>clemastine fum 2.68 mg tab</i> MO	1	
COMBIVENT RESPIMAT 20 MCG-100 MCG/ACTUATION SOLUTION FOR INHALATION MO	3	QL (4 per 20 days)
<i>cromolyn 100 mg/5 ml oral conc</i> MO	1	
<i>cromolyn 20 mg/2 ml neb soln</i> DL	4	B vs D
<i>cyproheptadine 2 mg/5 ml syrup</i> MO	1	
<i>cyproheptadine 4 mg tablet</i> MO	1	
DALIRESP 250 MCG TABLET MO	2	QL (28 per 365 days)
DALIRESP 500 MCG TABLET MO	2	QL (30 per 30 days)
<i>desloratadine 2.5 mg, 5 mg odt</i> MO	1	ST,QL (30 per 30 days)
<i>desloratadine 5 mg tablet</i> MO	1	QL (30 per 30 days)
<i>dexchlorpheniramine 2 mg/5 ml</i> MO	1	PA
<i>diphen 12.5 mg/5 ml oral elixir</i> MO	1	
<i>diphenhydramine 12.5 mg/5 ml</i> MO	1	
<i>diphenhydramine 50 mg/ml syrng</i> MO	1	
<i>diphenhydramine 50 mg/ml vial</i> MO	1	
DOPRAM 20 MG/ML INTRAVENOUS SOLUTION MO	3	
DUAKLIR PRESSAIR 400 MCG-12 MCG/ACTUATION BREATH ACTIVATED DL	4	PA,QL (1 per 30 days)
DULERA 100 MCG-5 MCG/ACTUATION HFA AEROSOL INHALER; DULERA 200 MCG-5 MCG/ACTUATION HFA AEROSOL INHALER; DULERA 50 MCG-5 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL (13 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DYMISTA 137 MCG-50 MCG/SPRAY NASAL SPRAY MO	3	ST,QL (23 per 28 days)
ELIXOPHYLLIN 80 MG/15 ML ORAL ELIXIR MO	1	
<i>epinephrine 0.15 mg auto-inject; epinephrine 0.3 mg auto-inject</i> MO	1	QL (4 per 30 days)
EPIPEN 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR MO	3	PA,QL (4 per 30 days)
EPIPEN 2-PAK 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR MO	3	PA,QL (4 per 30 days)
EPIPEN JR 0.15 MG/0.3 ML INJECTION,AUTO-INJECTOR MO	3	PA,QL (4 per 30 days)
EPIPEN JR 2-PAK 0.15 MG/0.3 ML INJECTION,AUTO-INJECTOR MO	3	PA,QL (4 per 30 days)
<i>epoprostenol sodium 0.5 mg, 1.5 mg vl</i> DL	4	PA
ESBRIET 267 MG CAPSULE DL, LA	4	PA,QL (270 per 30 days)
ESBRIET 267 MG TABLET DL, LA	4	PA,QL (270 per 30 days)
ESBRIET 801 MG TABLET DL, LA	4	PA,QL (90 per 30 days)
FASENRA 30 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (1 per 28 days)
FASENRA PEN 30 MG/ML SUBCUTANEOUS AUTO-INJECTOR DL	4	PA,QL (1 per 28 days)
FLOVENT DISKUS 100 MCG/ACTUATION, 250 MCG/ACTUATION, 50 MCG/ACTUATION POWDER FOR INHALATION MO	2	QL (60 per 30 days)
FLOVENT HFA 110 MCG/ACTUATION, 220 MCG/ACTUATION AEROSOL INHALER MO	2	QL (24 per 30 days)
FLOVENT HFA 44 MCG/ACTUATION AEROSOL INHALER MO	2	QL (10.6 per 30 days)
<i>flunisolide 0.025% spray</i> MO	1	QL (50 per 30 days)
<i>fluticasone-salmeterol 100-50; fluticasone-salmeterol 250-50;</i>	1	QL (60 per 30 days)
<i>fluticasone-salmeterol 500-50</i> MO		
<i>fluticasone-salmeterol 113-14; fluticasone-salmeterol 232-14;</i>	2	QL (1 per 30 days)
<i>fluticasone-salmeterol 55-14</i> MO		
<i>fluticasone prop 50 mcg spray</i> MO	1	QL (16 per 30 days)
GASTROCROM 100 MG/5 ML ORAL CONCENTRATE DL	4	
GRASTEK 2,800 BAU SUBLINGUAL TABLET MO	3	PA,QL (30 per 30 days)
<i>hydroxyzine pam 100 mg, 25 mg, 50 mg cap</i> MO	1	
INCRUSE ELLIPTA 62.5 MCG/ACTUATION POWDER FOR INHALATION MO	3	PA,QL (30 per 30 days)
<i>ipratropium 0.03% spray</i> MO	1	QL (30 per 30 days)
<i>ipratropium 0.06% spray</i> MO	1	QL (45 per 30 days)
<i>ipratropium br 0.02% soln</i> MO	1	B vs D
<i>iprat-albut 0.5-3(2.5) mg/3 ml</i> MO	1	B vs D
KALYDECO 150 MG TABLET DL	4	PA,QL (60 per 30 days)
KALYDECO 25 MG, 50 MG, 75 MG ORAL GRANULES IN PACKET DL	4	PA,QL (56 per 28 days)
KARBINAL ER 4 MG/5 ML ORAL SUSPENSION,EXTENDED RELEASE MO	3	
LETAIRIS 10 MG, 5 MG TABLET DL	4	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
levalbuterol 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml sol; levalbuterol conc 1.25 mg/0.5 MO	1	B vs D
levalbuterol tar hfa 45mcg inh MO	1	ST,QL (30 per 30 days)
levocetirizine 2.5 mg/5 ml sol MO	1	QL (300 per 30 days)
levocetirizine 5 mg tablet MO	1	QL (30 per 30 days)
LONHALA MAGNAIR REFILL 25 MCG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL (60 per 30 days)
LONHALA MAGNAIR STARTER 25 MCG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL (60 per 365 days)
metaproterenol 10 mg, 20 mg tablet MO	1	
metaproterenol 10 mg/5 ml syr MO	1	
mometasone furoate 50 mcg spry MO	1	ST,QL (34 per 30 days)
montelukast sod 10 mg tablet MO	1	QL (30 per 30 days)
montelukast sod 4 mg granules MO	1	QL (30 per 30 days)
montelukast sod 4 mg, 5 mg tab chew MO	1	QL (30 per 30 days)
NASONEX 50 MCG/ACTUATION SPRAY MO	3	ST,QL (34 per 30 days)
NUCALA 100 MG, 100 MG/ML SUBCUTANEOUS AUTO-INJECTOR; NUCALA 100 MG, 100 MG/ML SUBCUTANEOUS SOLUTION DL	4	PA,QL (3 per 28 days)
NUCALA 100 MG/ML SUBCUTANEOUS SYRINGE DL	4	PA,QL (3 per 28 days)
ODACTRA 12 SQ-HDM SUBLINGUAL TABLET MO	3	PA,QL (30 per 30 days)
OFEV 100 MG, 150 MG CAPSULE DL, LA	4	PA,QL (60 per 30 days)
olopatadine 665 mcg nasal spry MO	1	ST,QL (30.5 per 30 days)
OMNARIS 50 MCG NASAL SPRAY MO	3	ST,QL (12.5 per 30 days)
OPSUMIT 10 MG TABLET DL	4	PA,QL (30 per 30 days)
ORALAIR 100 INDEX OF REACTIVITY SUBLINGUAL TABLET; ORALAIR 100 INDEX OF REACTIVITY(3)/300 IDX REACT.(6) SUBLINGUAL TABLET; ORALAIR 300 IR SUBLINGUAL TABLET MO	3	PA,QL (30 per 30 days)
ORENITRAM 0.125 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (1000 per 30 days)
ORENITRAM 0.25 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (500 per 30 days)
ORENITRAM 1 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (720 per 30 days)
ORENITRAM 2.5 MG TABLET,EXTENDED RELEASE DL	4	PA,QL (300 per 30 days)
ORENITRAM 5 MG TABLET, EXTENDED RELEASE DL	4	PA,QL (150 per 30 days)
ORKAMBI 100 MG-125 MG ORAL GRANULES IN PACKET; ORKAMBI 150 MG-188 MG ORAL GRANULES IN PACKET DL	4	PA,QL (56 per 28 days)
ORKAMBI 100 MG-125 MG TABLET; ORKAMBI 200 MG-125 MG TABLET DL	4	PA,QL (112 per 28 days)
PATANASE 0.6 % NASAL SPRAY MO	3	ST,QL (30.5 per 30 days)
PERFORMIST 20 MCG/2 ML SOLUTION FOR NEBULIZATION MO	3	PA,QL (120 per 30 days)
PROAIR DIGIHALER 90 MCG/ACTUATION AEROSOL POWDER BREATH ACT, SENSOR MO	3	ST,QL (2 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROAIR HFA 90 MCG/ACTUATION AEROSOL INHALER MO	3	ST,QL (36 per 30 days)
PROAIR RESPICLICK 90 MCG/ACTUATION BREATH ACTIVATED MO	3	ST,QL (2 per 30 days)
PROVENTIL HFA 90 MCG/ACTUATION AEROSOL INHALER MO	3	ST,QL (36 per 30 days)
PULMICORT 0.25 MG/2 ML, 0.5 MG/2 ML, 1 MG/2 ML SUSPENSION FOR NEBULIZATION MO	3	B vs D
PULMICORT FLEXHALER 180 MCG/ACTUATION, 90 MCG/ACTUATION BREATH ACTIVATED MO	3	ST,QL (2 per 30 days)
PULMOZYME 1 MG/ML SOLUTION FOR INHALATION DL	4	B vs D
QNASL 40 MCG/ACTUATION NASAL AEROSOL SPRAY MO	3	ST,QL (6.8 per 30 days)
QNASL 80 MCG/ACTUATION NASAL AEROSOL SPRAY MO	3	ST,QL (10.6 per 30 days)
QUZYTIR 10 MG/ML INTRAVENOUS SOLUTION MO	3	B vs D
QVAR REDIHALER 40 MCG/ACTUATION HFA BREATH ACTIVATED AEROSOL MO	3	ST,QL (10.6 per 30 days)
QVAR REDIHALER 80 MCG/ACTUATION HFA BREATH ACTIVATED AEROSOL MO	3	ST,QL (21.2 per 30 days)
RAGWITEK 12 AMB A 1 UNIT SUBLINGUAL TABLET MO	3	PA,QL (30 per 30 days)
REMODULIN 1 MG/ML, 10 MG/ML, 2.5 MG/ML, 5 MG/ML INJECTION SOLUTION DL	4	PA
REVATIO 10 MG/ML ORAL SUSPENSION DL	4	PA,QL (180 per 30 days)
REVATIO 20 MG TABLET DL	4	PA,QL (90 per 30 days)
RYCLORA 2 MG/5 ML ORAL SOLUTION MO	1	
RYVENT 6 MG TABLET MO	1	QL (120 per 30 days)
SEEBRI NEOHALER 15.6 MCG CAPSULE WITH INHALATION DEVICE MO	3	PA,QL (60 per 30 days)
SEREVENT DISKUS 50 MCG/DOSE POWDER FOR INHALATION MO	3	PA,QL (60 per 30 days)
<i>sildenafil 10 mg/ml oral susp</i> DL	4	PA,QL (180 per 30 days)
<i>sildenafil 20 mg tablet</i> MO	1	PA,QL (90 per 30 days)
SINGULAIR 10 MG TABLET MO	3	PA,QL (30 per 30 days)
SINGULAIR 4 MG ORAL GRANULES IN PACKET MO	3	PA,QL (30 per 30 days)
SINGULAIR 4 MG, 5 MG CHEWABLE TABLET MO	3	PA,QL (30 per 30 days)
SPIRIVA RESPIMAT 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION SOLUTION FOR INHALATION MO	2	QL (4 per 28 days)
SPIRIVA WITH HANDIHALER 18 MCG AND INHALATION CAPSULES MO	2	QL (30 per 30 days)
STIOLTO RESPIMAT 2.5 MCG-2.5 MCG/ACTUATION SOLUTION FOR INHALATION MO	2	QL (4 per 28 days)
STRIVERDI RESPIMAT 2.5 MCG/ACTUATION SOLUTION FOR INHALATION MO	2	QL (4 per 30 days)
SYMBICORT 160 MCG-4.5 MCG/ACTUATION HFA AEROSOL INHALER; SYMBICORT 80 MCG-4.5 MCG/ACTUATION HFA AEROSOL INHALER MO	2	QL (10.2 per 30 days)
SYMDEKO 100 MG-150 MG (DAY)/150 MG (NIGHT) TABLETS; SYMDEKO 50 MG-75 MG (DAY)/75 MG (NIGHT) TABLETS DL	4	PA,QL (56 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SYMJEPI 0.15 MG/0.3 ML, 0.3 MG/0.3 ML INJECTION SYRINGE; SYMJEPI 0.15 MG/0.3 ML, 0.3 MG/0.3 ML INJECTION SYRINGE (FOR 33 LB TO 66 LB PATIENTS) MO	2	QL (4 per 30 days)
tadalafil 20 mg tablet MO	1	PA,QL (60 per 30 days)
terbutaline sulf 1 mg/ml vial DL	4	
terbutaline sulfate 2.5 mg, 5 mg tab MO	1	
THEO-24 100 MG, 200 MG, 300 MG, 400 MG CAPSULE,EXTENDED RELEASE MO	1	
theophylline 80 mg/15 ml soln MO	1	
theophylline er 100 mg, 200 mg, 300 mg tab; theophylline er 100 mg, 200 mg, 300 mg tablet MO	1	
theophylline er 400 mg, 600 mg tablet MO	1	
theophylline er 450 mg tab MO	1	QL (30 per 30 days)
theophylline 200 mg/100 ml, 200 mg/50 ml, 400 mg/250 ml, 400 mg/500 ml, 800 mg/250 ml d5w MO	1	
TOBI PODHALER 28 MG CAPSULE WITH INHALATION DEVICE; TOBI PODHALER 28 MG INHALE CAP DL	4	PA,QL (224 per 28 days)
TRACLEER 125 MG, 62.5 MG TABLET DL	4	PA,QL (60 per 30 days)
TRACLEER 32 MG TABLET FOR ORAL SUSPENSION DL	4	PA,QL (120 per 30 days)
TRELEGY ELLIPTA 100 MCG-62.5 MCG-25 MCG POWDER FOR INHALATION MO	2	QL (60 per 30 days)
treprostinil 100 mg/20 ml vial; treprostinil 20 mg/20 ml vial; treprostinil 200 mg/20 ml vial; treprostinil 50 mg/20 ml vial DL	4	PA
TRIKAFTA 100-50-75 MG (D)/150 MG (N) TABLETS DL	4	PA,QL (84 per 28 days)
TUDORZA PRESSAIR 400 MCG/ACTUATION BREATH ACTIVATED MO	3	PA,QL (1 per 30 days)
TYVASO 1.74 MG/2.9 ML (0.6 MG/ML) SOLUTION FOR NEBULIZATION DL	4	PA
TYVASO INSTITUTIONAL STARTER KIT 1.74 MG/2.9 ML SOLN FOR NEBULIZATION DL	4	PA
TYVASO REFILL KIT 1.74 MG/2.9 ML (0.6 MG/ML) SOLUTION FOR NEBULIZATION DL	4	PA
TYVASO STARTER KIT 1.74 MG/2.9 ML SOLUTION FOR NEBULIZATION DL	4	PA
UPTRAVI 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG TABLET DL	4	PA,QL (60 per 30 days)
UPTRAVI 200 MCG (140)-800 MCG (60) TABLETS IN A DOSE PACK DL	4	PA,QL (200 per 30 days)
UTIBRON NEOHALER 27.5 MCG-15.6 MCG CAPSULE WITH INHALATION DEVICE MO	3	PA,QL (60 per 30 days)
VELETRI 0.5 MG, 1.5 MG INTRAVENOUS SOLUTION DL	4	PA
VENTAVIS 10 MCG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL (150 per 30 days)
VENTAVIS 20 MCG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL (90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VENTOLIN HFA 90 MCG/ACTUATION AEROSOL INHALER MO	2	QL (36 per 30 days)
VISTARIL 25 MG, 50 MG CAPSULE MO	3	
wixela inhub 100 mcg-50 mcg/dose powder for inhalation; wixela inhub 250 mcg-50 mcg/dose powder for inhalation; wixela inhub 500 mcg-50 mcg/dose powder for inhalation MO	1	QL (60 per 30 days)
XHANCE 93 MCG/ACTUATION BREATH ACTIVATED AEROSOL MO	3	PA,QL (32 per 30 days)
XOPENEX 0.31 MG/3 ML, 0.63 MG/3 ML, 1.25 MG/3 ML SOLUTION FOR NEBULIZATION MO	3	B vs D
XOPENEX CONCENTRATE 1.25 MG/0.5 ML SOLUTION FOR NEBULIZATION MO	3	B vs D
XOPENEX HFA 45 MCG/ACTUATION AEROSOL INHALER MO	3	ST,QL (30 per 30 days)
YUPELRI 175 MCG/3 ML SOLUTION FOR NEBULIZATION DL	4	PA,QL (90 per 30 days)
zafirlukast 10 mg, 20 mg tablet MO	1	QL (60 per 30 days)
ZETONNA 37 MCG/ACTUATION NASAL HFA INHALER MO	3	ST,QL (6.1 per 28 days)
zileuton er 600 mg tablet DL	4	ST,QL (120 per 30 days)
ZYFLO 600 MG TABLET DL	4	ST,QL (120 per 30 days)
ZYFLO CR 600 MG TABLET DL	4	ST,QL (120 per 30 days)
Skeletal Muscle Relaxants		
AMRIX 15 MG, 30 MG CAPSULE,EXTENDED RELEASE DL	4	ST,QL (21 per 30 days)
carisoprodol 250 mg, 350 mg tablet MO	1	QL (120 per 30 days)
carisoprodol-aspirin 200-325 mg MO	1	
carisoprodol-aspirin-codein tb DL	1	QL (360 per 30 days)
chlorzoxazone 250 mg tablet MO	1	ST,QL (360 per 30 days)
chlorzoxazone 375 mg, 750 mg tablet MO	1	ST,QL (120 per 30 days)
chlorzoxazone 500 mg tablet MO	1	ST
cyclobenzaprine 10 mg, 5 mg tablet MO	1	
cyclobenzaprine 7.5 mg tablet MO	1	QL (90 per 30 days)
cyclobenzaprine er 15 mg, 30 mg cap MO	1	ST,QL (21 per 30 days)
FEXMID 7.5 MG TABLET MO	1	ST,QL (90 per 30 days)
LORZONE 375 MG, 750 MG TABLET MO	1	ST,QL (120 per 30 days)
metaxall 800 mg tablet MO	1	QL (120 per 30 days)
metaxalone 400 mg, 800 mg tablet MO	1	QL (120 per 30 days)
methocarbamol 1,000 mg/10 ml MO	1	
methocarbamol 500 mg, 750 mg tablet MO	1	
NORGESIC FORTE 50 MG-770 MG-60 MG TABLET DL	4	PA,QL (120 per 30 days)
orphenadrine 30 mg/ml vial MO	1	
orphenadrine er 100 mg tablet MO	1	
orphenad-asa-caff 50-770-60 mg DL	4	PA,QL (120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>orphengesic forte 50 mg-770 mg-60 mg tablet</i> DL	4	PA,QL (120 per 30 days)
ROBAXIN 100 MG/ML INJECTION SOLUTION DL	4	
ROBAXIN 500 MG TABLET MO	3	
ROBAXIN-750 750 MG TABLET MO	3	
SKELAXIN 800 MG TABLET DL	4	PA,QL (120 per 30 days)
SOMA 250 MG TABLET DL	4	PA,QL (120 per 30 days)
SOMA 350 MG TABLET MO	3	PA,QL (120 per 30 days)
<i>vanadom 350 mg tablet</i> MO	1	QL (120 per 30 days)
SLEEP DISORDER AGENTS		
AMBIEN 10 MG, 5 MG TABLET MO	3	PA,QL (30 per 30 days)
AMBIEN CR 12.5 MG, 6.25 MG TABLET,EXTENDED RELEASE MO	3	PA,QL (30 per 30 days)
<i>armodafinil 150 mg, 200 mg, 250 mg tablet</i> MO	1	PA,QL (30 per 30 days)
<i>armodafinil 50 mg tablet</i> MO	1	PA,QL (60 per 30 days)
BELSOMRA 10 MG TABLET MO	2	QL (60 per 30 days)
BELSOMRA 15 MG, 20 MG TABLET MO	2	QL (30 per 30 days)
BELSOMRA 5 MG TABLET MO	2	QL (120 per 30 days)
DAYVIGO 10 MG, 5 MG TABLET MO	3	PA,QL (30 per 30 days)
<i>doxepin hcl 3 mg, 6 mg tablet</i> MO	1	QL (30 per 30 days)
EDLUAR 10 MG SUBLINGUAL TABLET MO	3	
EDLUAR 5 MG SUBLINGUAL TABLET MO	3	QL (30 per 30 days)
<i>estazolam 1 mg, 2 mg tablet</i> DL	1	QL (30 per 30 days)
<i>eszopiclone 1 mg, 2 mg, 3 mg tablet</i> MO	1	QL (30 per 30 days)
<i>flurazepam 15 mg capsule</i> DL	1	QL (60 per 30 days)
<i>flurazepam 30 mg capsule</i> DL	1	QL (30 per 30 days)
HALCION 0.25 MG TABLET DL	3	PA,QL (30 per 30 days)
HETLIOZ 20 MG CAPSULE DL	4	PA,QL (30 per 30 days)
INTERMEZZO 1.75 MG, 3.5 MG SUBLINGUAL TABLET MO	3	PA,QL (30 per 30 days)
LUNESTA 1 MG, 2 MG, 3 MG TABLET MO	3	PA,QL (30 per 30 days)
<i>modafinil 100 mg, 200 mg tablet</i> MO	1	PA,QL (60 per 30 days)
NUVIGIL 150 MG, 200 MG, 250 MG TABLET DL	4	PA,QL (30 per 30 days)
NUVIGIL 50 MG TABLET DL	4	PA,QL (60 per 30 days)
PROVIGIL 100 MG, 200 MG TABLET DL	4	PA,QL (60 per 30 days)
<i>ramelteon 8 mg tablet</i> MO	1	ST,QL (30 per 30 days)
RESTORIL 15 MG, 22.5 MG, 30 MG, 7.5 MG CAPSULE DL	4	PA,QL (30 per 30 days)
ROZEREM 8 MG TABLET MO	3	ST,QL (30 per 30 days)
SILENOR 3 MG, 6 MG TABLET MO	3	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SONATA 10 MG, 5 MG CAPSULE MO	3	PA,QL (30 per 30 days)
SUNOSI 150 MG, 75 MG TABLET DL	4	PA,QL (30 per 30 days)
<i>temazepam 15 mg, 22.5 mg, 30 mg, 7.5 mg capsule</i> DL	1	QL (30 per 30 days)
<i>triazolam 0.125 mg, 0.25 mg tablet</i> DL	1	QL (30 per 30 days)
WAKIX 17.8 MG, 4.45 MG TABLET DL	4	PA,QL (60 per 30 days)
XYREM 500 MG/ML ORAL SOLUTION DL	4	PA,QL (540 per 30 days)
<i>zaleplon 10 mg, 5 mg capsule</i> MO	1	QL (30 per 30 days)
<i>zolpidem tart 1.75 mg, 10 mg, 12.5 mg, 3.5 mg, 5 mg, 6.25 mg tab sl;</i> <i>zolpidem tart 1.75 mg, 10 mg, 12.5 mg, 3.5 mg, 5 mg, 6.25 mg tablet sl;</i> <i>zolpidem tart er 1.75 mg, 10 mg, 12.5 mg, 3.5 mg, 5 mg, 6.25 mg tab;</i> <i>zolpidem tartrate 1.75 mg, 10 mg, 12.5 mg, 3.5 mg, 5 mg, 6.25 mg tablet</i> MO	1	QL (30 per 30 days)
ZOLPIMIST 5 MG/SPRAY (0.1 ML) ORAL SPRAY MO	3	QL (23.1 per 365 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

Index

A

- a-hydrocort... 124
- abacavir... 65
- abacavir-lamivudine... 65
- abacavir-lamivudine-zidovudine... 66
- ABELCET... 42
- ABILIFY MAINTENA... 62
- ABILIFY MYCITE... 62
- ABILIFY... 61
- abiraterone... 48
- ABOUTTIME PEN NEEDLE... 150
- ABRAXANE... 48
- ABSORICA LD... 101, 102
- ABSORICA... 101
- ABSTRAL... 10
- acamprosate... 20
- ACANYA... 102
- acarbose... 72
- ACCOLATE... 167
- ACCUPRIL... 82
- ACCURETIC... 82
- acebutolol... 82
- ACETADOTE... 150
- acetaminophen-caff-dihydrocod... 10
- acetaminophen-codeine... 10
- acetazolamide sodium... 82
- acetazolamide... 82
- acetic acid... 21, 150
- acetylcysteine... 150, 167
- ACIPHEX SPRINKLE... 117
- ACIPHEX... 117
- acitretin... 102
- ACTEMRA ACTPEN... 140
- ACTEMRA... 140
- ACTHAR... 124
- ACTHIB (PF)... 140
- ACTICLATE... 21
- ACTIGALL... 118
- ACTIMMUNE... 140
- ACTIQ... 10
- ACTIVELLA... 128
- ACTONEL... 148
- ACTOPLUS MET XR... 72
- ACTOPLUS MET... 72
- ACTOS... 72
- ACULAR LS... 162
- ACULAR... 162
- ACUVAIL (PF)... 162
- acyclovir sodium... 66
- acyclovir... 66
- ACZONE... 102
- ADACEL(TDAP ADOLESN/ADULT)(PF)... 140
- ADAGEN... 121
- ADAKVEO... 150
- ADALAT CC... 82
- adapalene... 102
- adapalene-benzoyl peroxide... 102
- ADCETRIS... 48
- ADCIRCA... 167
- ADDERALL XR... 96
- ADDERALL... 96
- adefovir... 66
- ADEMPAS... 167
- adenosine... 82
- ADLYXIN... 72
- ADMELOG SOLOSTAR U-100 INSULIN... 72
- ADMELOG U-100 INSULIN LISPRO... 72
- ADRENALIN... 167
- adriamycin... 48
- adrucil... 48
- ADVAIR DISKUS... 167
- ADVAIR HFA... 167
- ADVOCATE PEN NEEDLE... 150
- ADVOCATE SYRINGES... 150
- ADZENYS ER... 97

ADZENYS XR-ODT... 97	ALBENZA... 59	ALORA... 128
AEMCOLO... 118	albuterol sulfate... 168	alosetron... 118
afeditab cr... 82	ALCAINE... 162	ALPHAGAN P... 162, 163
AFINITOR DISPERZ... 48	alclometasone... 102	alprazolam intensol... 71
AFINITOR... 48	ALCOHOL PADS... 150	alprazolam... 71
afirmelle... 128	ALCOHOL PREP PADS... 150	ALREX... 163
AFREZZA... 73	ALCOHOL SWABS... 150	ALTABAX... 102
AGGRASTAT CONCENTRATE... 78	ALCOHOL WIPES... 150	ALTACE... 83
AGGRASTAT IN SODIUM CHLORIDE... 78	ALDACTAZIDE... 82	altavera (28)... 128
AGGRENOX... 78	ALDACTONE... 83	ALTOPREV... 83
AGRYLIN... 78	ALDARA... 102	ALTRENO... 102
AIMOVIG AUTOINJECTOR (2 PACK)... 45	ALDURAZYME... 121	ALUNBRIG... 48
AIMOVIG AUTOINJECTOR... 45	ALECENSA... 48	ALVESCO... 168
AIRDUO DIGIHALER... 167	alendronate... 148	alyacen 1/35 (28)... 128
AIRDUO RESPICLICK... 168	alfuzosin... 123	alyacen 7/7/7 (28)... 128
AJOVY AUTOINJECTOR... 45	ALIMTA... 48	alyq... 168
AJOVY SYRINGE... 45	ALINIA... 59	amabelz... 128
ak-poly-bac... 162	ALIQOPA... 48	amantadine hcl... 59, 60
AKLIEF... 102	aliskiren... 83	AMARYL... 73
AKTEN (PF)... 162	ALKERAN (AS HCL)... 48	AMBIEN CR... 175
AKTIPAK... 102	ALKERAN... 48	AMBIEN... 175
AKYNZEO (FOSNETUPITANT)... 40	allopurinol sodium... 45	AMBISOME... 42
AKYNZEO (NETUPITANT)... 41	allopurinol... 45	ambrisentan... 168
ALA-CORT... 102	ALLZITAL... 10	amcinonide... 102
ALA-SCALP... 102	almotriptan malate... 46	AMERGE... 46
albendazole... 58	ALOCRIL... 162	amethia lo... 128
	ALOMIDE... 162	amethia... 128
	ALOPRIM... 45	amethyst (28)... 128

AMICAR... 78	amlodipine... 83	ANCOBON... 42
amifostine crystalline... 48	amlodipine-atorvastatin... 83	ANDRODERM... 128
amikacin... 22	amlodipine-benazepril... 83	ANDROGEL... 128
amiloride... 83	amlodipine-olmesartan... 83	ANDROID... 128
amiloride-hydrochlorothiazide... 83	amlodipine-valsartan... 83	ANGELIQ... 128
aminocaproic acid... 78, 79	amlodipine-valsartan-hcthiazyd... 83	ANNOVERA... 128
aminophylline... 168	ammonium lactate... 102	ANORO ELLIPTA... 168
AMINOSYN II 10 %... 111	AMMONUL... 150	ANTABUSE... 20
AMINOSYN II 15 %... 111	amnesteem... 102	ANTARA... 83
AMINOSYN II 7 %... 111	amoxapine... 37	anusol-hc... 102
AMINOSYN II 8.5 %... 111	amoxicil-clarithromy-lansopraz... 118	ANZEMET... 41
AMINOSYN II 8.5 %-ELECTROLYTES... 111	amoxicillin... 22	apexicon e... 102
AMINOSYN M 3.5 %... 111	amoxicillin-pot clavulanate... 22	APIDRA SOLOSTAR U-100 INSULIN... 73
AMINOSYN 10 %... 110	amphetamine sulfate... 97	APIDRA U-100 INSULIN... 73
AMINOSYN 7 % WITH ELECTROLYTES... 110	amphetamine... 97	APLENZIN... 37
AMINOSYN 8.5 %... 110	amphotericin b... 42	APOKYN... 60
AMINOSYN 8.5 %-ELECTROLYTES... 110	ampicillin sodium... 22	apraclonidine... 163
AMINOSYN-HBC 7%... 111	ampicillin... 22	apri... 128
AMINOSYN-PF 10 %... 111	ampicillin-sulbactam... 22	APRISO... 147
AMINOSYN-PF 7 % (SULFITE-FREE)... 111	AMPYRA... 97	APTENSIO XR... 97
AMINOSYN-RF 5.2 %... 111	AMRIX... 174	APTIOM... 31
amiodarone... 83	AMZEEQ... 102	APTIVUS (WITH VITAMIN E)... 66
AMITIZA... 118	ANADROL-50... 128	APTIVUS... 66
amitriptyline... 37	ANAFRANIL... 37	ARALAST NP... 121
amitriptyline-chlordiazepoxide... 37	anagrelide... 79	aranelle (28)... 128
	ANAPROX DS... 10	ARANESP (IN POLYSORBATE)... 79
	anastrozole... 48	

ARAVA... 140	ashlyna... 128	AUGMENTIN ES-600... 22
ARAZLO... 102	ASMANEX HFA... 168	AUGMENTIN XR... 22
ARCALYST... 140	ASMANEX TWISTHALER... 168	AUGMENTIN... 22
ARCAPTA NEOHALER... 168	ASPARLAS... 48	aurovela fe 1.5/30 (28)... 129
ARICEPT... 36	aspirin-dipyridamole... 79	aurovela fe 1-20 (28)... 129
ARIKAYCE... 22	ASSURE ID DUO-SHIELD... 150	aurovela 1.5/30 (21)... 129
ARIMIDEX... 48	ASSURE ID INSULIN SAFETY... 150	aurovela 1/20 (21)... 129
aripiprazole... 62	ASSURE ID PEN NEEDLE... 150	aurovela 24 fe... 129
ARISTADA INITIO... 62	ASTAGRAF XL... 140	AURYXIA... 111
ARISTADA... 62	ATACAND HCT... 83	AUSTEDO... 97
ARISTOSPAN INTRA-ARTICULAR... 124	ATACAND... 83	AUTOJECT 2 INJECTION DEVICE... 150
ARISTOSPAN INTRALESIONAL... 124	atazanavir... 66	AUTOPEN 1 TO 21 UNITS... 150
ARIXTRA... 79	ATELVIA... 148	AUTOPEN 2 TO 42 UNITS... 150
armodafinil... 175	atenolol... 83	AVALIDE... 83
ARMONAIR RESPICLICK... 168	atenolol-chlorthalidone... 83	AVANDIA... 73
ARMOUR THYROID... 137	ATGAM... 140	AVAPRO... 83
ARNUITY ELLIPTA... 168	ATIVAN... 71	AVASTIN... 48
AROMASIN... 48	atomoxetine... 97	AVC VAGINAL... 22
ARRANON... 48	atorvastatin... 83	AVEED... 129
arsenic trioxide... 48	atovaquone... 59	AVELOX IN NACL (ISO-OSMOTIC)... 22
ARTHROTEC 50... 10	atovaquone-proguanil... 59	AVELOX... 22
ARTHROTEC 75... 10	ATRALIN... 102	aviane... 129
ARYMO ER... 10	ATRIPLA... 66	avidoxy... 22
ARZERRA... 48	atropine... 118, 163	AVITA... 102
ASACOL HD... 147	ATROVENT HFA... 168	AVODART... 123
ASCENIV... 140	AUBAGIO... 97	AVONEX (WITH ALBUMIN)... 97
ascomp with codeine... 10	aubra eq... 129	
	aubra... 129	

AVONEX... 97	BACIGUENT... 163	BD AUTOSHIELD DUO PEN NEEDLE... 151
AVSOLA... 140	baciim... 23	BD ECLIPSE LUER-LOK... 151
AVYCAZ... 22	bacitracin... 23, 163	BD INSULIN SYRINGE HALF UNIT... 151
AXIRON... 129	bacitracin-polymyxin b... 163	BD INSULIN SYRINGE MICRO-FINE... 151
AYGESTIN... 129	baclofen... 65	BD INSULIN SYRINGE SAFETY-LOK... 151
ayuna... 129	BACTRIM DS... 23	BD INSULIN SYRINGE SLIP TIP... 151
AYVAKIT... 48	BACTRIM... 23	BD INSULIN SYRINGE U-500... 151
azacitidine... 49	BACTROBAN NASAL... 103	BD INSULIN SYRINGE ULTRA-FINE... 151
AZACTAM IN DEXTROSE (ISO-OSM)... 22	BACTROBAN... 102	BD INSULIN SYRINGE... 151
AZACTAM... 22	BAFIERTAM... 97	BD LO-DOSE MICRO-FINE IV... 151
AZASAN... 140	BAL IN OIL... 150	BD LO-DOSE ULTRA-FINE... 151
AZASITE... 163	bal-care dha... 111	BD NANO 2ND GEN PEN NEEDLE... 151
azathioprine sodium... 140	balanced salt... 163	BD SAFETYGLIDE INSULIN SYRINGE... 151
azathioprine... 140	BALCOLTRA... 129	BD SAFETYGLIDE SYRINGE... 151
azelaic acid... 102	balsalazide... 147	BD ULTRA-FINE MICRO PEN NEEDLE... 151
azelastine... 163, 168	BALVERSA... 49	BD ULTRA-FINE MINI PEN NEEDLE... 151
azelastine-fluticasone... 168	balziva (28)... 129	BD ULTRA-FINE NANO PEN NEEDLE... 151
AZELEX... 102	BAND-AID GAUZE PADS... 151	BD ULTRA-FINE ORIG PEN NEEDLE... 151
AZILECT... 60	BANZEL... 31	BD ULTRA-FINE SHORT PEN NEEDLE... 151
azithromycin... 22	BAQSIMI... 73	
AZOPT... 163	BARACLUDGE... 66	
AZOR... 83	BASAGLAR KWIKPEN U-100 INSULIN... 73	
aztreonam... 23	BAVENCIO... 49	
AZULFIDINE EN-TABS... 147	BAXDELA... 23	
AZULFIDINE... 147	BCG VACCINE, LIVE (PF)... 140	
azurette (28)... 129	BD ALCOHOL SWABS... 151	

B

BD VEO INSULIN SYR HALF UNIT... 151	betamethasone dipropionate... 103	bisoprolol-hydrochlorothiazide... 84
BD VEO INSULIN SYRINGE UF... 151	betamethasone valerate... 103	BIVIGAM... 140
BECONASE AQ... 168	betamethasone, augmented... 103	BLENREP... 49
bekyree (28)... 129	BETAPACE AF... 84	bleomycin... 49
BELBUCA... 10	BETAPACE... 84	BLEPH-10... 163
BELEODAQ... 49	BETASERON... 97	BLEPHAMIDE S.O.P... 163
BELSOMRA... 175	betaxolol... 84, 163	BLEPHAMIDE... 163
benazepril... 83	bethanechol chloride... 123	blisovi fe 1.5/30 (28)... 129
benazepril-hydrochlorothiazide... 83	BETHKIS... 23	blisovi fe 1/20 (28)... 129
BENDEKA... 49	BETIMOL... 163	blisovi 24 fe... 129
BENICAR HCT... 84	BETOPTIC S... 163	BONIVA... 148
BENICAR... 83	BEVESPI AEROSPHERE... 168	BONJESTA... 41
BENLYSTA... 140	BEVYXA... 79	BOOSTRIX TDAP... 140
BENTYL... 118	bexarotene... 49	BORDERED GAUZE... 151
BENZAACLIN PUMP... 103	BEXSERO... 140	bortezomib... 49
BENZAACLIN... 103	BEYAZ... 129	bosentan... 169
BENZAMYCIN... 103	bicalutamide... 49	BOSULIF... 49
benznidazole... 59	BICILLIN C-R... 23	BRAFTOVI... 49
benztropine... 60	BICILLIN L-A... 23	BREO ELLIPTA... 169
BEPREVE... 163	BICNU... 49	bretylium tosylate... 84
BERINERT... 140	BIDIL... 84	BREVIBLOC IN NACL (ISO-OSM)... 84
beser... 103	BIJUVA... 129	BREVIBLOC... 84
BESIVANCE... 163	BIKTARVY... 66	BREZTRI AEROSPHERE... 169
BESPONSA... 49	BILTRICIDE... 59	briellyn... 129
BETADINE OPHTHALMIC PREP... 163	bimatoprost... 163	BRILINTA... 79
betamethasone acet,sod phos... 124	BINOSTO... 148	brimonidine... 163
	BIORPHEN... 84	BRISDELLE... 37
	bisoprolol fumarate... 84	BRIVIACT... 31

bromfenac... 163	BUSULFEX... 49	calcitonin (salmon)... 148
bromocriptine... 60	butalbital compound w/codeine... 10	calcitrene... 103
BROMSITE... 163	butalbital-acetaminop-caf-cod... 10	calcitriol... 103, 148
BROVANA... 169	butalbital-acetaminophen... 10	calcium acetate(phosphat bind)... 111
BRUKINSA... 49	butalbital-acetaminophen-caff... 10	calcium chloride... 111
BRYHALI... 103	butalbital-aspirin-caffeine... 10	calcium disodium versenate... 151
BSS PLUS... 163	butorphanol... 10, 11	calcium gluc in nacl, iso-osm... 111
BSS... 163	BUTRANS... 11	calcium gluconate... 111
budesonide... 147, 169	BYDUREON BCISE... 73	CALDOLOR... 11
bumetanide... 84	BYDUREON... 73	CALQUENCE... 49
BUNAVAIL... 21	BYETTA... 73	CAMBIA... 11
bupap... 10	BYNFEZIA... 138	camila... 129
BUPHENYL... 121	BYSTOLIC... 84	CAMPTOSAR... 49
bupivacaine (pf)... 19	BYVALSON... 84	camrese lo... 129
bupivacaine... 19		camrese... 129
bupivacaine-dextrose-water(pf)... 19	C	CANASA... 147
bupivacaine-epinephrine (pf)... 19	c-nate dha... 111	CANCIDAS... 42
bupivacaine-epinephrine bitart... 19	cabergoline... 138	candesartan... 84
bupivacaine-epinephrine... 19	CABLIVI... 79	candesartan-hydrochlorothiazid... 84
BUPRENEX... 10	CABOMETYX... 49	CAPASTAT... 47
buprenorphine hcl... 10, 21	CADUET... 84	CAPEX... 103
buprenorphine... 10	CAFECIT... 151	CAPLYTA... 62
buprenorphine-naloxone... 21	CAFERGOT... 46	CAPRELSA... 49
bupropion hcl (smoking deter)... 21	caffeine citrate... 151	captopril... 84
bupropion hcl... 37	CALAN SR... 84	captopril-hydrochlorothiazide... 84
bupirone... 71	CALAN... 84	CARAC... 103
busulfan... 49	calcipotriene... 103	
	calcipotriene-betamethasone... 103	

CARAFATE... 118	carmustine... 49	cefotetan... 23
CARBAGLU... 111	CARNITOR (SUGAR-FREE)... 111	cefoxitin in dextrose, iso-osm... 23
carbamazepine... 31	CARNITOR... 111	cefoxitin... 23
CARBATROL... 31	CAROSPIR... 85	cefpodoxime... 24
carbidopa... 60	carteolol... 163	cefprozil... 24
carbidopa-levodopa... 60	cartia xt... 85	ceftazidime in d5w... 24
carbidopa-levodopa-entacapone... 60	carvedilol phosphate... 85	ceftazidime... 24
carbinoxamine maleate... 169	carvedilol... 85	ceftriaxone in dextrose,iso-os... 24
CARBOCAINE (PF)... 19	CASODEX... 49	ceftriaxone... 24
CARBOCAINE WITH NEO-COBEFRIN... 19	caspofungin... 42	cefuroxime axetil... 24
CARBOCAINE... 19	CATAPRES... 85	cefuroxime sodium... 24
carboplatin... 49	CATAPRES-TTS-1... 85	CELEBREX... 11
carboprost tromethamine... 128	CATAPRES-TTS-2... 85	celecoxib... 11
CARDIZEM CD... 84	CATAPRES-TTS-3... 85	CELESTONE SOLUSPAN... 125
CARDIZEM LA... 85	CAYSTON... 169	CELEXA... 37, 38
CARDIZEM... 84	caziant (28)... 129	CELLCEPT INTRAVENOUS... 141
CARDURA XL... 85	cefaclor... 23	CELLCEPT... 140, 141
CARDURA... 85	cefadroxil... 23	CELONTIN... 31
CAREFINE PEN NEEDLE... 152	cefazolin in dextrose (iso-os)... 23	CENTANY... 103
CARETOUCH ALCOHOL PREP PAD... 152	cefazolin... 23	cephalexin... 24
CARETOUCH INSULIN SYRINGE... 152	cefdinir... 23	CEQUA... 163
CARETOUCH PEN NEEDLE... 152	cefepime in dextrose 5 %... 23	CERDELGA... 121
carisoprodol... 174	cefepime in dextrose,iso-osm... 23	CEREBYX... 31
carisoprodol-aspirin... 174	cefepime... 23	CEREZYME... 121
carisoprodol-aspirin-codeine... 174	cefixime... 23	CERVIDIL... 152
	CEFOTAN... 23	CESAMET... 41
	cefotaxime... 23	cetirizine... 169
	cefotetan in dextrose, iso-osm... 23	cevimeline... 101

CHANTIX CONTINUING MONTH BOX... 21
 CHANTIX STARTING MONTH BOX... 21
 CHANTIX... 21
 charlotte 24 fe... 129
 chateal (28)... 129
 chateal eq (28)... 129
 CHEMET... 111
 CHENODAL... 118
 chloramphenicol sod succinate... 24
 chlordiazepoxide hcl... 71
 chlorhexidine gluconate... 101
 chlorprocaine (pf)... 19
 chloroquine phosphate... 59
 chlorothiazide sodium... 85
 chlorothiazide... 85
 chlorpromazine... 62
 chlorpropamide... 73
 chlorthalidone... 85
 chlorzoxazone... 174
 CHOLBAM... 121
 cholestyramine (with sugar)... 85
 cholestyramine light... 85
 CHORIONIC GONADOTROPIN, HUMAN... 127
 CIALIS... 123
 ciclodan... 42
 ciclopirox... 42, 43
 cidofovir... 66
 cilostazol... 79
 CILOXAN... 163
 CIMDUO... 66
 cimetidine hcl... 118
 cimetidine... 118
 CIMZIA POWDER FOR RECONST... 141
 CIMZIA STARTER KIT... 141
 CIMZIA... 141
 cinacalcet... 148
 CINQAIR... 169
 CINRYZE... 141
 CINVANTI... 152
 CIPRO HC... 167
 CIPRO... 24
 CIPRODEX... 167
 ciprofloxacin (mixture)... 24
 ciprofloxacin hcl... 24, 163, 167
 ciprofloxacin in 5 % dextrose... 24
 ciprofloxacin... 24
 ciprofloxacin-dexamethasone... 167
 ciprofloxacin-fluocinolone... 167
 cisplatin... 49
 citalopram... 38
 CITRANATAL B-CALM (FE GLUC)... 111
 cladribine... 49
 CLAFORAN... 24
 claravis... 103
 CLARINEX... 169
 CLARINEX-D 12 HOUR... 152
 clarithromycin... 24
 clemastine... 169
 CLENPIQ... 118
 CLEOCIN HCL... 24
 CLEOCIN IN 5 % DEXTROSE... 25
 CLEOCIN PEDIATRIC... 25
 CLEOCIN T... 103
 CLEOCIN... 24
 CLEVIPREX... 85
 CLICKFINE PEN NEEDLE... 152
 CLIMARA PRO... 129
 CLIMARA... 129
 clindacin etz... 103
 clindacin p... 103
 CLINDAGEL... 103
 clindamycin hcl... 25
 clindamycin in 0.9 % sod chlor... 25
 clindamycin in 5 % dextrose... 25
 clindamycin palmitate hcl... 25
 clindamycin pediatric... 25
 clindamycin phosphate... 25, 104
 clindamycin-benzoyl peroxide... 104
 clindamycin-tretinoin... 104
 CLINDESSE... 25

CLINIMIX E 2.75%/D10W SUL FREE... 112	CLINISOL SF 15 %... 112	colesevelam... 85
CLINIMIX E 2.75%/D5W SULF FREE... 112	CLINOLIPID... 112	COLESTID FLAVORED... 85
CLINIMIX E 4.25%/D10W SUL FREE... 112	clobazam... 32	COLESTID... 85
CLINIMIX E 4.25%/D25W SUL FREE... 112	clobetasol... 104	colestipol... 85
CLINIMIX E 4.25%/D5W SULF FREE... 112	clobetasol-emollient... 104	colistin (colistimethate na)... 25
CLINIMIX E 5%/D15W SULFIT FREE... 112	CLOBEX... 104	colocort... 147
CLINIMIX E 5%/D20W SULFIT FREE... 112	clocortolone pivalate... 104	COLY-MYCIN M PARENTERAL... 25
CLINIMIX E 5%/D25W SULFIT FREE... 112	clodan... 104	COLY-MYCIN S... 167
CLINIMIX 2.75%/D5W SULFIT FREE... 111	CLODERM... 104	COLYTE WITH FLAVOR PACKS... 118
CLINIMIX 4.25%-D20W SULF-FREE... 111	clofarabine... 49	COMBIGAN... 163
CLINIMIX 4.25%-D25W SULF-FREE... 111	CLOLAR... 49	COMBIPATCH... 129
CLINIMIX 4.25%/D10W SULF FREE... 111	clomipramine... 38	COMBIVENT RESPIMAT... 169
CLINIMIX 4.25%/D5W SULFIT FREE... 112	clonazepam... 71	COMBIVIR... 66
CLINIMIX 5%-D20W(SULFITE-FREE)... 112	clonidine hcl... 85, 97	COMETRIQ... 49, 50
CLINIMIX 5%/D15W SULFITE FREE... 111	clonidine... 85	COMFORT EZ INSULIN SYRINGE... 152
CLINIMIX 5%/D25W SULFITE-FREE... 111	clopidogrel... 79	COMFORT EZ PEN NEEDLES... 152
	clorazepate dipotassium... 71	COMPAZINE... 41
	CLOROTEKAL... 19	COMPLERA... 66
	clotrimazole... 43	complete natal dha... 112
	clotrimazole-betamethasone... 43	compro... 41
	clovique... 112	COMTAN... 60
	clozapine... 62	CONCERTA... 97
	CLOZARIL... 62	CONDYLOX... 104
	COARTEM... 59	constulose... 118
	codeine sulfate... 11	CONZIP... 11
	codeine-butalbital-asa-caff... 11	COPAXONE... 97
	COGENTIN... 60	COPIKTRA... 50
	COLAZAL... 147	

CORDRAN TAPE LARGE ROLL... 104	CREON... 121	CYRAMZA... 50
CORDRAN... 104	CRESEMBA... 43	cyred eq... 130
COREG CR... 85	CRESTOR... 86	cyred... 130
COREG... 85	CRINONE... 129	CYSTADANE... 122
coremino... 25	CRIXIVAN... 66	CYSTAGON... 122
CORGARD... 85	cromolyn... 163, 169	CYSTARAN... 163
CORLANOR... 86	crotan... 104	cytarabine (pf)... 50
CORLOPAM... 86	cryselle (28)... 129	cytarabine... 50
cormax... 104	CRYSVITA... 121, 122	CYTOGAM... 141
CORTEF... 104	CUBICIN RF... 25	CYTOMEL... 137
CORTENEMA... 147	CUBICIN... 25	CYTOTEC... 118
CORTIFOAM... 147	CUPRIMINE... 112	CYTOVENE... 66
cortisone... 125	CURITY ALCOHOL SWABS... 152	D
CORTISPORIN... 104	CURITY GAUZE... 152	D.H.E.45... 46
CORTISPORIN-TC... 167	CUTAQUIG... 141	dacarbazine... 50
CORVERT... 86	CUTIVATE... 105	DACOGEN... 50
CORZIDE... 86	CUVPOSA... 118	dactinomycin... 50
COSENTYX (2 SYRINGES)... 141	cyclafem 1/35 (28)... 129	DAKLINZA... 66
COSENTYX PEN (2 PENS)... 141	cyclafem 7/7/7 (28)... 130	dalfampridine... 97
COSENTYX PEN... 141	cyclobenzaprine... 174	DALIRESP... 169
COSENTYX... 141	cyclophosphamide... 50	DALVANCE... 25
COSMEGEN... 50	cycloserine... 47	danazol... 130
COSOPT (PF)... 163	CYCLOSET... 73	DANTRIUM... 65
COSOPT... 163	cyclosporine modified... 141	dantrolene... 65
COTELLIC... 50	cyclosporine... 141	dapsone... 47, 105
COTEMPLA XR-ODT... 97	CYKLOKAPRON... 79	DAPTACEL (DTAP PEDIATRIC) (PF)... 141
COUMADIN... 79	CYMBALTA... 38	daptomycin... 25
COZAAR... 86	cyproheptadine... 169	

DARAPRIM... 59	DEPACON... 32	desoximetasone... 105
darifenacin... 123	DEPAKENE... 32	DESOXYN... 97
DARZALEX FASPRO... 50	DEPAKOTE ER... 32	desvenlafaxine succinate... 38
DARZALEX... 50	DEPAKOTE SPRINKLES... 32	desvenlafaxine... 38
dasetta 1/35 (28)... 130	DEPAKOTE... 32	DETROL LA... 123
dasetta 7/7/7 (28)... 130	DEPEN TITRATABS... 112	DETROL... 123
daunorubicin... 50	DEPO-ESTRADIOL... 130	dexabliss... 125
DAURISMO... 50	DEPO-MEDROL... 125	dexamethasone intensol... 125
DAYPRO... 11	DEPO-PROVERA... 130	dexamethasone sodium phos (pf)... 125
daysee... 130	DEPO-SUBQ PROVERA 104... 130	dexamethasone sodium phosphate... 125, 164
DAYTRANA... 97	DEPO-TESTOSTERONE... 130	dexamethasone... 125
DAYVIGO... 175	DERMA-SMOOTH/FS BODY OIL... 105	dexchlorpheniramine maleate... 169
DDAVP... 127	DERMA-SMOOTH/FS SCALP OIL... 105	DEXEDRINE SPANSULE... 97
deblitane... 130	DERMACEA... 152	DEXILANT... 118
decadron... 125	DERMATOP... 105	dexmethylphenidate... 97
decitabine... 50	DERMOTIC OIL... 167	DEXPAK 10 DAY... 125
deferasirox... 112	DESCOVY... 66	DEXPAK 13 DAY... 125
deferoxamine... 112	DESFERAL... 112	DEXPAK 6 DAY... 125
DEFITELIO... 152	desipramine... 38	dexrazoxane hcl... 50
DELESTROGEN... 130	desloratadine... 169	DEXTENZA... 164
DELSTRIGO... 66	desmopressin... 127	dextroamphetamine... 98
DELZICOL... 147	desog-e.estradiol/e.estradiol... 130	dextroamphetamine-amphetamine... 98
DEMADEX... 86	desogestrel-ethinyl estradiol... 130	dextrose 10 % and 0.2 % nacl... 112
demeclocycline... 25	DESONATE... 105	dextrose 10 % in water (d10w)... 112
DEMEROL (PF)... 11	desonide... 105	
DEMEROL... 11	DESOWEN... 105	
DEMSER... 86		
DENAVIR... 66		

dextrose 20 % in water (d20w)...	dicyclomine... 118	disopyramide phosphate... 86
112	didanosine... 66	disulfiram... 21
dextrose 25 % in water (d25w)...	DIFFERIN... 105	DITROPAN XL... 123
112	DIFICID... 25	DIURIL IV... 86
dextrose 30 % in water (d30w)...	diflorasone... 105	DIURIL... 86
112	DIFLUCAN... 43	divalproex... 32
dextrose 40 % in water (d40w)...	diflunisal... 11	DIVIGEL... 130
112	digitek... 86	dobutamine in d5w... 86
dextrose 5 % in water (d5w)...	digox... 86	dobutamine... 86
113	digoxin... 86	DOCEFREZ... 50
dextrose 5 %-lactated ringers... 113	dihydroergotamine... 46	docetaxel... 50
dextrose 5%-0.2 % sod chloride...	DILANTIN EXTENDED... 32	dofetilide... 87
113	DILANTIN INFATABS... 32	DOJOLVI... 152
dextrose 5%-0.3 % sod.chloride...	DILANTIN... 32	DOLOPHINE... 12
113	DILANTIN-125... 32	donepezil... 36
dextrose 50 % in water (d50w)...	DILATRATE-SR... 86	dopamine in 5 % dextrose... 87
113	DILAUDID... 11	dopamine... 87
dextrose 70 % in water (d70w)...	dilt-xr... 86	DOPRAM... 169
113	diltiazem hcl... 86	DOPTELET (10 TAB PACK)... 79
DIASTAT ACUDIAL... 32	dimenhydrinate... 41	DOPTELET (15 TAB PACK)... 79
DIASTAT... 32	DIOVAN HCT... 86	DOPTELET (30 TAB PACK)... 79
diazepam intensol... 71	DIOVAN... 86	doripenem... 25
diazepam... 32, 71	DIPENTUM... 147	DORYX MPC... 25
diazoxide... 73	diphen... 169	DORYX... 25
DIBENZYLINE... 86	diphenhydramine hcl... 169	dorzolamide... 164
DICLEGIS... 41	diphenoxylate-atropine... 118	dorzolamide-timolol (pf)... 164
diclofenac epolamine... 11	DIPROLENE... 105	dorzolamide-timolol... 164
diclofenac potassium... 11	dipyridamole... 79	dothelle dha... 113
diclofenac sodium... 11, 105, 164		
diclofenac-misoprostol... 11		
dicloxacillin... 25		

dotti... 130	DUET DHA WITH OMEGA-3... 113	d5 %-0.45 % sodium chloride... 112
DOVATO... 66	DUETACT... 73	E
DOVONEX... 105	DUEXIS... 12	E.E.S. GRANULES... 26
doxazosin... 87	DULERA... 169	E.E.S. 400... 26
doxepin... 71, 105, 175	duloxetine... 38	EASY COMFORT ALCOHOL PAD... 153
doxercalciferol... 148	DUOBRII... 105	EASY COMFORT INSULIN SYRINGE... 153
DOXIL... 50	DUOPA... 60	EASY COMFORT PEN NEEDLES... 153
doxorubicin... 50	DUPIXENT PEN... 141	EASY GLIDE INSULIN SYRINGE... 153
doxorubicin, peg-liposomal... 50	DUPIXENT SYRINGE... 141	EASY GLIDE PEN NEEDLE... 153
doxy-100... 25	DURAGESIC... 12	EASY TOUCH ALCOHOL PREP PADS... 153
doxycycline hyclate... 25, 26	DURAMORPH (PF)... 12	EASY TOUCH FLIPLOCK INSULIN... 153
doxycycline monohydrate... 26	DUREZOL... 164	EASY TOUCH INSULIN SAFETY SYR... 154
doxylamine-pyridoxine (vit b6)... 41	DURYSTA... 164	EASY TOUCH INSULIN SYRINGE... 154
DRIZALMA SPRINKLE... 38	dutasteride... 123	EASY TOUCH LUER LOCK INSULIN... 154
dronabinol... 41	dutasteride-tamsulosin... 124	EASY TOUCH PEN NEEDLE... 154
droperidol... 62	DUTOPROL... 87	EASY TOUCH SAFETY PEN NEEDLE... 154
DROPLET INSULIN SYR HALF UNIT... 153	DUZALLO... 45	EASY TOUCH SHEATHLOCK INSULIN... 154
DROPLET INSULIN SYRINGE... 153	dvorah... 12	EASY TOUCH UNI-SLIP... 154
DROPLET MICRON PEN NEEDLE... 153	DXEVO... 125	EASY TOUCH... 153
DROPLET PEN NEEDLE... 153	DYANAVEL XR... 98	EC-NAPROSYN... 12
DROPSAFE PEN NEEDLE... 153	DYAZIDE... 87	ec-naproxen... 12
drospirenone-e.estradiol-lm.fa... 130	DYMISTA... 170	econazole... 43
drospirenone-ethinyl estradiol... 130	DYRENIUM... 87	
DROXIA... 153	d10 %-0.45 % sodium chloride... 112	
DUAKLIR PRESSAIR... 169	d2.5 %-0.45 % sodium chloride... 112	
DUAVEE... 130	d5 % and 0.9 % sodium chloride... 112	

EDARBI... 87	ELITEK... 50	ENDARI... 118
EDARBYCLOR... 87	ELIXOPHYLLIN... 170	endocet... 12
EDECIN... 87	ELLA... 130	ENDOMETRIN... 130
EDLUAR... 175	ELLECE... 50	ENGERIX-B (PF)... 141
EDURANT... 66	ELMIRON... 124	ENGERIX-B PEDIATRIC (PF)... 141
efavirenz... 66	ELOCON... 105	ENHERTU... 51
EFFEXOR XR... 38	eluryng... 130	enoxaparin... 80
EFFIENT... 79	ELZONRIS... 50	enpresse... 130
EFUDEX... 105	EMADINE... 164	enskyce... 130
EGATEN... 59	EMBEDA... 12	ENSPRYNG... 141
EGRIFTA SV... 127	EMCYT... 50	ENSTILAR... 105
EGRIFTA... 127	EMEND (FOSAPREPITANT)... 41	entacapone... 60
ELAPRASE... 122	EMEND... 41	entecavir... 67
electrolyte-48 in d5w... 113	EMFLAZA... 125	ENTOCORT EC... 147
ELELYSO... 122	EMGALITY PEN... 46	ENTRESTO... 87
ELESTAT... 164	EMGALITY SYRINGE... 46	ENTYVIO... 141
ELESTRIN... 130	emoquette... 130	enulose... 118
eletriptan... 46	EMPLICITI... 50	ENVARUSUS XR... 141
ELIDEL... 105	EMSAM... 38	EPANED... 87
ELIGARD (3 MONTH)... 138	EMTRIVA... 66, 67	EPCLUSA... 67
ELIGARD (4 MONTH)... 138	emverm... 59	EPIDIOLEX... 32
ELIGARD (6 MONTH)... 138	ENABLEX... 124	EPIDUO FORTE... 106
ELIGARD... 138	enalapril maleate... 87	EPIDUO... 106
ELIMITE... 105	enalapril-hydrochlorothiazide... 87	EPIFOAM... 106
elinst... 130	enalaprilat... 87	epinastine... 164
ELIQUIS DVT-PE TREAT 30D START... 80	ENBREL MINI... 141	epinephrine... 170
ELIQUIS... 79, 80	ENBREL SURECLICK... 141	EPIPEN JR 2-PAK... 170
	ENBREL... 141	EPIPEN JR... 170

EPIPEN 2-PAK... 170	ERYPED 200... 26	ethacrynic acid... 87
EPIPEN... 170	ERYPED 400... 26	ethambutol... 47
epirubicin... 51	ERYTHROCIN (AS STEARATE)... 26	ethosuximide... 32
epitol... 32	ERYTHROCIN... 26	ethynodiol diac-eth estradiol... 131
EPIVIR HBV... 67	erythromycin ethylsuccinate... 26	ETHYOL... 51
EPIVIR... 67	erythromycin with ethanol... 106	etidronate disodium... 148
eplerenone... 87	erythromycin... 26, 164	etodolac... 12
EPOGEN... 80	erythromycin-benzoyl peroxide... 106	etonogestrel-ethinyl estradiol... 131
epoprostenol (glycine)... 170	ESBRIET... 170	ETOPOPHOS... 51
eprosartan... 87	escitalopram oxalate... 38	etoposide... 51
eptifibatide... 80	ESGIC... 12	EUCRISA... 106
EPZICOM... 67	esmolol in nacl (iso-osm)... 87	EURAX... 106
EQUETRO... 32	esmolol... 87	EUTHYROX... 137
ERAXIS(WATER DILUENT)... 43	esomeprazole magnesium... 118	EVAMIST... 131
ERBITUX... 51	esomeprazole sodium... 118	EVEKEO ODT... 98
ergoloid... 36	esomeprazole strontium... 118	EVEKEO... 98
ERGOMAR... 46	estarylla... 130	EVENITY... 148
ergotamine-caffeine... 46	estazolam... 175	everolimus (immunosuppressive)... 141, 142
ERIVEDGE... 51	ESTRACE... 130	EVISTA... 131
ERLEADA... 51	estradiol valerate... 131	EVOCLIN... 106
erlotinib... 51	estradiol... 131	EVOMELA... 51
errin... 130	estradiol-norethindrone acet... 131	EVOTAZ... 67
ERTACZO... 43	ESTRING... 131	EVOXAC... 101
ertapenem... 26	ESTROGEL... 131	EVZIO... 21
ERWINAZE... 51	ESTROSTEP FE-28... 131	EXALGO ER... 12
ery pads... 106	eszopiclone... 175	EXEL INSULIN... 154
ERY-TAB... 26	ethacrynate sodium... 87	EXELDERM... 43
ERYGEL... 106		

EXELON... 36	felbamate... 32	FIASP U-100 INSULIN... 73
exemestane... 51	FELBATOL... 32	FIBRICOR... 88
EXFORGE HCT... 87	FELDENE... 12	FINACEA... 106
EXFORGE... 87	felodipine... 88	finasteride... 124
EXJADE... 113	FEMARA... 51	FINTEPLA... 32
EXTAVIA... 98	FEMHRT LOW DOSE... 131	FIORICET WITH CODEINE... 13
EXTINA... 43	FEMRING... 131	fioricet... 13
EZALLOR SPRINKLE... 87	femynor... 131	FIORINAL... 13
ezetimibe... 87	fenofibrate micronized... 88	FIORINAL-CODEINE #3... 13
ezetimibe-simvastatin... 87	fenofibrate nanocrystallized... 88	FIRAZYR... 142
	fenofibrate... 88	FIRDAPSE... 98
F	fenofibric acid (choline)... 88	FIRMAGON KIT W DILUENT SYRINGE... 138
FABIOR... 106	fenofibric acid... 88	FIRMAGON... 138
FABRAZYME... 122	FENOGLIDE... 88	FIRVANQ... 26
falmina (28)... 131	fenoprofen... 12	flac otic oil... 167
famciclovir... 67	FENSOLVI... 138	FLAGYL... 26
famotidine (pf)... 118	fentanyl citrate (pf)... 12	FLAREX... 164
famotidine (pf)-nacl (iso-os)... 118	fentanyl citrate... 12	flavoxate... 124
famotidine... 118	fentanyl... 12	FLEBOGAMMA DIF... 142
FANAPT... 62	FENTORA... 13	flecainide... 88
FARESTON... 51	FERRIPROX (2 TIMES A DAY)... 113	FLECTOR... 13
FARXIGA... 73	FERRIPROX... 113	FLOLIPID... 88
FARYDAK... 51	FETROJA... 26	FLOMAX... 124
FASENRA PEN... 170	FETZIMA... 38	FLOVENT DISKUS... 170
FASENRA... 170	FEXMID... 174	FLOVENT HFA... 170
FASLODEX... 51	FIASP FLEXTOUCH U-100 INSULIN... 73	floxuridine... 51
fayosim... 131	FIASP PENFILL U-100 INSULIN... 73	fluconazole in dextrose(iso-o)... 43
FAZACLO... 62, 63		
febuxostat... 45		

fluconazole in nacl (iso-osm)... 43	fluticasone propionate... 106, 107, 170	FREAMINE III 10 %... 113
fluconazole... 43	fluvastatin... 88	FREESTYLE PRECISION... 154
flucytosine... 43	fluvoxamine... 38	FROVA... 46
fludarabine... 51	FML FORTE... 164	frovatriptan... 46
fludrocortisone... 125	FML LIQUIFILM... 164	FULPHILA... 80
FLUMADINE... 67	FML S.O.P.... 164	fulvestrant... 51
flumazenil... 154	FOCALIN XR... 98	FURADANTIN... 26
flunisolide... 170	FOCALIN... 98	furosemide... 88
fluocinolone acetonide oil... 167	FOLOTYN... 51	FUSILEV... 51
fluocinolone and shower cap... 106	fomepizole... 154	FUZEON... 67
fluocinolone... 106	fondaparinux... 80	fyavolv... 131
fluocinonide... 106	FORFIVO XL... 38	FYCOMPA... 32
fluocinonide-e... 106	FORTAMET... 73	G
fluocinonide-emollient... 106	FORTAZ... 26	gabapentin... 32, 33
fluorometholone... 164	FORTEO... 149	GABITRIL... 33
FLUOROPLEX... 106	FORTESTA... 131	GALAFOLD... 122
fluorouracil... 51, 106	FOSAMAX PLUS D... 149	galantamine... 36, 37
fluoxetine... 38	FOSAMAX... 149	GAMASTAN S/D... 142
fluphenazine decanoate... 63	fosamprenavir... 67	GAMASTAN... 142
fluphenazine hcl... 63	fosaprepitant... 41	GAMMAGARD LIQUID... 142
flurandrenolide... 106	FOSCAVIR... 67	GAMMAGARD S-D (IGA < 1 MCG/ML)... 142
flurazepam... 175	fosinopril... 88	GAMMAKED... 142
flurbiprofen sodium... 164	fosinopril-hydrochlorothiazide... 88	GAMMAPLEX (WITH SORBITOL)... 142
flurbiprofen... 13	fosphenytoin... 32	GAMMAPLEX... 142
flutamide... 51	FOSRENOL... 113	GAMUNEX-C... 142
fluticasone propion-salmeterol... 170	FRAGMIN... 80	ganciclovir sodium... 67
	FREAMINE HBC 6.9 %... 113	

GARDASIL 9 (PF)... 142	GILENYA... 98	glydo... 19
GASTROCROM... 170	GILOTRIF... 51	GLYNASE... 74
gatifloxacin... 164	GIVLAARI... 154	GLYSET... 74
GATTEX ONE-VIAL... 118	GLASSIA... 122	GLYXAMBI... 74
GATTEX 30-VIAL... 118	glatiramer... 98	GOCOVRI... 60
GAUZE BANDAGE... 154	glatopa... 98	GOLYTELY... 119
GAUZE PAD... 154	GLEEVEC... 51	GONITRO... 88
gavilyte-c... 119	glimepiride... 73	GRALISE 30-DAY STARTER PACK... 98
gavilyte-g... 119	glipizide... 73	GRALISE... 98
gavilyte-n... 119	glipizide-metformin... 73	granisetron (pf)... 41
GAZYVA... 51	GLOPERBA... 45	granisetron hcl... 41
GELNIQUE... 124	GLUCAGEN HYPOKIT... 73	GRANIX... 80
gemcitabine... 51	GLUCAGON (HCL) EMERGENCY KIT... 73	GRASTEK... 170
gemfibrozil... 88	GLUCAGON EMERGENCY KIT (HUMAN)... 73	griseofulvin microsize... 43
GEMZAR... 51	GLUCOPHAGE XR... 74	griseofulvin ultramicrosize... 43
GENERESS FE... 131	GLUCOPHAGE... 74	guanfacine... 88, 98
generlac... 119	GLUCOTROL XL... 74	guanidine... 47
gengraf... 142	GLUCOTROL... 74	GVOKE HYPOPEN 1-PACK... 74
GENOTROPIN MINIQUICK... 127	GLUMETZA... 74	GVOKE HYPOPEN 2-PACK... 74
GENOTROPIN... 127	glyburide micronized... 74	GVOKE PFS 1-PACK SYRINGE... 74
gentak... 164	glyburide... 74	GVOKE PFS 2-PACK SYRINGE... 74
gentamicin in nacl (iso-osm)... 26	glyburide-metformin... 74	gynazole-1... 43
gentamicin sulfate (ped) (pf)... 26	GLYCATE... 119	H
gentamicin sulfate (pf)... 26	GLYCOPHOS... 113	HAEGARDA... 142
gentamicin... 26, 164	glycopyrrolate (pf) in water... 119	hailey fe 1.5/30 (28)... 131
GENVOYA... 67	glycopyrrolate... 119	hailey fe 1/20 (28)... 131
GEODON... 63		hailey 24 fe... 131
gianvi (28)... 131		hailey... 131

HALAVEN... 51	HERCEPTIN HYLECTA... 52	HUMIRA... 142
halcinonide... 107	HERCEPTIN... 52	HUMIRA(CF) PEDI CROHNS STARTER... 143
HALCION... 175	HERZUMA... 52	HUMIRA(CF) PEN CROHNS-UC-HS... 143
HALDOL DECANOATE... 63	HETLIOZ... 175	HUMIRA(CF) PEN PSOR-UV-ADOL HS... 143
HALDOL... 63	HEXALEN... 52	HUMIRA(CF) PEN... 143
halobetasol propionate... 107	HIBERIX (PF)... 142	HUMIRA(CF)... 143
HALOG... 107	hidex... 125	HUMULIN N NPH INSULIN KWIKPEN... 75
haloperidol decanoate... 63	HIPREX... 27	HUMULIN N NPH U-100 INSULIN... 75
haloperidol lactate... 63	HIZENTRA... 142	HUMULIN R REGULAR U-100 INSULN... 75
haloperidol... 63	HORIZANT... 98	HUMULIN R U-500 (CONC) INSULIN... 75
HARVONI... 67	HUMALOG JUNIOR KWIKPEN U-100... 74	HUMULIN R U-500 (CONC) KWIKPEN... 75
HAVRIX (PF)... 142	HUMALOG KWIKPEN INSULIN... 74	HUMULIN 70/30 U-100 INSULIN... 74
HEALTHWISE INSULIN SYRINGE... 154	HUMALOG MIX 50-50 INSULN U-100... 74	HUMULIN 70/30 U-100 KWIKPEN... 75
HEALTHWISE PEN NEEDLE... 154	HUMALOG MIX 50-50 KWIKPEN... 74	HYCAMTIN... 52
HEALTHY ACCENTS UNIFINE PENTIP... 155	HUMALOG MIX 75-25 KWIKPEN... 74	hydralazine... 88
heather... 131	HUMALOG MIX 75-25(U-100)INSULN... 74	HYDREA... 52
HECTOROL... 149	HUMALOG U-100 INSULIN... 74	hydrochlorothiazide... 88
helidac... 119	HUMAPEN LUXURA HD... 155	hydrocodone bitartrate... 13
HEMABATE... 128	HUMATROPE... 127	hydrocodone-acetaminophen... 13
HEMADY... 125	HUMIRA PEDIATRIC CROHNS START... 142	hydrocodone-ibuprofen... 13
HEMANGEOL... 88	HUMIRA PEN CROHNS-UC-HS START... 142	
hemenatal ob + dha... 113	HUMIRA PEN PSOR-UVEITS-ADOL HS... 142	
heparin (porcine)... 80	HUMIRA PEN... 142	
heparin, porcine (pf)... 80		
HEPATAMINE 8%... 113		
HEPSERA... 67		

hydrocortisone butyr-emollient... 107	IBUDONE... 14	IMURAN... 143
hydrocortisone butyrate... 107	ibuprofen... 14	INBRIJA... 60
hydrocortisone valerate... 107	ibuprofen-oxycodone... 14	incassia... 131
hydrocortisone... 107, 147	ibutilide fumarate... 89	INCONTROL ALCOHOL PADS... 155
hydrocortisone-acetic acid... 167	icatibant... 143	INCONTROL PEN NEEDLE... 155
hydrocortisone-min oil-wht pet... 107	ICLUSIG... 52	INCRELEX... 127
hydromorphone (pf)... 13	IDAMYCIN PFS... 52	INCRUSE ELLIPTA... 170
hydromorphone... 13	idarubicin... 52	indapamide... 89
hydroxychloroquine... 59	IDHIFA... 52	INDERAL LA... 89
hydroxyprogesterone (pf)(preg presv)... 131	IFEX... 52	INDOCIN... 14
hydroxyprogesterone cap(ppres)... 131	ifosfamide... 52	indomethacin sodium... 14
hydroxyprogesterone caproate... 131	ILEVRO... 164	indomethacin... 14
hydroxyurea... 52	ILUMYA... 143	INFANRIX (DTAP) (PF)... 143
hydroxyzine hcl... 71, 72	imatinib... 52	INFLECTRA... 143
hydroxyzine pamoate... 170	IMBRUVICA... 52	INFUGEM... 52
HYPERRAB (PF)... 143	IMFINZI... 52	INFUMORPH P/F... 14
HYPERRAB S/D (PF)... 143	imipenem-cilastatin... 27	INGREZZA INITIATION PACK... 98
HYPERTET S/D (PF)... 143	imipramine hcl... 38	INGREZZA... 98
HYSINGLA ER... 13	imipramine pamoate... 38	INLYTA... 52
HYZAAR... 88	imiquimod... 107	INNOPRAN XL... 89
I	IMITREX STATDOSE PEN... 46	INQOVI... 52
ibandronate... 149	IMITREX STATDOSE REFILL... 46	INREBIC... 52
IBRANCE... 52	IMITREX... 46	INSPIRA... 89
ibu... 14	IMLYGIC... 52	INSULIN ASP PRT-INSULIN ASPART... 75
	IMOGAM RABIES-HT (PF)... 143	INSULIN ASPART U-100... 75
	IMOVAX RABIES VACCINE (PF)... 143	INSULIN LISPRO PROTAMIN-LISPRO... 75
	IMPAVIDO... 59	
	IMPOYZ... 107	

INSULIN LISPRO... 75	IPOL... 143	ivermectin... 59, 107
INSULIN SYR/NDL U100 HALF MARK... 155	ipratropium bromide... 170	IXEMPRA... 53
INSULIN SYRINGE MICROFINE... 155	ipratropium-albuterol... 170	IXIARO (PF)... 143
INSULIN SYRINGE NEEDLELESS... 155	irbesartan... 89	J
INSULIN SYRINGE... 155	irbesartan-hydrochlorothiazide... 89	JADENU SPRINKLE... 113
INSULIN SYRINGE-NEEDLE U-100... 155	IRESSA... 52	JADENU... 113
INSUPEN... 155	irinotecan... 53	jaimiess... 132
INTEGRILIN... 81	ISENTRESS HD... 67	JAKAFI... 53
INTELENCE... 67	ISENTRESS... 67	JALYN... 124
INTERMEZZO... 175	isibloom... 132	jantoven... 81
INTRALIPID... 113	isochron... 89	JANUMET XR... 75
INTRON A... 143	ISOLYTE S PH 7.4... 113	JANUMET... 75
introvale... 132	ISOLYTE-P IN 5 % DEXTROSE... 113	JANUVIA... 75
INTUNIVER... 98	ISOLYTE-S... 113	JARDIANCE... 75
INVANZ... 27	isoniazid... 47	jasmiel (28)... 132
INVEGA SUSTENNA... 63	ISOPTO CARPINE... 164	jencycla... 132
INVEGA TRINZA... 63	ISORDIL TITRADOSE... 89	JENTADUETO XR... 75
INVEGA... 63	ISORDIL... 89	JENTADUETO... 75
INVELTYS... 164	isosorbide dinitrate... 89	jevantique lo... 132
INVIRASE... 67	isosorbide mononitrate... 89	JEVTANA... 53
INVOKAMET XR... 75	isotretinoin... 107	jinteli... 132
INVOKAMET... 75	isradipine... 89	jolessa... 132
INVOKANA... 75	ISTALOL... 164	jolivette... 132
IONOSOL-B IN D5W... 113	ISTODAX... 53	JORNAY PM... 99
IONOSOL-MB IN D5W... 113	ISTURISA... 155	JUBLIA... 43
IOPIDINE... 164	ISUPREL... 89	juleber... 132
	itraconazole... 43	JULUCA... 67
	IV PREP WIPES... 155	junel fe 1.5/30 (28)... 132

june fe 1/20 (28)... 132
june fe 24... 132
june 1.5/30 (21)... 132
june 1/20 (21)... 132
JUXTAPID... 89
JYNARQUE... 113
K
K-TAB... 113
KABIVEN... 113
KADCYLA... 53
KADIAN... 14
kaitlib fe... 132
KALETRA... 67
kalliga... 132
KALYDECO... 170
KANJINTI... 53
KANUMA... 122
KAPSPARGO SPRINKLE... 89
KAPVAY... 99
KARBINAL ER... 170
kariva (28)... 132
KATERZIA... 89
KAZANO... 75
KEDRAB (PF)... 143
KEFLEX... 27
kelnor 1-50... 132
kelnor 1/35 (28)... 132
KENALOG... 125

KENALOG-80... 125
KENGREAL... 81
KEPIVANCE... 101
KEPPRA XR... 33
KEPPRA... 33
KERYDIN... 43
ketoconazole... 43
ketodan... 43
ketoprofen... 14
ketorolac... 14, 164
KEVEYIS... 122
KEVZARA... 143
KEYTRUDA... 53
KHAPZORY... 53
KHEDEZLA... 39
KINERET... 143
KINRIX (PF)... 143
kionex (with sorbitol)... 114
KISQALI FEMARA CO-PACK... 53
KISQALI... 53
KITABIS PAK... 27
KLARON... 27
KLONOPIN... 72
klor-con m10... 114
KLOR-CON M15... 114
klor-con m20... 114
klor-con sprinkle... 114
KLOR-CON 10... 114

KLOR-CON 8... 114
klor-con... 114
KOMBIGLYZE XR... 75, 76
KORLYM... 155
KOSELUGO... 53
KOSHER PRENATAL PLUS IRON...
114
KRINTAFEL... 59
KRISTALOSE... 119
kurvelo (28)... 132
KUVAN... 122
KYNMOBI... 60
KYPROLIS... 53
L
l norgest/e.estradiol-e.estradiol... 132
labetalol... 89
LACRISERT... 164
lactated ringers... 114, 155
lactulose... 119
LAMICTAL ODT STARTER (BLUE)... 33
LAMICTAL ODT STARTER (GREEN)...
33
LAMICTAL ODT STARTER (ORANGE)...
33
LAMICTAL ODT... 33
LAMICTAL STARTER (BLUE) KIT... 33
LAMICTAL STARTER (GREEN) KIT...
33

LAMICTAL STARTER (ORANGE) KIT... 33

LAMICTAL XR STARTER (BLUE)... 33

LAMICTAL XR STARTER (GREEN)... 33

LAMICTAL XR STARTER (ORANGE)... 33

LAMICTAL XR... 33

LAMICTAL... 33

lamivudine... 67, 68

lamivudine-zidovudine... 68

lamotrigine... 33

LANOXIN PEDIATRIC... 89

LANOXIN... 89

lansoprazole... 119

lanthanum... 114

LANTUS SOLOSTAR U-100 INSULIN... 76

LANTUS U-100 INSULIN... 76

larin fe 1.5/30 (28)... 132

larin fe 1/20 (28)... 132

larin 1.5/30 (21)... 132

larin 1/20 (21)... 132

larin 24 fe... 132

larissia... 132

LARTRUVO... 53

LASIX... 89

LASTACAPT... 164

latanoprost... 164

LATUDA... 63

LAYOLIS FE... 132

LAZANDA... 14

ledipasvir-sofosbuvir... 68

leena 28... 132

leflunomide... 143

LEMTRADA... 99

LENVIMA... 53

LESCOL XL... 89

LESCOL... 89

lessina... 132

LETAIRIS... 170

letrozole... 53

leucovorin calcium... 53

LEUKERAN... 53

LEUKINE... 81

leuprolide... 138

levalbuterol hcl... 171

levalbuterol tartrate... 171

LEVAQUIN... 27

LEVEMIR FLEXTOUCH U-100 INSULN... 76

LEVEMIR U-100 INSULIN... 76

levetiracetam in nacl (iso-os)... 34

levetiracetam... 34

LEVO-T... 137

levobunolol... 164

levocarnitine (with sugar)... 114

levocarnitine... 114

levocetirizine... 171

levofloxacin in d5w... 27

levofloxacin... 27, 164

levoleucovorin calcium... 53

levonest (28)... 132

levonorg-eth estrad triphasic... 132

levonorgestrel-ethinyl estrad... 132

LEVOPHED (BITARTRATE)... 89

levora-28... 133

levorphanol tartrate... 14

levothyroxine... 137

LEVOXYL... 138

LEVULAN... 53

LEXAPRO... 39

LEXETTE... 107

LEXIVA... 68

LIALDA... 147

LIBTAYO... 54

LICART... 14

lidocaine (pf) in d7.5w... 19

lidocaine (pf)... 19, 90

lidocaine hcl... 19

lidocaine in 5 % dextrose (pf)... 90

lidocaine viscous... 19

lidocaine... 19

lidocaine-epinephrine bit... 19

lidocaine-epinephrine... 19

lidocaine-prilocaine... 19

LIDODERM... 20	LOCOID... 107	loryna (28)... 133
lillow (28)... 133	LODINE... 14	LORZONE... 174
LINCOCIN... 27	LODOSYN... 60	losartan... 90
lincomycin... 27	LOESTRIN FE 1.5/30 (28-DAY)... 133	losartan-hydrochlorothiazide... 90
lindane... 107	LOESTRIN FE 1/20 (28-DAY)... 133	LOSEASONIQUE... 133
linezolid in dextrose 5%... 27	LOESTRIN 1.5/30 (21)... 133	LOTEMAX SM... 164
linezolid... 27	LOESTRIN 1/20 (21)... 133	LOTEMAX... 164
linezolid-0.9% sodium chloride... 27	lojaimiess... 133	LOTENSIN HCT... 90
LINZESS... 119	LOKELMA... 114	LOTENSIN... 90
liothyronine... 138	LOMOTIL... 119	loteprednol etabonate... 165
LIPITOR... 90	LONHALA MAGNAIR REFILL... 171	LOTREL... 90
lipodox 50... 54	LONHALA MAGNAIR STARTER... 171	LOTRISONE... 44
lipodox... 54	LONSURF... 54	LOTRONEX... 119
LIPOFEN... 90	loperamide... 119	lovastatin... 90
lisinopril... 90	LOPID... 90	LOVAZA... 90
lisinopril-hydrochlorothiazide... 90	lopinavir-ritonavir... 68	LOVENOX... 81
LITE TOUCH INSULIN PEN NEEDLES... 155	lopreeza... 133	low-ogestrel (28)... 133
LITE TOUCH INSULIN SYRINGE... 156	LOPRESSOR HCT... 90	loxapine succinate... 63
lithium carbonate... 72	LOPRESSOR... 90	LUCEMYRA... 21
lithium citrate... 72	LOPROX (AS OLAMINE)... 44	luliconazole... 44
LITHOBID... 72	LOPROX... 44	LUMIGAN... 165
LITHOSTAT... 156	lorazepam intensol... 72	LUMIZYME... 122
LIVALO... 90	lorazepam... 72	LUMOXITI... 54
LO LOESTRIN FE... 133	LORBRENA... 54	LUNESTA... 175
lo-zumandimine (28)... 133	lorcet (hydrocodone)... 14	LUPANETA PACK (1 MONTH)... 138
LOCOID LIPOCREAM... 107	lorcet hd... 14	LUPANETA PACK (3 MONTH)... 139
	lorcet plus... 14	LUPRON DEPOT (3 MONTH)... 139
	lortab elixir... 14	LUPRON DEPOT (4 MONTH)... 139

LUPRON DEPOT (6 MONTH)... 139	magnesium sulfate in water... 114	MAVENCLAD (8 TABLET PACK)... 99
LUPRON DEPOT... 139	magnesium sulfate... 114	MAVENCLAD (9 TABLET PACK)... 99
LUPRON DEPOT-PED (3 MONTH)... 139	MAKENA (PF)... 133	MAVYRET... 68
LUPRON DEPOT-PED... 139	MAKENA... 133	MAXALT... 46
lutra (28)... 133	MALARONE PEDIATRIC... 59	MAXALT-MLT... 46
LUXIQ... 107	MALARONE... 59	MAXI-COMFORT INSULIN SYRINGE... 156
LUZU... 44	malathion... 108	MAXICOMFORT II PEN NEEDLE... 156
LYNPARZA... 54	mannitol 10 %... 90	MAXICOMFORT INSULIN SYRINGE... 156
LYRICA CR... 99	mannitol 20 %... 90	MAXICOMFORT SAFETY PEN NEEDLE... 156
LYRICA... 99	mannitol 25 %... 90	MAXIDEX... 165
LYSODREN... 138	mannitol 5 %... 90	MAXIPIME... 27
LYSTEDA... 81	maprotiline... 39	MAXITROL... 165
LYUMJEV KWIKPEN U-100 INSULIN... 76	MARCAINE (PF)... 20	MAXZIDE... 90
LYUMJEV KWIKPEN U-200 INSULIN... 76	MARCAINE SPINAL (PF)... 20	MAXZIDE-25MG... 90
LYUMJEV U-100 INSULIN... 76	MARCAINE... 20	MAYZENT STARTER PACK... 99
lyza... 133	MARCAINE-EPINEPHRINE (PF)... 20	MAYZENT... 99
	MARCAINE-EPINEPHRINE... 20	meclizine... 41
	MARINOL... 41	meclofenamate... 14
	marlissa (28)... 133	MEDROL (PAK)... 125
	MARPLAN... 39	MEDROL... 125
	MARQIBO... 54	medroxyprogesterone... 133
	MATULANE... 54	mefenamic acid... 14
	matzim la... 90	mefloquine... 59
	MAVENCLAD (10 TABLET PACK)... 99	MEGACE ES... 133
	MAVENCLAD (4 TABLET PACK)... 99	megestrol... 133
	MAVENCLAD (5 TABLET PACK)... 99	MEKINIST... 54
	MAVENCLAD (6 TABLET PACK)... 99	
	MAVENCLAD (7 TABLET PACK)... 99	

M

MEKTOVI... 54	metadate er... 99	methylprednisolone sodium succ... 125
melodetta 24 fe... 133	metaproterenol... 171	methylprednisolone... 125
meloxicam... 14	metaxall... 174	methyltestosterone... 133
melphalan hcl... 54	metaxalone... 174	metipranolol... 165
melphalan... 54	metformin... 76	metoclopramide hcl... 41
memantine... 37	methadone intensol... 15	metolazone... 90
MENACTRA (PF)... 144	methadone... 15	metoprolol succinate... 90
MENEST... 133	METHADOSE... 15	metoprolol ta-hydrochlorothiaz... 91
MENOSTAR... 133	methamphetamine... 99	metoprolol tartrate... 91
MENTAX... 44	methazolamide... 90	METRO I.V.... 27
MENVEO A-C-Y-W-135-DIP (PF)... 144	methenamine hippurate... 27	METROCREAM... 27
meperidine (pf)... 15	methergine... 156	METROGEL VAGINAL... 27
meperidine... 15	methimazole... 139	METROGEL... 27
mepivacaine (pf)... 20	METHITEST... 133	METROLOTION... 27
meprobamate... 72	methocarbamol... 174	metronidazole in nacl (iso-os)... 27
MEPRON... 59	methotrexate sodium (pf)... 144	metronidazole... 27
MEPSEVII... 122	methotrexate sodium... 144	metyrosine... 91
mercaptopurine... 54	methoxsalen... 108	mexiletine... 91
meropenem... 27	methscopolamine... 119	MIACALCIN... 149
meropenem-0.9% sodium chloride... 27	methylclothiazide... 90	mibelas 24 fe... 133
MERREM... 27	methyldopa... 90	micafungin... 44
mesalamine... 147, 148	methyldopa-hydrochlorothiazide... 90	MICARDIS HCT... 91
mesna... 54	methyl dopate... 90	MICARDIS... 91
MESNEX... 54	methylergonovine... 156	miconazole nitrate-zinc ox-pet... 44
MESTINON TIMESPAN... 47	METHYLIN... 99	miconazole-3... 44
MESTINON... 47	methylphenidate hcl... 99, 100	micort-hc... 126
	methylprednisolone acetate... 125	

MICRODOT INSULIN PEN NEEDLE... 156	minoxidil... 91	MONOJECT ULTRA COMFORT INSULIN... 157
microgestin fe 1.5/30 (28)... 133	MIOSTAT... 165	mononessa (28)... 134
microgestin fe 1/20 (28)... 133	MIRAPEX ER... 60	montelukast... 171
microgestin 1.5/30 (21)... 133	MIRAPEX... 60	MONUROL... 28
microgestin 1/20 (21)... 133	MIRCERA... 81	morgidox... 28
MICROGESTIN 24 FE... 133	MIRCETTE (28)... 134	MORPHABOND ER... 15
MICROZIDE... 91	mirtazapine... 39	morphine (pf)... 16
midodrine... 91	MIRVASO... 108	morphine concentrate... 16
migergot... 46	misoprostol... 119	morphine... 15, 16
miglitol... 76	MITIGARE... 45	MOTEGRITY... 119
miglustat... 122	mitigo (pf)... 15	MOTOFEN... 119
MIGRANAL... 46	mitomycin... 54	MOVANTIK... 119
mili... 133	mitoxantrone... 54	MOVIPREP... 119
millipred dp... 126	MOBIC... 15	MOXEZA... 165
millipred... 126	modafinil... 175	moxifloxacin... 28, 165
milrinone in 5 % dextrose... 91	moderiba... 68	moxifloxacin-sod.ace,sul-water... 28
milrinone... 91	moexipril... 91	moxifloxacin-sod.chloride(iso)... 28
mimvey lo... 134	moexipril-hydrochlorothiazide... 91	MOZOBIL... 81
mimvey... 134	molindone... 63	MS CONTIN... 16
MINASTRIN 24 FE... 134	mometasone... 108, 171	MULPLETA... 81
MINI ULTRA-THIN II... 156	mondoxyne nl... 28	MULTAQ... 91
MINIPRESS... 91	MONJUVI... 144	mupirocin calcium... 108
minitran... 91	mono-lyyah... 134	mupirocin... 108
MINIVELLE... 134	MONODOX... 28	MUSTARGEN... 54
MINOCIN... 27, 28	MONOJECT INSULIN SAFETY SYRING... 156	MUTAMYCIN... 54
minocycline... 28	MONOJECT INSULIN SYRINGE... 157	MVASI... 54
MINOLIRA ER... 28	MONOJECT SYRINGE... 157	

MYALEPT... 119	naloxone... 21	necon 0.5/35 (28)... 134
MYAMBUTOL... 47	naltrexone... 21	nefazodone... 39
MYCAMINE... 44	NAMENDA TITRATION PAK... 37	NEMBUTAL SODIUM... 34
MYCAPSSA... 139	NAMENDA XR... 37	neo-polycin hc... 165
MYCOBUTIN... 47	NAMENDA... 37	neo-polycin... 165
mycophenolate mofetil (hcl)... 144	NAMZARIC... 37	NEO-SYNALAR... 108
mycophenolate mofetil... 144	NAPRELAN CR... 16	neomycin... 28
mycophenolate sodium... 144	NAPROSYN... 16	neomycin-bacitracin-poly-hc... 165
MYDAYIS... 100	naproxen sodium... 16	neomycin-bacitracin-polymyxin... 165
MYFORTIC... 144	naproxen... 16	neomycin-polymyxin b gu... 157
MYLOTARG... 54	naproxen-esomeprazole... 16	neomycin-polymyxin b-dexameth... 165
myorisan... 108	naratriptan... 46	neomycin-polymyxin-gramicidin... 165
MYRBETRIQ... 124	NARCAN... 21	neomycin-polymyxin-hc... 165, 167
MYSOLINE... 34	NARDIL... 39	NEORAL... 144
MYTESI... 119	NAROPIN (PF)... 20	NEPHRAMINE 5.4 %... 114
myzilra... 134	NASONEX... 171	NERLYNX... 54
N	NATACHEW (FE BIS-GLYCINATE)... 114	NESACAINE... 20
nabumetone... 16	NATACYN... 165	NESACAINE-MPF... 20
nadolol... 91	NATAZIA... 134	NESINA... 76
nadolol-bendroflumethiazide... 91	nateglinide... 76	neuac... 108
nafcillin in dextrose iso-osm... 28	NATESTO... 134	NEULASTA... 81
nafcillin... 28	NATPARA... 149	NEUPOGEN... 81
naftifine... 44	NATRECOR... 91	NEUPRO... 60
NAFTIN... 44	NATROBA... 108	NEURONTIN... 34
NAGLAZYME... 122	NAVELBINE... 54	NEVANAC... 165
nalbuphine... 16	NAYZILAM... 34	nevirapine... 68
NALFON... 16	NEBUPENT... 59	
nalocet... 16		

NEXAVAR... 54	nitroglycerin in 5 % dextrose... 92	NORMOSOL-R IN 5 % DEXTROSE... 114
NEXIUM IV... 119	nitroglycerin... 92	NORMOSOL-R PH 7.4... 114
NEXIUM PACKET... 119	NITROLINGUAL... 92	NORMOSOL-R... 114
NEXIUM... 119	NITROSTAT... 92	NORPACE CR... 92
NEXLETOL... 91	NITYR... 122	NORPACE... 92
NEXLIZET... 91	NIVESTYM... 81	NORPRAMIN... 39
NEXTERONE... 91	nizatidine... 119	NORTHERA... 92
niacin... 91	NIZORAL... 44	nortrel 0.5/35 (28)... 134
niacor... 91	NOCDURNA (MEN)... 127	nortrel 1/35 (21)... 134
NIASPAN EXTENDED-RELEASE... 91	NOCDURNA (WOMEN)... 127	nortrel 1/35 (28)... 134
nicardipine... 91	nolix... 108	nortrel 7/7/7 (28)... 134
NICOTROL NS... 21	nora-be... 134	nortriptyline... 39
NICOTROL... 21	NORCO... 16	NORVASC... 92
nifedipine... 91, 92	NORDITROPIN FLEXPEN... 127	NORVIR... 68
nikki (28)... 134	norepinephrine bitartrate... 92	NOURIANZ... 60
NILANDRON... 54	noreth-ethinyl estradiol-iron... 134	NOVAREL... 127
nilutamide... 54	norethindrone (contraceptive)... 134	NOVOFINE AUTOCOVER... 157
nimodipine... 92	norethindrone ac-eth estradiol... 134	NOVOFINE PLUS... 157
NINLARO... 54	norethindrone acetate... 134	NOVOFINE 32... 157
NIPENT... 54	norethindrone-e.estradiol-iron... 134	NOVOLIN N FLEXPEN... 76
nisoldipine... 92	NORGESIC FORTE... 174	NOVOLIN N NPH U-100 INSULIN... 76
nitisinone... 122	norgestimate-ethinyl estradiol... 134	NOVOLIN R FLEXPEN... 76
NITRO-BID... 92	NORITATE... 28	NOVOLIN R REGULAR U-100 INSULN... 76
NITRO-DUR... 92	norlyda... 134	NOVOLIN 70-30 FLEXPEN U-100... 76
nitrofurantoin macrocrystal... 28	NORMOSOL-M IN 5 % DEXTROSE... 114	
nitrofurantoin monohyd/m-cryst... 28		
nitrofurantoin... 28		

NOVOLIN 70/30 U-100 INSULIN... 76	NUVIGIL... 175	okebo... 28
NOVOLOG FLEXPEN U-100 INSULIN... 76	NUZYRA (7 DAY WITH LOAD DOSE)... 28	olanzapine... 64
NOVOLOG MIX 70-30 U-100 INSULN... 76	NUZYRA (7 DAY)... 28	olanzapine-fluoxetine... 39
NOVOLOG MIX 70-30FLEXPEN U-100... 76	NUZYRA... 28	olmesartan... 92
NOVOLOG PENFILL U-100 INSULIN... 76	nyamyc... 44	olmesartan-amlodipin-hcthiazyd... 92
NOVOLOG U-100 INSULIN ASPART... 77	NYMALIZE... 92	olmesartan-hydrochlorothiazide... 92
NOVOPEN ECHO... 157	nystatin... 44	olopatadine... 165, 171
NOVOTWIST... 157	nystatin-triamcinolone... 44	OLUMIANT... 144
NOXAFIL... 44	nystop... 44	OLUX... 108
NUBEQA... 54	O	OLUX-E... 108
NUCALA... 171	O-CAL PRENATAL... 114	OMECLAMOX-PAK... 120
NUCYNTA ER... 17	OB COMPLETE ONE... 114	omega-3 acid ethyl esters... 92
NUCYNTA... 17	OB COMPLETE PETITE... 114	OMEGAVEN... 114
NUEDEXTA... 100	OB COMPLETE PREMIER... 114	omeppi... 120
NULYTELY LEMON-LIME... 120	OCALIVA... 120	omeprazole... 120
NULYTELY WITH FLAVOR PACKS... 120	ocella... 134	omeprazole-sodium bicarbonate... 120
NUPLAZID... 63	OCREVUS... 100	OMNARIS... 171
NURTEC ODT... 157	OCTAGAM... 144	OMNIPOD DASH 5 PACK POD... 157
NUTRESTORE... 120	octreotide acetate... 139	OMNIPOD INSULIN MANAGEMENT... 157
NUTRILIPID... 114	OCUFLOX... 165	OMNIPOD INSULIN REFILL... 157
NUTROPIN AQ NUSPIN... 127	ODACTRA... 171	OMNIPRED... 165
NUVARING... 134	ODEFSEY... 68	OMNITROPE... 127
NUVESSA... 28	ODOMZO... 54	ONCASPAR... 55
	OFEV... 171	ondansetron hcl (pf)... 41, 42
	ofloxacin... 28, 165, 167	ondansetron hcl... 41
	ogestrel (28)... 134	
	OGIVRI... 54	

ondansetron... 41	orphenadrine citrate... 174	oxandrolone... 135
ONEXTON... 108	orphenadrine-asa-caffeine... 174	oxaprozin... 17
ONFI... 34	orphengesic forte... 175	OXAYDO... 17
ONGENTYS... 60	orsythia... 134	oxazepam... 72
ONGLYZA... 77	ORTHO MICRONOR... 134	OXBRYTA... 157
ONIVYDE... 55	ORTHO TRI-CYCLEN (28)... 134	oxcarbazepine... 34
ONMEL... 44	ORTHO TRI-CYCLEN LO (28)... 134	OXERVATE... 165
ONTRUZANT... 55	ORTHO-CYCLEN (28)... 135	oxiconazole... 44
ONUREG... 55	ORTHO-NOVUM 1/35 (28)... 135	OXISTAT... 44
ONZETRA XSAIL... 46	ORTHO-NOVUM 7/7/7 (28)... 135	OXSORALEN ULTRA... 108
OPANA... 17	ORTIKOS... 148	OXTELLAR XR... 34
OPDIVO... 55	oseltamivir... 68	oxybutynin chloride... 124
opium tincture... 120	OSENI... 77	oxycodone... 17
OPSUMIT... 171	OSMITROL 10 %... 92	oxycodone-acetaminophen... 17
ORACEA... 28	OSMITROL 15 %... 93	oxycodone-aspirin... 17
ORALAIR... 171	OSMITROL 20 %... 93	OXYCONTIN... 17
oralone... 101	OSMITROL 5 %... 93	oxymorphone... 17
ORAP... 64	OSMOLEX ER... 60, 61	oxytocin... 157
ORAPRED ODT... 126	OSMOPREP... 120	OXYTROL... 124
ORAVIG... 44	OSPHENA... 135	OZEMPIC... 77
ORBACTIV... 28	OTEZLA STARTER... 108	P
ORENCIA CLICKJECT... 144	OTEZLA... 108	PACERONE... 93
ORENCIA... 144	OTOVEL... 167	paclitaxel... 55
ORENITRAM... 171	OTREXUP (PF)... 144	PADCEV... 55
ORFADIN... 122	OVIDE... 108	paliperidone... 64
ORIAHNN... 157	oxacillin in dextrose(iso-osm)... 28	PALYNZIQ... 122
ORLISSA... 139	oxacillin... 28	PAMELOR... 39
ORKAMBI... 171	oxaliplatin... 55	pamidronate... 149

PANCREAZE... 122	PEGASYS PROCLICK... 144	PERJETA... 55
PANDEL... 108	PEGASYS... 144	permethrin... 108
PANRETIN... 55	PEGINTRON... 144	perphenazine... 64
pantoprazole... 120	PEMAZYRE... 55	perphenazine-amitriptyline... 39
PANZYGA... 144	PEN NEEDLE... 157	PERSERIS... 64
paraplatin... 55	PEN NEEDLE, DIABETIC... 157	PERTZYE... 122
paricalcitol... 149	penicillamine... 114	PEXEVA... 39
PARLODEL... 61	penicillin g pot in dextrose... 29	pfizerpen-g... 29
PARNATE... 39	penicillin g potassium... 29	phenadoz... 42
paroex oral rinse... 101	penicillin g procaine... 29	phenelzine... 39
paromomycin... 28	penicillin g sodium... 29	PHENERGAN... 42
paroxetine hcl... 39	penicillin v potassium... 29	phenobarbital sodium... 34
paroxetine mesylate(menop.sym)... 39	PENLAC... 44	phenobarbital... 34
PASER... 47	PENNSAID... 17	phenoxybenzamine... 93
PATADAY... 165	PENTACEL (PF)... 144	phenylephrine hcl... 93
PATANASE... 171	PENTAM... 59	PHENYTEK... 34
PATANOL... 165	pentamidine... 59	phenytoin sodium extended... 34
PAXIL CR... 39	PENTASA... 148	phenytoin sodium... 34
PAXIL... 39	pentazocine-naloxone... 17	phenytoin... 34
PAZEO... 165	PENTIPS... 157	PHESGO... 55
PEDIAPRED... 126	pentobarbital sodium... 34	philith... 135
PEDIARIX (PF)... 144	pentoxifylline... 93	PHOSLYRA... 115
PEDVAX HIB (PF)... 144	pepcid... 120	PHOSPHOLINE IODIDE... 165
peg 3350-electrolytes... 120	PERCOCET... 17	phrenilin forte(with caffeine)... 17
peg-electrolyte soln... 120	PERFOROMIST... 171	PHYSIOLYTE... 157
peg-prep... 120	PERIKABIVEN... 115	PHYSIOSOL IRRIGATION... 157
PEGANONE... 34	perindopril erbumine... 93	PICATO... 108
	periogard... 101	PIFELTRO... 68

pilocarpine hcl... 101, 165	polymyxin b sulf-trimethoprim... 165	pr natal 430... 115
pimecrolimus... 108	polymyxin b sulfate... 29	PRADAXA... 81
pimozide... 64	POLYTRIM... 165	PRALUENT PEN... 93
pimtrea (28)... 135	POMALYST... 55	pramipexole... 61
pindolol... 93	portia 28... 135	PRANDIN... 77
pioglitazone... 77	PORTRAZZA... 55	prasugrel... 81
pioglitazone-glimepiride... 77	posaconazole... 45	PRAVACHOL... 93
pioglitazone-metformin... 77	potassium acetate... 115	pravastatin... 93
piperacillin-tazobactam... 29	potassium chlorid-d5-0.45%nacl... 115	praziquantel... 59
PIQRAY... 55	potassium chloride in lr-d5... 115	prazosin... 93
pirmella... 135	potassium chloride in water... 115	PRECOSE... 77
piroxicam... 17	potassium chloride in 0.9%nacl... 115	PRED FORTE... 165
PITOCIN... 157	potassium chloride in 5 % dex... 115	PRED MILD... 165
PLAQUENIL... 59	potassium chloride... 115	PRED-G S.O.P... 166
PLASMA-LYTE A... 115	potassium chloride-d5-0.2%nacl... 115	PRED-G... 166
PLASMA-LYTE 148... 115	potassium chloride-d5-0.3%nacl... 115	prednicarbate... 108
PLAVIX... 81	potassium chloride-d5-0.9%nacl... 115	prednisolone acetate... 166
PLEGRIDY... 100	potassium chloride-0.45 % nacl... 115	prednisolone sodium phosphate... 126, 166
plenamine... 115	potassium citrate... 115	prednisolone... 126
PLENVU... 120	POTELIGEO... 55	prednisone intensol... 126
PLIAGLIS... 20	pr natal 400 ec... 115	prednisone... 126
plixda... 108	pr natal 400... 115	PREFEST... 135
pnv ob+dha... 115	pr natal 430 ec... 115	pregabalin... 100
podofilox... 108		PREGNYL... 127
POLIVY... 55		PREMARIN... 135
polocaine... 20		PREMASOL 10 %... 115
polocaine-mpf... 20		PREMASOL 6 %... 115
polycin... 165		

PREMPHASE... 135	PRIMSOL... 29	PRODIGY INSULIN SYRINGE... 158
PREMPRO... 135	PRINIVIL... 93	profeno... 17
PRENATA... 115	PRISTIQ... 39	progesterone micronized... 135
PRENATABS FA... 115	PRIVIGEN... 144	progesterone... 135
prenatal plus (calcium carb)... 116	PRO COMFORT ALCOHOL PADS... 158	PROGLYCEM... 77
prenatal plus dha... 116	PRO COMFORT INSULIN SYRINGE... 158	PROGRAF... 144, 145
prenatal vitamin plus low iron... 116	PRO COMFORT PEN NEEDLE... 158	PROLASTIN-C... 123
PRENATE ELITE... 116	PROAIR DIGIHALER... 171	prolate... 17
preplus... 116	PROAIR HFA... 172	PROLENSA... 166
PREPOPIK... 120	PROAIR RESPICLICK... 172	PROLEUKIN... 55
PRESTALIA... 93	probenecid... 45	PROLIA... 149
PRETOMANID... 47	probenecid-colchicine... 45	PROMACTA... 81, 82
PREVACID SOLUTAB... 120	procainamide... 93	promethazine vc... 158
PREVACID... 120	PROCALAMINE 3%... 116	promethazine... 42
prevalite... 93	PROCARDIA XL... 93	promethazine-phenylephrine... 158
PREVENT DROPSAFE PEN NEEDLE... 157	PROCARDIA... 93	promethegan... 42
previfem... 135	procentra... 100	PROMETRIUM... 135
PREVYMIS... 68	prochlorperazine edisylate... 42	propafenone... 93
PREZCOBIX... 68	prochlorperazine maleate... 42	propantheline... 120
PREZISTA... 68	prochlorperazine... 42	proparacaine... 166
PRIALT... 157	PROCRIPT... 81	propranolol... 93
PRIFTIN... 47	procto-med hc... 108	propranolol-hydrochlorothiazid... 93
PRILOSEC... 120	procto-pak... 109	propylthiouracil... 140
primaquine... 59	PROCTOFOAM HC... 148	PROQUAD (PF)... 145
PRIMAXIN IV... 29	proctosol hc... 109	PROSCAR... 124
primidone... 34	proctozone-hc... 109	PROSOL 20 %... 116
primlev... 17	PROCYSBI... 122	protamine... 158
		PROTONIX... 120

PROTOPIC... 109	QUARTETTE... 135	rasagiline... 61
protriptyline... 39	quasense... 135	RASUVO (PF)... 145
PROVENTIL HFA... 172	QUDEXY XR... 34, 35	RAVICTI... 123
PROVERA... 135	QUESTRAN LIGHT... 93	RAYALDEE... 149
PROVIGIL... 175	QUESTRAN... 93	RAYOS... 126
PROZAC... 39	quetiapine... 64	RAZADYNE ER... 37
PRUDOXIN... 109	QUILLICHEW ER... 100	RAZADYNE... 37
psorcon... 109	QUILLIVANT XR... 100	REBETOL... 68
PULMICORT FLEXHALER... 172	quinapril... 93	REBIF (WITH ALBUMIN)... 100
PULMICORT... 172	quinapril-hydrochlorothiazide... 93	REBIF REBIDOSE... 100
PULMOZYME... 172	quinidine gluconate... 94	REBIF TITRATION PACK... 100
PURE COMFORT ALCOHOL PADS... 158	quinidine sulfate... 94	REBLOZYL... 82
PURE COMFORT PEN NEEDLE... 158	quinine sulfate... 59	RECARBRIO... 29
PURIXAN... 55	QUZYTIR... 172	RECLAST... 149
PYLERA... 120	QVAR REDIHALER... 172	reclipsen (28)... 135
pyrazinamide... 47		RECOMBIVAX HB (PF)... 145
pyridostigmine bromide... 47	R	RECTIV... 158
pyrimethamine... 59	RABAVERT (PF)... 145	REGLAN... 42
	rabeprazole... 120	REGONOL... 47
Q	RADICAVA... 100	REGRANEX... 109
QBRELIS... 93	RAGWITEK... 172	RELAFEN DS... 18
QBREXZA... 109	rajani... 135	RELAFEN... 18
QINLOCK... 55	raloxifene... 135	RELENZA DISKHALER... 68
QMIIZ ODT... 18	ramelteon... 175	relexxii... 100
QNASL... 172	ramipril... 94	RELION NEEDLES... 158
QTERN... 77	RANEXA... 94	RELION PEN NEEDLES... 158
QUADRACEL (PF)... 145	ranolazine... 94	RELISTOR... 120
QUALAQUIN... 59	RAPAFLO... 124	RELPAK... 46
	RAPAMUNE... 145	

REMERON SOLTAB... 39	REVCOVI... 123	RISPERDAL CONSTA... 64
REMERON... 39	REVLIMID... 55	RISPERDAL... 64
REMICADE... 145	revonto... 65	risperidone... 64
REMODULIN... 172	REXULTI... 64	RITALIN LA... 100
RENACIDIN... 158	REYATAZ... 69	RITALIN... 100
RENAGEL... 116	REYVOW... 46	ritonavir... 69
RENFLEXIS... 145	RHOFADE... 109	RITUXAN HYCELA... 55
REVELA... 116	RHOPHYLAC... 145	RITUXAN... 55
REOPRO... 82	RHOPRESSA... 166	rivastigmine tartrate... 37
repaglinide... 77	RIASTAP... 82	rivastigmine... 37
repaglinide-metformin... 77	RIBASPHERE RIBAPAK... 69	rivelsa... 135
REPATHA PUSHTRONEX... 94	ribaspHERE... 69	rizatriptan... 46
REPATHA SURECLICK... 94	ribavirin... 69, 158	ROBAXIN... 175
REPATHA SYRINGE... 94	RIDAURA... 145	ROBAXIN-750... 175
REQUIP XL... 61	rifabutin... 47	ROBINUL FORTE... 121
REQUIP... 61	RIFADIN... 47, 48	ROBINUL... 120
RESCRIPTOR... 68	RIFAMATE... 48	ROCALTROL... 149
RESECTISOL... 94	rifampin... 48	ROCKLATAN... 166
RESTASIS MULTIDOSE... 166	RIFATER... 48	romidepsin... 56
RESTASIS... 166	RILUTEK... 100	ropinirole... 61
RESTORIL... 175	riluzole... 100	ropivacaine (pf)... 20
RETACRIT... 82	rimantadine... 69	rosadan... 29
RETEVMO... 55	RIMSO-50... 158	rosuvastatin... 94
RETIN-A MICRO PUMP... 109	ringer's... 116, 158	ROTARIX... 145
RETIN-A MICRO... 109	RINVOQ... 145	ROTATEQ VACCINE... 145
RETIN-A... 109	RIOMET ER... 77	ROWASA... 148
RETROVIR... 68, 69	RIOMET... 77	roweepra xr... 35
REVATIO... 172	risedronate... 149	roweepra... 35

ROXICODONE... 18	SANTYL... 109	SEREVENT DISKUS... 172
ROXYBOND... 18	SAPHRIS... 64	SERNIVO... 109
ROZEREM... 175	SARAFEM... 40	SEROQUEL XR... 64, 65
ROZLYTREK... 56	SARCLISA... 56	SEROQUEL... 64
RUBRACA... 56	SAVAYSA... 82	SEROSTIM... 128
RUCONEST... 145	SAVELLA... 101	sertraline... 40
RUKOBIA... 69	scopolamine base... 42	setlakin... 135
RUXIENCE... 56	se-natal 19 chewable... 116	sevelamer carbonate... 116
RUZURGI... 100	SEASONIQUE... 135	sevelamer hcl... 116
RYBELSUS... 77	SECONAL SODIUM... 35	SEYSARA... 29
RYCLORA... 172	SECUADO... 64	SFROWASA... 148
RYDAPT... 56	SEEBRI NEOHALER... 172	sharobel... 135
RYTARY... 61	SEGLUROMET... 77	SHINGRIX (PF)... 145
RYTHMOL SR... 94	SELECT-OB (FOLIC ACID)... 116	SIGNIFOR... 139
RYVENT... 172	SELECT-OB + DHA... 116	SIKLOS... 158
S	SELECT-OB... 116	sildenafil (pulm.hypertension)... 172
SABRIL... 35	selegiline hcl... 61	SILENOR... 175
SAFESNAP INSULIN SYRINGE... 158	selenium sulfide... 109	SILIQ... 145
SAFETY PEN NEEDLE... 158	SELZENTRY... 69	silodosin... 124
SAFYRAL... 135	SEMGLEE PEN U-100 INSULIN... 77	SILVADENE... 109
SAIZEN SAIZENPREP... 128	SEMGLEE U-100 INSULIN... 77	silver sulfadiazine... 109
SAIZEN... 127	SEMPREX-D... 158	SIMBRINZA... 166
SALAGEN (PILOCARPINE)... 101	SENSIPAR... 149	simliya (28)... 135
SAMSCA... 116	SENSORCAINE... 20	simpesse... 135
SANCUSO... 42	sensorcaine-epinephrine... 20	SIMPONI ARIA... 146
SANDIMMUNE... 145	sensorcaine-mpf spinal... 20	SIMPONI... 145
SANDOSTATIN LAR DEPOT... 139	SENSORCAINE-MPF... 20	SIMULECT... 146
SANDOSTATIN... 139	sensorcaine-mpf/epinephrine... 20	simvastatin... 94

SINEMET CR... 61	SOLARAZE... 109	spironolacton-hydrochlorothiaz... 94
SINEMET... 61	solifenacin... 124	spironolactone... 94
SINGULAIR... 172	SOLQUA 100/33... 77	SPORANOX PULSEPAK... 45
sirolimus... 146	SOLODYN... 29	SPORANOX... 45
SIRTURO... 48	SOLOSEC... 29	sprintec (28)... 136
SITAVIG... 69	soloxide... 29	SPRITAM... 35
SIVEXTRO... 29	SOLTAMOX... 56	SPRIX... 18
SKELAXIN... 175	SOLU-CORTEF ACT-O-VIAL (PF)... 126	SPRYCEL... 56
SKLICE... 59	SOLU-CORTEF... 126	SPS (WITH SORBITOL)... 117
SKYRIZI... 146	SOLU-MEDROL (PF)... 126	sronyx... 136
SLYND... 135	SOLU-MEDROL... 126	SSD... 109
SMOFLIPID... 116	SOMA... 175	STALEVO 100... 61
sodium acetate... 116	SOMATULINE DEPOT... 139	STALEVO 125... 61
sodium benzoate-sod phenylacet... 158	SOMAVERT... 139	STALEVO 150... 61
sodium bicarbonate... 116	SONATA... 176	STALEVO 200... 61
sodium chloride 0.45 %... 116	SOOLANTRA... 109	STALEVO 50... 61
sodium chloride 0.9 %... 116	sorbitol-mannitol... 158	STALEVO 75... 61
sodium chloride 3 %... 116	SORIATANE... 109	STARLIX... 77
sodium chloride 5 %... 116	SORILUX... 109	stavudine... 69
sodium chloride... 116, 158	sorine... 94	STEGLATRO... 77
SODIUM EDECRIN... 94	sotalol af... 94	STEGLUJAN... 77
sodium lactate... 116	sotalol... 94	STELARA... 146
sodium phenylbutyrate... 123	SOTYLIZE... 94	STIMATE... 128
sodium phosphate... 116	SOVALDI... 69	STIOLTO RESPIMAT... 172
sodium polystyrene (sorb free)... 116	SPIRIVA RESPIMAT... 172	STIVARGA... 56
sodium polystyrene sulfonate... 116, 117	SPIRIVA WITH HANDIHALER... 172	STRATTERA... 101
		STRENSIQ... 123

streptomycin... 29	SUNOSI... 176	SYMPROIC... 121
STRIANT... 136	SUPRAX... 29	SYMTUZA... 69
STRIBILD... 69	SUPREP BOWEL PREP KIT... 121	SYNAGIS... 159
STRIVERDI RESPIMAT... 172	SURE COMFORT ALCOHOL PREP PADS... 158	SYNALAR... 109
STROMECTOL... 59	SURE COMFORT INS. SYR. U-100... 158	SYNAREL... 139
SUBOXONE... 21	SURE COMFORT INSULIN SYRINGE... 159	SYNDROS... 42
SUBSYS... 18	SURE COMFORT PEN NEEDLE... 159	SYNERA... 20
subvenite starter (blue) kit... 35	SURE-FINE PEN NEEDLES... 159	SYNERCID... 29
subvenite starter (green) kit... 35	SURE-JECT INSULIN SYRINGE... 159	SYNJARDY XR... 77
subvenite starter (orange) kit... 35	SURE-PREP ALCOHOL PREP PADS... 159	SYNJARDY... 77
subvenite... 35	SURMONTIL... 40	SYNRIBO... 56
SUCRAID... 123	SUSTIVA... 69	SYNTHROID... 138
sucralfate... 121	SUTENT... 56	SYPRINE... 117
SULAR... 94	syeda... 136	T
sulfacetamide sodium (acne)... 29	SYLATRON... 146	TABLOID... 56
sulfacetamide sodium... 29, 166	SYLVANT... 146	TABRECTA... 56
sulfacetamide-prednisolone... 166	SYMBICORT... 172	TACLONEX... 109
sulfadiazine... 29	SYMBYAX... 40	tacrolimus... 109, 146
sulfamethoxazole-trimethoprim... 29	SYMDEKO... 172	tadalafil (pulm. hypertension)... 173
SULFAMYLON... 109	SYMFI LO... 69	tadalafil... 124
sulfasalazine... 148	SYMFI... 69	TAFINLAR... 56
SULFATRIM... 29	SYMJEPI... 173	TAGRISSO... 56
sulindac... 18	SYMLINPEN 120... 77	TAKHZYRO... 146
sumatriptan succinate... 46, 47	SYMLINPEN 60... 77	TALICIA... 121
sumatriptan... 46	SYMPAZAN... 35	TALTZ AUTOINJECTOR (2 PACK)... 146
sumatriptan-naproxen... 47		TALTZ AUTOINJECTOR (3 PACK)... 146
SUMAVEL DOSEPRO... 47		

TALTZ AUTOINJECTOR... 146	TECFIDERA... 101	terbinafine hcl... 45
TALTZ SYRINGE... 146	TECHLITE INSULIN SYR HALF UNIT... 159	terbutaline... 173
TALWIN... 18	TECHLITE INSULIN SYRINGE... 159	terconazole... 45
TALZENNA... 56	TECHLITE PEN NEEDLE... 159	TERUMO INSULIN SYRINGE... 159
TAMIFLU... 69	TEFLARO... 30	TESTIM... 136
tamoxifen... 56	TEGRETOL XR... 35	testosterone cypionate... 136
tamsulosin... 124	TEGRETOL... 35	testosterone enanthate... 136
TAPAZOLE... 140	TEGSEDI... 123	testosterone... 136
taperdex... 126	TEKTURNA HCT... 94	TESTRED... 136
TARCEVA... 56	TEKTURNA... 94	TETANUS,DIPHTHERIA TOX PED(PF)... 146
TARGADOX... 30	telmisartan... 94	tetrabenazine... 101
TARGRETIN... 56	telmisartan-amlodipine... 95	tetracycline... 30
tarina fe 1-20 eq (28)... 136	telmisartan-hydrochlorothiazid... 95	TEXACORT... 109
tarina fe 1/20 (28)... 136	temazepam... 176	THALOMID... 56
tarina 24 fe... 136	TEMIXYS... 69	THAM... 117
TARKA... 94	TEMODAR... 56	THEO-24... 173
TASIGNA... 56	TEMOVATE... 109	theophylline in dextrose 5 %... 173
TASMAR... 61	temsirolimus... 56	theophylline... 173
TAVALISSE... 82	tencon... 18	THINPRO INSULIN SYRINGE... 160
TAXOTERE... 56	teniposide... 56	THIOLA EC... 124
TAYTULLA... 136	TENIVAC (PF)... 146	THIOLA... 124
tazarotene... 109	tenofovir disoproxil fumarate... 69	thioridazine... 65
tazicef... 30	TENORETIC 100... 95	thiotepa... 57
TAZORAC... 109	TENORETIC 50... 95	thiothixene... 65
taztia xt... 94	TENORMIN... 95	THYMOGLOBULIN... 146
TAZVERIK... 56	TEPEZZA... 159	THYROLAR-1... 138
TDVAX... 146	terazosin... 95	THYROLAR-1/2... 138
TECENTRIQ... 56		

THYROLAR-1/4... 138	tobramycin in 0.225 % nacl... 30	TOUJEO MAX U-300 SOLOSTAR... 78
THYROLAR-2... 138	tobramycin sulfate... 30	TOUJEO SOLOSTAR U-300 INSULIN... 78
THYROLAR-3... 138	tobramycin with nebulizer... 30	tovet emollient... 110
tiadylt er... 95	tobramycin... 166	TOVIAZ... 124
tiagabine... 35	tobramycin-dexamethasone... 166	TPN ELECTROLYTES... 117
TIAZAC... 95	TOBEX... 166	TRACLEER... 173
TIBSOVO... 57	TOFRANIL... 40	TRADJENTA... 78
TIGAN... 42	TOLAK... 110	tramadol... 18
tigecycline... 30	tolazamide... 78	tramadol-acetaminophen... 18
TIGLUTIK... 101	tolbutamide... 78	trandolapril... 95
TIKOSYN... 95	tolcapone... 61	trandolapril-verapamil... 95
tilia fe... 136	tolmetin... 18	tranexamic acid... 82
timolol maleate... 95, 166	TOLSURA... 45	TRANSDERM-SCOP... 42
TIMOPTIC OCUDOSE (PF)... 166	tolterodine... 124	TRANXENE T-TAB... 72
TIMOPTIC... 166	tolvaptan... 117	tranylcypromine... 40
TIMOPTIC-XE... 166	TOPAMAX... 35	TRAVASOL 10 %... 117
TINDAMAX... 30	TOPCARE CLICKFINE... 160	TRAVATAN Z... 166
tinidazole... 30	TOPCARE ULTRA COMFORT... 160	travoprost... 166
TIROSINT... 138	TOPICORT... 110	TRAZIMERA... 57
TIROSINT-SOL... 138	topiramate... 35	trazodone... 40
TIVICAY PD... 70	toposar... 57	TREANDA... 57
TIVICAY... 69, 70	topotecan... 57	TRECATOR... 48
TIVORBEX... 18	TOPROL XL... 95	TRELEGY ELLIPTA... 173
tizanidine... 65	toremifene... 57	TRELSTAR... 139
TOBI PODHALER... 173	TORISEL... 57	TREMFYA... 146
TOBI... 30	torseamide... 95	treprostinil sodium... 173
TOBRADEX ST... 166	TOSYMRA... 47	TRESIBA FLEXTOUCH U-100... 78
TOBRADEX... 166	TOTECT... 57	

TRESIBA FLEXTOUCH U-200... 78	triazolam... 176	TRIUMEQ... 70
TRESIBA U-100 INSULIN... 78	TRIBENZOR... 95	triveen-duo dha... 117
TRETIN-X... 110	TRICARE... 117	trivora (28)... 136
tretinoin (antineoplastic)... 57	TRICOR... 95	TRIZIVIR... 70
tretinoin microspheres... 110	triderm... 126	TROGARZO... 70
tretinoin... 110	TRIDESILON... 110	TROKENDI XR... 35
TREXALL... 146	trientine... 117	TROPHAMINE 10 %... 117
TREXIMET... 47	trifluoperazine... 65	TROPHAMINE 6%... 117
TREZIX... 18	trifluridine... 166	tropium... 124
tri femynor... 136	TRIGLIDE... 95	TRUE COMFORT ALCOHOL PADS... 160
tri-estarylla... 136	trihexyphenidyl... 61	TRUE COMFORT INSULIN SYRINGE... 160
tri-legest fe... 136	TRIJARDY XR... 78	TRUE COMFORT PEN NEEDLE... 160
tri-linyah... 136	TRIKAFTA... 173	TRUEPLUS INSULIN... 160
tri-lo-estarylla... 136	triklo... 95	TRUEPLUS PEN NEEDLE... 160
tri-lo-marzia... 136	TRILEPTAL... 35	TRULANCE... 121
tri-lo-mili... 136	TRILIPIX... 95	TRULICITY... 78
tri-lo-sprintec... 136	trilyte with flavor packets... 121	TRUMENBA... 146
tri-mili... 136	trimethobenzamide... 42	TRUSOPT... 166
TRI-NORINYL (28)... 136	trimethoprim... 30	TRUVADA... 70
tri-previfem (28)... 136	trimipramine... 40	TRUXIMA... 57
tri-sprintec (28)... 136	trinatal rx 1... 117	TUDORZA PRESSAIR... 173
tri-vylibra lo... 136	trinessa (28)... 136	TUKYSA... 57
tri-vylibra... 136	trinessa lo... 136	tulana... 136
triamcinolone acetonide... 101, 126	TRINTELLIX... 40	TURALIO... 57
triamterene... 95	TRIOSTAT... 138	TWINRIX (PF)... 146
triamterene-hydrochlorothiazid... 95	TRIPTODUR... 139	TWYNSTA... 95
trianex... 126	TRISENOX... 57	
	TRISTART DHA... 117	

TYBOST... 70	ULTRA CMFT INS SYR HALF UNIT... 161	URECHOLINE... 124
tydemy... 137	ULTRA COMFORT INSULIN SYRINGE... 161	UROCIT-K 10... 117
TYGACIL... 30	ULTRA FLO INSULIN SYRINGE... 161	UROCIT-K 15... 117
TYKERB... 57	ULTRA FLO PEN NEEDLE... 161	UROCIT-K 5... 117
TYLENOL-CODEINE #3... 18	ULTRA THIN PEN NEEDLE... 161	UROXATRAL... 124
TYLENOL-CODEINE #4... 18	ULTRA-THIN II (SHORT) INS SYR... 161	URSO FORTE... 121
TYMLOS... 149	ULTRA-THIN II (SHORT) PEN NDL... 161	URSO 250... 121
TYPHIM VI... 146	ULTRA-THIN II INS PEN NEEDLES... 161	ursodiol... 121
TYSABRI... 101	ULTRA-THIN II INSULIN SYRINGE... 161	UTIBRON NEOHALER... 173
TYVASO INSTITUTIONAL START KIT... 173	ULTRACARE INSULIN SYRINGE... 162	UVADEX... 110
TYVASO REFILL KIT... 173	ULTRACARE PEN NEEDLE... 162	
TYVASO STARTER KIT... 173	ULTRACET... 18	V
TYVASO... 173	ULTRAM... 18	V-GO 20... 162
U	ULTRAVATE... 110	V-GO 30... 162
UBRELVY... 160	UNASYN... 30	V-GO 40... 162
UCERIS... 148	UNIFINE PENTIPS MAXFLOW... 162	VABOMERE... 30
UDENYCA... 82	UNIFINE PENTIPS PLUS MAXFLOW... 162	VAGIFEM... 137
ULORIC... 45	UNIFINE PENTIPS PLUS... 162	valacyclovir... 70
ULTICARE INSULIN SYR HALF UNIT... 160	UNIFINE PENTIPS... 162	VALCHLOR... 57
ULTICARE INSULIN SYRINGE... 160	UNIFINE SAFECONTROL... 162	VALCYTE... 70
ULTICARE PEN NEEDLE... 160	UNITHROID... 138	valganciclovir... 70
ULTICARE... 160	UNITUXIN... 57	VALIUM... 72
ULTIGUARD SAFE PACK... 161	UPTRAVI... 173	valproate sodium... 36
ULTILET ALCOHOL SWAB... 161		valproic acid (as sodium salt)... 36
ULTILET INSULIN SYRINGE... 161		valproic acid... 36
ULTILET PEN NEEDLE... 161		valrubicin... 57
		valsartan... 95
		valsartan-hydrochlorothiazide... 95
		VALSTAR... 57

VALTOCO... 36	VELCADE... 57	vicodin... 18
VALTRES... 70	VELETRI... 173	VICTOZA 2-PAK... 78
vanadom... 175	velivet triphasic regimen (28)... 137	VICTOZA 3-PAK... 78
vanatol lq... 18	VELPHORO... 117	VIDAZA... 57
vanatol s... 18	VELTASSA... 117	VIDEX EC... 70
VANCOGIN... 30	VELTIN... 110	VIDEX 2 GRAM PEDIATRIC... 70
vancomycin in dextrose 5 %... 30	VEMLIDY... 70	VIDEX 4 GRAM PEDIATRIC... 70
vancomycin in 0.9 % sodium chl... 30	VENCLEXTA STARTING PACK... 57	VIEKIRA PAK... 70
vancomycin... 30	VENCLEXTA... 57	vienva... 137
vancomycin-water inject (peg)... 30	venlafaxine... 40	vigabatrin... 36
VANDAZOLE... 30	VENTAVIS... 173	vigadrone... 36
VANISHPOINT INSULIN SYRINGE... 162	VENTOLIN HFA... 174	VIGAMOX... 166
VANISHPOINT SYRINGE... 162	verapamil... 96	VIIBRYD... 40
VANOS... 110	VERDESO... 110	VIMOVO... 18
VAPRISOL IN 5 % DEXTROSE... 117	VEREGEN... 110	VIMPAT... 36
VAQTA (PF)... 146	VERELAN PM... 96	vinblastine... 57
VARIVAX (PF)... 146	VERELAN... 96	vincasar pfs... 57
VARIZIG... 146	VERIFINE PEN NEEDLE... 162	vincristine... 57
VARUBI... 42	VERIPRED 20... 126	vinorelbine... 57
VASCEPA... 95, 96	VERSACLOZ... 65	VIOKACE... 123
VASERETIC... 96	VERZENIO... 57	viorele (28)... 137
VASOTEC... 96	VESICARE... 124	VIRACEPT... 70
VAZCULEP... 96	VFEND IV... 45	VIRAMUNE XR... 70
vecamyl... 96	VFEND... 45	VIRAMUNE... 70
VECTIBIX... 57	VIBATIV... 30	VIRAZOLE... 162
VECTICAL... 110	VIBERZI... 121	VIREAD... 70
	VIBRAMYCIN... 30	virt-c dha... 117
	vicodin hp... 18	virt-nate dha... 117

VISTARIL... 174	VUSION... 45	XALATAN... 166
VISTOGARD... 58	VYEPTI... 47	XALKORI... 58
VITAFOL FE PLUS... 117	vyfemla (28)... 137	XANAX XR... 72
VITAFOL GUMMIES... 117	vylibra... 137	XANAX... 72
VITAFOL NANO... 117	VYNDAMAX... 123	XARELTO DVT-PE TREAT 30D START... 82
VITAFOL ULTRA... 117	VYNDAQEL... 123	XARELTO... 82
VITAFOL-OB... 117	VYONDYS-53... 123	XATMEP... 147
VITAFOL-OB+DHA... 117	VYTORIN 10-10... 96	XCOPRI MAINTENANCE PACK... 36
VITAFOL-ONE... 117	VYTORIN 10-20... 96	XCOPRI TITRATION PACK... 36
VITAMED MD ONE RX... 117	VYTORIN 10-40... 96	XCOPRI... 36
VITRAKVI... 58	VYTORIN 10-80... 96	XELJANZ XR... 147
vivacaine... 20	VYVANSE... 101	XELJANZ... 147
VIVELLE-DOT... 137	VYXEOS... 58	XELPROS... 166
VIVITROL... 21	VYZULTA... 166	XEMBIFY... 147
VIVLODEX... 18	W	XENAZINE... 101
VIZIMPRO... 58	WAKIX... 176	XENICAL... 162
VOGELXO... 137	warfarin... 82	XENLETA... 31
volnea (28)... 137	water for irrigation, sterile... 162	XEPI... 110
VOLTAREN... 18	WEBCOL... 162	XERAVA... 31
VOLTAREN-XR... 19	WELCHOL... 96	XERESE... 70
voriconazole... 45	WELLBUTRIN SR... 40	XERMELLO... 121
VOSEVI... 70	WELLBUTRIN XL... 40	XGEVA... 149
VOTRIENT... 58	wera (28)... 137	XHANCE... 174
VP-PNV-DHA... 117	WINRHO SDF... 147	XIFAXAN... 121
VPRIV... 123	wixela inhub... 174	XIGDUO XR... 78
VRAYLAR... 65	wymzya fe... 137	XIIDRA... 166
vtol lq... 19	X	XIMINO... 31
VUMERITY... 101	XADAGO... 61	

XOFLUZA... 70	ZALTRAP... 58	ZETIA... 96
XOLAIR... 147	ZANAFLEX... 65	ZETONNA... 174
XOLEGEL... 45	ZANOSAR... 58	ZIAC... 96
XOPENEX CONCENTRATE... 174	zarah... 137	ZIAGEN... 70, 71
XOPENEX HFA... 174	ZARONTIN... 36	ZIANA... 110
XOPENEX... 174	ZARXIO... 82	zidovudine... 71
XOSPATA... 58	ZAVESCA... 123	ZIEXTENZO... 82
XPOVIO... 58	ZCORT... 127	zileuton... 174
XTAMPZA ER... 19	ZEBUTAL... 19	ZILRETTA... 127
XTANDI... 58	ZEGERID... 121	ZILXI... 110
xulane... 137	ZEJULA... 58	ZINECARD (AS HCL)... 58
XULTOPHY 100/3.6... 78	ZELAPAR... 61	ZINPLAVA... 121
XURIDEN... 123	ZELBORAF... 58	ZIOPTAN (PF)... 166
XYOSTED... 137	ZELNORM... 121	ziprasidone hcl... 65
XYREM... 176	ZEMAIRA... 123	ziprasidone mesylate... 65
Y	ZEMBRACE SYMTOUCH... 47	ZIPSOR... 19
YASMIN (28)... 137	ZEMDRI... 31	ZIRABEV... 58
YAZ (28)... 137	ZEMPLAR... 149	ZIRGAN... 71
YERVOY... 58	zenatane... 110	ZITHROMAX TRI-PAK... 31
YF-VAX (PF)... 147	ZENPEP... 123	ZITHROMAX Z-PAK... 31
YONDELIS... 58	zenzedi... 101	ZITHROMAX... 31
YONSA... 58	ZEPATIER... 70	ZOCOR... 96
YOSPRALA... 82	ZEPZELCA... 58	ZOFRAN ODT... 42
YUPELRI... 174	ZERBAXA... 31	ZOFRAN... 42
yuvaferm... 137	ZERIT... 70	ZOHYDRO ER... 19
Z	ZERVIATE... 166	ZOLADEX... 139
zafirlukast... 174	ZESTORETIC... 96	zoledronic ac-mannitol-0.9nacl... 149
zaleplon... 176	ZESTRIL... 96	

zoledronic acid... 149, 150	ZUPLENZ... 42
zoledronic acid-mannitol-water... 150	ZURAMPIC... 45
ZOLINZA... 58	ZYBAN... 21
zolmitriptan... 47	ZYCLARA... 110
ZOLOFT... 40	ZYDELIG... 58
zolpidem... 176	ZYFLO CR... 174
ZOLPIMIST... 176	ZYFLO... 174
ZOMACTON... 128	ZYKADIA... 58
ZOMETA... 150	ZYLET... 167
ZOMIG ZMT... 47	ZYLOPRIM... 45
ZOMIG... 47	ZYMAXID... 167
ZONALON... 110	ZYPITAMAG... 96
ZONEGRAN... 36	ZYPREXA RELPREV... 65
zonisamide... 36	ZYPREXA ZYDIS... 65
ZONTIVITY... 82	ZYPREXA... 65
ZORBTIVE... 128	ZYTIGA... 58
ZORTRESS... 147	ZYVOX... 31
ZORVOLEX... 19	1ST TIER UNIFINE PENTIPS PLUS... 150
ZOSTAVAX (PF)... 147	1ST TIER UNIFINE PENTIPS... 150
ZOSYN IN DEXTROSE (ISO-OSM)... 31	
ZOSYN... 31	
zovia 1/35e (28)... 137	
ZOVIRAX... 71	
ZTLIDO... 20	
ZUBSOLV... 21	
ZULRESSO... 40	
zumandimine (28)... 137	

Important!

At Humana, it is important you are treated fairly.

Humana Inc. and its subsidiaries do not discriminate or exclude people because of their race, color, national origin, age, disability, sex, sexual orientation, gender identity, or religion. Discrimination is against the law. Humana and its subsidiaries comply with applicable Federal Civil Rights laws. If you believe that you have been discriminated against by Humana or its subsidiaries, there are ways to get help.

- You may file a complaint, also known as a grievance:
Discrimination Grievances, P.O. Box 14618, Lexington, KY 40512-4618
If you need help filing a grievance, call **1-866-396-8810** or if you use a **TTY**, call **711**.
- You can also file a civil rights complaint with the **U.S. Department of Health and Human Services**, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at **<https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>**, or by mail or phone at **U.S. Department of Health and Human Services**, 200 Independence Avenue, SW, Room 509F, HHH Building, Washington, DC 20201, **1-800-368-1019, 800-537-7697 (TDD)**.

Complaint forms are available at **<https://www.hhs.gov/ocr/office/file/index.html>**.

Auxiliary aids and services, free of charge, are available to you.

1-866-396-8810 (TTY: 711)

Humana provides free auxiliary aids and services, such as qualified sign language interpreters, video remote interpretation, and written information in other formats to people with disabilities when such auxiliary aids and services are necessary to ensure an equal opportunity to participate.

Language assistance services, free of charge, are available to you.

1-866-396-8810 (TTY: 711)

Español (Spanish): Llame al número arriba indicado para recibir servicios gratuitos de asistencia lingüística.

繁體中文 (Chinese): 撥打上面的電話號碼即可獲得免費語言援助服務。

Tiếng Việt (Vietnamese): Xin gọi số điện thoại trên đây để nhận được các dịch vụ hỗ trợ ngôn ngữ miễn phí.

한국어 (Korean): 무료 언어 지원 서비스를 받으려면 위의 번호로 전화하십시오.

Tagalog (Tagalog – Filipino): Tawagan ang numero sa itaas upang makatanggap ng mga serbisyo ng tulong sa wika nang walang bayad.

Русский (Russian): Позвоните по номеру, указанному выше, чтобы получить бесплатные услуги перевода.

Kreyòl Ayisyen (French Creole): Rele nimewo ki pi wo la a, pou resevwa sèvis èd pou lang ki gratis.

Français (French): Appelez le numéro ci-dessus pour recevoir gratuitement des services d'aide linguistique.

Polski (Polish): Aby skorzystać z bezpłatnej pomocy językowej, proszę zadzwonić pod wyżej podany numer.

Português (Portuguese): Ligue para o número acima indicado para receber serviços linguísticos, grátis.

Italiano (Italian): Chiamare il numero sopra per ricevere servizi di assistenza linguistica gratuiti.

Deutsch (German): Wählen Sie die oben angegebene Nummer, um kostenlose sprachliche Hilfsdienstleistungen zu erhalten.

日本語 (Japanese): 無料の言語支援サービスをご要望の場合は、上記の番号までお電話ください。

فارسی (Farsi)

برای دریافت تسهیلات زبانی بصورت رایگان با شماره فوق تماس بگیرید.

Diné Bizaad (Navajo): Wóda hí béésh bee hani'í bee wolta'ígíí bich'í' hódíílnih éí bee t'áá jiik'eh saad bee áká'ánída'áwo'déé nika'adoowoł.

العربية (Arabic)

الرجاء الاتصال بالرقم المبين أعلاه للحصول على خدمات مجانية للمساعدة بلغتك



This formulary was updated on 09/18/2020. For more recent information or other questions, please contact Humana Medicare Employer Plan at the number on the back of your membership card or, for TTY users, 711, Monday through Friday, from 8 a.m. - 9 p.m. Eastern Time. The automated phone system may answer your call on Saturdays, Sundays, and some public holidays. Please leave your name and telephone number, and we'll call you back by the end of the next business day, or visit **Humana.com**.



Humana.com

GRP02PDG2180021C_v1